Lipoprotein Metabolism in the Horse by Watson, Timothy David George
 
 
 
 
 
 
 
https://theses.gla.ac.uk/ 
 
 
 
 
Theses Digitisation: 
https://www.gla.ac.uk/myglasgow/research/enlighten/theses/digitisation/ 
This is a digitised version of the original print thesis. 
 
 
 
 
 
 
 
 
Copyright and moral rights for this work are retained by the author 
 
A copy can be downloaded for personal non-commercial research or study, 
without prior permission or charge 
 
This work cannot be reproduced or quoted extensively from without first 
obtaining permission in writing from the author 
 
The content must not be changed in any way or sold commercially in any 
format or medium without the formal permission of the author 
 
When referring to this work, full bibliographic details including the author, 
title, awarding institution and date of the thesis must be given 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enlighten: Theses 
https://theses.gla.ac.uk/ 
research-enlighten@glasgow.ac.uk 
LIPOPROTEIN METABOLISM IN THE HORSE 
TIMOTHY DAVID GEORGE WATSON
Departments
For the Degree of DOCTOR OF PHILOSOPHY
UNIVERSITY OF GLASGOW
Veterinary Medicine and Pathological Biochemistry 
University of Glasgow Glasgow Royal Infirmary
Veterinary School
November 1991
(c) Timothy D.G. Watson, 1991.
ProQuest Number: 11008055
All rights reserved
INFORMATION TO ALL USERS 
The quality of this reproduction is dependent upon the quality of the copy submitted.
In the unlikely event that the author did not send a com p le te  manuscript 
and there are missing pages, these will be noted. Also, if material had to be removed,
a note will indicate the deletion.
uest
ProQuest 11008055
Published by ProQuest LLC(2018). Copyright of the Dissertation is held by the Author.
All rights reserved.
This work is protected against unauthorized copying under Title 17, United States C ode
Microform Edition © ProQuest LLC.
ProQuest LLC.
789 East Eisenhower Parkway 
P.O. Box 1346 
Ann Arbor, Ml 48106- 1346
1ABSTRACT
Hyperlipaemia is a disease of ponies in which massive hypertriglyceridaemia is 
associated with fatty infiltration of body tissues and organ failure. The aim of the 
work described here was to identify the causal defect in lipoprotein metabolism.
Plasma lipid transport in healthy horses and ponies was first characterised. The 
high density lipoproteins (HDL) predominated and were homogeneous with respect to 
particle size and density. Three subfractions were found within the low density 
lipoproteins (LDL), and although the very low density lipoproteins (VLDL) were 
heterogeneous in size, discrete subpopulations were not identified. Two 
apolipoprotein (apo) B-100 like proteins were present in VLDL and LDL, and VLDL 
contained a third shorter species that appeared of hepatic origin. Lipoprotein lipase 
(LPL) and hepatic lipase (HL) were isolated and used to develop a selective assay for 
their measurement in post-heparin plasma. The activity of lecithimcholesterol acyl 
transferase was dependent upon apoA-I and determined the mass of cholesteryl esters 
in HDL. Equine plasma lacked cholesteryl ester transfer activity because of a 
deficiency of the protein rather the masking of its function by an inhibitory factor. 
The plasma concentrations of triglyceride and VLDL were higher in Shetland ponies 
than in Thoroughbred horses. Moderate hypertriglyceridaemia was prevalent in 
Shetland pony mares during the last trimester of pregnancy and was associated with 
changes in VLDL composition similar to those found in ponies with hyperlipaemia.
Although adult ponies showed no evidence of post-prandial lipaemia in response 
to feeding or an oral fat tolerance test, chylomicrons were found in the plasma of 
suckling foals where triglyceride and VLDL concentrations, and the activities of LPL 
and LCAT were higher than in adults. The plasma concentrations of LDL were also 
higher in the foals, and these lipoproteins were enriched with free cholesterol and 
phospholipid, and contained albumin and apoA-I. In the mares, lactation was 
associated with increased LPL activity.
The plasma concentrations of triglyceride and VLDL were increased by an 
average of 165 and 20 fold, respectively, in ponies with hyperlipaemia. This was due 
to the emergence of larger, more buoyant particles that were enriched in triglyceride 
and free cholesterol and depleted of cholesteryl esters and protein, specifically of 
apoB-100. The plasma concentrations of free fatty acids (FFA) and the activities of 
LPL and HL were increased. These data suggested that hepatic overproduction of 
VLDL, rather than compromised catabolism, was responsible for the condition. This 
was confirmed by kinetic analysis of plasma FFA and VLDL-triglyceride (VLDL- 
TG) metabolism in two ponies with hyperlipaemia, where the hepatic synthesis of 
VLDL-TG was 30 times higher than that in four healthy control ponies. This was 
driven by an increased flux of FFA from plasma into the liver. The residence time and 
fractional catabolic rate of VLDL was unaltered. Recycling of FFA into the plasma 
precursor pool from VLDL-TG lipolysis became a significant component of the 
hepatic input.
This thesis concludes that lipid lowering agents that reduce VLDL synthesis by 
reducing FFA flux to the liver should prove effective in treating equine hyperlipaemia 
and that such agents might be prescribed to those ponies identified at risk from 
hyperlipaemia, for example those mares in the last trimester of pregnancy.
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CHAPTER I 
INTRODUCTION
This thesis concerns the structure and function of the equine plasma lipoproteins and 
focuses on the disruption in their metabolism that leads to the hypertriglyceridaemic 
crisis in ponies called hyperlipaemia. In this introduction, the clinical features of this 
condition are described and followed by an account of lipoprotein metabolism, largely 
based on the human system, which shows how defects in the production and clearance 
of the triglyceride rich particles give rise to hypertriglyceridaemia. The information 
that is available on lipoprotein metabolism in the horse, in both healthy animals and 
ponies with hyperlipaemia, is then reviewed and the aims of the present studies 
defined.
1. EQUINE HYPERLIPAEMIA
1.1. The First Report
A disturbance in the lipid metabolism of ponies marked by gross lipaemia was first 
described in 1969 by Schotman and Wagenaar who called the condition 
hyperlipaemia. Over the seven year period to 1966 they saw a total of 138 cases at the 
State University of Utrecht, the majority were Shetland ponies and many were in foal, 
or had recently foaled or aborted. The disease thus appeared more common in the 
spring months coinciding with the seasonal pattern of horse breeding. The affected 
animals appeared dull and produced either no faeces or had severe diarrhoea, which 
was related to the fact that many (61%) had concurrent disorders of the gastro­
intestinal tract such as "worms, sand in the intestines and enteritis". A further 22% of 
cases were suffering from afflictions that did not concern the gastrointestinal tract, 
chiefly upper respiratory tract infections. The hyperlipaemia was of unknown origin 
in 17% of the cases. The mortality rate was high, in the region of 65%, and fatty 
degeneration of the liver and other parenchymous organs was obvious at necropsy.
Schotman and Wagenaar (1969) recounted how in severe cases the blood took 
on a bluish colour and suggested that the lipaemia could be demonstrated by pouring 
blood onto a dark surface, such as the floor, where a thin blue surface could be seen 
within a few seconds. They reported that total blood lipids were increased from 130- 
190 mg/dl in healthy ponies to 1000-7000 mg/dl in hyperlipaemic ponies, due to 
elevated levels of total and free cholesterol, phospholipids, fatty acid esters and free 
fatty acids (FFA), and the 6 -lipoprotein fraction. Blood glucose concentrations were
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reduced in some cases and there was often evidence of hepatic damage as the serum 
activities of alkaline phosphatase, and sorbitol and lactate dehydrogenase were 
increased.
Anorexia was a consistent feature of the case histories and this prompted the 
authors to speculate that the hyperlipaemia was caused by failure of the animals to 
eat, often because of some underlying illness. This was supported by showing a four 
fold increase in total blood lipids in two healthy ponies that were fasted for seven 
days. They concluded that body fat was mobilised to satisfy energy demands and that 
this resulted in fatty infiltration of the liver. The prognosis for individual cases 
appeared to be determined by the nature of the primary illness and was inversely 
related to their total blood lipids. In addition to correcting any concurrent disease, the 
authors advocated that calories be provided with intravenous glucose and soaked 
grass meal administered through a nasogastric tube, and suggested using prednisolone 
to stimulate the appetite and heparin to help clear the plasma of neutral lipids. Their 
final comment was that "the treatment of hyperlipaemic ponies requires much effort 
and is often disappointing".
Figure 1. Lipaemia: the appearance of a centrifuged blood sample from a pony with 
hyperlipaemia (right) compared with that from a healthy pony (left).
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1.2. Epidemiology
Equine hyperlipaemia has since been described in most parts of the world, including 
Denmark (Eriksen and Simesen 1970), Australia (Gay, Sullivan, Wilkinson, McLean 
and Blood 1978), North America (Naylor, Kronfeld and Acland 1980) and South 
Africa (Gilbert 1986). Meaningful data on the epidemiology of the condition came 
from a prospective survey of members of the Australian Pony Stud Book that ran for 
12 months and covered a total population of 592 ponies (Jeffcott and Field 1985a). 
Thirty cases (5%) of hyperlipaemia were reported, 27 (90%) of which were Shetland 
ponies which comprised only 25% of the total population. Mares were also over­
represented, 27 (90%) of the cases were females and of these, 80% were lactating and 
15% were pregnant. The physical condition of the affected ponies was reported as 
good to overweight in 90% of the animals and 50% of the cases had been subjected to 
some form of stress, principally transportation or food deprivation, in the four weeks 
prior to the onset of disease. The average course of the condition was seven days and 
the total mortality rate was 57%. Although the study did not report details of any 
underlying or concurrent disease, the results confirmed the predisposition of the 
Shetland pony and the eminence of obesity, stress, pregnancy and lactation as risk 
factors for hyperlipaemia.
There are few reports of hyperlipaemia in types of horses other than ponies. 
Naylor et al. (1980) included three Standardbred colts, a Thoroughbred colt and mare, 
and an Arab in their study, all of which had hyperlipaemia secondary to severe multi­
organ failure. The condition has been recorded in a post-parturient Paso Fino mare 
(Murray 1985) and a Quarter horse suffering the combined effects of 
hyperadrenocorticalism and acorn poisoning (Field 1988). A donkey was in the series 
reported by Naylor et al. (1980) and hyperlipaemia is now recognised as a significant 
cause of mortality in obese donkeys subjected to stress (Fowler 1989). Congenital 
hyperlipaemia was described in a Shetland pony foal bom to a hyperlipaemic mother 
(Gilbert 1986) and apart from the three severely compromised foals of 1, 3.5 and 7 
months reported by Naylor et al. (1980), hyperlipaemia appears rare in animals less 
than two years of age.
1.3. Clinical Signs, Blood Chemistry and Pathology
The clinical signs and pathology associated with this condition were best described by 
Gay et al. (1978) following their experiences with 15 cases of hyperlipaemia. 
Dullness, depression and lethargy were the earliest features. As the disease 
progressed, the animals became reluctant to move and showed incoordination, 
weakness, and muscular fasciculations after minor exercise. Mild abdominal pain was 
present in some cases and usually lasted for one to two days and was followed by
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diarrhoea with foetid faeces that persisted until death. Five ponies developed ventral 
subcutaneous oedema. Inappetance progressed to anorexia, and depression to signs of 
severe nervous dysfunction as the animals became recumbent with paddling 
convulsions, champing, and nystagmus, and mania as an occasional agonal event. The 
clinical course varied from six to ten days, and 1 2  of the 15 ponies died despite 
intensive therapy. In Jeffcott and Field's survey (1985a), failure to drink, loss of body 
condition and halitosis were recorded as less frequent and more variable signs.
Eriksen and Simesen (1970) showed that the major changes in blood lipid 
content related to triglycerides which were 38.1 ±1.9 (mean ±sd) mmol/1 in four 
hyperlipaemic ponies compared with 0.09 ±0.05 mmol/1 in eight healthy ponies. 
Plasm a concentrations of cholesterol and phospholipids were increased by an average 
o f three and four fold, respectively. Similar changes were noted by Naylor et al. 
(1980), who emphasised that elevated plasma FFA concentrations might be 
significant in the aetiology of the disease.
In addition to confirming the evidence of hepatic pathology presented by 
Schotman and Wagenaar (1969), Eriksen and Simesen (1970) reported that blood urea 
and ketone concentrations were normal, that hypoglycaemia was present in some but 
not all cases, and that total clotting time was increased and bromosulphothalein 
clearance prolonged. Naylor et al. (1980) confirmed that ketonaemia was not a feature 
of the disease and showed that bilirubin levels were not elevated, consistent with the 
absence of icterus as a clinical sign. Both Gay et al. (1978) and Naylor et al. (1980) 
suggested that elevated blood urea and creatinine concentrations, and metabolic 
acidosis develop terminally.
At necropsy, Gay et al. (1978) found widespread fatty infiltration of body 
organs marked by pallor, swelling and a greasy texture. These changes were most 
severe in the liver and kidneys, to the extent that the liver had ruptured in two cases, 
and less so in skeletal muscle, adrenal cortex and myocardium. Focal haemorrhages 
were sometimes scattered throughout the carcase, there was extensive infarction of 
the left ventricular myocardium in one case, two animals had renal infarcts and 
another had thrombosis of the portal vein. Pulmonary oedema was a consistent 
finding and considered an agonal event. Histopathology confirmed the severity of the 
lipid infiltration and revealed extensive venous thrombosis in the lung, kidney and 
brain, as well as the heart, liver, adrenals and subcutis. In the kidneys, there was 
evidence of a proliferative glomerulitis superimposed upon the fatty change. Other 
findings included hyaline degeneration of skeletal muscle, nutritional atrophy of the 
exocrine pancreas and depletion of lymphoid follicles in the spleen and lymph nodes. 
The clinical signs were attributed to developing hepatic failure and encephalopathy, 
with renal failure and acidosis as terminal events. The vascular pathology was
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peculiar to this report, but prompted the authors to speculate that the widespread 
vascular thrombosis might be initiated by the hyperlipidaemia and fat embolism.
Figure 2. Fatty infiltration: histological sections of liver from a healthy pony (top) 
and a pony with hyperlipaemia (bottom) (hematoxylin and eosin, x400).
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1.4. Current Concepts of Pathogenesis and Therapy
A number of studies have shown that plasma triglyceride levels rise when food is 
withheld from healthy ponies for three to eight days (Baetz and Pearson 1972; Morris, 
Zilversmit and Hintz 1972; Bauer 1983) and that this is preceded by increases in FFA 
concentrations (Naylor et al. 1980; Rose and Sampson 1982). These data have 
strengthened Schotman and Wagenaar's (1969) original belief that hyperlipaemia 
results from the mobilisation of body lipids in response to an energy imbalance. Such 
a deficit may arise due to the increased metabolic demands of pregnancy and 
lactation, simple undemutrition, and anorexia secondary to stress or underlying 
disease (Jeffcott and Field 1985b). However, because the disease is most commonly 
associated with states, such as obesity, stress, pregnancy and lactation, that in other 
species are associated with insulin insensitivity, attention has focused on what role 
insulin resistance might play in its aetiology. To this end, Jeffcott, Field, McLean and 
O'Dea (1986) demonstrated that ponies are glucose intolerant and insulin insensitive 
compared with larger horses, an insensitivity accentuated by obesity, and Fowden, 
Comline and Silver (1984) showed that insulin resistance is a natural feature of the 
equine pregnancy. It is therefore believed that once adipose lipolysis is initiated, the 
mobilisation of fatty acids proceeds in an exaggerated and unregulated fashion as 
insulin is unable to exert control over the hormone sensitive lipase. The mobilised 
fatty acids, as well as providing substrates for gluco- and ketoneogenesis, are thought 
to be re-esterified in the liver and secreted in to the circulation thus leading to the 
hypertriglyceridaemia (Jeffcott and Field 1985b).
Present therapies for hyperlipaemia rely on the identification and treatment of 
any underlying disease, the maintenance of energy intake with enteral glucose 
solutions and supportive therapy with intravenous electrolytes, B vitamins and 
anabolic steroids. A combination of insulin and glucose or galactose aimed at 
curtailing adipose lipolysis has been advocated by Wensing (1972), and heparin 
suggested to promote the clearance of triglycerides from the circulation (Schotman 
and W agenaar 1969). The efficacy of insulin and heparin has questioned been by 
clinical experience where mortality rates remained in excess of 65% (Gay et al. 
1978), and their use is controversial given the role for insulin insensitivity in the 
aetiology of the disease and the fact that impaired clotting function is present in many 
cases. Clearly, there is therefore a need for an effective lipid lowering therapy based 
on rational understanding of the biochemical mechanisms that link the mobilisation of 
fatty acids with the massive accumulation of triglyceride in the circulation.
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2. L IPO PR O T E IN  STR U C TU R E AND FUNCTION
The plasma lipoproteins have evolved to overcome the difficulties presented in 
distributing aqueous-insoluble lipids from their sites of assimilation and synthesis to 
the tissues of utilisation, storage and excretion. These particles contain the intensely 
hydrophobic neutral lipids (cholesteryl esters and triglyceride) in a spherical core that 
is protected from the hostile environment of plasma by a polar coat of free 
cholesterol, phospholipids and specialised proteins called the apolipoproteins (apo) 
(Fig. 3). A number of discrete populations of lipoproteins are identifiable in plasma 
on the basis of their size, hydrated density, and lipid and apolipoprotein compositions 
(Tables 1 and 2). While each class has evolved separate and diverse roles in the 
transport of lipids, they interact intimately with one another and, in health at least, are 
capable of providing a coordinate response to the demands placed upon them. The 
strong association of certain classes with the occurrence of coronary artery disease 
(CAD) in man and some animal species has been a major stimulus for intense interest 
in the biology of these particles. The structure, function and metabolism of the major 
lipoprotein classes are reviewed in the succeeding sections.
FREE CHOLESTEROL
PROTEIN (Apolipoprotein)
CHOLESTERYL ESTER HOSPHOLIPID
TRIGLYCERIDE
Figure 3. Schematic representation of a lipoprotein particle.
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Lipoprotein
Electrophoretic
Mobility
Diameter
nm
Weight 
k Da
Density
g/ml
Chylomicrons Origin 75-1200 >400,000 <0.93
Very Low Density pre-B 30-80 10-80,000 0.93-1.006
Intermediate Density slow pre-B 25-35 5-10,000 1.006-1.019
Low Density B 18-25 2,300 1.019-1.063
High Density; HDL2 a 9-12 360 1.063-1.125
h d l 3 a 5-9 175 1.125-1.210
Table 1. The physical properties of the human plasma lipoprotein classes.
Percentage Particle Mass
Lipoprotein Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
Chylomicrons 2 90 1 5 2
VLDL 13 54 7 16 1 0
IDL 34 2 0 9 2 0 17
LDL 41 4 1 1 2 1 23
h d l 2 13 5 5 35 42
h d l 3 15 3 3 23 56
Table 2. Typical composition of the human plasma lipoproteins.
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2.1. Chylomicrons
The human diet is rich in fat, each day we consume approximately lOOg of 
triglycerides, 2 .2 g of phospholipids and lg  of cholesterol and these are distributed to 
their target organs by chylomicrons, the largest and most buoyant of the lipoprotein 
classes. The ingested lipids are hydrolysed in the upper small intestine and enter 
adjacent mucosal cells by passive diffusion. Triglyceride, phospholipid and 
cholesteryl esters are re-synthesised within the smooth endoplasmic reticulum (SER) 
and are complexed with apolipoproteins B-48, A-I, A-II and A-IV near to the junction 
with the rough endoplasmic reticulum (RER). The particles are then transported to the 
Golgi apparatus, from where secretory vesicles migrate towards and fuse with the 
lateral plasma membrane and discharge their contents into the intercellular space 
(Sabesin and Frase 1977). From there, the chylomicrons enter the intestinal lacteals 
passing through the lymphatic system so that one hour after fat consumption they 
enter the general circulation.
The transfer of the chylomicron lipids to tissues is accomplished in two 
stages. First, the core triglyceride is hydrolysed by the enzyme lipoprotein lipase 
(LPL) releasing fatty acids that are taken up by adipose tissue and skeletal muscle for 
energy production or storage. The activity of this enzyme requires the presence of 
apoC-II on the chylomicron surface and this is acquired from HDL, along with apoC- 
III and apoE, as the particles enter the circulation. As triglyceride is progressively 
removed, the core of the chylomicron shrinks leaving an excess of surface material 
(phospholipid, free cholesterol, apoA-I and apoA-II) that is transferred to HDL (Tall, 
Green, Glickman and Riley 1979). Once approximately 75% of the triglyceride has 
been removed, apoC-II is also lost from the particle and lipolysis stops. The remnant 
particles formed by this process are cleared by a hepatic receptor that recognises apoE 
so that cholesterol of dietary origin reaches the liver where it is used for bile salt 
synthesis, stored, or secreted in VLDL (Rubinsztein, Cohen, Berger, van der 
Westhuyzen, Coetzee and Gevers 1990). The identity of this chylomicron remnant 
receptor had remained elusive until the recent description of an LDL receptor related 
protein (LRP) which satisfies the functional criteria applied to the remnant receptor 
(reviewed by Brown, Herz, Kowal and Goldstein 1991).
The assimilation and clearance of dietary fat is an efficient process that returns 
plasm a triglycerides to fasting levels within 6  to 8  hours of finishing a meal. In 
response to the digestion and absorption of fat, the synthesis of apoB (Davidson, 
Magun, Brasitus and Glickman 1987), apoA-I (Go, Schonfield, Pfleger, Cole, 
Sussman and Alpers 1988), and apoA-IV (Black, Rohwer-Nutter and Davidson 1990) 
are increased. In fact, synthesis of apoB is an absolute requirement for chylomicron 
assembly as shown by the absence of these particles in patients who inherit the
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condition abetalipoproteinaemia and are deficient in this protein (Bouma, Beucler, 
Pessah, Heinzmann, Lusis, Naim, Ducastelle, Leluyer, Schmitz, Infante and 
Aggerbeck 1990). The clearance of chylomicrons is influenced by the activity of LPL 
(Patsch, Prasad, Gotto and Patsch 1987), the availability and function of apoC-II and 
apoC-III, and there is recent evidence that the uptake of chylomicron remnants is 
dependent on the activity of hepatic lipase (Sultan, Lagrange, Jansen and Griglio 
1990), and the quantity (Annuzzi, Holmquist, and Carlson 1989) and phenotype of 
apoE (Weintraub, Eisenberg and Breslow 1987).
2.2. Very Low Density Lipoproteins
The very low density lipoproteins (VLDL) are composed predominantly of 
triglyceride, which in contrast to the chylomicrons, is of endogenous origin. These 
particles are the precursors of LDL and so serve as vehicles for the distribution of 
both triglyceride and cholesterol from the liver to peripheral tissues. Nascent VLDL 
particles are continuously secreted by the liver and to a minor extent by the intestine 
(Green and Glickman 1981), and are stabilised by a single molecule of apoB-100 
(Elovson, Chatterton, Bell, Schumaker, Reuben, Puppione, Reeve and Young 1988). 
The assembly and secretion of hepatic VLDL has recently been the subject of an 
extensive review by Gibbons (1990). Following synthesis in the RER, apoB is 
complexed with cholesteryl esters and transferred to a transitional area at the junction 
with the SER. There triglycerides, synthesised in the SER, are added and the 
immature particles transferred to the Golgi apparatus where the surface lipids are 
added. The nascent particles are held in secretory storage vesicles that bud off from 
the Golgi in to the space of Disse where the majority of the other apolipoproteins 
found on VLDL, namely apoE and apoC, are acquired.
Once in the circulation, VLDL enter the LPL lipolytic cascade and are 
stripped of their core triglyceride in a stepwise manner identical to that described for 
chylomicrons. This gives rise to smaller particles that are further processed to EDL 
and LDL by hepatic lipase (HL), or cleared from the circulation following recognition 
of their apoE component by the LDL receptor (Brown et al. 1991). There is presently 
debate as to what role the LRP might play in the clearance of these remnants 
(Eisenberg 1990). Considerable heterogeneity exists within the VLDL class and is 
evident when particles are separated according to size (Sata, Havel and Jones 1972) or 
hydrated density (Patsch, Patsch, Kostner, Sailer and Braunsteiner 1978). Indeed, as 
particle size decreases and density increases along the VLDL spectrum, the 
contribution of triglyceride and non-apoB proteins declines as the particles become 
enriched in cholesteryl esters and apoB (Kuchinskiene and Carlson 1982). It appears 
that the smaller particles continue through the lipolytic cascade to LDL, while the
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remnants of larger VLDL are cleared directly from the circulation (Packard, Munro, 
Lorimer, Gotto and Shepherd 1984).
The hepatic synthesis of triglyceride and apoB, and the secretion of VLDL, in 
vitro at least, appear sensitive to nutritional and metabolic changes. Triglyceride 
synthesis is enhanced in fed compared with fasted animals (Wilcox and Heimberg 
1987), in animals fed carbohydrate precursors of triglyceride (Yamamoto, Yamamoto, 
Tunaka and Ontko 1987), in hyperphagic rats (Vance and Russell 1990), and is 
related to the supply of FFA (Dashti and W olfbauer 1987). The neutral lipid 
composition o f VLDL is largely directed by the lipid content of the hepatocyte so that 
the cholesterol content of VLDL is increased by feeding cholesterol, in exchange for a 
reduction in VLDL triglyceride content (Davis, McNeal and Moses 1982). Hepatic 
VLDL secretion is enhanced by glucose and inhibited by insulin (Durrington, 
Newton, Weinstein and Steinberg 1982). This latter effect appears due to decreased 
secretion rather than synthesis of VLDL and may result in the accumulation of 
triglyceride within the liver (Patsch, Franz and Schonfeld 1983). Glucagon appears to 
inhibit triglyceride secretion while the thyroid hormones and oestrogens have the 
reverse effect (Haagsman and Van Golde 1984).
As for chylomicrons, the catabolism of VLDL is largely dependent upon the 
activity of LPL. In addition, evidence has recently emerged from human (Eisenberg, 
Friedman and Vogel 1988) and animal (Mahley, Weisgraber, Hussain, Greenman, 
Fisher, Vogel and Gorecki 1989) studies to suggest that the removal of VLDL 
remnants may also be saturable and limited by the quantity and quality of apoE in 
plasma and VLDL.
2.3. Intermediate Density Lipoproteins
Removal of VLDL core triglyceride causes the particle to shrink in size and become 
more dense. These intermediate density lipoproteins (IDL) are enriched in cholesteryl 
esters and protein relative to their precursors. The loss of surface components during 
lipolysis means that apoB comprises the majority of their protein moiety. The plasma 
concentrations of IDL are normally low, reflecting their rapid conversion to LDL by 
hepatic lipase and their direct removal from the circulation by cell surface receptors 
(Demant, Shepherd and Packard 1988).
2.4. Low Density Lipoproteins
The completion of IDL hydrolysis and continued loss of surface components produces 
a particle extremely rich in cholesteryl esters and which contains very few 
apolipoproteins other than a single molecule of apoB. These low density lipoproteins 
(LDL) are the major human cholesterol transporter and as such are the agents
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provocateurs of atherosclerosis. This is evidenced by the strong correlation between 
the plasma concentration of LDL and the incidence of CAD observed in large scale 
epidemiological studies such as that of Framingham (Kannel, Castelli, Gordon and 
McNamara 1971), and by the reduction in CAD that can be achieved by reducing 
LDL levels (The Lipid Research Clinics Coronary Primary Prevention Trial Results 
1984).
With kinetic analysis of apoB metabolism it has become clear that LDL 
particles do not originate exclusively from VLDL precursors (Demant et al. 1988) and 
that as many as 50% may be secreted directly into the circulation (Soutar, Myant and 
Thompson 1977; Goldberg, Le, Ginsberg, Patemiti and Brown 1983). In support of 
this, lipoproteins with the characteristics of LDL are secreted by hepatocytes in vitro 
(Dashti and Wolfbauer 1987). Advancements in understanding the origins of LDL 
have been accompanied by the realisation that this lipoprotein class is composed of a 
number of discrete subpopulations that are heterogeneous with respect to size, density 
and lipid composition (Shen, Krauss, Lindgren and Forte 1981). These subspecies 
differ in their kinetic behaviour (Marzetta, Foster and Brunzell 1989) and may possess 
varying potentials for promoting atherosclerosis, as a preponderance of the smaller 
more dense particles appears to be associated with CAD (Griffin, Caslake, Yip, Tait, 
Packard and Shepherd 1990).
The majority of LDL (80-90%) is cleared from the circulation by a 
glycoprotein cell surface receptor, the LDL receptor, that recognises and binds apoB- 
100 (Brown and Goldstein 1984). Much of this clearance occurs in the liver which 
contains 50-70% of the body's receptor complement, although high concentrations of 
receptor activity are found on the adrenals and ovaries reflecting their high cholesterol 
requirement for hormone synthesis (Fong, Bonney, Kosek and Cooper 1989). The 
expression of LDL receptor activity is closely regulated by the level of cholesterol 
within the cell so that when the supply of cholesterol exceeds requirements the 
transcription of the gene is suppressed and vice versa (Brown and Goldstein 1975). 
This has provided the basis for the cholesterol lowering drugs that upregulate receptor 
activity and so reduce plasma LDL levels, by inhibiting cholesterol biosynthesis or 
blocking the enterohepatic circulation of bile acids (Shepherd and Packard 1986). 
Defective expression of the receptor is the basis for the genetic disorders found in 
man (Familial hypercholesterolaemia) and the rabbit (Watanabe heritable 
hyperlipidaemia) which results in massive plasma LDL concentrations and premature 
atherosclerosis (Goldstein and Brown 1989).
The remainder of LDL clearance occurs by receptor independent pathways 
that appears in a number of tissues as a function of the ambient plasma LDL 
concentration (Spady, Meddings and Dietschy 1986). Further to this, macrophages
CHAPTER I 26
express high affinity binding sites for chemically modified LDL residues which 
avidly scavenge such particles in an unregulated fashion initiating and aggravating 
atherosclerosis (Mahley and Innerarity 1983).
2.5. High Density Lipoproteins
The high density lipoproteins are the smallest and most dense of the major classes 
and, in terms particle numbers, are the most abundant lipoprotein in human plasma. In 
contrast with the other classes, the HDL have protein as their major constituent and 
the majority of particle mass (80%) is attributable to shell rather than core 
components (Patsch and Gotto 1987). The major proteins in HDL are apoA-I and A- 
II, which together account for 75-85% of the protein mass, with minor contributions 
from apoA-IV, apoC and apoE. Interest in the metabolism of HDL stems from the 
inverse relationship that exists between plasma HDL concentrations and the incidence 
of CAD, suggesting a cardioprotective function for these lipoproteins (Miller and 
M iller 1975).
It has long been recognised that the human HDL class is composed of a 
number of thermodynamically stable subspecies that have diverse metabolic functions 
(reviewed by Eisenberg 1984). This heterogeneity is obvious when HDL is subjected 
to zonal ultracentrifugation (Patsch, Schonfeld, Gotto and Patsch 1980) and non­
denaturing polyacrylamide gel electrophoresis (Blanche, Gong, Forte and Nichols 
1981) when two major subclasses, HDL2  and HDL 3 , are identified. To complicate 
matters, the HDL class can be alternatively divided, by immunological means, into 
particles that contain apoA-I and apoA-II in a 2:1 molar ratio (LpA-I/A-II), and 
particles with apoA-I but no apoA-II (LpA-I) (Cheung and Albers 1982). It is 
apparent that the LpA-I particles exist at both extremes of the HDL spectrum with the 
bulk in HDL2, whereas the LpA-I/A-II particles are largely distributed within the 
H D L 3  compartment (Atmeh, Shepherd and Packard 1983).
Mature HDL evolve from disc-shaped bilayers of phospholipids, free 
cholesterol and protein that are secreted directly into the circulation by the liver and 
intestine (Musliner, Michelfender and Krauss 1988). The liver and intestine appear to 
share equally in this, the hepatic product being rich in apoA-I and apoE, whereas the 
nascent intestinal HDL contains only apoA-I (Wu and Windmueller 1979). Other 
sources of HDL precursors include the surface remnants of triglyceride rich 
lipoproteins undergoing lipolysis and apolipoprotein/phospholipid/free cholesterol 
complexes that form spontaneously in the circulation following the loss of individual 
surface components from other lipoproteins and from cell membranes (Patsch and 
Gotto 1987). The transformation of the discoidal particles deficient in neutral lipid is 
mediated by the enzyme lecithinrcholesterol acyl transferase (LCAT) which esterifies
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free cholesterol present on the surface of HDL. These esters, because of their 
hydrophobicity, move into the core of the particle thus creating a concentration 
gradient down which more free cholesterol can move into HDL from cell membranes 
and other lipoproteins so that the particle expands and evolves into mature H DL 3 .
Transfer of cholesteryl esters from HDL to the lower density lipoproteins in 
exchange for triglyceride, which is mediated by the cholesteryl ester transfer protein 
(CETP), then helps maintain this gradient and provides a route by which cholesterol 
o f peripheral origin can be returned to the liver (via the LDL receptor) for excretion 
or redistribution. Because of the larger molecular volume of triglyceride, this 
exchange process results in a further increase in particle size and decline in density so 
that the particles enter the HDL 2  spectrum. These lipoproteins are then susceptible to 
hydrolysis by HL which reduces the core volume and returns them to the HDL 3  range 
(Patsch, Prasad, Gotto and Bengtsson-Olivecrona 1984). Thus the circulating HDL 
are subject to extensive remodelling with the enzymes LCAT, CETP, HL and LPL all 
working together to coordinate the redistribution of HDL components (Newnham and 
Barter 1990) with the balance of this cycle shifted towards larger HDL in the post­
prandial period and back towards smaller HDL during fasting (Tall 1990).
The exact fate of HDL has been harder to follow than that of the apoB- 
containing particles as all the lipid and protein components enter and leave 
independently and, in contrast, to the other lipoproteins, HDL has a significant 
extravascular distribution (Shepherd and Packard 1984). However, the majority of 
HDL appears to be cleared by the liver, with the adrenals and ovaries also showing 
strong uptake activity (Stein, Dabach, Hollander, Halperin and Stein 1983). The 
mechanism of this uptake is unclear. The presence of apoE on a small minority of 
HDL particles will direct them to the LDL receptors for direct hepatic clearance 
(W illingham 1989). Since the discovery of the LDL receptor, the search has been on 
for a similar mechanism to explain HDL uptake, and two candidate proteins have 
recently been described that bind both apoA-I and apoA-II (Tozuka and Fidge 1989).
2.6. Miscellaneous Lipoproteins
Lipoprotein (a) (Lp(a)) is a LDL particle with an additional surface apolipoprotein 
(apo(a)) linked to its apoB molecule by a disulphide bond (reviewed by MBewu and 
Durrington 1990). These particles are distinct from LDL on the basis of a different 
electrophoretic mobility (pre-B), larger size and higher hydrated density (Table 3). 
Interest in this unusual lipoprotein stems from its association at high concentrations 
with both the incidence of myocardial infarction (Rhoads, Dahlen, Berg, Morton and 
Dannenberg 1986) and severity of CAD (Dahlen, Guyton, Attar, Farmer, Kautz and 
Gotto 1986). The plasma concentrations of Lp(a) are not distributed normally in the
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population, but are skewed in a positive direction with the majority of the population 
clustering at the lower end of the concentration range. This appears to result from 
genetic polymorphism at the apo(a) locus causing variable expression of several 
isoforms of the protein that differ in the number of pretzel-like domains called 
kringles (Utermann 1989).
Little is known of the origins, function and fate of Lp(a). The cDNA and 
protein sequences of apo(a) show a high degree of homology with those of 
plasminogen (McLean, Tomlinson, Kuang, Eaton, Chen, Fless, Scanu and Lawn 
1987) and the genes that code for both proteins are close together on the long arm of 
chromosome 6  (Utermann 1989). The major site of apo(a) synthesis appears the liver 
as demonstrated by the high quantities of mRNA in HepG2 cells (McLean et al. 1987) 
and the change in Lp(a) phenotype that is seen in patients after liver transplantation 
(Kraft, Menzel, Hopplicher, Vogel and Utermann 1989). However, Lp(a) does not 
have a VLDL precursor and it is unclear whether the particles are secreted ready 
assembled by the liver or LDL and apo(a) combine in the circulation. The site of 
Lp(a) clearance is also unknown. While Lp(a) concentrations are elevated in familial 
hypercholesterolaemia, suggesting a role for the LDL receptor (Utermann, 
Hoppichler, Dieplinger, Seed, Thompson and Boerwinkle 1989), stimulation of 
receptor activity in heterozygotes for this condition fails to reduce Lp(a) 
concentrations (Kostner, Gavish, Leopold, Bolzano, Weintraub and Breslow 1989).
Diameter Density % Particle Mass
Lipoprotein nm g/ml CE TG FC PL Prot(
Lp(a) 25 <1.090 36 3 9 34 18
Lp-X 35 1.019-1.063 5 3 25 61 6
6 -VLDL 30 <1.006 25 35 6 24 1 2
H DL! 15 <1.125 2 0 1 1 0 34 35
Table 3. Average composition of the unusual human lipoproteins (CE, cholesteryl 
esters; TG, triglyceride; FC, free cholesterol; PL, phospholipid).
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The mechanisms by which Lp(a) causes and aggravates atherosclerosis are 
speculative. Because of its homology with plasminogen, it has been suggested that 
apo(a) competes for the plasminogen binding sites present on endothelial cells 
reducing the formation of thrombolytic factors and setting up a precoagulant state that 
increases the risk of myocardial infarction (Scott 1989). Lp(a) also binds to fibrin, and 
while this may represent a route by which cholesterol is delivered to recently injured 
tissues to aid repair, it may also contribute to the cholesterol load of a compromised 
atherosclerotic artery (Brown and Goldstein 1987).
Lipoprotein X (LpX) is found in the plasma of patients with extra- or 
intrahepatic cholestasis (Seidel, Buff, Fauser and Bleyl 1976). These particles float in 
the LDL density range, but are composed almost entirely of phospholipids and free 
cholesterol and are devoid of apoB, having albumin, apoA-I, apoC and apoE as their 
proteins (Table 3). These lipoproteins are believed to originate from the regurgitation 
of bile salts in to the circulation, although somewhat similar particles are also found 
in patients with familial LCAT deficiency due to disturbed cholesterol esterification 
(Riesen and Kloer 1989).
In patients homozygous for the defective isoform of apoE (E2), the removal of 
chylomicron and VLDL remnants is impaired causing these cholesteryl ester enriched 
intermediates to accumulate in the circulation. These particles reside in the VLDL 
density range but migrate in the B-position on electrophoresis and are hence called B- 
VLDL (Table 3). Similar lipoproteins are found in dogs when fed high fat/high 
cholesterol diets and are avidly taken up by macrophages in a receptor mediated 
process that leads to cholesteryl ester deposition (Goldstein, Ho, Brown, Innerarity 
and Mahley 1980)
Feeding cholesterol to a number of species, including man, pigs and dogs, 
results in the appearance in plasma of large HDL particles that are enriched in 
cholesteryl esters and apoE and referred to as apoE rich HDL, alternatively HDLC 
or HDLj (Mahley and Innerarity 1983). These lipoproteins are present in small 
amounts in plasma from normolipidaemic humans (Weisgraber and Mahley 1978). 
The enrichment of this fraction with apoE appears functionally beneficial in directing 
the particles to the liver for the reverse transport of cholesterol (Koo, Innerarity and 
Mahley 1985).
3. THE APOLIPOPROTEINS
It is clear from the preceding discussion that the apolipoproteins serve a number of 
functions vital to the transport of lipids, the foremost of which is their ability to bind 
and emulsify aqueous insoluble lipids into lipoprotein packages. For this they are well
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adapted as much of their secondary structure consists of repeating amphipathic helical 
regions of 2 2  amino acids, in which the charged residues are localised to the polar 
surface of the helix extending into the aqueous phase and thereby contributing to the 
solubility by hydrogen bonding with water molecules (Edelstein, Kezdy, Scanu and 
Shen 1979). The opposite face of these regions contains mostly hydrophobic amino 
acids that are intimate with the fatty acyl chains of the surface phospholipids and to a 
lesser extent with the neutral lipids in the particle core. The apolipoproteins have 
subsequently evolved, by acting as enzyme cofactors (apoA-I, apoC-II) and receptor 
ligands (apoB, apoE), central roles in the direction and regulation of lipoprotein 
metabolism.
3.1. Apolipoprotein B
Two distinct species of apoB are found in human plasma (Kane, Hardman and Paulus
1980). The first, apoB-100, is one of the largest monomeric proteins known (4,563 
amino acids, approximately 549k Da), it is the structural protein of VLDL, IDL and 
LDL, and is synthesised in the liver and to a small extent in the small intestine. The 
second, designated apoB-48 on the basis that its apparent molecular weight (264k Da) 
is 48% of that of apo-100, is synthesised only in the small intestine where it is central 
to the production of chylomicrons.
It was initially thought that the two proteins were the product of separate 
genes or that apoB-48 arose from posttranslational cleavage of apoB-100. However, it 
has been shown that both the cDNA and protein sequences of apoB-48 (2,152 amino 
acids) are colinear with the amino-terminal half of apoB-100 and that the two proteins 
are the product of a single gene (Chen, Habib, Yang, Gu, Lee, Weng, Silberman, Cai, 
Deslypere, Rosseneu, Gotto, Li and Chan 1987). It is now clear that apoB-48 is 
synthesised following editing of the apoB message so that a stop translation codon 
(UAA) is found at position 2153 rather than the codon (CAA) that codes for 
glutamine in apoB-100 (Scott, Wallis, Davies, Wynne, Powell and Driscoll 1989). 
This organ specific editing appears to be catalysed by an enzyme that converts 
cytosine to uracil at a single position in the mRNA molecule (Brown and Goldstein
1987). Both proteins are synthesised in the liver of the rat (Wu and Windmueller
1981) and this has helped provide evidence that the editing mechanism is subject to 
metabolic (Coleman, Haynes, Sand and Davis 1988; Davidson, Carlos, Sherman and 
Hay 1990) and developmental (Jiao, Moberly and Schonfeld 1990) regulation.
The human apoB gene resides on the short arm of chromosome 2 and spans 43 
kb. The structure of its product, apoB-100, has largely been deduced from amino acid 
sequence analysis which predicts frequent alternation of hydrophilic and hydrophobic 
sequences (Rosseneu and Labeur 1990). Much of the secondary structure (33%) of
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apoB is in the form of 13-sheet (Goormaghtigh, De Meutter, Vanloo, Brasseur, 
Rosseneu and Ruysschaert 1989) which would explain the relative insolubility of 
delipidated apoB compared with the other apolipoproteins where the alpha helix 
predominates. This also suggests that apoB interacts more intimately with the 
hydrophobic core of the lipoprotein than the other proteins (Yang, Kim, Weng, Lee, 
Yang and Gotto 1990). Using the HepG2 cell culture system, it has become apparent 
that apoB secretion is increased by cholesterol and fatty acids and reduced by insulin 
due to changes at a co- or posttranslational, rather than a transcriptional, level 
(reviewed by Scott 1990). Apolipoprotein B-100 is subject to posttranslational 
modification including glycosylation (Yang, Gu, Weng, Kim, Chen, Pownall, Sharp, 
Liu, Li, Gotto and Chan 1989), acylation (Hoeg, Meng, Ronan, Demosky, Fairwell 
and Brewer 1988) and phosphorylation (Sparks, Sparks, Roncone and Amatruda
1988), the latter two of which may be involved in lipid binding and intracellular 
transport during lipoprotein assembly.
The precise location on the molecule of the receptor binding domain remains 
unclear, but it is in the region of residues 3330-3800 that is rich in basic amino acids 
(Milne, Theolis, Maurice, Pease, Weech, Rossart, Fruchart, Scott and Marcel 1989). 
This region is missing from apoB-48, explaining why the smaller protein does not 
interact with the LDL receptor. Recently, a condition named familial defective apoB- 
100 (FDB) has been described in which a point mutation at amino acid 3500 abolishes 
the receptor binding of LDL (by approximately 70%in in heterozygotes) and produces 
a hyperlipidaemia identical to familial hypercholesterolaemia (Innerarity, Mahley, 
Weisgraber, Bersot, Krauss, Vega, Grundy, Friedl, Davignon and McCarthy 1990).
3.2. Apolipoprotein E
Apolipoprotein E is the most cosmopolitan of the apolipoproteins exchanging freely 
between the lower density lipoproteins and HDL. The human apoE gene is located on 
chromosome 19 where it is closely linked to the genes for apoC-I and apoC-II and 
more distantly to the gene for the LDL receptor (Lusis, Heinzmann, Sparkes, Scott, 
Knott, Geller, Sparkes and Mohandas 1986). Messenger RNA is found in human liver 
cells and monocyte macrophages and translates a mature peptide of 299 amino acids 
(molecular weight 34.2k Da) after co-translational cleavage of an 18 amino acid 
signal peptide (Zannis, McPherson, Goldberger, Karathanasis and Breslow 1984). The 
protein forms a four-helix bundle with the LDL receptor binding domain at the NH 2 - 
terminal of helix four, which is unusually rich in basic residues. The binding of apoE 
to the surface of lipoproteins is mediated by the COOH-terminal region (Wilson, 
W arded, Weisgraber, Mahley and Agard 1991).
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In man, three major isoforms of apoE, which are the products of genetic 
polymorphism at the apoE locus, are identifiable by isoelectric focusing (Menzel and 
Utermann 1986). These isoforms differ by amino acid substitution at one or both of 
two sites (residues 112 and 158) and are coded for by distinct alleles; E4 has arginine, 
and E2 cysteine at both sites, whereas E3 has cysteine at 112 and arginine at 158. 
These determine six genotypes that have a significant impact on lipid and lipoprotein 
concentrations, the most striking of which is the hyperlipoproteinaemia associated 
with the E2/2 phenotype where the remnants of triglyceride rich lipoproteins 
accumulate because apoE2 is an ineffective ligand for receptor binding (Davignon, 
Gregg and Sing 1988). Further evidence of the essential role that apoE plays in the 
catabolism of these remnants is found in patients with familial apoE deficiency 
(Schaefer, Gregg, Ghiselli, Forte, Ordovas, Zech and Brewer 1986).
3.3. Apolipoprotein A
Apolipoprotein A-I is the major protein of HDL and is found in small quantities on 
chylomicrons and VLDL. Mature apoA-I (molecular weight 28k Da) is the prototypic 
amphipathic apolipoprotein and is the activator of LCAT. Human apoA-I is 
synthesised in the liver and intestine as a 267 amino acid preproprotein, which 
undergoes co-translational cleavage to produce a proprotein of 249 residues that is 
converted to mature apoA-I in lymph and plasma by the loss of a hexapeptide 
(Bojanovski, Gregg, Ghiselli, Schaefer, Light and Brewer 1985). A number of genetic 
variants of apoA-I, resulting from single amino acid substitutions, have been 
identified in man, some of which may influence plasma apoA-I and HDL 
concentrations and the activity of LCAT (Ordovas 1990).
The human apoA-I gene is located on the long arm of chromosome 11, 
alongside the gene for apoA-IV, with the gene for apoC-III on the opposite strand of 
that chromosome. These three genes, and those that code for apoA-II, apoC-II and 
apoE, all share a similar structural organisation with four exons and three introns 
suggesting that they have evolved from a common ancestor through partial or 
complete gene duplications (Breslow 1987).
Apolipoprotein A-II is a minor component of HDL. It is synthesised 
primarily in the liver (Eggerman, Hoeg, Meng, Tombragel, Bojanovski and Brewer 
1991) and exists in the circulation as a dimer made up of two identical 77 residue 
polypeptide chains (each 8.5k Da) linked by a disulphide bond between the cysteines 
at residue 6  (Brewer, Lux, Ronan and John 1972). The metabolic functions of apoA-II 
are unclear; there is in vitro evidence that it can modulate the activity of LCAT 
(Nishida, Nakanishi, Yen, Arai, Yen and Nishida 1986), and that it may play a role in 
the activation of HL (Jahn, Osbourne, Schaefer and Brewer 1983).
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Apolipoprotein A-IV is a component of newly secreted chylomicrons and in 
the circulation is found only in small amounts in HDL with the majority (>80%) 
present in the lipoprotein free fraction following ultracentrifugation (Bisgaier, 
Sachdev, Megna and Glickman 1985). The function of this protein is also unclear, 
although it is a potent activator of LCAT in vitro (Steinmetz and Utermann 1985) and 
may be required for the efficient transfer of apoC-II from HDL to triglyceride rich 
lipoproteins in preparation for hydrolysis (Goldberg, Scheraldi, Yacoub, Saxena and 
Bisgaier 1990). The plasma concentrations of apoA-IV increase after fat feeding 
(Bisgaier et al. 1985) prompting speculation that the protein is involved in 
chylomicron production, recently corroborated by the mild fat malabsorption seen in a 
kindred deficient in apoA-IV (Ordovas, Cassidy, Civeira, Bisgaier and Schaefer 
1989).
The human apoA-IV gene is located with those for apoA-I and apoC-III on 
chromosome 11; its mRNA is most abundant in the small intestine with less than 2% 
of the total message being of hepatic origin (Elshourbagy, Walker, Boguski, Gordon 
and Taylor 1986). Polymorphism of human apoA-IV has been described, but has 
apparently little effect on plasma lipoprotein metabolism (de Kniff, Rosseneu, 
Beisiegel, de Keersgieter, Frants and Havekes 1988). Proteins with the features of 
apoA-IV are detectable in the rat, where there is significant hepatic synthesis, 
(Swaney, Reese and Eder 1977) and the dog (Weisgraber, Bersot and Mahley 1978).
3.4. Apolipoprotein C
Apolipoproteins C-I, C-II and C-III are to varying extents present on chylomicrons, 
VLDL and HDL, and are synthesised predominantly in the liver with a minor 
contribution from the small intestine. Although they are collectively referred to as 
apoC, they are products of separate genes and have metabolically diverse functions.
There is evidence that there are two copies of the apoC-I gene, both located 
on chromosome 19; the first is adjacent to the apoE gene and the second is 3' to this 
apoE/apoC-I gene complex (Li, Tanimura, Luo, Datta and Chan 1988). Whether both 
genes are transcriptionally active is at present unclear as only a single protein of 6.5k 
Da is found in plasma (Breslow 1987). The metabolic function of apoC-I has not been 
defined, although it is a weak activator of LCAT in vitro (Soutar, Gamer, Baker, 
Sparrow, Jackson, Gotto and Smith 1975).
In contrast, the essential role that apoC-II plays in the activation of LPL is 
well established and shown most strikingly by the severe hypertriglyceridaemia that is 
found in patients with familial apoC-II deficiency. The apoC-II gene is located 
between the genes for apoE and apoC-I on chromosome 19 and codes for a mature 
protein of 79 amino acids (9k Da) (Fojo, Taam, Fairwell, Ronan, Bishop, Meng,
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Hoeg, Sprecher and Brewer 1986). The LPL activation site is in residues 77-79 and 
residues 44-55 possess the ability to bind to phospholipids (Breslow 1987).
Apolipoprotein C-III is the most abundant of the C proteins; it is a 
glycoprotein that contains none, one or two molecules of sialic acid so that three 
isomers identifiable by isoelectric focusing (Breslow 1987). ApoC-III has been shown 
to inhibit the activity of LPL in a non-competitive fashion both in vitro (Brown and 
Baginsky 1972) and in vivo (Wang, McConathy, Kloer and Alaupovic 1985) and may 
also conceal the apoE on triglyceride lipoproteins from cell surface receptors so that 
lipolysis is completed prior to remnant removal. The apoC-III gene is located between 
those for apoA-I and apoA-IV on chromosome 11 and codes for a mature protein of 
79 amino acids (9k Da) (Sharpe, Sidoli, Shelly, Lucemo, Shoulders and Baralle 
1984). Genetic variation within this gene complex has recently been associated with 
hyperlipidaemia (Shoulders, Ball and Baralle 1989).
4. THE ENZYMES OF LIPOPROTEIN METABOLISM
4.1. Lipoprotein Lipase
Lipoprotein lipase plays a key role in the metabolism of triglyceride rich lipoproteins 
of endogenous and exogenous origin and therefore in the generation of chylomicron 
and VLDL remnants and IDL. The human enzyme is coded for by a 30 kb gene 
containing 10 exons (Deeb and Peng 1989), that has been mapped to the p22 region of 
chromosome 8  (Sparkes, Zollman, Klisak, Kirchgessner, Komaromy, Mohandas, 
Schotz and Lusis 1987), and which predicts a 448 amino acid protein of molecular 
weight 50,314 Da (Wion, Kirchgessner, Lusis, Schotz and Lawn 1987). Comparison 
of the LPL cDNA sequences from man (Wion et al. 1987), the mouse (Kirchgessner, 
Svenson, Lusis and Schotz 1987), cattle (Senda, Oka, Brown, Quasba and Furichi 
1987) and the guinea pig (Enerback, Semb, Bengtsson-Olivecrona, Carlsson, 
Hermansson, Olivecrona and Bjursell 1987) reveals that the enzyme is extraordinarily 
conserved amongst species. Further, it is apparent that LPL is a member of a family of 
proteins that includes hepatic lipase and pancreatic lipase, which are believed to 
originate from a single ancestral gene (Kirchgessner, Chuant, Heinzmann, Etienne, 
Guilhot, Ameis, Pilon, D'Auriol, Anadalibi, Schotz, Galibert and Lusis 1989).
While LPL mRNA can be identified in a number of body tissues, including 
adipose, skeletal and cardiac muscle, lactating mammary gland, brain, adrenal, lung, 
ovary and kidney (Goldberg, Soprano, Wyatt, Vanni, Kirchgessner and Schotz 1989), 
it is in the heart and adipose tissue that the signal is strongest and the enzyme activity 
metabolically most significant (Semenkovich, Chen, Wims, Luo, Li and Chan 1989). 
Following synthesis and glycosylation in the endoplasmic reticulum, the protein is
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transported to the Golgi apparatus where the N-linked oligosaccharide chains are 
processed allowing the enzyme to fold, adopt a dimeric conformation and acquire 
hydrolytic activity (Vannier and Ailhaud 1989). Only approximately 30% of newly 
synthesised LPL is released, the remainder being degraded in an intracellular 
com partment that might represent a reservoir of secretory capacity (Vannier, Amri, 
Etienne, Negrel and Ailhaud 1985). The mature enzyme attaches to the vascular 
endothelium via the glycan chains of heparan sulphate proteoglycans and high affinity 
binding sites on the luminal surface of these cells direct the enzyme to its site of 
functional activity (Blanchette-Mackie, Masuno, Dwyer, Olivecrona and Scow 1989). 
This association is not permanent and the enzyme appears to move along the vascular 
tree eventually reaching tissues remote from those of LPL synthesis, including the 
liver where the enzyme is taken up and degraded (Olivecrona and Bengtsson- 
O livecrona 1987).
In addition to the heparin binding domain, the enzyme has a site that anchors 
the substrate particle (lipid interface recognition site), a site for its cofactor apoC-II 
and a catalytic site that hydrolyses tri- and monoglycerides (Brunzell 1989). There is 
evidence that LPL possesses phospholipase activity in vitro (Scow and Egelrud 1986) 
and that the enzyme might be important in the transfer of vitamin E from 
chylomicrons to peripheral tissues (Traber, Olivecrona and Kayden 1985). The 
mechanism by which apoC-II activates LPL is unclear; the protein is not required for 
substrate binding but may serve as a recognition signal for the lipase (Olivecrona and 
Bengtsson-Olivecrona 1987). Enzyme activity is also modulated by apoC-III, which 
appears to inhibit apoC-II activation in a non-competitive fashion (Wang et al. 1985), 
and by apoA-IV which may play a role in releasing apoC-II from HDL for the 
hydrolysis of nascent particles (Goldberg et al. 1990). Recent evidence suggests that 
apoE may inhibit the activity of LPL and direct remnants of triglyceride rich 
lipoproteins for removal (McConathy and Wang 1989).
The regulation of LPL activity in vivo appears complex. Feeding and fasting 
have profound and opposite effects; adipose LPL activity increases post-prandially 
and returns to normal on fasting, while muscle LPL decreases on feeding and 
increases during fasting (Olivecrona and Bengtsson-Olivecrona 1990). This 
coordinate response seems a rational mechanism by which lipids of dietary origin can 
be stored in plenty without deleterious effects on skeletal and cardiac function, and 
are then redistributed to these organs when required during times of fasting. This 
appears to be controlled posttranslationally as adipose and cardiac LPL mRNA levels 
and rates of LPL synthesis do not correlate with changes in LPL activity on fasting 
(Doolittle, Ben-Zeev, Elovson, Martin and Kirchgessner 1990). Rather, these authors 
suggest that LPL activity is modified by diverting newly synthesised enzyme towards
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or away from the intracellular degradation compartment to alter the amount of 
enzyme secreted. The major signal responsible for this regulation appears to come 
from insulin, although glucagon, glucocorticoids, thyroxine and the catecholamines 
may also play roles (Kissebah and Schectman 1987). Elevated insulin levels in 
obesity and hyperinsulinaemia are associated with increased adipose LPL activity 
(Pykalisto, Smith and Brunzell 1975) and insulin has been shown to increase human 
adipose LPL activity (Sadur and Eckel 1982) by increasing both the synthesis (Ong, 
Kirchgessner, Schotz and Kern 1988) and secretion (Chan, Lisanti, Rodriguez-Boulan 
and Saltiel 1988) of LPL from adipocytes. In contrast, insulin seems to decrease LPL 
activity in skeletal muscle (Kiens, Lithel, Mikines and Richter 1989).
Tumour necrosis factor is a powerful inhibitor of adipose LPL synthesis and 
activity in vitro (Fried and Zechner 1989) and may play an important role in the 
genesis of the hypertriglyceridaemia that accompanies infection and malignancy. 
Mammary gland LPL activity increases greatly at the onset of lactation in humans 
(Neville, Waxman, Jensen and Eckel 1991) and the cow (Iverius and Ostlund-Linqvist 
1976). This is largely accomplished by prolactin stimulation of mammary tissue and 
is accompanied by a decrease in adipose LPL activity that serves to channel plasma 
triglycerides for milk production (Scow and Chernick 1987). Recently, additional 
roles have been ascribed for LPL in the provision of fatty acids to neurones (Ben- 
Zeev, Doolittle, Singh, Chang and Schotz 1990) and in generating fatty acids to 
participate in lung alveolar defences (Coonrod, Karathanasis and Lin 1989).
4.2. Hepatic Lipase
Hepatic lipase, also known as the salt resistant lipase or hepatic triglyceride lipase, is 
an endothelial bound glycoprotein that shares with LPL the ability to bind to lipid 
surfaces, a common catalytic site that hydrolyses tri- and monoglycerides, and a 
heparin binding site. In contrast to LPL, HL does not require a serum cofactor and has 
significant phospholipase activity (Ehnholm, Shaw, Greten and Brown 1975). The 
functional significance of HL has only become clear within the last decade as 
lipoprotein metabolism has been studied in animals following blockade of the enzyme 
(Grossner, Schreckner and Greten 1981; Goldberg, Le, Paterniti, Ginsberg, Lindgren 
and Brown 1982) and in human patients with a familial deficiency of the enzyme. The 
enzyme is essential for the final stages of VLDL and IDL catabolism and the 
conversion of IDL to LDL, for the interconversion of HDL subfractions (HDL2  to 
HDL 3 ) and for the remodelling of large, buoyant LDL to smaller and denser particles. 
In addition, there is recent evidence to suggest a role in the uptake of chylomicron 
remnants both in vitro (Sultan, Lagrange, Le Liepvre, and Griglio 1989) and in vivo 
(Sultan et al. 1990).
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The human HL gene has been mapped to the q21 region of chromosome 15 
(Sparkes et al. 1987); it is 35 kb in length and translates a 477 amino acid protein of 
53k Da (Cal, Wong, Chen and Chan 1989). Evidence from the rat indicates that 
although HL activity is found in hepatic, adrenal and ovarian tissue (Doolittle, Wong, 
Davis and Schotz 1987), HL synthesis is confined to the liver (Semenkovic et al.
1989) and that the enzyme in extrahepatic tissues results from transport along the 
vascular bed and the presence of specialised binding sites in these tissues. In common 
with LPL, oligosaccharide processing is essential for the secretion of active HL 
(Verhoeven and Jansen 1990) and the native enzyme appears to exist as a complex of 
four subunits (Twu, Garfinkel and Schotz 1984).
In contrast to LPL, little is known of the regulation of HL activity. There is 
evidence that apoC-III may inhibit triglyceride but not monoglyceride or phospholipid 
hydrolysis in vitro (Twu et al. 1984) and that the recognition of surface lipid by the 
enzyme is sensitive to the apolipoprotein configuration of the substrate particle 
(Taskinen and Kuusi 1987). The modulation of HL by sex hormones is well 
established. Oestrogen supplementation decreases HL activity in post-menopausal 
women (Applebaum-Bowden, McLean, Steinmetz, Fontana, Matthys, Warnick, 
Cheung, Albers and Hazzard 1989) and hepatic mRNA levels rise in ovarectomized 
rats and decrease when oestrogens are supplemented (Staels, Jansen, van Tol, 
Stahnke, Will, Verhoeven and Auwerx 1990). Conversely, androgen derived 
progestins appear to increase HL activity (Tikkanen, Nikkila, Kuusi and Sipinen 
1982).
4.3. Lecithin:Cholesterol Acyl Transferase
When plasma is incubated at 37°C, a net esterification of cholesterol occurs as fatty 
acids are transferred from the 2 -position of lecithin (phosphatidylcholine) to the 3- 
hydroxy group of cholesterol forming cholesteryl esters and lysolecithin (Glomset 
1968). This reaction is catalysed by lecithinxholesterol acyl transferase (LCAT) and 
is the major source of cholesteryl esters in human plasma (Barter, Hopkins and 
Rajaram 1987). Following synthesis in the liver (McLean, Wion, Drayna, Fielding 
and Lawn 1986), LCAT is released into the circulation where it complexes with the 
lipids present on the surface of HDL and thus becomes intimate with its substrates 
and obligate cofactor apoA-I. The conversion of free cholesterol to cholesteryl esters 
is central to the maturation of HDL from their precursors, and is essential for 
maintaining the concentration gradient down which excess free cholesterol can move 
from tissue membranes into the plasma compartment in the first step of reverse 
cholesterol transport (Reichl and Miller 1989). Under experimental conditions, up to 
50% of the cholesteryl esters synthesised by LCAT are derived from cholesterol of
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cell membrane origin (Fielding, Davison, Karasek and Fielding 1982), the remainder 
coming from free cholesterol secreted in nascent HDL particles and from the transfer 
o f surface remnants from lower density lipoproteins (Francone, Fielding and Fielding
1990).
The physiological significance of LCAT activity is confirmed by studies of 
cholesterol metabolism in patients with the rare condition of familial LCAT 
deficiency. Here, plasma cholesterol esterification is minimal, the lipoproteins are 
almost entirely devoid of cholesteryl esters (Glomset, Norum and King 1970), and the 
HDL particles remain small and discoidal in shape resembling nascent HDL of 
hepatic and intestinal origin (Chen, Applegate, King, Glomset, Norum and Gjone 
1984). The patient's inability to generate a concentration gradient results in the 
accumulation of free cholesterol in cell membranes (Hovig and Gjone 1974) which is 
manifested by diffuse comeal opacities, increased red blood cell fragility leading to a 
normochromic anaemia, and proteinuria with late renal insufficiency (Gjone 1974).
The presence of LCAT activity in equine serum is well documented, first by 
Yamamoto, Tunaka and Sugano (1979a), who showed that the enzyme exhibited 
some specificity to form the linoleate ester in the cholesterol ester product, and in 
common with human LCAT was completely blocked by DTNB. Although the 
enzyme was active in all lipoprotein fractions isolated by precipitation or 
ultracentrifugation, HDL appeared the preferred substrate accounting for 53-80% of 
the decrease in free cholesterol (Yamamoto, Tunaka and Sugano 1979b). This, 
together with the significant activity that they found in the density >1.225 g/ml 
fraction, suggested that the equine enzyme is also associated with HDL particles and 
dissociates from this complex during ultracentrifugation. This group recently purified 
the enzyme free of apolipoproteins, it had an apparent molecular weight on 
polyacrylamide gel electrophoresis of 64k Da and was resistant to reduction by 2- 
mercaptoethanol suggesting that it was constructed of a single polypeptide chain 
(Yamamoto, Yamamoto, Tunaka and Sugano 1987). Chen and Albers (1983) found 
that LCAT in equine plasma was activated by apoA-I isolated from man, horses, 
sheep, goats and rabbits, and that equine apoA-I was an effective activator of LCAT 
in plasma from these species.
4.4. The Plasma Lipid Transfer Proteins
In man and some animal species, the exchange and net transfer of lipids between 
lipoprotein particles is facilitated by two specialist lipid transfer proteins (LTP) (Tall 
1986). The first of these, the cholesteryl ester transfer protein (CETP) also known as 
LTP-I, promotes the redistribution of cholesteryl esters from HDL to the lower 
density lipoproteins (VLDL and LDL) in exchange for triglycerides (Chajek and
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Fielding 1978). This 74k Da protein (Jarnagin, Kohr and Fielding 1987) is 
synthesised by the liver, small intestine, adrenals and spleen in man (Drayna, 
Jarnagin, McLean, Henzel, Kohr, and Fielding 1987) and chiefly in the liver in the 
rabbit (Nagashima, McLean and Lawn 1988). In common with LCAT, CETP appears 
to be complexed to HDL by electrostatic attractions that are be separated by 
ultracentrifugation at density >1.215 g/ml (Marcel, McPherson, Hogue, Czarnecka, 
Zawadzki, Weech, Whitlock, Tall and Milne 1990). Evidence suggests that CETP 
acts as a carrier between lipoproteins with single binding sites for cholesteryl ester, 
triglyceride and phosphatidylcholine (Swenson, Brocia and Tall 1988) and that the 
kinetics of transfer are favoured by the formation of a ternary collision complex 
comprising CETP and the donor and acceptor particles (Ihm, Quinn, Busch, Chataing 
and Harmony 1982). While CETP has some capacity to exchange phospholipids in 
vitro (Tall, Abreu and Shuman 1983), the majority of human phospholipid transfer is 
m ediated by a second protein (LTP-II) that has no cholesteryl ester or triglyceride 
transfer capacity, but which may enhance cholesteryl ester transfer mediated by LTP-I 
(Tollefson, Ravnik and Albers 1988).
The transfer of LCAT derived cholesteryl esters to the apoB containing 
lipoproteins provides a route by which cholesterol of peripheral origin may be 
returned to the liver in the second step of reverse cholesterol transport. To help this, 
there is evidence that CETP may directly influence cholesteryl ester efflux from 
peripheral cells into the vascular compartment (Morton 1988). As the LDL receptor is 
not confined to the liver, the benefits of this process must be reappraised in the light 
of the atherogenic potential of cholesteryl ester rich lower density lipoproteins 
(Griffin et al. 1990). Because CETP plays a prominent role in the remodelling of 
lipoproteins in the vascular compartment, particularly in the interconversion between 
HDL subclasses (Lagrost, Gambert, Dangremont, Athias and Lallemant 1990) and the 
genesis o f LDL heterogeneity (Gambert, Bouzerand-Gambert, Athias, Farmer and 
Lallemant 1990), the activity of this protein may directly influence the atherogenicity 
o f an individual's lipoprotein phenotype and their risk of CAD.
The physiological impact of CETP has only been recently confirmed by 
studies of lipoprotein metabolism in humans with an inherited deficiency of the 
protein (Brown, Inazu, Hesler, Agellon, Mann, Whitlock, Marcel, Milne, Koizumi, 
Mabuchi, Takeda and Tall 1989). These patients have markedly increased HDL 
concentrations, enlarged HDL particles that are enriched with cholesteryl esters and 
depleted of triglyceride, and a reduced cholesteryl ester content of VLDL and LDL 
(Koizumi, Mabuchi, Yoshimura, Michishita, Takeda, Itoh, Sakai, Sakai, Ueda and 
Takeda 1985). These findings are supported by examination of animal species with 
little or no CETP activity (Ha and Barter 1982), by studies in which antibodies have
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been used to inhibit rabbit transfer protein activity in vivo (Whitlock, Swenson, 
Ramakrishnan, Leonard, Marcel, Milne and Tall 1989; Abbey and Calvert 1989), and 
where CETP has been injected into a deficient species (Ha, Chang and Barter 1985; 
Groener, van Gent and van Tol 1989). These all show that in the absence of CETP, 
HDL particles expand and become enriched in cholesteryl esters (through the agency 
of LCAT) and apoE so that they resemble H DLj. When CETP is added or its 
blockade removed, these particles are lost as the HDL fraction is depleted of 
cholesteryl esters and enriched in triglyceride, and the cholesteryl ester content of the 
lower density lipoproteins increases.
The species distribution of CETP has been well documented by Ha and Barter 
(1982) who divided animals into groups of high (possum, rabbit and trout), 
intermediate (man, wallaby guinea pig, chicken, turkey, toad, lizard and snake) and 
low (cow, sheep, pig, dog and rat) activity. More recent studies have shown that low 
CETP activity might be the result of an inhibitor to transfer activity which is 
expressed variably amongst species, as transfer activity in plasma from rats and pigs 
has been unmasked by separation from the inhibitor on phenyl sepharose (Tollefson, 
Liu and Albers 1988). An inhibitor to CETP has been isolated from human plasma 
(Son and Zilversmit 1984) and recently characterised (Nishide, Tollefson and Albers
1989).
5. T H E  M ETA BO LIC BASIS OF H Y PER T R IG L Y C E R ID A EM IA
The prevalence of hyperlipidaemia in the human populations of developed countries 
led Fredrickson and colleagues (1967) to define five types of hyperlipoproteinaemia 
based on changes in the concentration and composition of the plasma lipoproteins. 
This phenotypic classification has, however, been made redundant by improvements 
in understanding the nature of the genetic, molecular and metabolic defects that 
disturb lipoprotein metabolism. The origins of increased plasma triglyceride 
concentrations in man are considered here as the model mechanisms on which 
investigations of the aetiology of equine hyperlipaemia were based.
Hypertriglyceridaemia represents the accumulation of triglyceride rich 
lipoproteins in the circulation and because both chylomicrons and VLDL are large 
particles, they scatter light when present in high concentrations and impart upon 
plasma the turbidity or lactescence that is recognised as lipaemia. In addition, the 
buoyancy of chylomicrons causes them to float to the top of plasma when left to stand 
at 4°C to form a creamy layer, the "creaming in the cold test" (Brunzell and Bierman
1982).
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5.1. Familial Deficiencies of Lipoprotein Lipase and Apolipoprotein C-II, 
Familial Inhibitor of Lipoprotein Lipase
Havel and Gordon (1960) first described an inherited deficiency of LPL as the cause 
of defective chylomicron clearance in three siblings with massive 
hypertriglyceridaemia. This is a rare condition, occurring in approximately one person 
in a million, which presents in childhood with recurrent pancreatitis accompanied by 
hepatosplenomegaly, eruptive xanthomatosis and lipaemia retinalis (Brunzell 1989). 
A presumptive diagnosis can be made on the basis of a marked reduction in 
triglycerides after a week on a severely fat restricted diet and confirmed by the 
measurement of negligible LPL activity in post-heparin plasma or adipose tissue 
biopsies.
This condition appears to be inherited in an autosomal recessive manner and a 
number of point mutations in the LPL gene have been described that lead to the 
synthesis of a truncated inactive protein (Emi, Hata, Robertson, Iverius, Hegele and 
Lalouel 1990), and defects in the lipid interface recognition site (Henderson, Ma, 
Hassan, Monsalve, Marais, Winkler, Gubernator, Peterson, Brunzell and Hayden
1991), the heparin binding site (Beg, Meng, Skarlatos, Previato, Brunzell, Brewer and 
Fojo 1990) and the catalytic site of the enzyme (Monsalve, Henderson, Roederer, 
Julien, Deeb, Kastelein, Peritz, Devlin, Bruin, Murthy, Cagne, Davignon, Lupien, 
Brunzell and Hayden 1990). A more extensive internal gene duplication (Devlin, 
Deeb, Brunzell, and Hayden 1990) and major rearrangement of the gene have been 
described (Langlois, Deeb, Brunzell, Kastelein and Hayden 1989). The treatment of 
familial LPL deficiency rests on reducing chylomicron synthesis by limiting dietary 
fat intake and providing medium chain triglycerides, which do not contribute to 
chylomicron formation, as energy supplements.
Although LPL deficiency was long held synonymous with Fredrickson's type I 
hyperlipoproteinaemia, two other genetic accidents have subsequently been recorded 
as causes of this lipid phenotype. In the first of these, LPL activity is normal in vitro 
but the patient's plasma is deficient in apoC-II and therefore unable to activate the 
enzyme in vivo (Breckenridge, Little, Steiner, Chow and Poapst 1978). Familial 
deficiency of apoC-II has now been recognised in 1 1  families world-wide and 
appears to be inherited in an autosomal recessive fashion (Brunzell 1989). This 
condition tends to be milder and later in onset than LPL deficiency and infusion of 
plasma from healthy donors, or biologically active apoC-II, corrects the 
hypertriglyceridaemia and may offer some therapeutic potential (Baggio, Manzato, 
Gabelli, Fellin, Martini, Enzi, Verlato, Baiocchi, Sprecher, Kashyap, Brewer and 
Crepaldi 1986). Recently an inactive variant of apoC-II has been described in a
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kindred with familial apoC-II deficiency (Sprecher, Taam, Gregg, Fojo, Wilson, 
Kashyap and Brewer 1988). More recently, type I hyperlipoproteinaemia was 
described in a mother and son who had an inhibitor of LPL in their plasma, which 
appeared to be inherited in an autosomal dominant fashion (Brunzell, Miller, 
Alaupovic, St. Hilaire, Wang, Sarson, Bloom and Lewis 1983).
5.2. Other Inherited Forms of Hypertriglyceridaemia
Familial hypertriglyceridaemia (endogenous hypertriglyceridaemia, type IV 
hyperlipoproteinaemia) is a heterogeneous disorder in which increased production of 
VLDL saturates the removal system and causes moderate hypertriglyceridaemia 
(Brunzell, Albers, Chait, Grundy, Groszek and McDonald 1983). Some patients also 
have an underlying defect in LPL activity, a subset of which may be heterozygotes for 
LPL deficiency (Babirak, Iverius, Fujimoto and Brunzell 1989; Wilson, Emi, Iverius, 
Hata, Wu, Hillas, Williams and Lalouel 1990). In these cases, reduced transfer of core 
and surface remnants would explain the low concentrations of LDL and HDL that 
accompany the hypertriglyceridaemia (Packard, Shepherd, Joems, Gotto and Taunton 
1980)
Familial combined hyperlipidaemia defines a condition characterised by 
moderate elevations of plasma cholesterol and/or triglyceride and the presence of 
hyperlipidaemia in one or more family members (Brunzell et al. 1983; Austin, 
Brunzell, Fitch and Krauss 1990). Kinetic studies of apoB show that VLDL is 
overproduced and that increased mass transfer to LDL accounts for the elevated 
plasma and LDL cholesterol concentrations (Chait, Foster, Albers, Failor and 
Brunzell 1986). Overproduction of VLDL is also thought to be the mechanism behind 
hyperapobetalipoproteinaemia, a condition where plasma and LDL cholesterol 
concentrations appear normal but apoB levels are elevated because of a 
preponderance of small dense LDL (Teng, Sniderman, Soutar and Thompson 1986).
Plasma triglyceride and cholesterol concentrations are elevated in familial 
dysbetalipoproteinaemia (type III hyperlipoproteinaemia, broad/floating 8  disease, 
remnant removal disease) where there is defective clearance of chylomicron and 
VLDL remnants due to the apoE2 isoform. The condition is marked by the presence 
o f B-VLDL, characteristic striate palmar and tuberose xanthomata, and premature 
CAD (Durrington 1989a). The expression of this hyperlipidaemia is not, however, a 
strict consequence of the E2/2 phenotype and in some patients is dependant on 
secondary factors such as obesity, diabetes mellitus and hypothyroidism. A similar 
lipid phenotype is seen in patients with the rare condition of familial hepatic lipase 
deficiency (Breckenridge, Little, Alaupovic, Wang, Kuksis, Kakis, Lindgren and 
Gardiner 1983)
CHAPTER I 43
The treatment for each of these conditions involves restriction of fat intake, in 
particular of saturated fatty acids, supplemented by lipid lowering drugs that act to 
reduce VLDL secretion. Such agents include nicotinic acid and its analogues (Fattore 
and Sirtori 1991), and the fibrate derived group of drugs, some of which also increase 
LPL activity (Gaw and Shepherd 1991).
5.3. Secondary or Acquired Causes of Hypertriglyceridaemia
A number of conditions have secondary effects on the metabolism of chylomicrons 
and VLDL and give rise to hypertriglyceridaemia, either alone or by superimposing 
upon the more subtle familial defects in the metabolism of triglyceride rich 
lipoproteins outlined above.
The most common of these is diabetes mellitus, where hypertriglyceridaemia 
in concert with low levels of HDL, hypertension and hyperinsulinaemia, presents a 
m ajor increase in CAD risk. In patients with both uncontrolled insulin dependent 
(EDDM) and non-insulin dependent (NIDDM) diabetes mellitus, there is increased 
synthesis of VLDL that is triglyceride enriched with an increased triglyceride/apoB 
ratio (Howard 1987). This probably relates to the poor regulation of adipose tissue 
lipolysis in these people resulting in increased flux of FFA to the liver rather than any 
direct effect of insulin, in deficiency or excess, on hepatic triglyceride synthesis 
.(Brunzell, Chait and Bierman 1985). Decreased fractional clearance of VLDL and 
chylomicrons may also contribute to the hypertriglyceridaemia as the permissive 
effects of insulin on the expression of LPL activity are lost (Abbate and Brunzell
1990). Plasma triglyceride concentrations are normalised with good glycaemic control 
in patients with IDDM but not in NIDDM. This latter fact may be related to the 
prevalence and effects of chronic hyperinsulinaemia, obesity, high alcohol intake, 
concurrent renal disease and drug therapy (diuretics and 6  blockers) in people with 
NIDDM (Durrington 1989b).
Obesity, and in particular abdominal rather than gluteal-femoral fat, is 
associated with insulin resistance, glucose intolerance, hypertension and 
hypertriglyceridaemia and as such represents a major CAD risk factor (Kissebah and 
Peiris 1989). The hypertriglyceridaemia appears to result from a greater rate of fatty 
acid turnover in abdominal adipose tissue, leading to high portal FFA concentrations 
and increased triglyceride synthesis and VLDL secretion (Despres 1991).
Mild hypertriglyceridaemia is occasionally observed with overt 
hypothyroidism, although increases in plasma and LDL cholesterol are more usual 
because of reduced receptor clearance of LDL (Abrams and Grundy 1981). In cases 
where triglyceride levels are elevated, the clearance of triglyceride rich lipoproteins is
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reduced (Abrams, Grundy and Ginsberg 1981) because of a decrease in post-heparin 
plasma LPL activity (Valdemarsson, Hansson, Hedner and Nilsson-Ehle 1983).
Chronic excessive alcohol consumption results in hypertriglyceridaemia by 
increasing adipose lipolysis and reducing hepatic oxidation and gluconeogenesis so 
that the proportion of FFA channelled into triglyceride synthesis is increased 
(Taskinen, Nikkila, Valimaki, Sane, Kuusi, Kesaniemi and Ylikahri 1987). However, 
some consolation comes from the evidence that moderate alcohol consumption 
increases LPL activity and may therefore buffer mild increases in VLDL production, 
that is until the lipolytic capacity is exceeded (Schneider, Liesenfeld, Mardsini, 
Schubotz, Zofel, Vandre-Plozzitzka and Kaffamik 1985).
Although hyperlipidaemia is commonly seen in people with the nephrotic 
syndrome, the precise nature of the disturbances in lipoprotein metabolism are 
unclear (Keane and Kasiske 1990). Approximately 69% of cases have 
hypertriglyceridaemia, alone or in combination with hypercholesterolaemia, which is 
entirely due to increased VLDL, and not chylomicron, concentrations (Joven, 
Villabona, Vilella, Masana, Alberti and Valles 1990). Increased secretion and reduced 
fractional catabolism of VLDL has recently been reported in these patients (Warwick, 
Packard, Demant, Bedford, Boulton-Jones and Shepherd 1991).
Other secondary causes of mild to moderate hypertriglyceridaemia include 
therapy with B blockers, diuretics, oestrogen supplements, and corticosteroid excess 
due to Cushing's syndrome or exogenous glucocorticoid administration (Durrington 
1989b).
6 . L IPO PR O T E IN  M ETABOLISM  IN TH E H ORSE
Awareness of lipoprotein metabolism in animals has been stimulated in recent years 
as certain species have proved useful as experimental models of hyperlipidaemia 
(Reue, Warden and Lusis 1990) and atherosclerosis (Armstrong and Heistad 1990). 
The horse was instrumental in providing Macheboeuf (1929) with the earliest source 
of a soluble lipid-protein complex. Since then, relatively little research effort has been 
devoted to understanding how the horse accomplishes plasma lipid transport, such 
that in Chapman's comprehensive review of animal lipoproteins (1980), the horse 
occupied half a paragraph while insects, fish, reptiles and birds commanded 27 pages 
between them. The information that is available concerning the structure and function 
o f the equine plasma lipoproteins, in both healthy animals and in ponies with 
hyperlipaemia, is reviewed in the next two sections.
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6.1. The Equine Plasma Lipoproteins
The earliest quantitative data on the blood lipids of the horse were published as 
recently as 1960 by Forenbacher, Keler-Bacoka and Pucar (1960) who measured the 
concentrations of cholesterol, phospholipids and total lipids in serum from 61 horses. 
The mean cholesterol was 98.8 mg/dl (2.56 mmol/1) with a range of 6 6  to 218 mg/dl 
(1.71-5.65 mmol/1), and was higher in geldings (104.4 mg/dl) and stallions (113 
mg/dl) than mares (89 mg/dl), and also in eight animals being fed a mix of brewers' 
grain and sunflower seed cake (152.4 mg/dl) compared with 53 horses on the 
common diet of hay and maize ( 8 8  mg/dl). The mean phospholipid concentrations 
were also higher in the stallions (129.5 mg/dl) and geldings (134.3 mg/dl) than the 
mares (106.4 mg/dl). The total lipids were unaffected by sex or diet, and none of the 
three parameters measured were influenced by age. Fifteen years later, Robie, Janson, 
Smith and O'Connor (1975a) found that serum phospholipid and cholesterol 
concentrations were higher in Morgan than Thoroughbred horses and Shetland ponies, 
and that the ponies had higher FFA and lower glucose concentrations than the two 
breeds of horse. Triglyceride concentrations appeared to decline in the two horse 
breeds during the cold months (December to March), but remained unchanged in the 
Shetland ponies whose serum FFA concentrations rose during this period.
Forenbacher et al. (1960) also used paper strip electrophoresis to show that 
equine serum consisted predominantly of a-lipoproteins, with minor contributions 
from B-lipoproteins and neutral fats [sic] that stayed at the origin. Campbell (1963) 
subsequently found only two areas of staining on paper electrophoresis of serum from 
10 horses that corresponded to the a -  and B-lipoproteins of human serum. These 
accounted for 71.9% and 28.1% of total lipoprotein lipid, respectively. Robie, Smith 
and O'Connor (1975) found a third peak in a post-a position using slab 
polyacrylamide gel electrophoresis. This band represented a constant 26% of the 
lipoprotein spectrum in both the Morgan and the Thoroughbred horses, whereas the 
relative percentage of the a-lipoproteins was higher and that of the B-lipoproteins 
lower in the Thoroughbred than in the Morgan horses. Later, van Dijk and Wensing 
(1989) showed, by using a combination of ultracentrifugation and precipitation, that 
plasma VLDL levels were higher in three ponies than four horses of undefined 
breeding.
In the third of their series of papers, Robie, Janson, Smith and O'Connor 
(1975b) isolated lipoproteins by preparative ultracentrifugation at densities of <1.006 
(VLDL), <1.063 (LDL) and >1.063 g/ml (HDL). There were no significant 
differences in the lipid composition of each fraction between the two breeds, 76% of 
the total lipid was in HDL, 17% in LDL and 7% in VLDL. The VLDL class was 
typically triglyceride rich, and the LDL and HDL were reported as consisting
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predominantly of FFA and phospholipid, respectively. Most of the total serum 
phospholipid and cholesterol was found in the HDL and the triglyceride was divided 
between VLDL and HDL. Electrophoresis of these fractions showed that the post-a 
band previously reported was a component of the density >1.063 g/ml fraction, and 
that the density <1.063 g/ml fraction migrated in the 6 -position. The authors noted 
that there was a minor 6 -component in the HDL fraction and commented that the 
VLDL fraction did not migrate in the electrophoresis systems used, yet a pre - 6  band is 
obvious on the gel scans presented in the paper. Leat, Northrop, Buttress and Jones 
(1979) subsequently reported a prominent pre - 6  band in two horses by electrophoresis 
on cellulose acetate. In addition, these authors used analytical ultracentrifugation to 
quantify the relative amounts of HDL (81.1%) and LDL (18.9%) and showed that the 
LDL was of complex composition consisting of two peaks.
More recent studies have employed density gradient ultracentrifugation. In the 
first of these, Terpstra, Sanchez-Muniz, West and Woodward (1982) pre-stained the 
serum with Sudan Black to visualise the lipoproteins after ultracentrifugation and 
found, in the two horses examined, that the LDL was divided into two subtractions 
while the HDL presented a single band. The fractions corresponding to human VLDL, 
LDL and HDL were collected from the two equine samples by tube slicing and their 
cholesterol concentrations (mmol/1 serum) measured as 0.04 and 0.09 for VLDL, 0.70 
and 0.92 for LDL, and 1.98 and 1.81 for HDL.
In the second study, Hollanders, Mougin, N Diaye, Hentz, Aude and Girard 
(1986) unloaded their gradients through a fractionator and monitored the protein 
content at OD280nm- They f°unci LDL in the single horse examined within the density 
limits of 1.022 to 1.068 g/ml, with a peak at 1.035, and commented that this class was 
polydisperse. The HDL peak was found between 1.092 and 1.095 g/ml and was 
almost perfectly symmetrical with no evidence of heterogeneity. The lipoprotein 
concentrations of VLDL, LDL and HDL were 33.3, 47.7 and 222.1 mg/dl serum, 
respectively. The HDL fractions were delipidated and subjected to sodium dodecyl 
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) which revealed that apoA-I 
was the major protein of this lipoprotein, and identified apoA-II as a dimer, and a 
single apoC band with a molecular weight of 12.5k Da. The molecular weights of 
apoA-I and apoA-II were not reported, but a 45k Da protein assumed to be apoA-IV 
was found in the density >1.16 g/ml fraction.
In the third and most comprehensive study of this type, Le Goff, Nouvelot, 
Fresnel, and Silberzahn (1987) employed the lipid staining method used by Terpstra 
et al. (1982) to isolate lipoproteins from six Thoroughbred horses. Four major colour 
bands were found (I, II, III, IV) that corresponded in electrophoretic mobility and 
chemical composition to human VLDL (I), LDL (II and III) and HDL (IV). The
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VLDL fraction contributed 5% of the total lipoprotein mass and was very similar to 
that of human VLDL in lipid composition, but was composed of somewhat smaller 
particles (mean diameter 22.3nm) when measured by electron microscopy. The LDL 
class represented 19% of the lipoprotein mass and was almost equally divided 
between two subfractions (LDL]) and (LDL2) found in the density ranges 1.028- 
1.044 and 1.044- 1.066 g/ml, respectively. These two fractions were distinguishable 
by the higher protein and lower cholesteryl ester content of LDL2. The cholesteryl 
ester content of both fractions was less than that of human LDL and the particles were 
very much smaller with mean diameters of 14.2 and 11.6 nm, respectively. The HDL 
fraction was remarkable for its low triglyceride (0.5%) content compared with human 
HDL and appeared as a homogeneous population of relatively small particles (5.1- 
7.3nm). In five of the six animals, the HDL appeared as a single band and in the other 
there was a second band early in the HDL density range that the authors reported was 
chemically heterogeneous to the bulk of HDL, with a lower protein and higher 
phospholipid content.
In a sequel to the last paper, Le Goff, Pastier, Hannan, Petit, Ayrault-Jarrier 
and Nouvelot (1989) measured the apoB content of VLDL and LDL using a 
tetramethylurea precipitation technique and determined the distribution of 
apolipoproteins by SDS-PAGE. The mass of apoB represented 29.6% of VLDL 
protein and 84.4% of LDL protein, and presented two clearly separated bands on 
SDS-PAGE with molecular weights corresponding to human apoB-100, and a third 
similar to that of apoB-48. A 40k Da protein, thought to be apoE, was reported in 
LDL but not HDL, where bands of molecular weight 27k Da and 17k Da 
corresponding to human apoA-I and dimeric apoA-II predominated. Evidence of 
apoA-IV was found only as a faint band of molecular weight 45k Da in the second 
fraction beyond HDL at density >1.178 g/ml. Isoelectric focusing gels suggested that 
there was one major and three minor isoforms of apoA-I and only one isoform each of 
apoA-II, apoC-II and apoC-III. The identity of the apoA-II band was confirmed by 
immunoblotting the focused gels with a human anti apoA-II polyclonal antibody. By 
calculation of theoretical particle masses, the LDL] and LDL 2  subfractions were 
believed to contain 0.8 and 0.6 molecules of apoB-100, respectively, and HDL three
molecules of apoA-I.
Finally, two other papers include reference to the equine apolipoproteins. 
Chen and Albers (1983), in the course of their LCAT study, isolated apoA-I from 
equine plasma by chromatography on DEAE-sepharose and found a single band on 
SDS-PAGE with an apparent molecular weight of 27.25k Da ±0.5 (mean ±sd, n=4). 
The presence of apoA-IV in equine plasma was confirmed by Juneja, Gahne, Lukka 
and Ehnholm (1989) who used isoelectric focusing and immunoblotting with rabbit
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anti-human apoA-IV to show that the majority of the protein existed in a monomeric 
rather than a dimeric form. The molecular weight and lipoprotein distribution were 
not assessed. This protein had previously been designated as serum protein 2  and 
showed a high degree of polymorphism which was explained by four co-dominant 
alleles acting at a single locus (Juneja, Anderson, Sandberg, Adalsteinsson and 
Gunnaesson 1984).
6.2. The Plasma Lipoproteins in Ponies with Hyperlipaemia
In the earliest, and most extensive study of the pathogenesis of hyperlipaemia Morris 
et al. (1972) fasted four ponies for 184 hours thereby inducing hyperlipidaemia in 
three of the animals (plasma triglycerides 3.5, 6.3 and 11.1 mmol/1; cholesterol 3.8,
4.4 and 2.6 mmol/1, respectively). This was accompanied by the appearance of a 
pronounced pre-B band on agarose electrophoresis, the intensity of which 
approximated to the increase in plasma lipids. Plasma FFA concentrations increased 
from 0.04-0.2 umol/ml in the pre-fasted samples to a mean of 0.6 umol/ml after eight 
days of fasting. One pony showed no change in plasma triglyceride or cholesterol 
concentrations over the eight day period. The hyperlipidaemia was subsequently 
induced in two other ponies, and VLDL isolated by ultracentrifugation shown to 
consist of 5.5% protein, 5.8% free cholesterol, 1.5% cholesteryl esters, 13.3% 
phospholipids and 73.8% triglycerides. Unfortunately, the authors did not isolate 
VLDL from non-fasted ponies but commented that, relative to human and rat VLDL, 
these lipoproteins were low in cholesterol with an unusual distribution of cholesterol 
between the free and esterified forms. They called the condition a
hyperprebetalipoproteinaemia and suggested that this response to fasting was unique 
to the equine species.
To estimate the contribution of VLDL secretion to the hypertriglyceridaemia, 
Morris et al. (1972) in the same paper reported attempts to block the activity of LPL 
by injecting the fasted ponies with Triton WR 1339. Although this precipitated an 
acute intravascular haemolytic crisis in each of the animals, plasma triglyceride and 
cholesterol concentrations continued to rise in a linear fashion for between 6  and 42.4 
hours. The triglycerides increased at a rate about 10 times higher than that of 
cholesterol compatible with the secretion of VLDL with the ratio of triglyceride to 
cholesterol found in the isolated VLDL (11.7:1). However, the rate of secretion of 
triglyceride did not appear to be related to the magnitude of the fasting
hypertriglyceridaemia, which tempted the authors to postulate that the "mechanism
of the hyperprebetalipoproteinaemia resides in the suppression of lipoprotein
degradation".
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W ensing, Van Gent, Schotman and Kroneman (1975) isolated lipoproteins 
from nine ponies with hyperlipaemia by a combination of ultracentrifugation 
(chylomicrons and VLDL) and precipitation (LDL and HDL). In addition to marked 
increases in the concentration of VLDL, they described the appearance of 
considerable concentrations of chylomicrons in some animals, including one that had 
not eaten for 13 days. On the basis of this, Schotman and Wensing (1977) attempted 
to define three phenotypes of hyperlipaemia; the first was characterised by increased 
VLDL, and the second and third by increases in both chylomicrons and VLDL with 
the contribution of chylomicrons much less in the third. Although the chylomicron 
class apparently presented a band well separated from that of the pre-B lipoproteins 
(Wensing et al. 1975), neither the fact that this fraction was present in animals that 
had 'Very poor appetites”, nor the lipid composition of this class (34.8-75.5% 
triglyceride, 9.8-19.9% cholesterol) supported their conclusion that these lipoproteins 
were chylomicrons. This aside, Wensing et al. (1975) reported a high percentage of 
triglyceride in the VLDL and LDL fractions relative to those from a single healthy 
control animal, and that the phospholipid content of HDL was reduced.
In a study of identical design to that of Morris et al. (1972), Bauer (1983) 
induced triglyceride levels of between 7.5 and 20.3 mmol/1 in three ponies that were 
fasted for 144 hours, and failed to identify any chylomicrons on ultracentrifugation. In 
addition, he found no lipoproteins at the origin on agarose electrophoresis and 
reported that the hyperlipidaemia was entirely accounted for by the appearance of a 
pre-B band. The concentrations of VLDL (density <1.006 g/ml) and LDL (density 
<1.064 g/ml) isolated by flotation ultracentrifugation were increased compared with 
two fed ponies by five to 19 fold and 1.6 to 2.4 fold, respectively, while that of HDL 
(density <1.21 g/ml) was unchanged. Although the triglyceride content of the VLDL 
was no different to that from the controls, the relative amounts of cholesterol and 
protein in this lipoprotein fraction were reduced and the triglyceride to protein ratio 
increased.
In a study recently published, Freestone, Wolfsheimer, Ford, Church and 
Bessin (1991) attempted to show that insulin insensitivity is indeed at the metabolic 
heart of equine hyperlipaemia. They defined two groups of ponies as normal or 
hyperinsulinaemic on the basis of differential responses to an oral glucose load and 
induced hypertriglyceridaemia by withholding food for 72 hours. There was, 
however, no difference between the normal and hyperinsulinaemic ponies in plasma 
triglyceride, cholesterol and lipoprotein (VLDL, LDL and HDL) triglyceride 
concentrations at any time point during this period. This was perhaps due to the fact 
that insulin levels in both groups declined to the limits of detection, so that there were 
then negligible differences in insulin and glucose concentrations between the two
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groups. After 72 hours, half the ponies in each group were given dexamethasone and 
the other half placebo and the fast continued for a further 48 hours. The 
dexamethasone led to suppressed plasma cortisol levels for 24 hours and increased 
glucose concentrations for 8  hours, but had no effect on any of the lipid parameters in 
either the normal or hyperinsulinaemic groups compared with each other or with the 
placebo-treated animals. The authors admitted that the differences in insulin 
concentration between the two groups were perhaps inadequate to define the presence 
or absence of insulin resistance, and that the single bolus of dexamethasone was 
insufficient to antagonise insulin. One pony, who was neither obese or 
hyperinsulinaemic, died from hyperlipaemia during the course of the study and the 
authors concluded that "Consideration should be given to the possibility that these 
ponies may have a defect in their ability to clear the VLDL triglyceride fraction from 
plasma".
1.7. AIMS OF THE STUDY
The work described in this thesis was driven by the desire to reduce the threat that 
hyperlipaemia poses to the health and welfare of ponies. The aim of the study was to 
identify the underlying defect in lipoprotein metabolism so that effective preventive 
and therapeutic strategies could be developed.
At the outset, it was clear that these objectives could not be met without a 
better understanding of plasma lipid transport in the equine species. To this end, the 
physical and chemical properties of the lipid transport vehicles, that is the plasma 
lipoproteins, were first examined in healthy horses and ponies (Chapter III). This was 
followed by an assessment of the enzymes that are responsible for modelling and 
mediating the metabolism of the lipoproteins in the circulation (Chapter IV). These 
studies were carried out in Shetland ponies and Thoroughbred horses, and repeated in 
pregnant and lactating ponies (Chapter V), with the hope of identifying differences in 
lipoprotein metabolism that might explain the almost exclusive occurrence of 
hyperlipaemia in the pony breeds, and in pregnancy and lactation in particular. The 
description of lipoprotein metabolism in the horse was completed by examining the 
plasma transport of dietary fat and analysing the plasma lipoproteins in suckling foals 
(Chapter V).
Each of the above components provided essential baseline data for showing 
how the structure and metabolism of the plasma lipoproteins is perturbed in ponies 
with hyperlipaemia (Chapters VI). On this basis, the metabolism of VLDL 
triglyceride was quantified in vivo to show that hepatic overproduction, rather than 
defective catabolism, of these lipoproteins is responsible for the disease (Chapter
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VII). In the final section (Chapter VIII), the significant contributions from this thesis 
are highlighted, a plan of the pathogenesis of equine hyperlipaemia proposed, and the 
implications of this work for improving the therapy of the condition discussed.
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CHAPTER n  
GENERAL METHODS
The suppliers of reagents and equipment are listed in Appendix 1.
1. ROUTINE BLOOD CHEMISTRIES
1.1. Lipid and Lipoprotein Concentrations
Blood was collected into potassium EDTA (final concentration 1.2-2.0 mg/ml blood), 
plasma separated by centrifugation at 2400 rpm for 15 mins. and kept at 4°C until 
analysis. Plasma cholesterol and triglyceride concentrations were measured using 
reagent kits (704161 and 237574; Boehringer Mannheim GmbH) on an automated 
discrete analyser (BM/Hitachi 717). Quality control was monitored using Seronorm 
Lipid (Nycomed Pharma AS) and Precipath U (Boehringer M annheim GmbH).
Plasma lipoprotein cholesterol concentrations were measured by a combined 
ultracentrifugation precipitation technique. Five ml of plasma was placed in a 6.5 ml 
thermoplastic ultracentrifuge tube (Ultra-Clear; Beckman Instruments, Inc.) and 
overlayered with normal saline until a meniscus appeared at the top. The tubes were 
sealed, placed in a Ti50.4 rotor (Beckman Instruments, Inc.) and centrifuged at 37k 
rpm, 4°C for 18 hours. The supernatant was then removed by tube slicing and 
transferred to a 3 ml volumetric flask, the cutter was washed with normal saline and 
the washings used to make up the volume to 3 ml. The infranatant was transferred to a 
5 ml volumetric flask and made up to volume with normal saline. One ml of the 
infranatant was then transferred to a second ultracentrifuge tube and the apoB 
containing lipoproteins were precipitated by adding 50 ul of 92 mM heparin- 
manganese chloride reagent. This was made up mixing 9.56 g M nCl2 .4HO in 6  ml 
distilled water (dH 2 0 )  with 1.05 g heparin (5xl0 5  units; Sigma H-3125) dissolved in 
12.5 ml normal saline, made up to 25 ml with dH20  and stored at 4°C. The tubes 
were mixed on vortex and incubated at 4°C for 15 mins., then spun at 10k rpm for 30 
mins. in the Ti50.4 rotor with the vacuum off to pellet the precipitate. Aliquots of the 
VLDL fraction, the original infranatant (LDL+HDL) and the second supernatant 
(HDL) were transferred to autoanalyser cups and their cholesterol concentrations 
determined as above. The LDL cholesterol concentration was calculated as the 
difference between that in the infranatant and the second supernatant.
Free fattv acid and free glycerol concentrations were determined manually 
using colorimetric kits (Wako NEFA C test kit; Wako Chemicals GmbH and Glycerol 
GY 105; Randox Laboratories Ltd).
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1.2. Clinical Chemistries
Plasm a (collected into lithium heparin) concentrations of urea (urease method), 
creatinine (Jaffe method) and alkaline phosphatase were measured using Roche kits 
(Roche) and gamma glutamyl transferase (carboxy'NA method) using a BCL kit 
(Boehringer Mannheim GmbH), on a Cobas Mira (Roche) autoanalyser.
2. LIPOPROTEINS ISOLATION AND CHARACTERISATION
2.1. Gel Filtration
Gel filtration (gel chromatography, molecular sieve chromatography) was used to 
separate the lipoprotein classes from plasma on the basis of their differences in 
particle size (Rudel, Marzetta and Johnson 1986). A 6 % agarose gel (Bio-Gel A-5m, 
200-400 mesh; Bio-Rad Laboratories Ltd) was prepared as the support medium 
according to the manufacturers' instructions and packed into a 1 .6 x 1 0 0  cm glass 
column which was maintained at 4°C.
The solvent density of 10 ml plasma was raised to 1.225 g/ml by adding 3.517 
g NaBr, placed in a 26.3 ml polycarbonate centrifuge bottle (Beckman Instruments, 
Inc.) and overlayered with 15 ml of density 1.225 g/ml solution (36.7 g KBr in 100 ml 
dH 2 0 ) . The density of this and all other density solutions used in the following 
methods was checked using a digital density meter (DMA 35; Paar Scientific Ltd). 
After centrifugation at 39k rpm, 15°C for 60 hours, the lipoprotein fraction was 
removed in the top 2 ml and applied directly to the column or stored at 4°C for no 
longer than 72 hours. The column was eluted by gravity with phosphate buffered 
saline containing 0.01% NaN 3  at a flow rate of 6  ml/hr. Fractions were collected 
every 20 mins. (Ultrovac 7000 Fraction Collector; LKB Bromma) and their elution 
volume plotted against protein content monitored at OD280iim (on a DU-70 
Spectrophotometer; Beckman Instruments, Inc.). The fractions comprising the peaks 
were pooled and concentrated using the Diaflo Ultrafiltration system (Amicon Ltd) 
with ultrafilters of molecular weight limits of 300k Da (Diaflo XM300) for VLDL 
and LDL, and 50k Da (Diaflo XM50) for HDL.
2.2. Rate-zonal Ultracentrifugation
The major lipoprotein classes were isolated from plasma according to flotation rate by 
rate-zonal ultracentrifugation using a two step procedure described by Patsch, Sailer, 
Kostner, Sandhofer, Holasek and Braunsteiner (1974). In the first step, HDL was 
separated from the lower density lipoproteins in a stepped gradient of density of 1 .0 -
1 . 4  g/ml, which were collected, concentrated and applied in the second step to a linear
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gradient of 1.0-1.3 g/ml to resolve LDL from VLDL and IDL. The density solutions 
were made up as follows: density LOO g/ml, 10 ml 1 M Tris pH 7.6, 0.1 g Na2EDTA 
made up to 1 1 with dH 2 0 ; density 1.3 g/ml, 400 g NaBr, 10 ml 1M Tris pH 7.6, 0.1 g 
Na2EDTA made up to 1 1 with dH2 0 ; density 1.4 g/ml, 450 g NaBr, 10 ml Tris pH
7.6, 0.1 g Na2EDTA made up to 1 1 with dH 2 0 . The gradients were formed in a zonal 
rotor (Ti-14; Beckman Instruments, Inc.) at 3.5k rpm over 30 mins. using a gradient 
mixer (11300; LKB Bromma) and peristaltic pump (2115; LKB Bromma) set at a rate 
o f 2 1  ml/min.
The density of 50 ml of plasma was raised to 1.4 g/ml by adding 26.6 g NaBr 
and loaded onto the first gradient through a rotating seal assembly (Beckman 
Instruments, Inc.) and centrifuged at 45k rpm, 15°C for 18 hours. The rotor was 
unloaded at 3.5k rpm by pumping density 1.4 g/ml solution through the peripheral 
lead of the filling head. The discharge was monitored at OD 2 gonm (Type 6  Optical 
U nit connected to a Model U-A Absorbance Monitor; Isco Instrument Specialities 
Co.) and collected into 14 ml fractions. Those fractions (1-10) that contained the 
lower density lipoproteins were concentrated as above to a volume of 25 ml, adjusted 
to density 1.3 g/ml by adding 7.5 g NaBr, and loaded onto the second gradient. The 
VLDL and LDL were then separated by centrifugation at 45k rpm, 10°C for 110 
mins. and unloaded with density 1.3 g/ml solution.
2.3. Sequential Flotation Ultracentrifugation
As the plasma lipoproteins have lower hydrated densities than the other plasma 
proteins, and because the densities of each class are discrete from one another, 
progressively raising the solvent density of plasma between ultracentrifugation steps 
allows the isolation of defined lipoprotein classes. This provides the simplest method 
of simultaneously isolating lipoproteins from a number of samples and in a form that 
does not require further concentration.
VLDL, IDL, LDL and HDL were isolated at the density limits of 1.006, 1.019, 
1.063 and 1.210 g/ml as originally described for man by Havel, Eder and Bragdon 
(1955). Four ml of plasma was placed in a 6.5 ml thermoplastic ultracentrifuge tube 
(Ultra-Clear; Beckman Instruments, Inc.) overlayered with 2 ml of density 1.006 g/ml 
solution (11.4 g NaCl, O.lg Na2EDTA in 1 1 dH20  to which was added 1 ml of 1 N 
NaOH and 3 ml dH 2 0 )  and centrifuged in a Beckman Ti50.3 rotor at 39k rpm, 4°C 
for 18 hours. The VLDL was then removed in the top 1 ml with a fine bore pipette, 
the next 1 ml was discarded and 0.32 ml of density 1.182 g/ml solution (24.98 g NaBr 
in 100 ml density 1.006 g/ml solution) was added to the remaining 4 ml. The sample 
was mixed, overlayered with 1.68 ml density 1.019 g/ml solution ( 8  ml 1.182 plus 
100 ml normal saline) and centrifuged as above. The IDL was then removed in the top
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1  ml and, after disposing the next 1  ml, 1 . 4 7  ml of density 1.182 g/ml solution was 
added, the solution mixed and overlayered with 0 . 5 3  ml density 1.063 g/ml solution 
(made up of a 2:1 mix of 1.006 and 1.182 g/ml solutions). Centrifugation was 
repeated, the LDL removed in the top 1ml, and 0.944 g NaBr added to the sample 
after discarding a further 1 ml. The contents of the tube were mixed thoroughly, 
overlayered with 2  ml density 1 . 2 1  g/ml solution (made up of a 2 : 1  mix of 1.006 and 
1.478 g/ml solutions; the latter made from 78.32 g NaBr in 100 ml density 1.006 
g/ml) and centrifuged for 24 hours after which the HDL was removed in the top 1 ml.
When necessary, chylomicrons were first isolated from the samples by 
overlayering 4ml plasma with 2 ml normal saline and centrifuging at 20k rpm, 4°C 
for 30 mins. The chylomicrons were removed in the top 2 ml and cleaned of plasma 
proteins by twice overlayering with 4 ml normal saline and repeating the 
centrifugation.
2.4. Measurement of Lipoprotein Particle Size
The size of VLDL, LDL and HDL was estimated by visualisation of intact 
lipoproteins by negative contrast electron microscopy. Lipoprotein fractions were 
extensively dialysed in Spectrapor membrane tubing (Spectrum Medical Industries 
Inc.) against 0.125M ammonium acetate, 2.6 mM ammonium carbonate, 0.26 mM 
tetra sodium EDTA at pH 7.4 for 24 hours at 4°C. The samples were negatively 
stained with sodium phosphotungstate at pH 7.0-7.5 and applied to Formvar-carbon- 
coated grids as described by Forte and Nordhausen (1986).
The particle size distribution of LDL and HDL was also examined by non­
denaturing polyacrylamide gel electrophoresis on pre-prepared polyacrylamide 
gradient gels of 2-16% for LDL (PAA 2/16; Pharmacia AB) and 4-30% for HDL 
(PAA 4/30; Pharmacia AB) using the GE4 apparatus (Pharmacia AB). The gels were 
first pre-equilibrated in the electrophoresis buffer (0.09M Tris, 0.08M Boric acid, 
2.5mM EDTA, pH 8.4) for 20 mins. at 70 volts. The samples were mixed in a 2:1 
ratio with tracking dye made up of 4 g sucrose and 1 mg bromophenol blue in 10 ml 
of the electrophoresis buffer. Approximately 10 ug of protein was loaded on to the gel 
in an application volume of 8-12 ul and electrophoresed at 20 volts for 20 mins., 70 
volts for 30 mins., after which time the buffer was circulated to both the upper and 
lower tanks and electrophoresis carried out at 120 volts for at least 24 hours. A high 
molecular weight marker (HMW; Pharmacia AB), containing thyroglobin (radius 8.5 
nm), apoferritin (6.1 nm), lactate dehydrogenase (4.08 nm) and bovine serum albumin 
(3.55 nm), and a 10% solution of latex beads (diameter 38 nm; Dow Chemical Ltd), 
were used to obtain Rf values for each band. The gels were fixed in 10% 
sulphosalicylic acid for 30 mins., stained with 0.1% w/v Coomassie Brilliant Blue G-
CHAPTER II 56
250 (Bio-Rad Laboratories Ltd) for 60 mins. and destained in 7 % acetic acid before 
being scanned by computer assisted video densitometry (Model 620, Bio-Rad 
Laboratories Ltd).
2.5. Chemical Composition of Lipoproteins
The triglyceride and total cholesterol content of the isolated lipoprotein fractions were 
measured as described for plasma in section 1 . 1 ., and free cholesterol and 
phospholipids were determined using enzymatic colorimetric kits (310328 and 
691844; Boehringer Mannheim GmbH) on a centrifugal analyser (Encore Chemistry 
System; Baker Systems). The masses of triglyceride and free cholesterol in mg/dl 
were calculated by multiplying their molar concentrations by 88.5 and 38.6, 
respectively. The mass of cholesteryl esters was calculated as the difference between 
the molar concentration of total and free cholesterol multiplied by 38.6 and again by 
1.68 to correct for the mass of the esters. Total protein content was determined by the 
modified method of Lowry et al. (Peterson 1977) using human serum albumin as the 
standard. When dealing with turbid fractions, i.e. chylomicrons and VLDL, 1 mg/ml 
SDS was added to the Biuret reagent. The contribution of each component to 
lipoprotein mass was then calculated by dividing their respective masses by their 
combined masses.
2.6. Resolution of Apolipoproteins
The apolipoprotein content of the isolated lipoprotein fractions was resolved by SDS- 
PAGE as described by Maguire, Lee and Connelly (1989). Electrophoresis was 
performed using a vertical slab gel apparatus (SE600; Hoefer Scientific Instruments),
1.5 mm thick gels and a 15 tooth well former. The gel consisted of 3.5% acrylamide 
with an acrylamide-bisacrylamide ratio of 20:1, 18% glycerol (v/v), 0.1% SDS, 
0.075% TEMED, 0.01% ammonium persulphate, 0.1M tris/phosphate, pH 6 . 8  and 
was made up according to the authors' protocol. Lipoprotein fractions were freeze 
dried in aliquots of 50 ug and stored at -70°C prior to analysis. The samples were 
resolubilised, reduced and applied to the gels as described. The lower buffer chamber 
was filled with 4  1 of 0.1 M sodium phosphate, pH 7.0, and the upper with the same 
buffer containing 0.1% SDS. Electrophoresis was carried out at a constant current of 
20 mA for 30 mins. and then 60 mA for 4.5 hours. The gels were fixed in 4% 
formaldehyde for 30 mins., stained overnight in 0.025% Coomassie Brilliant Blue G- 
250 (Bio-Rad Laboratories Ltd) in 45.4% methanol, 9.2% acetic acid, then destained 
with 7.5% acetic acid, 5% methanol and stored in 5% acetic acid.
High and low molecular weight markers (LMW and HMW-SDS; Pharmacia 
AB) were included in each run. ApoA-I, apoA-II and the C peptides were identified
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using the proteins partially purified by high performance liquid chromatography, and 
apoB by Western blot analysis.
The apolipoprotein content of each lipoprotein class was estimated by 
scanning the stained gels and calculating the area under each protein peak by 
com puter assisted video densitometry using the Model 620, Bio-Rad Laboratories 
Ltd. In doing so, no attempt was made to correct for differing chromogenicities 
between the various proteins. Quantification of apoB-100 and apoB-48 by gel 
scanning has been shown to be linear and accurate over the range 0.35-35 ug of apoB 
(Zilversmit and Shea 1989). Although the percentage contribution of the the non- 
apoB apolipoproteins to protein mass can not be guaranteed true, the method provided 
the means by which inter-animal comparisons could be made in the absence of other 
apolipoprotein quantification methodologies.
2.7. Preparation of Apolipoproteins A-I, A-II, C
Human and equine HDL were isolated by rate-zonal ultracentrifugation, concentrated 
to 20 ml and dialysed against 0.15 M NaCl, 0.01 M Tris, 0.01% EDTA, pH 7.6 for 
two days at 4°C. This was lyophilised and then sequentially delipidated with 3:1 
ethanolrether, 3:2 ethanokether, and finally ether, over a two day period. The freeze 
dried powder was combined with the solvent in a rounded bottom glass flask, mixed 
on rollers (Spiramix 5; Denley-Tech Ltd) at 4°C, and the supernatant removed 
following centrifugation at 3000rpm, 4°C for 10 mins. The delipidated powder 
(apoHDL) was dried in a gentle stream of nitrogen and stored at -20°C until use.
Approximately 1 g of apoHDL was dissolved in 2.5 ml of 1.0 M NaCl and 1.8 
g o f urea (cyanide removed by ion exchange chromatography on Bio-Rad AG501- 
X 8 D; Bio-Rad Laboratories Ltd) added with stirring. The pH was adjusted to 3.15 
with formic acid and the volume bought up to 5 ml with dH 2 0 . The solution was then 
passed through a 0.45 um filter (Minisart NML; Sartorius Ltd) and applied to 2.15x60 
cm HPLC column (G3000SW; TSK-Gel) coupled to a 2.15x7.5 cm guard column of 
the same material on a Gilson HPLC system consisting of a model 303 pump, 802 
Manometric Module and Halochrome monitor. The column was eluted with 6.0 M 
urea, 0 . 5  M NaCl, pH 3.15 at a flow rate of 3ml/min. and monitored at OD28onm and 
fractions collected every minute. The peaks that corresponded to those reported for 
human apoA-I, apoA-II and the C peptides (Polacek, Edelstein and Scanu 1981) were 
dialysed extensively against 0.05 M NH4 H C 0 3  , lyophilised and stored at -20 °C . 
The fractions corresponding to apoA-I and apoA-II were then further purified by 
repeating the process.
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2.8. W estern Blotting of Apolipoprotein B
Antisera to equine apoB was raised in two New' Zealand White rabbits using LDL 
isolated from plasma by rate-zonal ultracentrifugation as the antigen. This was 
concentrated to give a protein content of approximately 1 mg/ml, and was emulsified 
with complete Freund's adjuvant and injected intradermally (1 mg/rabbit). This was 
boosted at two week intervals with 0.2 mg of fresh LDL protein in incomplete 
Freund's adjuvant and the specificity of the antisera was checked against equine 
plasma, VLDL, LDL and HDL by immunodiffusion in 1% agarose (Ouchterlony 
1967). After four booster immunisations the rabbits were sedated and exsanguinated 
by cardiac puncture and the serum stored in 0.5 ml aliquots at -20°C.
For blotting, the SDS-PAGE gels, nitrocellulose membranes (Whatmann 
3MM) and Scotch-Brite pads were soaked in transfer buffer (192 mM glycine, 25 mM 
Tris 20% methanol, pH 7.9) for 30 mins., assembled, and blotted overnight at 80 mA 
using the Trans-Blot transfer cell (Bio-Rad Laboratories Ltd). The blot was then 
incubated in blocking buffer (5 g milk powder in 100 ml transfer buffer) for 60 mins. 
on an orbital mixer (Denley-Tech Ltd) and washed in three changes of transfer buffer 
for 20 mins. each. The blot was incubated with the anti-LDL (1ml serum in 5 ml 10 
mM  Tris-HCl, 0.05% v/v Tween 20 (Sigma P-1379), 0.15 M NaCl, pH 7.4) for 3 
hours, washed as before and incubated with HRP donkey anti-rabbit IgG (S083-201; 
Scottish Antibody Production Unit) for 2 hours. The blot was then developed for 10 
mins. in a substrate solution containing 50 ml 0.1 M phosphate pH 7.4, 60 ul 
hydrogen peroxide and 25 mg 3,4,3',4'-Tetra-aminobiphenyl hydrochloride (BDH 
Laboratory Supplies).
3. ANALYSIS OF POST-HEPARIN LIPOLYTIC ACTIVITY
3.1. Principle
Lipoprotein and hepatic lipase are released into the circulation following an 
intravenous injection of heparin and harvested in plasma. The post-heparin plasma 
(PHP) is incubated with an emulsion containing triglycerides radiolabelled in the fatty 
acid moiety. The free fatty acid products of lipolysis are captured by albumin, 
separated from the glycerides and counted by liquid scintillation. Lipolytic activity is 
expressed as umol fatty acids released per ml of PHP per hour (umolFA/ml/h).
3.2. Collection of Post-heparin Plasma
Sodium heparin (Heparin (Mucous) Injection BP; Leo Laboratories Ltd) was 
administered by intravenous injection (70 iU/kg body weight) and blood samples
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collected into potassium EDTA, placed on ice and the plasma separated at 4°C. This 
was stored at -20°C for no longer than 12 weeks.
3.3. Preparation of Serum Cofactor
Pooled horse serum was used as the source of apoC-II for the activation of LPL. A 
total of 250 ml blood was collected in to potassium EDTA from four ponies, the 
plasma separated and 0.1% w/v CaCl2  and 1 U/ml bovine thrombin (Sigma T-4265) 
added. The clot was removed after incubation at 37°C for 120 mins. and the serum 
dialysed against 0.15 M NaCl at 4°C overnight. Any endogenous lipase activity was 
removed by heating the serum at 56° C for 30 mins., the serum was then dialysed 
overnight against PBS at 4°C and stored in aliquots of 1 ml at -50° C.
3.4. Preparation of Substrate
Fifty uCi of glycerol tr i[ l - 1 4  C]oleate (CFA 258; Amersham International pic) was 
dissolved in 24.5 ml of toluene, divided into seven aliquots of 3.5 ml and placed in 
round bottomed glass flasks. To each was added 3.5 ml of 500 mg triolein (Sigma T- 
7140) in 25 ml toluene. The solution in each was dried down under nitrogen in a 
water bath at 55°C, washed three times with 3 ml heptane, and sealed and stored 
under nitrogen at -20°C. The substrate emulsion was prepared fresh on the day of 
assay by adding 5.25 ml of 5% gum arabic (Sigma G-9752) in 0.2 M Tris-HCl, pH
8.4. This was mixed on vortex and sonicated on ice at 18 microns for 4 mins. until 
there were no oily droplets visible on the surface. Finally 5.25 ml of 10% bovine 
serum albumin (Fraction V; Sigma A-4503) in 0.2 M Tris-HCl, pH 8.4 was added.
3.5. Assay Method
Ten ul of PHP was incubated in duplicate with 200 ul substrate, 250 ul 0.2 M Tris 
buffer pH 8 .6 , containing NaCl, and 50 ul serum (for LPL) or 0.15 M NaCl (for HL) 
at 28°C for 60 mins. The fatty acids were extracted by adding 3.25 ml 
methanol:chloroform:heptane (1.41:1.25:1 parts) and 0.75 ml 0.14 M K2 CO 3 , 0.14 
M H 3 BO 3 , pH 10.5 to each tube, which were vortexed and centrifuged at 3,000 rpm, 
4° C for 30 mins. One ml of the supernatant was removed and counted in 10 ml liquid 
scintillant (Ultima Gold; Packard Instrument Co.) and 200 ul acetic acid. Blank 
incubations contained 10 ul 0.15 M NaCl instead of PHP and were subtracted from 
the sample counts. The total radioactivity was taken as the counts in 1 ml of the 
infranatant from the blank incubations. The lipolytic activity was calculated according 
to the equation derived in Appendix 2.
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4. LECITHIN:CHOLESTEROL ACYL TRANSFERASE ASSAY
4.1. Principle
Lipoprotein deficient plasma (LPDP) is incubated with a substrate emulsion 
containing lecithin and radiolabelled cholesterol in the presence of the LCAT cofactor 
apoA-I. Free and esterified cholesterol are then extracted, separated by thin layer 
chromatography on silica sheets and the radioactivity in each counted by liquid 
scintillation. LCAT activity is expressed in nmol cholesterol esterified per ml LPDP 
per hour (nmolCE/ml/h).
4.2. Preparation of Lipoprotein Deficient Plasma
Blood was collected into EDTA, placed on ice and plasma harvested at 4°C, and used 
immediately or stored at -20°C for not more than 6  weeks. The density of 4 ml was 
raised to 1.215 g/ml by adding 1.346 g KBr, placed in a 6.5 ml ultracentrifuge tube 
(Ultra-Clear; Beckman Instruments, Inc.) and overlayered with 2 ml of KBr solution 
of the same density (3.49 g KBr in 10 ml dH 2 0). This was centrifuged for 24 hours at 
50k rpm, 4°C, the lipoproteins were removed in the top 2 ml and the LPDP in the 
infranatant dialysed overnight against 0.15 M NaCl, 10 mM Tris, 1 mM EDTA, 
0.05% NaN3, pH 7.4 at 4°C.
4.3. Assay Method
Substrate micelles were prepared fresh on the day of assay by drying down 8  ul of a 
100 mg/ml solution of phosphatidyl choline (Sigma P-4279) in toluene and 0.15 umol 
(8.4 uCi) of [4-1 4 C]cholesterol (CFA 128; Amersham International pic) under a 
stream of nitrogen in a polypropylene tube. To this, 1 ml of phosphate buffer (50 mM 
KH 9 PO 4  , 0.025% EDTA, 2 mM NaN g pH 7.4) was added, the tube mixed and 
sonicated on ice by four 5 mins. bursts at 2 microns to give a final activity of 
approximately 70k dpm/5 ul.
Twenty five ul of substrate vesicles were mixed with 45 ul of the assay buffer 
(0.015% apoA-I, 2% bovine serum albumin, 8  mM 2-mercaptoethanol made up in the 
phosphate buffer) in a 1.5 ml tube, flushed with nitrogen, capped and equilibrated at 
37°C for 30 mins. The LPDP was diluted 1:1 with the phosphate buffer and 20 ul 
added at 30 second intervals to the tubes in triplicate, which were mixed, flushed with 
nitrogen, capped and incubated for 45 mins. at 37°C. Blank incubations included 
buffer instead of LPDP.
The reaction was stopped by adding 750 ul of hexane/isopropanol (3:2 v/v) 
containing 50 ug of unlabelled cholesterol (Sigma C-8253) and cholesteryl linoleate 
(Sigma C-0289) followed by 100 ul of 60% ethanol containing 0.02% Coomassie 
Brilliant Blue G-250 (Bio-Rad Laboratories Ltd). The tubes were mixed on vortex
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and centrifuged at 1750 rpm for 3 mins. The upper organic (clear) phase was 
removed, evaporated to dryness at room temperature, and dissolved in 1 0 0  ul of 
chloroform. Twenty five ul of this was spotted onto silica sheets (Empore; 
Analytichem International), separated by thin layer chromatography in petroleum 
spirit/diethyl ether (85:15 v/v), and developed by exposure to iodine crystals. 
Cholesterol and cholesteryl linoleate (5mg in 25 ml chloroform) were used as 
standards. The regions corresponding to free and esterified cholesterol were cut out, 
placed in scintillation vials to which were added 0.5 ml toluene and 5 ml liquid 
scintillant (Opti-fluor O; Packard Instrument Co.).
The fractional enzyme activity was calculated by dividing the counts in the 
esterified region by the sum of the counts in the free and esterified cholesterol 
regions. This was converted to molar activity (nmolCE/ml/h) by multiplying by the 
concentration of cholesterol in the substrate mixture.
5. CHOLESTERYL ESTER TRANSFER PROTEIN ASSAY
5.1. Principle
Lipoprotein deficient plasma is incubated with radiolabelled HDL 3  as donor and 
VLDL/LDL as acceptor particles for cholesteryl ester transfer. At the end of the 
reaction the lower density particles are precipitated and the radioactivity remaining in 
HDL counted to calculate the percentage transfer.
5.2. Preparation of Donor Particles
Human and equine HDL3  were prepared from 20 ml of pooled plasma collected into 
potassium EDTA from healthy donors. The plasma was raised to density 1.125 g/ml 
by adding 3.66 g KBr, placed in a 26.3 ml polycarbonate centrifuge bottle (Beckman 
Instruments, Inc.) and overlayered with 5 ml of density 1.125 g/ml solution (1.96 g 
KBr in 10 ml dH2 0). After centrifugation at 50k rpm, 20°C for 24 hours, the less 
dense lipoproteins were removed in the upper 5 ml and the infranatant dialysed 
against Tris-saline buffer (0.15 M NaCl, 10 mM Tris, ImM EDTA, 0.05% NaN 3 , pH 
7.4) at 4°C overnight. A second batch of equine HDL was prepared from 20 ml 
plasma by rate-zonal ultracentrifugation, concentrated to 5 ml, and similarly dialysed.
To label the HDL, the following were dried down in a siliconised glass tube 
under a stream of nitrogen; 9 ul of triolein (Sigma T-7140) in hexane (lOmg/ml), 15 
ul of L-a-phosphatidylcholine (Sigma P-4279) in hexane (100 mg/ml), 8 . 8  ul 
butylated hydroxytoluene (Sigma B-1378) in chloroform (1 mM), 160 ul of [ la -  
2 a(n )- 3 H]cholesteryl oleate in toluene (160 uCi; Amersham International pic) and 
184 ul of cholesteryl oleate (Sigma C-9253) in hexane (lm g/ml). To this was added
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0.8 ml of Tris-EDTA buffer (50 mM Tris-HCl, 0.01% Na2 EDTA, pH 7.4), the tube 
flushed with nitrogen, covered with sealing film (Whatman International Ltd) and 
mixed on vortex for 10 mins. to give a cloudy suspension. This was then clarified by 
sonication for two 2 0  mins. bursts at 2  microns and transferred to a siliconised glass 
conical flask containing 20 ml of the dialysed HDL3, 1.66 ml of 14 mM 5,5'-dithio- 
Z?w-(2-Nitrobenzoic acid) (Sigma D-8130) and 0.2 ml of 0.4 M Na2EDTA containing 
4% NaN3. The mixture was incubated for 18 hours at 37°C under nitrogen. The 
[3 H]HDL was first isolated by raising the density of the solution to 1.215 g/ml by 
adding 0.349 g/ml KBr, overlayering with density 1.215 g/ml solution (as prepared 
for 4.2.) and centrifuging at 50k rpm, 20°C for 24 hours. The HDL was removed in 
the supernatant, adjusted to density 1.125 g/ml by adding 0.196 g/ml KBr, 
overlayered with density 1.125 g/ml solution and centrifuged as before to remove any 
remaining HDL2. The [3 H]HDL3  was then isolated from the infranatant by 
ultracentrifugation at density 1.215 g/ml. The supernatant was collected and loaded 
onto an 80 ml (1.5x44 cm) sepharose gel filtration column (CL-6 B; Pharmacia AB) 
and eluted by gravity with Tris-saline buffer at a flow rate of 11 ml/hour. Fractions 
were collected every 15 mins., and 50 ul aliquots removed for counting by liquid 
scintillation (in 5 ml Ultima-Gold; Packard Instrument Co.). The fractions comprising 
the peak of [3 H]HDL3  were pooled. The protein content of the mixture was assayed 
by the dye binding method of Bradford (1976), and where necessary concentrated to a 
protein content of approximately 0.5 mg/ml (5-8000 cpm/lOul), passed through a 0.2 
um filter (Minisart NML; Sartorius Ltd) and stored at 4°C.
5.3. P reparation  of Acceptor Particles
Plasma collected into potassium EDTA from fasting healthy volunteers was pooled 
and the density of 20 ml raised to 1.063 g/ml by adding 0.085 g/ml KBr. This was 
overlayered in a polycarbonate centrifuge bottle (Beckman Instruments, Inc.) with 
density 1.063 g/ml solution (0.973 g KBr in 10 ml dH 2 0 )  and centrifuged at 45k rpm, 
10°C for 20 hours. The supernatant was removed, overlayered with density 1.063 
g/ml solution and centrifuged for a second time. The supernatant from the second spin 
was dialysed overnight at 4°C against Tris-saline, sterilised by passing through a 0.2 
um filter (Minisart NML; Sartorius) and stored at 4°C. The protein content of the 
mixture was assayed by the method of Bradford (1976), and where necessary 
concentrated to give 0 . 8  mg/ml protein.
5.4. Assay M ethod
Polypropylene tubes (3.5 ml capacity) were coated in protein by incubating in 3% 
bovine serum albumin for one hour at 42°C, shaking off excess solution and leaving
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to dry at room temperature overnight. Lipoprotein deficient plasma was prepared as 
the enzyme source as described in section 4.2. and its protein content assayed by the 
method described by Bradford (1976).
The assay incubation consisted of 10 ul of [^H jH D L j, 10 ul of VLDL/LDL,
5 ul of 0.7 mM 5,5'-Dithio-b/s-(2-Nitrobenzoic acid) (Sigma D-8130), with LPDP and 
Tris-saline buffer up to a volume of 60 ul. In general, three to five tubes were set up 
for each sample containing volumes of LPDP in the range 1-35 ul so that percentage 
transfer could be plotted over a range of protein concentrations. Six blank incubations 
containing no LPDP were included in each assay. The tubes were incubated for 150 
mins. at 42°C with shaking (Varishaker-Incubator; Dynatech Laboratories Ltd) and 
the assay stopped by placing the tubes on ice and adding 150 ul chilled plasma. The 
VLDL/LDL were precipitated by adding 25 ul of heparin manganese (5000 units 
heparin (Sigma H-9133) /ml of 0.8 M M n C y , mixing and leaving the tubes to stand 
for 25 mins. on ice, and then pelleted by centrifugation at 2800 rpm, 4°C for 25 mins. 
The radioactivity in 150 ul of the supernatant was then counted (in 5 ml Ultima Gold; 
Packard Instruments Co.).
The percentage transfer of cholesteryl esters from super- (HDL) to infranatant 
(VLDL, LDL) was calculated as the difference between the counts in the blanks and 
each sample tube divided by the counts in the blanks. A curve was then plotted of the 
LPDP protein concentration against ^ transfer and the %transfer/ug protein taken 
from the linear portion of the curve, which was generally between 0 and 25-35 
% transfer.
6. ORAL FAT TOLERANCE TEST
6.1. Principle
The assimilation and clearance of lipids of dietary origin are studied by giving a bolus 
of fat labelled with retinyl palmitate and the magnitude of the post-prandial lipaemia 
is monitored by measuring plasma triglyceride concentrations. Retinyl esters are 
hydrolysed in the small intestine, absorbed into the adjacent mucosal cells along with 
cholesterol and monoglycerides and co-secreted in the chylomicron particle. 
Following chylomicron catabolism, these esters are taken up by the liver where they 
enter a storage pool and do not re-enter the circulation in VLDL, and are therefore 
truthful markers of the synthesis and clearance of chylomicrons.
6.2. Method
The oral fat load, for a 200 kg pony, consisted of 700 ml fresh cream, 50 g sucrose, 50 
g of dried skim milk, made up to 1.25 1 with water. To this was added 750,000 iU of 
retinyl palmitate (Ro-A-Vit; Roche) and the mixture homogenised with a kitchen
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blender. This was given through a nasogastric tube to animals that had been fasted for 
16 hours and blood samples (10 ml) collected into potassium EDTA at 0, 2, 4, 6 , 8  
and 10 or 24 hours. In all subsequent manipulations, the plasma was protected as far 
as possible from light and stored at 4°C.
Plasma triglyceride concentrations were measured as in section 1 . 1 . 
Chylomicrons and VLDL were isolated together from 4 ml plasma by flotation 
ultracentrifugation at density <1.006 g/ml. The retinyl palmitate in these fractions was 
quantified by HPLC as follows; 500 ul of sample was mixed with 500 ul normal 
saline, 50 ul acetic acid, and 50 ul retinyl acetate (10 ug/ml) as an internal standard. 
This was extracted into 1 ml diethyl ether and then a further 2 ml of diethyl ether and 
blown to dryness under a gentle stream of nitrogen. This was redissolved in 250 ul of 
isopropanol and the retinyl esters in 100 ul separated on a Brownlea Aquapore RP- 
300 reversed phase column (4.6x250 mm) with a guard of the same (4.6x30 mm) 
using a gradient of 50-100% acetonitrile in water . The column was eluted at a flow 
rate of 2 ml/min. and monitored at 326 nm (Gilson HPLC system consisting of a 
model 303 pump, 802 Manometric Module and Halochrome monitor). The retinoid 
absorption peaks were quantified by a HP 3396A Integrator (Hewlett-Packard Ltd) 
and the concentration of retinyl palmitate calculated by reference to those of the 
internal standards and five runs of retinyl acetate and palmitate (each 0.5 ug) external 
standards.
7. KINETIC ANALYSIS OF FREE FATTY ACID AND VERY LOW 
DENSITY LIPOPROTEIN TRIGLYCERIDE METABOLISM
7.1. Principle
Radiolabelled FFA and glycerol are injected into the patient as tracers of the 
synthesis, secretion and catabolism of triglyceride. Blood samples are collected at 
increasing intervals from this time point and the radioactivity in plasma FFA and 
VLDL triglycerides (VLDL-TG) counted. Percutaneous liver biopsies taken during 
the course of the study add information on the hepatic pools. The disappearance from 
plasma of the of FFA tracer, and the appearance and disappearance and of the tracers 
in VLDL-TG are analysed by a computerised multicompartmental modeling 
programme that provides values for the kinetic parameters that describe plasma FFA 
and VLDL-TG metabolism.
7.2. Preparation of Tracers
[2-3 H]glycerol (TRA-118) and [ l - 1 4 C]palmitic acid (CFA-23) were purchased from 
Amersham International pic and stored at -20° C. The tracers were either made up
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fresh on the day of study or frozen at -20°C. Aliquots of 500 or 1000 uCi of 
[^H] glycerol were made up in a total volume of 1 0  ml sterile normal saline and 
sterilised by filtration. Aliquots of 100 or 200 uCi of [1 4 C]palmitic acid were placed 
in polypropylene tubes and the toluene base blown off under a gentle stream of 
nitrogen. The fatty acids were converted to the potassium salt by adding 1  ml 
ethanol:water (1:1 v/v) containing 1 M K 2 CO3  and heating in a boiling water bath for 
2  mins.* and prepared for injection by adding 2.5 ml of 25% bovine serum albumin 
and the solution sterilised by filtration (0.45 um Acrodisc; Gelman Science). The 
containers were weighed before and after administration of their contents so that the 
injection volume could be accurately determined. Approximately 5 ul of each tracer 
was retained for counting by liquid scintillation.
7 3 .  Extraction o f Free Fatty  Acids and  Triglycerides
Blood samples were collected into EDTA, placed on ice and plasma harvested at 4°C. 
A five ml aliquot of this was used to spin up VLDL as described in section 2.3. 
Percutaneous liver biopsies were obtained via a right flank approach on a line 
between the tuber coxa and the point of the shoulder at the thirteenth intercostal 
space. The area was surgically prepared and infiltrated with 2% lignocaine. An 11.4 
cm, 14 gauge Tru-Cut biopsy cannula with a 20 mm specimen notch (Baxter Health 
Caie Lid) was inserted through a stab incision in the skin and directed towards the 
contralateral elbow. The biopsy material was placed immediately in chilled sterile 
normal saline, transported to the laboratory, blotted dry and frozen under nitrogen at - 
20°C.
The lipids were extracted from plasma, VLDL and the liver specimens by the 
method of Folch, Lees and Sloane Stanely (1957). To 0.5 ml plasma or 0.9 ml VLDL 
was added 15 ml chloroformrmethanol (2:1), which was mixed on rollers (Spiramix 5; 
Denley-Teeh Ltd) for 30 mins. at 4°C and filtered through paper (No 1; Whatman 
International Ltd) into glass graduated tubes. The solid residue was washed with 5 ml 
methanol and 10 ml chloroform. The liver samples were weighed (10-30 mg wet 
weight) and homogenised in 1 ml methanol for 1  min., then 2  ml chloroform was 
added and homogenisation continued for a further 2 mins. This solution was filtered 
as for plasma/VLDL, the solid residue was resuspended in 3 ml chlorofomr.ether, 
filtered and washed with 1 ml methanol .and 2 ml chloroform. To the combined 
filtrates of each extraction, a quarter volume of 0.88% KC1 was added, the solution 
shaken and allowed to settle. The upper layer was removed and a quarter of the 
volume of the lower layer of watenmethanol ( 1 : 1 ) added, the tube shaken and allowed 
to settle. This was washed with a second quarter volume of 0.88% KC1, shaken,
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allowed to settle and the upper aqueous layer discarded. The infranatant was then 
blown to dryness under nitrogen in a water bath at 56°C.
The free fatty acids and triglycerides were separated by thin layer 
chromatography. The extracted lipids were dissolved in 100 ul chloroform and 
spotted onto silica sheets (Empore; Analytichem International) which were run in a 
mixture of petroleum ethendiethyl ethenacetic acid (82:18:1 parts). Standards of 200 
mg/m l in chloroform of oleic acid (Sigma 0-0750) and triolein (Sigma T-7140) stored 
in 25 ul aliquots at -20°C were used. The sheets were developed by exposure to 
iodine crystals, the FFA (plasma) and triglyceride (VLDL and liver) regions were cut 
out, placed in liquid scintillation vials to which was added 1 ml toluene and 1 0  ml 
liquid scintillant (Ultima-Gold; Packard Instrument Co.) and counted for 14C and 3H 
activity. The recovery of activity by this method was 71% (n=5), necessitating that 
the measured cpm be multiplied by 1/0.71 in the calculation of specific activity as the 
FFA and triglyceride masses were measured before extraction.
Plasma FFA and VLDL-TG concentrations were determined as in section 1 . 1 . 
Only 50 ul of the extracted hepatic lipids were applied to the TLC sheets, the 
rem ainder was dried down and re-dissolved in 250 ul isopropanol and 250 ul water 
and used to measure FFA and triglyceride concentrations.
7.4. Modification of the Extraction Procedure
Because of the high lipid content of plasma and VLDL from ponies with 
hyperlipiaemia, the separation o f triglycerides from FFA on the TLC plates was poor 
as the spotted samples streaked along the length of the plate. VLDL-TG was therefore 
prepared free of the major sources of tracer contamination, i.e. phosholipids and FFA, 
by using a modification (Zech, Grundy, Steinberg and Berman 1979) of the Zeolite 
absorption method of Fletcher (1968). In this, 0.9 ml of VLDL was added dropwise to 
12 m l isopropanol in polypropylene tubes, which were shaken and 2 g of Zeolite 
mixture (Sigma 990-2) added that had been activated at 110°C overnight. The tubes 
were then mixed on rollers at room temperature for 30 mins., the supernatant was 
recovered after centrifugation at 3500 rpm for 15 mins. and dried down under 
nitrogen at 84°C (DB-3 Dri-Block, SC-3 Sample Concentrator; Techne). The extract 
was redissolved In 1.2 ml isopropanol and 1 ml removed for counting by liquid 
scintillation (in 10 ml Ultima-Gold; Packard Instruments Co). The remainder was 
assayed for triglyceride, as in section I.I., using isopropanol as a blank.
7.5. Data Analysis
A multicompartmental computer model describing the relationships between the
plasma precursor pools, the hepatic triglyceride synthetic pools and the plasma
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VLDL-TG pools was developed using the CONSAM 30 programme (Resource 
Facility for Kinetic Analysis, Seattle, USA) and is described in detail in Chapter VII.
8. STATISTICAL METHODS
Non-parametric tests of significance were used throughout this thesis using the 
M initab release 7 statistical package (Ryan, Joiner and Ryan 1985). Two group 
comparisons were resolved by the Mann-Whitney test and three or more groups 
com pared by the Kruskal-Wallis test. The Sign test was used to analyse paired data 
where derived from the same individual. The associations between variables were 
assessed using linear regression analysis. The level of significance, unless stated 
otherwise, was taken as p < 0.05.
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CHAPTER III
THE ISOLATION, CHARACTERISATION, AND QUANTIFICATION OF 
THE EQUINE PLASMA LIPOPROTEINS
1. INTRODUCTION
Much of the available knowledge of lipid transport in the horse concerns the actual 
transport vehicles, viz. the plasma lipoproteins, and was extensively reviewed in 
Chapter I. In brief, early studies that used paper electrophoresis showed that the horse 
possessed a-lipoproteins (HDL) as the predominant class and identified a B-migrating 
class typical of LDL. Subsequently, analytical and density gradient ultracentrifugation 
were used to demonstrate a third class corresponding to VLDL, and showed that LDL 
was disperse comprising two subfractions. These studies indicated that, in contrast to 
man, HDL was homogeneous with respect to particle size, density and composition. It 
is only recently that the distribution of apolipoproteins amongst these classes has been 
considered. In addition, these latter studies comprised a total of 11 subjects, all 
Thoroughbred horses, and with the exception of those of Le Goff et al. (1987, 1989) 
included one or two horses amongst a variety of laboratory and domestic species.
The investigations described in this and the following two chapters were 
therefore planned to provide more detailed and comprehensive information on the 
structure and function of the equine plasma lipoproteins. This was accomplished 
using techniques novel to the species, a much larger number of animals than before, 
and by paying attention to the fact that differences in lipid transport might exist 
between breeds that are resistant to, and those that are susceptible to, equine 
hyperlipaemia. Lipoproteins were first isolated from plasma using independent 
techniques that allowed direct visualisation of their size and density distribution, and 
provided material for more exact definition of structural heterogeneity within each 
class. The chemical composition of each class was then analysed and the distribution 
of the apolipoproteins defined and quantified. Finally the plasma concentrations of the 
major lipoprotein classes were measured. The results provided not only original and 
fundamental information on the equine lipoprotein transport system, but were the 
foundation for the investigations of plasma lipoprotein metabolism in ponies with 
hyperlipaemia described in Chapters VI and VII.
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2 . SUBJECTS, SAM PLES AND METHODS
Blood samples were collected from healthy adult (>2 years old) Thoroughbred horses 
and Shetland ponies, either geldings or non-pregnant mares. The animals were housed 
and fed a maintenance diet o f hay and concentrates, which was withdrawn for the 16 
hours prior to sampling. Plasma was separated within two hours of collection by 
centrifugation at 2,400 rpm for 15 mins., kept at 4°C and used that day. Where 
indicated, proteolysis of apolipoproteins was blocked by placing the blood samples on 
ice immediately after collection, separating the plasma at 4°C after which 
chloramphenicol (0.1 mg/ml), gentamicin (0.1 mg/ml), NaN 3  (0.05 mg/ml) and 
aprotinin (200 KiU/ml) were added.
The methods employed are described in their entirety in Chapter II. Plasma 
lipoproteins were isolated by gel filtration from eight Thoroughbred horses and 12 
Shetland ponies and the size distribution of particles within each class examined by 
electron microscopy. Lipoproteins were also separated from eight Thoroughbred 
horses and eight Shetland ponies by rate-zonal ultracentrifugation and heterogeneity 
within the LDL and HDL classes defined using non-denaturing polyacrylamide 
gradient gel electrophoresis. The identity of the isolated classes was confirmed by 
reference to the elution characteristics and chemical composition of the human 
lipoproteins isolated by similar techniques (Rudel, Lee, Morris and Felts 1974; Patsch 
et al. 1974). Size, heterogeneity within VLDL was investigated by gel filtration, as 
detailed in section II.2.1, but the matrix of the columns was replaced with 2 % agarose 
(BioGel A50m; Bio-Rad Laboratories Ltd) which resolves two populations of VLDL 
in man, one peak at the void volume and another broad peak in the included volume 
(SatacfaL 1972).
The lipid and protein compositions of VLDL, IDL, LDL and HDL isolated by 
sequential flotation ultracentrifugation from 18 Thoroughbred horses and 18 Shetland 
ponies were then determined. The distribution of the apolipoproteins in these classes 
was examined by SDS-PAGE, with reference to apoA-I, apoA-II and apoC partially 
purified by HPLC, and by Western blotting of apoB. The quantitative distribution of 
the proteins was determined by computer assisted densitometry of the stained gels. 
Plasma lipid and lipoprotein concentrations were measured in these 36 animals as 
outlined in section 1 1 . 1 .1 .
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3. RESULTS
3.1. Gel Filtration
A typical protein absorbance profile obtained following the elution of lipoproteins 
from the agarose gel column is shown in Fig. 4. Three well separated peaks were 
identified in each of the animals examined, with elution characteristics and 
compositional analyses that were similar to those of human VLDL, LDL and HDL. 
The first (VLDL) peak eluted soon after the void volume (calculated using dextran 
blue) and was typically triglyceride rich, and poor in cholesterol, phospholipids and 
protein, relative to the other classes (Table 4; Appendix 3) Examination of these 
fractions under the electron microscope revealed that the particles spanned a 
considerable size range, from 30-60 nm in diameter, with a mean of 45 nm (Fig. 5). 
The second peak (LDL) comprised particles in the range 20-30 nm that were depleted 
of triglyceride and enriched in each of the other components, especially cholesteryl 
esters relative to VLDL. The third peak (HDL) was composed of a more 
homogeneous population of particles than the first two, in the range 5-12 nm, and was 
rich in protein and poor in neutral lipids relative to VLDL and LDL.
Two other minor peaks were variably present in the profiles; the first extended 
the tail of the VLDL curve and was taken to represent IDL. The second followed 
HDL eluting near the total volume of the column at approximately 200 ml, it had a 
maximum OD 2 gonm 0 - 2 0  and was almost entirely composed of protein and 
therefore represented trace contamination of the initial lipoprotein preparation by 
plasma proteins.
The elution profiles for each animal were analysed and compared to provide 
information on the size distribution of lipoproteins between the two breeds of horse 
(Appendix 4). The peak elution volume for each curve was determined as a meter of 
the modal particle size, and the width of each peak was taken as a measure of the 
dispersity of particle size within each lipoprotein class. In order to reduce variation 
between runs, the same column was used for the duration of the study ( 6  weeks); 
however, there was an indication of some settling of the packing bed over the course 
o f the initial runs and in these cases the elution volumes were corrected with respect 
to that of the albumin peak. The results (Table 5) showed only small variations in 
particle size and dispersity between individuals of the same breed, and between 
animals of the two breed groups. Measurement of the amplitude of the peaks provided 
an assessment of the plasma concentration of each lipoprotein and showed that 
quantitative differences might exist between the two breeds, as the VLDL peak was 
significantly higher in the Shetland ponies than the Thoroughbreds, a result that 
would later be confirmed by fuller quantitative analyses.
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Figure 4. Profile of density <1.225 g/ml lipoproteins eluted from 6% agarose gel.
Lipoprotein
Percentage Particle Mass
Cholesterol Triglyceride Phospholipid Protein
VLDL 15.2 ±3.6 53.5 ±5.6 14.2 ±3.2 15.6 ±3.9
LDL 41.1 ± 6 . 8 5.5 ±1.6 23.4 ±3.3 28.1 ±4.2
HDLa 22.7 ±4.2 5.8 ±4.4 26.7 ±3.8 44.6 ±5.4
an=19
Table 4. Chemical composition of lipoprotein classes isolated from eight 
Thoroughbred horses and 12 Shetland ponies by gel filtration (mean ±sd).
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Figure 5. Electron micrographs of intact lipoproteins negatively stained with 
phosphotunstic acid: top VLDL; middle LDL; bottom HDL (x200,000).
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Parameter
VLDL LDL HDL
TB SP TB SP TB SP
Elution Volume 80.4 78.9 119.4 1 1 1 . 0 157.6 154.7
(ml) ± 2 . 1 ± 1 . 2 ±2.5 ±3.9 ± 2 . 6 ±3.5
Peak Width 10.4 1 1 . 1 28.4 31.6 34.8 36.2
(ml) ±0.7 ± 0 . 8 ± 2 . 8 ±3.5 ±3.0 ±2.9
Peak Height 0.17 0.46* 0.13 0.16 1.80 1.37
( ° D 280nm) ± 0 . 1 1 ±0.23 ±0.15 ± 0 . 1 1 ±0.23 ±0.40
* p < 0 . 0 1
Table 5. Comparison of elution profiles of lipoproteins from agarose gel from eight 
Thoroughbred horses (TB) and 12 Shetland ponies (SP) (mean ±sd).
All three of the major lipoprotein classes had symmetrical elution profiles. 
The VLDL and HDL curves had sharp peaks, but that of LDL was shallow and broad 
hinting at the size heterogeneity within that class. Despite the wide span of particle 
sizes seen in VLDL under the electron microscope and although the VLDL peak from 
four ponies appeared broader in the columns of 2% agarose and extended further into 
the included volume, there were no maxima or minima in the elution profiles to 
indicate that discrete subpopulations of VLDL exist in the equine species.
3.2. Rate-zonal Ultracentrifugation
On unloading the HDL zonal gradient, the emergence of the lower density 
lipoproteins (VLDL, IDL, LDL) early in the effluent was marked by visible turbidity 
of the first fraction collected. The profile then returned to baseline by the sixth or 
seven fraction after which there was a rapid rise in absorbance as the HDL emerged 
(Fig. 6 ). The HDL presented a single sharply peaked Gaussian profile in all the 
animals that suggested that the particles in this class were homogeneous with respect 
to flotation density. In each case, the HDL eluted between fractions 10 (±1) and 25 
(± 1 ) and was cleanly separated from both the lower density lipoproteins and the 
plasma proteins that succeeded it in the gradient effluent. The fractions composing
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the HDL peak were concentrated from four Thoroughbred horses and four Shetland 
ponies and their compositional analysis is shown in Table 6  (Appendix 5).
The possibility that size heterogeneity might exist within the HDL class, 
although apparently homogeneous with respect to flotation density, was refuted by the 
by the single band presented on polyacrylamide gradient gels by the concentrated 
zonal material (Fig. 7). This band represented a mean particle diameter of 8.37 nm (sd 
±0.08, range 8.24-8.48 nm; Appendix 5).
Separation of the lower density lipoproteins in the second gradient led to the 
appearance of VLDL in the first two fractions signalled by its turbidity and confirmed 
by its compositional analysis (Table 6 ; Appendix 5). Thereafter the trace declined to 
baseline by the tenth fraction with a shallow slope that was assumed to contain IDL. 
The LDL elution profile was markedly asymmetric and was resolved into three 
overlapping curves labelled LDL1? LDL2  and LDL 3  in order of increasing particle 
density (Fig. 6 ). The elution characteristics of each subfraction were a constant 
feature of each of the 16 animals examined; LDL! appeared between fractions 10.5 
(±1) and 13 (±1), LDL2  between fractions 14 (±1) and 18 (±1), and LDL 3  between 
fractions 19 (±1) and 24.5 (±1). Attempts were made to improve the resolution of 
these subfractions by increasing the sample volume and by using the greater gradient 
length provided by the Beckman T il5 rotor, but only succeeded in widening the LDL 
profile without enhancing the separation of the subfractions.
In the eight animals for which HDL composition and size were established, 
the LDL profile was divided into its constituent subfractions at the points of inflection 
and similarly analysed (Table 6 ; Appendix 5). The results indicated that as particle 
flotation density increased, there was an increase in cholesterol and progressive 
reduction in triglyceride content. The contributions of protein and phospholipids to 
particle mass remained relatively constant along the gradient. Although the mean 
cholesteryl ester contents of LDL| and LDL2  and were similar (43.1% and 42.8%, 
respectively), LDL 2  contained a greater mean mass of free cholesterol (4.4%) than
either LDLj (1.3%) or LDL 3  (1.3%).
Application of these fractions to polyacrylamide gradient gel electrophoresis 
showed that the changes in core composition along the LDL density range were 
accompanied by a progressive decrease in particle diameter represented by a pattern 
of three independently migrating bands (Fig. 7) Although there was some overlap 
between adjacent fractions, discrete maxima were identifiable both visually and by 
densitometric scanning, and the mean (±sd, range) particle diameters at each 
maximum calculated from their Rf were statistically independent of one another, 
LDL! 26.4 nm (±1.1, 24.4-27.8), LDL2  24.5 nm (±1.0, 23.6-25.8), LDL3  22.4 (±0.7, 
21.4-23.4) (Appendix 5).
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Figure 6. Elution profiles of equine HDL (top) and LDL (bottom) isolated by rate- 
zonal ultracentrifugation. The fractions within the shaded areas were pooled and 
concentrated for compositional analysis and gradient gel electrophoresis.
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Figure 7. Electrophoresis of HDL (left) on a 2-16% polyacrylamide gradient gel, and 
LDL subfractions (right) on a 4-30% polyacrylamide gradient gel. The lipoproteins 
were prepared by rate-zonal ultracentrifugation and the positions of the molecular 
weight markers are shown in the centre.
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Lipoprotein
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
VLDL 14.8 ±1.8 53.8 ±3.2 ND 12.4 ±1.0 20.0 ±1.3
L D L X 43.1 ±1.4 10.3 ±1.6 1.3 ±0.8 16.8 ±1.4 28.2 ± 2 . 0
l d l 2 42.8 ±3.2 7.9 ±1.4 4.4 ±1.1 19.4 ±0.9 25.3 ±2.7
LD L3* 49.9 ±2.9 5.6 ±0.8 1.3 ±0.7 17.5 ±1.2 24.7 ±2.1
HDL 24.0 ±0.9 3.9 ±1.3 0.6 ±0.3 28.5 ±1.1 43.1 ±1.7
an=7
Table 6. Chemical composition of VLDL, LDL subfractions and HDL isolated from 
four Thoroughbred horses and four Shetland ponies by rate-zonal ultracentrifugation 
(mean ±sem).
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3.3. Chemical Composition of the Lipoproteins
The chemical composition of VLDL, LDL and HDL fractionated by sequential 
flotation ultracentrifugation is shown in Table 7  (Appendix 6 ). Free cholesterol was 
below the level of detection in VLDL, and these lipoproteins contained more 
triglyceride and less cholesteryl esters than those prepared by gel filtration or rate- 
zonal ultracentrifugation. The lipid in the IDL fractions was below the level of 
detection, precluding analysis of lipoprotein composition. The triglyceride content of 
HDL was lower and the mass of free cholesterol higher than in that isolated by gel 
filtration and rate-zonal ultracentrifugation.
In VLDL from the Shetland ponies, the mass of cholesteryl esters was 
significantly higher and the protein content significantly lower than in the 
Thoroughbred horses. The mean mass of protein in LDL was also lower in the 
Shetland pony, but was not associated with any difference in the ratio of core to shell 
mass as the phospholipid mass of these lipoproteins was higher than that of the 
Thoroughbreds.
Percentage Particle Mass
Lipoprotein Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
VLDL TB 7.8 ±1.7 57.5 ±3.9 ND 13.8 ±2.0 20.9 ±4.1
SP 10.1* ±1.7 58.9 ±3.9 ND 15.3 ±2.3 16.6* ±2.4
LDL TB 41.9 ±5.1 5.4 ±1.9 4.7 ±2.1 21.2 ±3.5 27.0 ±4.0
SP 41.0 ±5.2 5.7 ±2.2 4.0 ±2.4 24.0 ±3.6 24.0 ± 6 . 6
HDL TB 20.2 ±3.3 0.7 ±0.6 2.6 ±0.9 26.9 ±4.0 49.6 ±5.0
SPa 19.7 ±4.1 0.7 ±0.4 2 . 8  ± 1 . 0 27.2 ±4.4 49.5 ±7.7
* p < 0 .0 1 , an =17
Table 7. Chemical composition of VLDL, LDL, and HDL isolated from 18 
Thoroughbred horses (TB) and 18 Shetland ponies (SP) by sequential flotation 
ultracentrifugation (mean ±sd).
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3.4. Distribution of the Apoiipoproteins
Equine VLDL and LDL presented two clearly resolved bands on SDS-PAGE with 
molecular weights of 542.5k Da (±15.3; mean ±sd, n=12) and 492k Da (±10.1), that 
migrated close to the apoB-100 component of human LDL. A third band with was 
found in VLDL (Fig. 8 ) but not LDL. The molecular weight 273.5k Da (±7.2) of this 
protein and the ratio of its mass to that of the larger apoB-100 band (50.4% mean, 
range 48-52%) were similar to those of human apoB-48.
The identity of all three bands as species of apoB was first confirmed by 
Western blot analysis of VLDL using rabbit anti-horse LDL as the first antibody (Fig. 
9; lanes 1 and 2). The possibility that the second and third bands might result from the 
proteolysis of apoB-100 was eliminated by demonstrating their persistence in VLDL 
after a cocktail of antiproteases had been added to the plasma immediately after 
separation (Fig. 9; lanes 3 and 4). Nor did they appear an artefact of the SDS-PAGE 
system used, as human VLDL and LDL similarly prepared present only a single 
apoB-100 band. Finally, the apoB-48 band was present in VLDL from two ponies that 
had been fasted for 48 hours (Fig. 9; lanes 5 and 6 ) allaying concerns that this might 
represent the persistence in the density <1.006 g/ml fraction of chylomicrons or their 
remnants. The two larger apoB bands contributed equally to the total protein mass of 
both VLDL and LDL, and are collectively referred to as apoB-100 as they appeared to 
be co-transferred from VLDL to LDL just as human apoB-100, although it may be 
argued that on the centile system used to name apoB, the second band in VLDL and 
LDL should be called apoB-91 and the third in VLDL apoB-50.
Three protein peaks were partially purified from equine HDL by HPLC. The 
first and dominant peak eluted between 12 and 27 ml with a retention time similar to 
that of human apoA-I and presented a single band on SDS-PAGE with a molecular 
weight of 29.5k Da (Fig. 10). The second peak eluted in the tail of the apoA-I 
between 30 and 54 ml in a position similar to apoA-II and contained apoA-I and a 
trace component with molecular weight 7.5k Da when electrophoresed under reducing 
conditions. This was purified free of apoA-I by a second ELPLC run (Fig. 10) The 
third peak was well separated from the first two, co-eluting with the human C 
peptides between 54 and 78 ml and contained two bands of molecular weight 14.5k 
and 12k Da that were assumed to represent the equine equivalent of apoC-II and 
apoC-III (Fig. 10).
The distribution of these proteins amongst VLDL, LDL and HDL is also 
shown in Fig. 10. Their relative contributions to lipoprotein protein mass was 
quantified in eight Thoroughbred horses and 18 Shetland ponies (Table 8 ; Appendix
7). Apolipoprotein B was confined to VLDL and LDL where it was the major protein. 
Apolipoprotein A-I was the major protein of HDL and was also in VLDL.
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212k Da
ApoB-100
ApoB-48
Figure 8. Separation of VLDL apoB by SDS-PAGE. The photograph shows the top 
third of the Coomassie stained gel with the position of a 212k Da marker on the left.
1 2 3 4 5 6
Figure 9. Western blot of VLDL apoB from SDS-PAGE. Lanes 1 and 2, native 
plasma VLDL; lanes 3 and 4, VLDL prepared from plasma treated with antiproteases; 
lanes 5 and 6, density <1.006 g/ml fraction from two ponies fasted for 48 hours.
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IB-100
<B-48
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4C-II
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*  4A-I
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V L H S
Figure 10. Resolution of VLDL, LDL and HDL apolipoproteins by SDS-PAGE. 
Lane V, VLDL; L, LDL; H HDL. The lane marked S consists of a cocktail of apoA-I, 
apoC-II, apoC-III and apoA-II purified by HPLC, and the position of molecular 
weight markers is shown on the left.
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Percentage of Protein Mass
Lipoprotein Breed B-100 B-48 E A-I C-II c-m A-II
VLDL TB 23.6
±2.7
10.9 10.5 
±1.6 ±4.3
4.3
±1.5
22.9
±3.8
27.8
± 2 . 2
-
SP 2 0 .8 *
±3.9
11.5 9.5 
±2.8 ±4.8
8 . 1 *
±4.0
22.5
± 6 . 1
31.3
±7.1
—
LDL TB 73.4
±6.5
6.5
± 2 . 8
— 9.4
±3.0
1 0 . 6
±2.7
—
SPa 77.8
± 6 . 2
6.5
±2.5
— 7.0
±2.3
8.9
+5.0
—
HDL TB — 6 . 6
± 2 . 0
79.9
±3.4
3.3
+2.7
3.0
+ 1 . 8
7.3
±2.5
SPb — 4.3*
±2.7
79.5
±4.9
4.5
±2.4
5.1*
+2 . 0
7.1
±3.5
* p < 0.05; an= I 6 , bn=17
Table 8. Apolipoprotein composition of the plasma lipoproteins isolated from eight 
Thoroughbred horses (TB) and 18 Shetland ponies (SP). The relative mass of each 
protein was calculated from the area under the curves of densitometric scans of the 
Coomassie stained gels.
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Apolipoprotein A-II was confined to HDL where it was very much the minor protein. 
The C peptides, apoC-II and apoC-III were present in significant amounts in VLDL 
and to a much lesser extent in LDL and HDL. In some gels, apoC-III appeared to be 
resolved into two bands, although it was not determined whether the variable upper 
band represented an isoform of apoC-III or another of the C peptides, and where 
present its mass was included in that of apoC-III. In addition, a broad band of 
molecular weight 39k Da was identified in VLDL, LDL and HDL and taken to 
represent apoE. A faint band with a molecular weight of 45k Da was occasionally 
identified in some HDL preparations, but was not quantified and may have 
represented apoA-IV that has remained with the HDL despite ultracentrifugation.
In VLDL, the relative mass of apoB-100 appeared significantly higher in the 
Thoroughbred horses than in the Shetland ponies so that the ratio of apoB-100 to 
apoB-48 was 2.2:1 in the former and 1.8:1 in the latter. There was a significantly 
greater mass of apoA-I in VLDL from the Shetland ponies than the Thoroughbreds, 
and the Thoroughbred HDL contained on average 53% more apoE and 41% less 
apoC-III than that of the Shetland ponies. The protein composition of LDL was 
similar in both breed groups.
3.5. Plasma Lipid and Lipoprotein Concentrations
Plasma cholesterol, triglyceride and lipoprotein cholesterol concentrations for the 18 
Thoroughbred horses and 18 Shetland ponies are summarised in Table 9 (Appendix
8 ). There was no difference between the two groups in total, LDL and HDL 
cholesterol concentrations. The concentrations of triglyceride and VLDL cholesterol 
were significantly higher in the Shetland ponies than the Thoroughbred horses.
Animal Cholesterol Triglyceride VLDL LDL HDL
Thoroughbred 2.23 0.34 0 . 2 0 0.61 1.41
±0.27 ±0.16 ± 0 . 1 0 ± 0 . 2 1 ± 0 . 2 1
Shetland pony 2.13 0.48* 0.29* 0.30 1.32
±0.41 ±0.17 ±0.14 ± 0 . 2 2 ±0.29
* p < 0.05
Table 9. Plasma cholesterol, triglyceride and lipoprotein cholesterol concentrations 
(mmol/1) in 18 Thoroughbred horses and 18 Shetland ponies (mean ±sd).
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4. DISCUSSION
4.1. Physical Properties of the Equine Plasma Lipoproteins
Gel filtration and rate-zonal ultracentrifugation were used in the initial isolation of 
lipoproteins as they do not presume knowledge of the density limits of the lipoprotein 
classes. While both techniques have been widely used to examine the plasma 
lipoproteins of other species, neither had been applied to the horse. Agarose gel 
filtration is renowned as a simple, gentle, and non-destructive means of fractionating 
lipoproteins from both healthy and hyperlipidaemic subjects (Margolis 1967; Sata, 
Estrich, Wood and Kinsell 1970; Rudel et al. 1986). In addition, the rate-zonal 
ultracentrifugation method has a high sample volume capacity that provided for the 
separation and analysis of lipoprotein subfractions. By monitoring of the protein 
content of the eluants at OD280nm’ techniques provided ready visualisation of the 
size and density distribution of the lipoprotein particles. The previous studies that had 
defined the density distribution of the equine lipoproteins, with the exception of the 
single animal examined by Hollanders et al. (1986), had relied upon lipid prestaining 
of the sample to provide visual identification of lipoprotein classes that were then 
removed manually from the gradient. The potential that such techniques possess for 
disturbing the gradient and contaminating the lipoprotein fractions was eliminated in 
the present study by collecting the freely flowing eluant.
Columns of 6 % agarose gel were used on the recommendation of Rudel et al. 
(1986) and provided good separation of the major equine lipoprotein classes from one 
another and from the other plasma proteins. Preliminary ultracentrifugation of the 
plasma samples was performed to concentrate the lipoproteins so that a smaller 
sample volume could be applied to the column to maximise its resolution. 
Visualisation of individual lipoproteins under the electron microscope indicated that 
both the VLDL and LDL peaks contained particles spanning a wide range in size. The 
apparent diameters of both VLDL (30-60 nm) and LDL (20-30 nm) are considerably 
larger than those of 10-48 nm for VLDL and 11-15 nm for LDL reported by Le Goff 
et al. (1987). The source of this discrepancy is not clear, as the masses of neutral 
lipids, the determinants of core volume and therefore particle size, were similar in 
both classes to those found here. In support of the present data, the size of LDL was 
independently calculated in the range 21.4-27.8 nm using non-denaturing 
polyacrylamide gradient gel electrophoresis.
The failure to demonstrate heterogeneity within the equine HDL class, despite 
using a high resolution stepped gradient designed to maximise the fractionation of 
HDL by rate-zonal ultracentrifugation, was consistent with previous reports. Although 
this technique might be criticised on the basis that the particles do not reach 
equilibrium within the gradient, the single HDL band found on non-denaturing
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polyacrylamide gradient gel electrophoresis justified the conclusion that this class was 
homogeneous with respect to particle size and density. Equine HDL occupied a 
position in the rate-zonal gradient similar to that reported for human HDL 3  (150-300 
ml) rather than that of HDL2  (90-140 ml) (Patsch et al. 1974). This alliance with the 
smaller, denser human subtraction was also borne out by the small size of the 
particles, their low triglyceride content and the predominance of apoA-I as their 
protein. Le Goff et al. (1987) commented that the size range of particles in HDL was 
particularly homogeneous (5.1-7.3 nm), and although they found a second HDL band 
in one animal, this was later shown to contain apoB (Le Goff et al. 1989) and may 
therefore have resulted from minor contamination of the HDL fraction by LDL.
The resolution of LDL provided by rate-zonal ultracentrifugation reinforced 
previous reports of its heterogeneity from analytical and density gradient 
ultracentrifugation and allowed us to demonstrate the existence of a third population 
of particles in this class. The size and lipid content of the subfractions support the 
conclusion that they represent discrete, thermodynamically stable subpopulations of 
LDL, rather than the presence of small IDL or large HDL particles in the LDL density 
range. The density distributions and lipid compositions of the two subfractions LDL 2  
and LDL3, rather than those of LDL], agree with the characteristics of the two 
subfractions previously described (Le Goff et al. 1987) indicating that LDL] is the 
novel species.
Heterogeneity of LDL is now well established in man (Shen et al. 1981) and 
animal models of atherosclerosis including primates (Puppione, Nicolosi, Kowala and 
Schumaker 1989) and swine (Checovich, Fitch, Krauss, Smith, Rapacz, Smith and 
Attie 1988). In contrast with HDL, the metabolic origins of heterogeneity within this 
class are not understood (Rudel, Parks, Johnson and Babiak 1986), but are clearly of 
interest because of the apparent link between a preponderance of certain cholesteryl 
ester rich LDL subfractions and the incidence of CAD in man and the animal models. 
Possible mechanisms for this heterogeneity may include the remodelling of LDL by 
the agencies of LPL, CETP and HL (Gambert et al. 1990), and the interaction of 
genetic (Austin and Krauss 1986) and environmental factors (Pownall, Jackson, Roth, 
Gotto, Patsch and Kummerow 1980). To what extent the individual subfractions 
represent LDL that arises from VLDL precursors or direct synthesis is not clear, but 
there is evidence that the subfractions differ in their kinetic behaviour (Swinkels, 
Demacker, Hak-Lemmers, Mol, Yap and van't Laar 1988; Marzetta et al. 1989).
The data presented here may help in understanding the origins of LDL 
heterogeneity. First, it should be noted that such heterogeneity exists even though 
LDL levels are much lower in the horse than in the other species for which this 
feature is described. Secondly, the pattern of subfraction size and density was
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constant between individuals and might indicate that the underlying mechanism is an 
inherent, basic feature of the equine lipoprotein system rather than the product of an 
acquired or environmental factor. And thirdly, as shown in the following chapter, the 
horse has no significant CETP activity indicating that the heterogeneity arises in the 
absence of neutral lipid exchange. Indeed, the changes in neutral lipid content of LDL 
along the density gradient could be held consistent with the step wise hydrolysis of 
core triglyceride by the endothelial lipases. More exact interpretation of the 
compositional data is hampered by the poor resolution of the fractions and the large 
standard errors in the data. However, comparison of the triglyceride and cholesteryl 
ester contents of LDLj and LDL 3  suggests that these subfractions may represent the 
two extremes of the LDL delipidation pathway. On the other hand, the reduction in 
particle size from LDLj to LDL 2  is accompanied by only minor changes in the 
neutral lipid content, while the surface is relatively enriched in free cholesterol, and it 
is therefore possible that these particles may originate independent of VLDL 
precursors.
Despite their obvious merits, gel filtration and rate-zonal ultracentrifugation 
suffered as preparative techniques in that their analytical capacity was low and at best 
restricted to four samples per week. In addition, both resulted in dilution of the 
samples that necessitated considerable concentration of the fractions prior to analyses. 
The unavoidable precipitation, contamination and loss of lipoprotein components 
during ultrafiltration was perhaps the source of the large standard errors in the 
compositions presented in Tables 4 and 6 . For these reasons sequential flotation 
ultracentrifugation was used to isolate the lipoprotein fractions in a ready 
concentrated form from a number of animals with considerably less demands on 
technical time. Initial concerns that the human density ranges would be unsuitable for 
the equine lipoprotein classes were allayed by the absences of apoB from HDL and 
apoA-I from LDL on SDS-PAGE. This refuted a previous suggestion that 1.070 g/ml 
should serve as the upper density limit for equine LDL made on the basis that the 
density >1.063 g/ml fraction displayed a minor 8 -migrating component on gel 
electrophoresis (Robie et al. 1975b).
4.2. Chemical Composition of the Lipoproteins
The compositions of VLDL, LDL and HDL isolated by the three methods here are 
very similar to those previously reported from density gradient ultracentrifugation (Le 
Goff et al. 1987), with the notable exception that these authors detected free 
cholesterol in VLDL (approximately 5% particle mass). There was good agreement in 
the compositions of the lipoprotein classes isolated by each of the three methods used 
here, with the notable exception that the masses of cholesteryl esters in VLDL, and
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triglyceride in HDL, were higher when isolated by gel filtration and rate-zonal 
ultracentrifugation. These differences are not readily explicable, but may have 
resulted from contamination of the VLDL with LDL, and HDL with LDL during 
concentration. The lower protein content of the VLDL isolated by gel filtration might 
be due to superior resolution of this lipoprotein from other plasma proteins in the gel 
matrix or have resulted from the loss of apolipoproteins from the surface of VLDL in 
the preliminary ultracentrifugation step or during the passage of particles through the 
gel. In refute of the former, the VLDL prepared by flotation ultracentrifugation was 
found to be free of contaminating proteins on SDS-PAGE. The protein content of 
VLDL reported here, and by Le Goff ex al. (1987), is high relative to that of human 
VLDL, but again does not appear to represent contamination of the density <1.006 
g/ml fraction with other plasma proteins.
The existence of multiple species of apoB in the horse is a peculiar and 
fascinating feature of its lipid transport system. The pattern presented on SDS-PAGE 
has previously been reported although not characterised by Le Goff et al. (1989), and 
is clearly at odds with the concepts of apoB metabolism in man outlined in Chapter I. 
In summary of our findings, equine VLDL contains three species of apoB, two that 
are in the molecular weight range of human apoB-100, and a third almost identical in 
size to human apoB-48 that is present in VLDL in the fasting state suggesting that it 
derives from hepatic synthesis. An analogous pattern is seen in the rat, where three 
species of apoB (B-100, B-95 and B-48) are synthesised in the liver and secreted in 
VLDL (Wu and Windmueller 1981). In the rat, the synthesis of apoB-48 in the liver 
involves an editing mechanism identical to that described in human enterocytes, but 
the origins of the two larger proteins are unclear. It is possible that these, and those 
described here in the horse, arise from post-translational modifications of apoB-100 
that might include glycosylation, acylation and phosphorylation.
If, as with human VLDL, the equine particles contain only a single molecule 
of apoB, the data presented here indicates that the horse liver secretes two types of 
VLDL particle. The first, containing either of the larger apoB proteins, would appear 
to proceed along the lipolytic cascade and enter the LDL density range. The second 
type would contain the smaller protein and are probably cleared directly from the 
circulation after lipolysis by receptor recognition of their apoE component as apoB-48 
does not appear in LDL. The masses of apoB-100 and apoB-48 are present in equine 
VLDL in an approximate ratio of 2:1 which, given that the mass of apoB-100 is twice 
that of apoB-48, indicates that the two types of particles are present in approximately 
equimolar concentrations. It is also likely that these particles do not reside in the 
circulation as discrete populations, in line with the findings from gel filtration, but 
that the liver retains the capacity to secrete a spectrum of sized particles depending
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upon its metabolic demands. In the rat, the smaller VLDL particles are relatively 
enriched with the larger apoB proteins, and increased hepatic triglyceride secretion is 
accomplished by producing larger particles that contain apoB-48 rather than apoB- 
100 or apoB-95 (Windmueller and Spaeth 1985). It is possible, especially given the 
evidence presented in Chapter VI, that the equine liver is also capable of regulating 
apoB synthesis and the activity of the editing mechanism in response to metabolic 
demands.
The molecular size and distribution of the equine apolipoproteins were largely 
similar to those found in man and a variety of animal species, with the exception that 
the C peptides were a little larger than those reported. The origin of the small amounts 
of apoA-I in VLDL are unclear as in man this protein is largely confined to HDL, 
with a small amount found in chylomicrons. It is possible that in the horse, this 
protein is secreted from the liver with the VLDL particle or transferred from HDL 
along with apoE and the C peptides in the circulation. The presence of apoE in HDL 
might well access a fraction those particles to direct hepatic clearance by the receptors 
that recognise this protein.
4.3. Differences in the Composition and Plasma Concentrations of the 
Lipoproteins between the Thoroughbred Horse and the Shetland pony.
There were few differences in either the composition or concentration of the 
lipoproteins, or their physical attributes, between the two breeds. The most significant 
divergence related to the composition of VLDL, which in the Shetland ponies, 
contained more cholesteryl esters and less protein, and was slightly enriched in 
triglyceride. This was associated with a reduction in the ratio of apoB-100 to apoB-48 
(1.8:1 compared with 2.2:1 in the Thoroughbreds) which would be compatible with a 
relative preponderance in the ponies of larger VLDL particles that have apoB-48 
rather than apoB-100 as their structural protein.
This alone might not be sufficient to explain the higher plasma triglyceride 
and VLDL cholesterol concentrations noted in the pony group here and in four ponies 
by van Dijk and Wensing (1989). It is therefore possible that the circulating numbers 
of VLDL are higher in ponies than Thoroughbred horses. If this is the case, there 
might exist a discrepancy between the two breeds in the rate of synthesis of VLDL 
and/or the rate of its clearance from the circulation that renders the pony breed 
susceptible to hyperlipaemia. As hepatic triglyceride synthesis, in other species, is 
enhanced by the supply of precursors, the higher plasma FFA levels found in the 
Shetland pony by Robie et al. (1975a) might provide a basis for increased synthesis of 
this lipoprotein.
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CH A PTER IV
THE ACTIVITY OF LIPOPROTEIN LIPASE, HEPATIC LIPASE, 
LECITHIN:CHOLESTEROL ACYL TRANSFERASE AND CHOLESTERYL  
ESTER TRANSFER PROTEIN IN THE HORSE
1. INTRODUCTION
Once in the circulation, the plasma lipoproteins are subject to the activities of an 
alliance of enzymes that model their composition and mediate their catabolism. The 
roles that these enzymes play in integrating and coordinating lipoprotein metabolism 
are reviewed in Chapter I and summarised here. Lipoprotein lipase (LPL) is 
responsible for the catabolism of triglyceride rich lipoproteins and thereby releases 
surface remnants that contribute to the conception and maturation of HDL. Its close 
relative hepatic lipase (HL) removes triglyceride from smaller particles so mediating 
the conversion of IDL to LDL, of HDL 2  to HDL3, and the remodelling of large 
buoyant LDL to smaller denser particles. The activity of lecithin:cholesterol acyl 
transferase (LCAT) is essential for the generation of cholesterol esters and the 
maturation of HDL from small discoidal precursors. The lipid transfer proteins, 
chiefly cholesteryl ester transfer protein (CETP), promote the net transfer and 
exchange of cholesteryl esters for triglyceride between HDL and the lower density 
lipoproteins. This is largely responsible for the conversion of HDL 3  to HDL 2  and, in 
concert with LCAT, supports the reverse transport of cholesterol from peripheral 
tissues to the liver.
Much of the understanding of the roles that these enzymes play in lipoprotein 
metabolism has come from the aberrancies of particle size, composition and plasma 
concentration observed in human patients with inherited deficiencies of the enzymes. 
The study of animals that are naturally deficient in one or another enzyme has also 
made a significant contribution. Yet, of the abundance of species examined the horse 
has largely been ignored. Notable exceptions are the four papers that examined equine 
LCAT activity (Yamamoto et al. 1979a, 1979b, 1987; Chen and Albers 1983) and an 
abstract describing the partial purification and quantification of LPL (Bauer, Miller, 
Beauchamp, and Sciscent 1987).
Any comprehensive study of lipid transport in the horse clearly requires that 
the function and activity of these enzymes be examined. In the work described here, 
LPL and HL were isolated from plasma and their enzymatic characteristics 
established. An assay system that selectively measured the activities of LPL and HL 
in equine PHP was then developed and validated. The cofactor dependence of LCAT
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was defined and the impact of the enzyme on the plasma concentration and 
composition of HDL determined. Preliminary analysis of transfer protein activity 
suggested that the horse was deficient in CETP and subsequent investigations focused 
on whether this was a true deficiency of the protein or the product of a plasma 
inhibitor of the enzyme. The results of these studies provided an insight into the 
pathways that govern the metabolism of the equine plasma lipoproteins and allowed 
the structural characteristics defined in Chapter III to be rationalised.
2. MATERIALS AND METHODS
The methods used for the measurement of LPL, HL, LCAT and CETP activities were 
described in Chapter II.
2.1. Subjects and Samples
Post-heparin plasma was collected as detailed in section n.3.2, and lipoprotein 
deficient plasma (LPDP) prepared as in section II.4.2. The subjects were healthy adult 
Thoroughbred horses or Shetland ponies (geldings and non-pregnant mares) that were 
housed and fed a maintenance diet of hay and proprietary concentrates that was 
withdrawn for 16 hours prior to sampling. HDL was prepared by flotation 
ultracentrifugation as described in section II.2.3.
2.2. Heparin Sepharose Affinity Chromatography
The two lipases were separated from PHP by affinity chromatography on heparin 
sepharose, using the protocol described by Iverius and Ostlund-Lindqvist (1986). PHP 
was collected from four ponies, pooled (total volume 250 ml) and adjusted to 0.4 M 
NaCl by adding solid NaCl (5.844 g). This was mixed with 30 ml Heparin Sepharose 
CL-6 B (Pharmacia AB) at 4°C for 30 mins. and then washed with 800 ml 0.4 M NaCl 
in 30% glycerol (v/v), 0.01 M phosphate, pH 7.5 on a scintered glass funnel. The 
mixture was resuspended in this buffer, poured into a 2 .0 x2 0  cm glass column and 
washed with one bed volume of buffer. The column was maintained at 4°C and eluted 
with a 145 ml linear gradient of 0.4 to 1.5 M NaCl in 30% glycerol (v/v), 0.01 M 
phosphate, pH 7.5, followed by 25 ml of the higher salt buffer. This was mixed with a 
gradient mixer (11300; LKB Bromma) and pumped through the column at 25 ml/hr 
using a peristaltic pump (2115; LKB Bromma). Fractions of 5 ml were collected and 
analysed for lipase activity using the standard method described in section II.3.5, with 
the Tris buffer containing 0.2 M NaCl, and in the presence of serum activator. The 
protein content of the fractions was monitored at OD280nm-
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The fractions comprising the peaks of activity were pooled and dialysed 
against 3.6 M ammonium sulphate, 0.01 M phosphate, pH 7.5 overnight at 4°C. The 
precipitate was retrieved by centrifugation, dissolved in 50% glycerol (v/v), 0.01 M 
phosphate, pH 7.5 and stored at -20°C. The protein content of the isolates was 
determined by the modified method of Lowry et al. (Peterson 1977). The identity of 
the isolates was confirmed by examining their activities when assayed ( 1 0  ul of a 1 : 1 0  
dilution in the glycerol/phosphate buffer) in the presence of high (2.0 M) and low (0.2 
M) concentrations of NaCl, and in the presence and absence of serum activator.
2.3. Phenyl Sepharose Affinity Chromatography
Chromatography of LPDP on phenyl sepharose has been shown to enhance human 
CETP activity and unmask lipid transfer activity in species (rat and pig) reportedly 
devoid of CETP (Tollefson et al. 1988a). Freshly prepared LPDP (20 ml) was pooled 
from four ponies, adjusted to 4 M NaCl, added to an equal volume of Phenyl 
Sepharose CL-4B (Pharmacia AB) and equilibrated in a total volume of 200 ml of 4 
M NaCl, 10 mM Tris, pH 7.4 at 4°C overnight. The mixture was then poured into a 
4.6x20 cm column and washed with 0.15 M NaCl, 10 mM Tris, pH 7.4 until the 
absorbance of the eluant at OD280nm was *ess 0-1* The bound material that is 
reported to contain transfer protein activity was eluted with distilled water containing 
0.02% NaN 3  at a rate of 2.5 ml/2mins and collected in 5 ml fractions until the 
OD280nm was less than 0.05. Aliquots from each fraction (35 ul) were assayed 
immediately for CETP activity.
Inhibitor protein was then eluted with either 15% ethanol (Son and Zilversmit 
1984), or a linear gradient of water to 100% ethanol (Tollefson et al. 1988a), until the 
absorbance was less than 0.05. These fractions were dialysed against 0.15 M NaCl, 10 
mM Tris, pH 7.4 at 4°C overnight and assayed directly for CETP activity. Inhibitory 
activity was assessed by adding an aliquot of each fraction to assay tubes containing 
human LPDP as a source of CETP.
3. RESULTS
3.1. Isolation and Characterisation of Lipoprotein Lipase and Hepatic Lipase
Two peaks of lipolytic activity were eluted from the heparin sepharose column (Fig.
11), the first (A) with approximately 0.58 M NaCl and the second (B) at 
approximately 1.02 M NaCl. The fractions under these peaks (A, 16-22 and B, 28-37) 
were pooled and concentrated. The activity in A was similar when assayed in the 
presence of 0.2 M and 2.0 M NaCl and did not require serum for the maximal 
expression of activity at either concentration (Table 10). This was typical of the salt
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Lipase Activity (umolFA/ml/hr) OD 280nm1
Lipase Activity * Protein
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Fraction Number
Figure 11. Elution o f  post-heparin plasm a lipase activity and protein (O D 2 gonm) 
from  heparin sepharose. The colum n was eluted with a linear gradient o f 0.4 M to 1.5 
M NaCl.
Peak Serum
Activity (% m axim al)
0.2 M NaCl 2.0 M  NaCl
A - 89 1 0 0
+ 92 1 0 0
B _ 52 4
+ 1 0 0 35
Table 10. Characterisation o f lipase activities separated from  equine post-heparin 
plasm a by affinity chrom atography. The two peaks of activity were assayed in 0.2 M 
and 2.0 M NaCl with (+) and without (-) 50 ul of serum as a source o f lipoprotein 
lipase activator. Enzym e activity is expressed as a percentage o f the maximum 
obtained, that is for A at 2.0 M NaCl and for B at 0.2 M NaCl with serum.
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resistant lipase of hepatic origin that is now called HL. In contrast, the enzyme 
activity in peak B was greatest at 0.2 M NaCl, it was reduced by 48% when serum 
was excluded from the assay, and was negligible when assayed at 2.0 M NaCl without 
serum (Table 10). The sensitivity of this enzyme to inactivation at high salt 
concentrations and the requirement of a serum cofactor were characteristic of LPL. 
Details of the purification and yield of each enzyme are given in Table 11.
3.2. Development of an Assay System for the Selective Measurement of 
Lipoprotein Lipase and Hepatic Lipase in Post-heparin Plasma
The partially purified enzymes were incubated in a series of Tris buffer NaCl 
concentrations as shown in Fig. 12. The activity of LPL was maximal at 0.1 M NaCl 
and declined rapidly thereafter. The HL isolate was characteristically resistant to 
changes in salt concentration and was maximally active at 1.0 M NaCl. These two salt 
concentrations were therefore used for all subsequent assays of activity in the isolates 
or PHP. Both enzymes were active over the pH range 8 .5-9.0, with optima of 8.5 and
9.0 for HL and LPL, respectively (Fig. 13).
The design of conditions that discriminated the activities of LPL and HL was 
the next step in the development of a selective assay system. The negligible (<8 %) 
LPL activity found at the salt concentration required for maximal HL activity when 
serum was excluded from the assay presented an uncomplicated means of measuring 
HL. However, in an effort to improve upon the inhibition of LPL in these assay 
conditions, protamine sulphate (final concentration 1.67 mg/ml) was added to the 
incubation mixture. This failed to abolish LPL activity, which remained at 6 %, and 
was abandoned as it caused an 11 % reduction in the activity of HL.
As HL retained approximately 67% of its activity when assayed under 
conditions optimal for LPL, there was clearly a need to remove this interference. Prior 
incubation of the isolates with an equal volume of 50 mM SDS in 0.2 M Tris-HCl at 
26°C for 60 mins., was found to reduce the activity of the HL isolate by 93% while 
leaving that of LPL unaffected (actually increased by 9%) when assayed under
conditions optimal for LPL.
The volume of serum required for maximal LPL activity was confirmed as 50 
ul (Fig. 14) and addition of volumes greater than this reduced the activity of the 
enzyme. An assay system was therefore adopted in which HL was measured in 10 ul 
o f PHP in the presence of 1.0 M NaCl and without serum, and LPL was analysed in 
20 ul of the incubated PHP/SDS solution, at 0.1 M NaCl in the presence of 50 ul 
serum.
The dose of heparin required for maximal enzyme recovery was determined in 
PHP collected from a pony injected with 0, 25, 50, 70, 90 and 120iU/kg
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Enzym e Source
Protein
(mg)
Activity 
Specific Total
Purification
-fo ld
Yield
%
HL Plasma 13,000 0.30 395.0
Peak A 2 105.39 2 1 1 . 2 347 54
LPL Plasma 13,000 0.19 297.5 - -
Peak B 2 84.8 172.3 442 58
Table 11. Purification and yield of lipoprotein lipase (LPL) and hepatic lipase (HL) 
isolated from equine post-heparin plasma by affinity chromatography on heparin 
sepharose. Specific activity is expressed in umolFA/mg protein/h and total activity in 
umolFA/h.
Enzyme Activity (% Maximum)
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Figure 12. Effect of NaCl on the activity of lipoprotein lipase (LPL) and hepatic 
lipase (HL) isolated by affinity chromatography on heparin sepharose. The partially 
purified isolates were assayed in the presence of the NaCl concentrations indicated.
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Figure 13. Effect of assay pH on the activity of lipoprotein lipase (LPL) and hepatic 
lipase (HL) isolated by affinity chromatography on heparin sepharose. The partially 
purified isolates were assayed in the buffer pH indicated.
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Figure 14. Volume of serum cofactor required to give maximal activity of 
lipoprotein lipase. Serum was added to the assay of LPL in the amounts indicated.
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at weekly intervals. The samples were analysed in a single assay run and the results 
(Fig. 15) confirmed that 70 iU/kg was the optimum dose, beyond which the activity of 
both enzymes declined. The appearance of the two enzyme activities in the PHP from 
a pony is shown in Fig. 16. Neither enzyme was detectable prior to injection of 
heparin; the activity of LPL peaked 5 minutes after injection and slowly declined over 
the next 60 mins., while the peak of HL was found at 10 mins.. As it would have been 
impractical to take and process separate blood samples for each enzyme, a ten minute 
interval between injection and sampling was adopted to ensure maximal recovery of 
HL with minimal loss of LPL activity.
The performance of the assay system was evaluated by selecting samples from 
healthy ponies with low and high activities of each enzyme (Appendix 9). Ten 
aliquots of each pool were analysed in duplicate in a single assay run to establish the 
intra-assay coefficients of variation, which ranged between 3.4% and 8.7% (Table
12). The interassay coefficients of variation were determined from seven consecutive 
assays of each aliquot performed over a seven week period, and varied between 5.2% 
and 7.1% (Table 12).
The activities of LPL and HL were measured in PHP from eight 
Thoroughbred horses (four mares and four geldings) and 16 Shetland ponies (10 
mares and six geldings) (Appendix 10) and no differences were found in the activity 
of either enzyme between the two breeds (Table 13).
3.3. Lecithin:Cholesterol Acyl Transferase Activity
Lecithinrcholesterol acyl transferase activity was found in LPDP from two ponies 
(SP-L, 24.89; SP-7, 25.36 nmolCE/ml/h) in a similar magnitude to that present in 
LPDP from a healthy human volunteer (TW, 39.16 nmolCE/ml/h). This activity was 
entirely dependent upon the inclusion of apoA-I in the assay incubation, being 
reduced by 79.8% and 88.5% to 5.02 and 2.93 nmolCE/ml/h, respectively, when 
equine apoA-I was excluded from the buffer. This cofactor dependency was not 
restricted to apoA-I of equine origin, as there was no statistical difference in the 
activity of LCAT in LPDP from five Shetland ponies (mean ±sd) when apoA-I of 
human (21.75 ±1.62 nmolCE/ml/h) or equine (22.52 ±1.34 nmolCE/ml/h) origin was
used (Appendix 11).
The activity of LCAT was found to be significantly higher in 12 Shetland 
ponies (three geldings and nine non-pregnant mares) than in 12 Thoroughbred horses
(Table 13; Appendix 12).
The impact of LCAT activity on HDL composition and concentration was
examined in 12 healthy adult Shetland ponies (nine mares and three geldings) 
(Appendix 13). The mean (±sd) activity of LCAT in this group was 21.48 (±3.94)
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Figure 15. Dose of heparin required for maximal recovery of lipoprotein lipase 
(LPL) and hepatic lipase (HL). Post-heparin plasma was collected at weekly intervals 
from a Shetland pony injected with the dosages indicated.
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Figure 16. Appearance of lipoprotein lipase (LPL) and hepatic lipase (HL) in equine 
plasma from injection of 70 iU/kg heparin. A healthy Shetland pony was injected with 
70 IU/kg of heparin and blood samples collected over the following hour.
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Precision
Lipoprotein Lipase Hepatic Lipase
Low High Low High
Intra-assay Mean Activity 2 . 2 1 6 . 1 0 2.78 7.04
(n= 1 0 ) sd 0.19 0 . 2 1 0.19 0.43
cv 8.7% 3.4% 6 .8 % 6 .0 %
Interassay Mean Activity 2.05 6.05 2.67 6.70
(n=7) sd 0 . 2 2 0.54 0.19 0.35
cv 10.7% 8.9% 7.1% 5.2%
Table 12. Performance of the assay for the selective measurement of lipoprotein 
lipase and hepatic triglyceride lipase in equine post-heparin plasma. Aliquots of 
plasma with high and low activities (umolFA/ml/h) of each enzyme were analysed in 
ten sets of duplicates in a single assay run to estimate the intra-assay error, and in 
duplicate in seven consecutive assays run over a seven week period (n, number of 
samples; sd, standard deviation; cv, coefficient of variance).
Breed
LPL HL LCAT
n umolFA/ml/h n nmolCE/ml/h
TB 8 3.31 3.22 1 2 2 0 . 2 1
±1.17 ±1.40 ±3.39
SP 16 3.54 4.46 1 2 23.76*
±1.62 ±1.73 ±4.22
* p < 0.05
Tabic 13. Activities of lipoprotein lipase (LPL), hepatic lipase (HL) and 
lecithin:cholesterol acyl transferase (LCAT) in healthy Thoroughbred horses(TB) and 
Shetland ponies (SP).
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nmolCE/ml/h and was correlated with the relative mass of cholesteryl esters in HDL 
(r = 0.47). There was no correlation between the activity of LCAT and the mass of 
triglyceride (r 0.04), free cholesterol (r = -0.14) and phospholipid (r = 0.16) in 
HDL.
3.4. Cholesteryl Ester Transfer Protein Activity
The protein (OD280nm) and radioactivity in the labelled human and equine HDL 
eluted from the sepharose column is shown in Fig. 17. In both cases, tubes 15-21 were 
taken as the peak. The human [3 H]HDL3  was preceded by a small peak of 
radioactivity and protein (fractions 9-12) that represented trace amounts of HDL 2  
which was discarded. The equine [3 H]HDL3  peak was relatively poor in counts and 
was preceded by a larger peak of non-protein associated radioactivity (fractions 7 - 1 1 ). 
The nature of this peak was not determined, it eluted earlier than the human HDL 2  
peak in the void volume of the column and may have consisted of aggregates of the 
labelling materials.
The assay method used gave results for CETP activity in LPDP from three 
healthy human volunteers of 0.150, 0.126 and 0.143 %T/ug that were compatible with 
values reported elsewhere (Freeman, Packard, Shepherd and Gaffney 1990). A single 
human sample was therefore included in each of the subsequent assays of equine 
CETP as a positive control. Initial analysis of activity in LPDP from two 
Thoroughbred horses and Shetland ponies failed to demonstrate any significant CETP 
activity (Table 14). Transfer of cholesteryl esters ranged from -4.5% to 5.8% (-0.050 
to 0.006 %T/ug) and was largely contained within the coefficient of variation of the 
five blank incubations (±4.2%T). In a second assay where LPDP from four Shetland 
ponies and a further four Thoroughbred horses was analysed (Appendix 14), 
percentage transfer outwith the blank range (±5.6%T) was found in only two ponies 
(11.1%, 6.1%) and two Thoroughbreds (11.2%, 7.0%), giving transfer activities of
0.007, 0.004, 0.007 and 0.077 %T/ug, respectively.
At this point, there were concerns that the poor recovery and inefficient 
labelling of the equine, compared with the human, substrate might have contributed to 
this failure to demonstrate any significant CETP activity. A second batch of substrate 
was then prepared for which HDL was isolated from 37.5 ml of pooled equine plasma 
by rate-zonal ultracentrifugation as previously described and the fractions comprising 
the HDL peak concentrated to a volume of 4 ml. As the labelling procedure itself is in 
part dependent upon lipid transfer, 2 ml of the equine HDL was mixed with 18 ml 
ofhuman LPDP, as a source of CETP, and incubated with [3 H]cholesteryl oleate as 
before. The FIDL (fractions 13-21) that eluted from the sepharose column (Fig. 18) 
was as rich in radioactivity as the human [3 H]HDL3  previously prepared.
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Figure 17. Elution of protein and radioactivity from sepharose of human (top) and 
equine (bottom) [ 3  H]HDL preparations. The density >1.125 g/ml fraction of plasma 
was incubated with [ 3  Hjcholesteryl oleate, the HDL was re-isolated at density <1.215 
g/ml, applied to sepharose columns and eluted with Tris-saline.
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% Transfer/2.5h
Animal 1  ul 2  ul
Volume of LPDP 
4 ul 20 ul 35 ul
Protein
ug/ml %T/ug
TB-13 -2 . 8 -2.7 3.9 - 1 . 6 -0 . 8 44.5
TB-14 -2.4 0.7 -2.4 - 1 . 0 0.9 41.5 -
SP-2 -2.3 -0.9 -0 . 1 2 . 0 2.5 41.0 -
SP-3 0.9 -4.5 0 . 1 5.2* 5.8* 41.0 *0.006
Human 6 . 8 10.9 19.5 62.8 68.5 44.5 0.125
Table 14. Cholesteryl ester transfer protein activity in two Thoroughbred horses, two 
Shetland ponies and a healthy human volunteer (*Tubes with % transfer greater then 
the coefficient of variation (±4.2%) of the five blanks were used to calculate %T/ug).
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Figure 18. Elution of radioactivity from sepharose of a second equine [3 H]HDL 
preparation. HDL was isolated by rate-zonal ultracentrifugation and incubated with 
[3 H]cholesteryl oleate in the presence of human LPDP. The incubation mixture was 
then applied to a sepharose column and eluted with Tns-sahne.
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The efficacy o f this substrate and an equine VLDL/LDL acceptor preparation 
to detect CETP activity was first tested using human LPDP as a source of CETP. The 
activity o f CETP was reduced by only 13% when equine instead of human [3 H]HDL 3  
was u s e < 3  (Tdbte 15). The equine acceptor preparation gave slightly higher activities 
when assayed with donor particles of human (+14%) or equine (+2%) origin. The 
equine substrate was therefore used with the equine VLDL/LDL preparation to 
measure CETP activity in LPDP from a further 12 Shetland ponies (Appendix 15). 
Percentage transfer beyond the coefficient of variation of blanks (±3.1%T) was found 
in 11 o f the animals and varied between 3.7% and 18.2%, giving transfer activities of 
0.004-0.013 %T/ug (0.007 ±0.004; mean +sd). However, as with the previous animals 
examined, these values represented single isolated results from a series of incubations 
containing 10-35 ul of LPDP rather than part of a linear relationship between volume 
of LPDP and percentage transfer as seen with human samples.
In a final attempt to demonstrate significant transfer activity in the horse, 
[3 H]HDL 3  and VLDL/LDL of human origin were used in the assay of LPDP from a 
Shetland pony. The results are summarised in Table 15 and show that no significant 
activity was obtained when any of the combinations of human and equine donor and 
acceptor particles were used.
Activity in human LPDP (%T/ug) 
VLDL/LDL
Activity in equine LPDP (%T) 
VLDL/LDL
[3H]HDL3 Human Equine [ 3 H]HDL 3  Human Equine
Human 0.145 0.165 Human 3.7% 7.9%
Equine 0.126 0.129 Equine 4.2% 5.1%
T able 15. Activities o f cholesteryl ester transfer protein (CETP) in human and equine 
lipoprotein deficient plasma (LPDP) when assayed with donor and acceptor particles 
o f human and equine origin.
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3.5. Separation of Transfer Proteins from Inhibitor Protein
The elution o f protein by water from the phenyl sepharose column is shown in Fig. 19 
together with the percentage transfer present in 35 ul of the fractions comprising the 
protein peak. Two separate activities were identified. The first was in fractions 10 
(35.8%) and 11 (11.8%) and the second in fractions 14 (9.6%) and 15 (22.9%). The 
protein contents of fractions 10 and 15 were 2.9 mg/ml and 0.58 mg/ml giving 
transfer activities of 0.353 and 1.138 %T/ug, respectively. However, the column 
fractions were not assayed in duplicate and two subsequent analyses using 1 0 - 3 5  ul of 
the fractions failed to demonstrate any significant transfer in either. This suggested 
that the two activities may have represented spurious results. The procedure was 
therefore repeated using fresh LPDP and phenyl sepharose; the fractions were assayed 
in duplicate and no significant activity was detected.
The first of the columns was eluted with 15% ethanol and the elution of 
protein is shown in Fig. 20. The fractions comprising the protein peak were tested for 
CETP inhibitory activity by adding 25 ul to assay incubations containing 3.3 ul of 
human LPDP that gave 40.4% transfer o f cholesteryl esters (0.269 %T/ug) (Appendix 
16). Contrary to the expected pattern, each of the fractions appeared to enhance the 
transfer activity in the LPDP by between 7-% and 50%. However, when 35 ul aliquots 
o f each fraction were assayed for CETP activity, no significant transfer activity was 
detected in any of the samples. The second column was eluted with a gradient of 
water to 1 0 0 % ethanol and the fractions were assayed for transfer activity and 
inhibition of CETP as with the first column. A similar pattern was obtained; there was 
a consistent augmentation of human LPDP in the inhibition assay which was not due 
to the presence o f CETP.
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F igure  19. Elution of protein and cholesteryl ester transfer activity from phenyl 
sepharose. Equine LPDP was applied to a phenyl sepharose column and eluted with 
distilled water, a single 35 ul aliquot from each 5 ml fraction was then analysed for 
cholesteryl ester transfer activity.
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F ig u re  20. Elution o f protein with 15% ethanol from phenyl sepharose. The column 
used in Fig. 17 was eluted with 15% ethanol and the protein content of the fractions
measured at OD^ggim.
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4. DISCUSSION
4.1. Lipoprotein Lipase and Hepatic Lipase
Hepann sepharose chromatography defined two lipolytic enzymes that were discrete 
with respect to their column affinities in the face of increasing salt concentrations. 
The first was typical of HL in that it eluted at a concentration of NaCl (0.58 M) 
similar to that reported for HL from human (0.62 M NaCl; Ostlund-Lindqvist and 
Boberg 1977) and pig (0.75 M; Ehnholm, Bensadoun and Brown 1977) PHP. The 
peak of activity in the second eluted with a salt concentration (1.02 M) that 
corresponded to that of LPL from man (0.94; Ostlund-Lindqvist and Boberg 1977) 
and the pig (1.2 M; Ehnholm et al. 1977). These identities were confirmed by the 
characteristic salt resistance of the HL isolate, and by the sensitivity of the LPL 
isolate to inactivation at high salt concentrations together with its dependence on a 
serum cofactor for maximal activity. The purification and yield of the two enzymes 
were compatible with those reported using similar methodologies for human HL 
(2943 fold, 72%; Augustin, Freeze, Tejada and Brown 1978) and LPL from human 
(329 fold, 31%; Ehnholm et al. 1975) and equine (260 fold, 75% Bauer et al. 1987) 
PHP. The equine LPL reported by Bauer et al. (1987) had an apparent molecular 
weight of 67k Da similar to that of human LPL (67k Da; Augustin et al. 1978) but, in 
contrast to the isolate described here, was only partially inhibited (by 50%) in the 
presence of 1 M NaCl. Although they did not isolate HL, the authors reported that 
some lipase activity was eluted with 0.72 M NaCl buffer prior to the collection of 
LPL, which may have been HL. It is therefore possible that contamination of LPL 
activity with this enzyme might explain why their LPL was only partially inhibited at
1.0 M NaCl. In addition, the authors did not state whether the inhibition of LPL was 
detected in the presence or absence of serum cofactor, which might also explain the 
discrepancy with the present data as the LPL isolate described here retained 40% of 
its activity when assayed at 1.0M NaCl in the presence of serum.
The presence of significant (65%) HL activity at 0.1 M NaCl presented 
problems in the measurement of LPL. Because the activity of HL was not the same at
0.1 and 1.0 M NaCl, any attempt to calculate LPL activity as the difference between 
"total” lipolytic activity at 0.1 M NaCl and HL activity at 1.0 M NaCl was invalid. In 
man, this has been overcome by using reagents that selectively inhibit one or both of 
the enzymes, such as protamine sulphate which inhibits LPL (Krauss, Levy and 
Fredrickson 1974), SDS that inactivates HL (Baginsky and Brown 1977) and 
inhibitory antisera directed to HL (Huttunen, Ehnholm, Kinnunen and Nikkila 1975). 
In the absence of antisera to either human or equine HL, the SDS method was tested 
against the equine HL isolate and shown to be a specific and highly effective inhibitor 
of the enzyme. The slight enhancement of LPL activity was not considered
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significant, but may have been due to the effects of SDS on the stability of the 
substrate or the efficiency of fatty acid partitioning during the retrieval of reaction 
products.
In their abstract, Bauer et al. (1987) based an assay of equine LPL on the 
almost complete inhibition (90-95%) of the enzyme in the presence of 3.3 mg/ml 
protamine sulphate, and calculated LPL activity as the difference between total and 
protamine resistant lipolytic activity. Although no details of the assay conditions or 
measured activities were given, the authors used the assay to show that LPL activity 
was increased three fold over controls in seven fasted ponies. This deserves caution as 
the effects of protamine sulphate on HL were not examined; when protamine sulphate 
was used here at 50% of their final concentration, the activity of HL was reduced by 
11%.
The inhibition of LPL activity by volumes of serum in excess of 50 ul might 
have been due to inhibition of LPL by unphysiological amounts apoC-III in the 
incubation mixture, or an effect of the serum on the stability of the assay substrate or 
the efficiency of fatty acid extraction. The time courses of the appearance and 
clearance of LPL and HL activity following heparin injection were similar to the 
human where HL peaks at 5-10 mins. and LPL at 15-20 mins. (Huttunen et al. 1975). 
However, the reduction in activities of both LPL and HL at doses of heparin greater 
than 90 iU/kg is not apparent in man where they plateau between 50 and 200 iU/kg 
(Huttunen et al. 1975). The reason for this discrepancy is not clear.
The assay system developed for PHP performed well with intra- and 
interassay precisions that are compatible with those reported using SDS in man (2-5% 
and 11%, respectively; Baginsky and Brown 1977). One criticism of post-heparin 
lipase assays of this type is the lack of a robust external standard with which to test 
the accuracy of, and correct for any variation between, assay runs. While the assay 
presented here was not validated against any other, it was shown to be reproducible 
and the inclusion of a "standard" PHP sample in each run helped keep a check on any 
drift encountered when using a new batch of substrate, serum or buffers. The assay 
showed that there were no significant differences in the activity of LPL between the 
Thoroughbred and the Shetland pony, and as such suggested that the higher plasma 
triglyceride and VLDL cholesterol concentrations found in the ponies in Chapter III 
do not result from differences in LPL activity.
Given that the characteristics of the two enzymes isolated were in vitro almost 
identical to those ascribed to human LPL and HL, it is hard not to conclude that the 
equine enzymes do not perform similar functions in vivo. Thus the activity of LPL 
would explain the decrease in particle triglyceride mass from VLDL through to IDL, 
and in concert with HL, the progression of IDL through to LDL. The presence of
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significant HL activity in the horse indicates that this enzyme, in contrast to CETP, is 
available to participate in the generation of discrete subfractions of LDL. It is harder 
to define any role for HL in the modelling of HDL as the horse does not appear to 
possess a suitable substrate i.e. HDL 2  .
4.2. Lecithin:Cholesterol Acyl Transferase
The studies of LCAT activity described here differed from those previously published 
in the respect that LPDP, rather than serum (Yamamoto et al. 1979a; 1979b) or 
plasm a (Chen and Albers 1983), was used as the source of enzyme. By using 
ultracentrifugation to prepare LPDP, the enzyme was dissociated from HDL and 
divorced from the apolipoproteins that modulate its activity. This enabled the cofactor 
requirements of equine LCAT to be truly defined. The equine enzyme, in common 
with that o f other species, was almost entirely dependent upon apoA-I for activity and 
the small amount of esterification that occurred in the absence of the protein could be 
attributable to free apoA-I present in the d >1.215 g/ml fraction after 
ultracentrifugation. The LCAT activity in LPDP did not demonstrate any preference 
for apoA-I of equine or human origin. Although Chen and Albers (1983) found that 
there was good cross species activation of LCAT, their assay used plasma in which 
there would have been endogenous apoA-I present.
The equine LCAT activity here was somewhat lower than that of 90.7 ±10.6 
nmolCE/ml/h (mean ±sd, n=8 ) reported by Chen and Albers (1983). These authors 
used substrate vesicles of almost identical composition and specific activity, but the 
apoA-I was incorporated into the liposomes rather than being added separately to the 
assay tubes, which they commented led to higher values for LCAT activity in both 
human and rabbit plasma. This might explain the discrepancy with the present data as 
the expression of activity in the assay used here does not appear to have been limited 
by the availability of cofactor, as the amount of apoA-I used (67.5 ug/10 ul LPDP) 
was slightly higher than that used by Chen and Albers (27.5 ug of purified apoA-I 
plus approximately 22.5 ug native apoA-I/15 ul plasma). Yamamoto et al. (1979a) 
reported serum LCAT activities in the range 30-90 nmolCE/ml/h in seven horses 
using very different methodologies that were based on a Tween 20 substrate or one 
prepared from heat inactivated plasma, neither of which used exogenous apoA-I.
The origins and significance of the differences in LCAT activity found 
between the two breeds of horse here are not clear. First, the increased activity in the 
Shetland ponies was not reflected by any differences in the HDL masses of 
cholesteryl esters and free cholesterol in Chapter III. Secondly, the mean activity of 
LCAT when measured in the same 12 ponies almost a year later during the course of 
the correlation study was not statistically different to the Thoroughbred values. This
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may reflect genuine changes in LCAT activity over the intervening period, or been 
due to drift in the precision of the assay. The limited size of the groups might also 
prevent any concrete conclusions at this point. Interestingly, in Chapter III the mass of 
cholesteryl ester in VLDL from the ponies was found to be significantly higher than 
that from the Thoroughbred horses. Although equine LCAT has been shown capable 
of esterifying cholesterol in VLDL in vitro (Yamamoto et al. 1979b) the degree of 
esterification was only one-twentieth of that in its preferred substrate HDL. It is 
therefore likely that the difference in VLDL composition reflected the neutral lipid 
content o f  the liver and the activity of acylrCoA cholesterol acyl transferase (ACAT) 
in particular.
The affinity of equine LCAT for HDL in vitro (Yamamoto et al. 1979b) was 
shown here in vivo by the positive correlation between LCAT activity and the mass of 
cholesteryl ester in HDL. Although Yamamoto et al. (1979b) reported that LCAT 
reduced the masses of free cholesterol and lecithin in HDL, no relationship was found 
here between the activity of the enzyme and these masses. This was not surprising, as 
in vivo the free cholesterol lost to LCAT would be rapidly replaced by the flux of 
fresh material into HDL from cell membranes and other lipoproteins. In man, this 
w ould be accompanied by the transfer or exchange of cholesteryl esters away from 
HDL, so that the composition of these lipoproteins in fact bear little relationship to 
LCAT activity. In the horse, the mass of cholesteryl ester in HDL was correlated with 
the activity of LCAT suggesting that the esters are "trapped" in HDL, providing 
further evidence that the horse is deficient in transfer protein activity.
4.3. Cholesteryl Ester Transfer Protein
A num ber of methodologies exist for the measurement of lipid transfer protein 
activity, differing in the nature of substrate (LDL, HDL, or lecithin/cholesterol 
liposomes, labelled in the triglyceride, cholesteryl ester or phospholipid moieties) and 
whether mass transfer or the rate of exchange of lipid are measured. The multitude of 
systems reported undoubtedly reflects the difficulties that exist in assaying transfer 
activity, and are likely to be superseded in the future by immunoassays that detect 
CETP mass rather than activity The assay used here was developed by Freeman 
(1990) and measured exchange activity. LPDP plasma was used as the source of 
enzyme because of an increasing weight of evidence that the proteins that inhibit lipid 
transfer activity are associated with the HDL fraction of plasma (Tollefson et al. 
1988a; Nishide et al. 1989). Cholesteryl ester labelled HDL 3  was used as the 
substrate to reflect the net function CETP and bovine serum albumin appears was 
included in the incubation to maintain the stability of the substrate and ensure 
minimal background activity. Cold plasma was added to the assay mixture after
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incubation to increase the mass of lipoproteins precipitated by the heparin-manganese 
and improve the pelleting of the lower density lipoproteins.
Although this methodology was designed for use with human LPDP, there 
was no obvious reason why, if donor and acceptor particles of equine origin were 
prepared, it should not detect CETP activity in the horse. Initial concerns over the 
quality o f the equine donor and acceptor preparations were proved to be unfounded. 
The decision to use rate-zonal ultracentrifugation to prepare a second batch of HDL 
was based on the evidence presented in the previous chapter that equine HDL was 
analogous with human HDL3  *n terms of physical and chemical structure. This 
substrate was proven capable of supporting CETP activity in human LPDP, and gave 
results for equine LPDP identical to the first batch. It is therefore hard to blame the 
inability to demonstrate significant CETP activity in the horse on the assay 
methodology employed. When activity was detected, it represented between 1 % and 
6 % of the human activity measured in that assay. This was significantly lower than 
the 14-27% range quoted for species (rat, sheep, cow, pig, dog) defined as low in 
CETP activity by Ha and Barter (1982).
The CETP activity in two of these "low" species has subsequently been 
unmasked by chromatography on phenyl sepharose, to the extent that activities 
approaching (rat) and in excess (pig) of the activity found in human LPDP were 
recovered (Tollefson et al. 1988a). This posed the question as to whether the 
negligible equine activity reflected a true deficiency of CETP or the masking of its 
activity by an inhibitor. The initial attempt to isolate transfer protein activity yielded 
equivocal results. Although transfer was found in two peaks, repeat analysis of the 
two m ost potent fractions failed to confirm their activity suggesting that the original 
results were erroneous. This was supported by the fact that no inhibitory activity was 
identified when the column was eluted with ethanol, and by the deficiency of transfer 
activity in fractions eluted from a second column.
Tollefson et al. (1988a) reported that they were unable to elute an inhibitor of 
CETP (rat or human) from pig LPDP using 15% ethanol, but showed that a 0-100% 
ethanol gradient eluted a nondialysable component that produced greater than 30% 
inhibition of CETP activity. For this reason the second of the columns was eluted with 
such a gradient, which also failed to identify any inhibitory activity. Rather, the eluted 
fractions from both columns enhanced CETP activity in human LPDP. The reason for 
this was not clear as the fractions did not possess transfer activity of their own. The 
conclusion therefore remains that the horse is deficient in CETP activity.
Species that have low levels of CETP activity classically have a prominent 
class of large cholesteryl ester and apoE rich HDLj particles (Tall 1986). These 
particles are formed by the agency of LCAT and the transfer of apoE from
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triglyceride rich lipoproteins undergoing lipolysis. However, as their conversion to 
HDL 2  and HDL 3  is dependent upon lipid transfer activity (Gavish, Oschry and 
Eisenberg 1987), they accumulate in species that lack CETP. Although the horse 
satisfies these criteria in having LCAT but not CETP, it has no recognisable HDLj 
and it is hard to understand how it retains a single homogeneous population of small 
HDL 3  like particles. In the following Chapter it is shown that post-prandial lipaemia, 
which is largely responsible for the generation of triglyceride rich HDL2, does not 
occur in the adult horse as it does in man and the dog. This might explain the 
deficiency of both HDLj and HDL2  in the horse. As the horse lacks CETP activity, 
how does it accomplish reverse cholesterol transfer? In those other species deficient 
in CETP, the prominence of apoE rich population of HDL provides the route for the 
transfer of cholesterol from peripheral tissues in the liver. Given that equine HDL 
contains less than 7% of its protein mass as apoE, compared with more than 22% in 
human HDLj (Kostner and Laggner 1989), this is unlikely to provide a significant 
contribution to reverse cholesterol transport.
I l l
CHAPTER V
LIPOPROTEIN METABOLISM IN THE FED ANIMAL, THE SUCKLING  
FOAL, AND IN PONY MARES DURING PREGNANCY AND LACTATION
1. INTRODUCTION
The information currently available concerning lipid transport in the horse is confined 
to the lipoproteins of endogenous, i.e. those present in the circulation when the animal 
is fasting, rather than exogenous origin. In other monogastric species, including man 
(Krasinski, Cohn, Russell and Schaefer 1990) and the dog (Melchoir, Mahley and 
Buckhold 1981), the digestion and absorption of dietary fat has profound effects on 
both the concentration and composition of the plasma lipoproteins. Most prominently, 
the plasm a concentrations of triglyceride and VLDL cholesterol, and the triglyceride 
and apoB-48 content of the density <1.006 g/ml fraction of plasma, increase as 
chylomicrons appear in the circulation (Rifai, Merrill and Holly 1990). This is 
accompanied by increases in the activity of LPL and in the plasma concentration and 
triglyceride content of the HDL 2  subfraction (Patsch et af!f. The latter results from the 
transfer of surface remnants to HDL, which first expand under the agency of LCAT 
and then become enriched with triglyceride as neutral lipid exchange, mediated by 
CETP, takes place.
While the lipid content of the adult equine diet is low compared with those of 
man and the dog, it is possible that the continued ingestion of grass or hay throughout 
the day may alter the lipoprotein profile. This was examined by analysing plasma 
lipoprotein concentrations, the composition of the density <1.006 g/ml fraction, and 
the activities of LPL, HL, and LCAT in plasma from ponies that were sampled with, 
and then without, access to food. The transport of dietary fat was subsequently studied 
using an oral fat tolerance test in which the metabolic fate of chylomicrons was traced 
with retinyl palmitate. Retinyl esters are a convenient marker for exogenous fat 
metabolism as they are taken up by enterocytes and incorporated in to the core of 
chylomicrons, where they remain until the remnants of these particles are taken up by 
the liver. In addition, these esters do not appear to be re-secreted by the liver and their 
exchange amongst lipoproteins is minimal (Berr and Kern 1984). The results 
suggested that the adult pony does not handle dietary fat in the way that humans and 
dogs do. However, in contrast to the adult animal, fat represents a major dietary 
component for the suckling foal and their lipoprotein system was therefore examined.
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A wealth of epidemiological evidence indicates that pregnancy and lactation 
represent significant risk factors for the occurrence of hyperlipaemia in ponies. The 
reasons for this are unclear. The demands placed on maternal energy metabolism by 
foetal growth and milk synthesis have been blamed for inciting the mobilisation of 
FFA from adipose stores (Jeffcott and Field 1985b). In late pregnancy this may be 
exacerbated by the peripheral insulin insensitivity that develops so that the supply of 
glucose to the foetus is maintained (Fowden et al. 1984). To examine how these two 
states affect lipoprotein metabolism in the horse, the concentrations and composition 
of the plasm a lipoproteins, and the activities of the two endothelial lipases were 
determined in six ponies in the last trimester of pregnacy and again soon after foaling. 
Hypertriglyceridaemia was found to be a significant feature of late gestation and was 
accompanied by changes in VLDL composition that establish a mechanistic basis for 
the risk posed by pregnancy.
2. SUBJECTS AND SAMPLES
Plasma cholesterol, triglyceride and lipoprotein concentrations were determined in 1 2  
healthy, non-pregnant Shetland ponies as described in section II. 1.1. Blood samples 
were collected at 9am when the animals were at grass, the ponies were then taken 
inside and given access to hay until 5pm, from which time they were fasted, and 
sampled at 9am the next day. The density <1.006 g/ml fraction was isolated from the 
plasma of four animals by flotation ultracentrifugation (section II.2.3.) and its lipid 
and apolipoprotein composition determined as described in sections II.2.5. and II.2.6 . 
These four ponies were then kept inside and fed a maintenance diet of hay and 
concentrates. After an acclimatisation period of two weeks, blood samples for the 
analysis of LPL and HL, and LCAT were collected following an overnight fast and 
again one week later when the animals had been left with free access to hay in the 
period prior to sampling. The activities of LPL and HL were determined using the 
selective assay conditions developed in Chapter IV, and that of LCAT by the method
described in section H.4.
Oral fat tolerance tests were performed according to the protocol described in 
section II . 6  on two non-pregnant ponies and two ponies that were four and eight 
months pregnant, respectively. The animals were fasted from 16 hours prior to the test 
through to the 8  hour sample, and then allowed free access to hay.
Six pregnant Shetland ponies were housed approximately one month prior to 
their estimated foaling dates, which was two to six weeks before they actually foaled. 
Plasma cholesterol, triglyceride, FFA and lipoprotein cholesterol concentrations were 
determined, lipoprotein fractions were isolated by sequential flotation
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ultracentrifugation and their composition analysed, and the activities of LPL and HL 
measured. The animals were sampled again between one and four weeks after foaling 
and these analyses repeated. On the second occasion that the mares were sampled, 
non-fasting blood was collected from their foals and, in addition to the analyses 
performed on the maternal samples, the apolipoprotein content of the isolated 
fractions were determined and the activity of LCAT measured.
3. RESULTS
3.1. Post-prandial Lipoprotein Metabolism
The mean plasma concentrations of triglyceride and VLDL cholesterol were 
significantly higher in the ponies sampled at grass than when fasted, while those of 
total and HDL cholesterol were significantly lower (Table 16; Appendix 17). There 
was no change in the LDL cholesterol concentration. In the fed state, the density 
<1.006 g/ml fraction was significantly enriched in triglyceride and depleted of 
cholesteryl esters relative to that isolated from the ponies when fasted, but was 
unchanged in respect of the masses of phospholipid and protein (Table 17; Appendix 
18). There were no significant differences in the apolipoprotein content of this 
fraction (Table 18; Appendix 18), and the ratio of the masses of apoB-100 and apoB- 
48 in the fed animals (1.8:1) was the same as that when the ponies were fasted (1.8:1). 
Although the fraction isolated from the fed ponies contained approximately twice as 
much apoE and apoA-I as that from the fasted animals, the differences were not 
significant. There were no significant differences in the activities of LPL, HL and 
LCAT (Table 19; Appendix 19).
The plasma triglyceride responses to the oral fat load are shown in Fig. 21. 
There was no peak of lipaemia in any of the four ponies examined and the plasma 
triglyceride concentrations of the two non-pregnant animals remained constant over 
the ten hours following the fat meal. Retinyl palmitate was detected in only one 
sample, at 24 hours from SP-R (0.64 ug/ml). In the two pregnant ponies, the plasma 
triglycerides rose in a linear fashion during the initial eight hours of the test and then 
declined after the animals were refed at that time point. This presumably represented 
a response to the deprivation of food in the period prior to the test as retinyl palmitate 
was detected in one pony (SP-L) only at 24 hours (0.43 ug/ml) and in the other (SP-B) 
at eight (0.41 ug/ml) and 24 hours (1.27 ug/ml).
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Animal
Plasma Concentration (mmol/1)
Cholesterol Triglyceride VLDL LDL HDL
Fed 2.13* 0.53* 0.43** 0.56 1.28**
±0.45 ±0.19 ±0.07 ±0.24 ±0.32
Fasted 2.43 0.42 0.25 0.48 1.70
±0.33 ±0.16 ±0.06 ± 0 . 2 1 ±0.19
* p <0.05, ** p <0.01
Table 16. Plasma cholesterol, triglyceride and lipoprotein cholesterol concentrations 
in 12 Shetland ponies sampled at grass (Fed) and after being fasted overnight (Fasted) 
(mean ±sd; Fed VLDL, LDL, HDL n=8 ).
Percentage Particle Mass
Animal
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
Fed 5.7* 6 6 .8 * ND 1 1 . 1 16.4
±0.4 ±3.4 ±0.9 ±3.6
Fasted 9.1 59.9 ND 13.5 17.6
±0.7 ±1.5 ±0.5 ± 1 . 2
* p < 0 .0 1 ; ND, not detected
Table 17. Chemical composition of density <1.006 g/ml lipoprotein fraction isolated 
from four Shetland ponies sampled at grass (Fed) and after being fasted overnight
(Fasted) (mean ±sd).
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Animal
Percentage of Protein Mass
B-100 B-48 E A-I C-II C-III
Fed 16.5 9.1 15.3 5.0 18.6 35.7
±2.5 ± 1 . 0 ± 2 . 6 ±4.6 ±5.4 ±2.9
Fasted 23.8 13.1 7.7 2.5 19.5 33.4
± 1 0 . 2 ±3.5 ±5.1 ±2.3 ±5.9 ±6.7
Table 18. Apolipoprotein composition of density <1.006 g/ml lipoprotein fraction 
isolated from four Shetland ponies sampled at grass (Fed) and after being fasted 
overnight (Fasted). The proteins were separated by SDS-PAGE and their masses 
calculated by densitometric scanning of the stained gels (mean ±sd).
Animal
LPL
(umolFA/ml/h)
HL
(umolFA/ml/h)
LCAT
(nmolCE/ml/h)
Fasted 2.39 3.12 20.17
±0.57 ±0.71 ±2.37
Fed 2.59 3 . 1 0 23.90
+0.42 ± 0 . 8 8 ±5.65
Table 19. Activities of lipoprotein lipase (LPL), hepatic lipase (HL) and 
lecithinxholesterol acyl transferase (LCAT) in four Shetland ponies sampled after 
being fasted overnight (Fasted) and after access to hay (Fed) (mean ±sd).
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Figure 21. Plasma triglyceride concentrations (TG) in two non-pregnant (top) and 
two pregnant (bottom) Shetland ponies following an oral fat tolerance test.
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3.2. Lipids, Lipoproteins and Enzymes in the Suckling Foal
The non-fasting plasma samples collected from each of the six foals were noticeably
hpaem ic compared with those from adult animals (Fig. 22). The plasma
concentrations of total cholesterol, triglyceride, VLDL and LDL cholesterol were
significantly higher than those of their parents in both the fasted and fed states (Table
20, Appendix 20). The concentrations of HDL cholesterol were similar to those of the 
fed adults.
The plasma samples were cleared of turbidity following flotation 
ultracentrifugation at density <1.006 g/ml, 2 0 k rpm for 2 0  mins. when a cloudy 
supernatant appeared (Fig. 22). This was presumed to contain chylomicrons, and was 
collected and purified of contaminating plasma proteins by two further spins at 
density <1.006 g/ml, 20k rpm for 20 mins. The chemical compositions of this, and the 
VLDL, LDL and HDL fractions are summarised in Table 21 (Appendix 21). There 
was insufficient material in the IDL fractions for compositional analysis. The 
composition of the chylomicron fraction was almost identical to that of the 
intestinally derived lipoproteins found in man as the particles were composed almost 
entirely of triglyceride, with small contributions from cholesteryl esters and protein. 
Despite the low cholesterol content, a significant mass of free cholesterol was 
detected and represented an average 25% of the total cholesterol mass. Phospholipids 
were below the level of detection.
Animal
Plasma Concentration (mmol/l)
Cholesterol Triglyceride VLDL LDL HDL
Foals 3.77** 0.87* 0.23 2.06** 1.48
±0.84 ± 0 . 2 0 ± 0 . 1 1 ±0.62 ±0.25
Mothers (Fed) 2.15 0.52 0.48 0.43 1.43
±0.14 ±0.15 ±0.14 ±0.23 ±0.18
* p < 0.05; **p< 0 .01
T able 20. Plasma cholesterol, triglyceride and lipoprotein cholesterol concentrations 
in non-fasting samples from six Shetland pony foals and their mothers (mean ±sd).
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Adult Foal Adult Foal
Figure 2 2 . Appearance of a non-fasting plasma sample from a suckling foal. Note 
the opacity of the plasma compared with a sample from a fasted adult pony on the 
left. After ultracentrifugation at density <1.006 g/ml, 20k rpm for 20 mins., the 
plasma has cleared as the chylomicron fraction has floated to the surface.
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The foal VLDL was distinct from that of adult ponies in that the mass of triglyceride 
was significantly lower and the protein content significantly higher. Free cholesterol 
was also detectable and represented 19% of the total cholesterol mass. The 
composition o f foal LDL was bizarre as a far greater proportion of the cholesterol was 
present in the unesterified form such that the ratio of esterified to free cholesterol was 
approximately 1.5.1 compared with 24:1 in the adults. These particles also contained 
significantly less triglyceride and protein and had a significantly higher mass of 
phospholipids. The triglyceride content of HDL was significantly lower than that of 
the adults.
The apolipoprotein composition of the chylomicron, VLDL LDL and HDL 
fractions are detailed in Table 22 (Appendix 22). The chylomicrons consisted almost 
exclusively of apoA-I, apoC-II and apoCTII. Apolipoprotein E was detected in one 
sample and very faint band in the region of adult apoB-48 was visible on the gel but 
not quantifiable by densitometric scanning. The protein compositions of the VLDL 
and HDL fractions were similar to those of adult animals. However, an appreciable 
amount o f albumin was present in all the LDL fractions, which also contained a minor 
component of apoA-I (Fig. 23). This did not appear the result of contamination of the 
HDL as there was no albumin in any of the HDL fractions.
Lipoprotein
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
Chylomicrons 2.7 89.7 0.9 ND 7.6
±1.5 ±3.1 ±0.5 ±1.9
VLDL 9.4 52.6 2 . 2 13.0 22.7
± 2 . 6 ±4.6 ± 1 . 1 ± 1 . 8 ±2.4
LDL 26.8 1 . 8 18.5 35.1 17.1
±6.4 ±0.4 ±4.5 ±3.5 ± 2 . 8
HDL 18.6 0.4 4.6 28.9 47.5
±3.3 ±0 . 2 ±0.7 ±1.3 ±3.7
Table 21. Chemical composition of lipoproteins isolated from six Shetland foals 
(mean ±sd).
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Figure 23. Resolution of foal apolipoproteins by SDS-PAGE. CM, chylomicrons; 
ALB, albumin. (The second and third LDL tracks have been overloaded to 
demonstrate the albumin and apoA-I bands present in this lipoprotein class, with the 
result that there has been some degredation of the protein).
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Lipoprotein
Percentage of Protein Mass
B-100 B-48 E A-I c-n C-III A-II
Chylomicrons — -------- 1 . 2 26.8 20.5 51.6
± 2 . 8 ±7.6 ±6.7 ± 6 . 1
VLDL 19.3 7.1 9.7 7.3 21.4 36.1 __
±5.3 ± 2 . 8 ±4.3 ± 2 . 6 ±4.9 ± 8 . 6
LDL 80.9 — 6.4 2.9 2 . 8 7.0 _____
±5.6 ±1.7 ± 1 . 6 ± 1 . 1 ±3.7
HDL — — 4.6 83.3 3.7 3.5 4.9
±2.3 ± 1 . 1 ± 1 . 1 ± 1 . 1 ± 1 . 8
Table 22. Apolipoprotein composition of lipoproteins from six Shetland pony foals 
(mean ±sd). The relative mass of each protein was calculated from the area under the 
peaks of densitometric scans of the Coomassie stained SDS-PAGE gels.
Animal
LPL
(umolFA/ml/h)
HL
(umolFA/ml/h)
LCAT
(nmolCE/ml/h)
Foals 10.93**±4.49 6.94 ±4.08 40.00* ±4.40a
M others: Non-pregnant 3.44 ±1.10 5.05 ±1.88 22.29 ±2.52
Pregnant 4.12 ±0.68 4.20 ±1.03 nd
Lactating 14.76* ±4.44 9.78 ±3.83 nd
* p < 0.05, ** p < 0 .0 1 , u n= 5 ; nd, not determined
Table 23. Lipoprotein lipase (LPL), hepatic lipase (HL), and lecithin:cholesterol 
acyl transferase (LCAT) activities in six Shetland pony foals and their mothers when 
non-pregnant, in late gestation and in early lactation (mean ±sd;_the foal data has been 
compared with that of the non-pregnant mares).
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The activities of LPL and LCAT were significantly higher in the foals than 
their mothers (Table 23), being increased by approximately three and two fold,
respectively. Although the activity of HL was also increased this was not significant 
(Appendix 23).
3.3. Lipids, Lipoproteins and Enzymes in Pregnancy and Lactation
The plasma concentrations of total cholesterol, triglyceride, and VLDL and HDL 
cholesterol were significantly higher in the mares in late pregnancy than they were 
when the animals were not in foal (Table 24; Appendix 20). The LDL cholesterol and 
FFA concentrations were unchanged. Once the animals had foaled, the concentrations 
of triglyceride returned to normal, but those of VLDL cholesterol were significantly 
lower than the non-pregnant values and the HDL cholesterol concentrations remained 
significantly elevated. Although plasma FFA concentrations were higher when the 
ponies were lactating, the differences were not of statistical significance.
Animal
Plasma Concentration (mmol/l)
CholesterolTriglyceride VLDL LDL HDL FFA
Non-pregnant 2 . 0 2 0.49 0.42 0.52 1.08 0.55
±0.33 ±0.06 ±0.05 ±0.24 ± 0 . 2 1 ± 0 . 1 0
Pregnant 2.91** 1.36** 0.55* 0.63 1.73** 0.43
±0.25 ±0.49 ±0 . 1 1 ± 0 . 1 2 ± 0 . 2 2 ± 0 . 2 0
Lactating 2.61 0.41 0 .2 2 ** 0.64 1.75** 1 . 1 0
±0.74 ±0.27 ±0.08 ±0.53 ±0.27 ±0.59
* p < 0.05; ** p < 0 . 0 1  compared with non-pregnant data.
Table 24. Plasma lipid and lipoprotein concentrations in six Shetland pony mares 
when non pregnant, in late gestation, and in early lactation (mean ±sd).
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There were significant changes in the composition of VLDL in the pregnant 
mares (Table 25, Appendix 24), which contained on average 13% more triglyceride 
and 51% less protein than the particles isolated prior to pregnancy. Although the total 
cholesterol content was unchanged, the mass of cholesteryl esters was significantly 
reduced such that free cholesterol represented 92% of the cholesterol mass. After 
foaling, the VLDL remained significantly enriched in triglyceride while the protein 
content was normal and the mass of phospholipid was significantly lower. Free 
cholesterol was not detected in the VLDL from the lactating mares and the mass of 
cholesteryl esters was similar to that found prior to pregnancy. These differences 
retained their statistical significance when the groups were compared with the data for 
12 non-pregnant Shetland pony mares in Chapter III.
Lipoprotein
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
VLDL NP 8 . 8  ±0.9 60.4 ±1.7 ND 16.6 ±2.3 16.4 ±2.0
Prega 0.7**±0.6 68.5**±2.1 7.8 ±2.0 15.0 ±1.0 8.0**±1.5
Lact 6 .6 * ± 1 . 8 67.8* ±4.7 ND 9.5**±1.4 16.2 ±3.6
LDL NP 41.2 ±2.6 5.9 ±2.5 1.2 ±1.9 21.4 ±1.6 29.1 ±3.8
Prega 37.8 ±3.5 5.9 ±1.2 8.0**±4.3 24.6 ±1.9 23.1* ±2.8
Lact 34.5 ±9.1 4.5 ±2.0 9.8**±5.6 27.3 ±8.1 25.5* ±6.3
HDL NP 19.5 ±3.4 1.0 ±0.4 3.3 ±4.1 31.0 ±4.1 45.3 ± 6 . 8
Prega 20.9 ±3.4 0.4* ±0.1 4.1 ±0.8 30.4 ±1.4 44.2 ±3.2
Lact 20.7 ±2.2 0 . 6  ±0 . 2 4.0 ±0.4 28.1 ±3.4 50.0 ±4.8
* p < 0.05, ** p < 0.01 compared with non-pregnant data; ND, not detected, an=5.
T ab le 25. Chemical composition of VLDL, LDL and HDL isolated from Shetland 
pony mares when not pregnant (NP), in late pregnancy (Preg) and early lactation 
(Lact) (mean ±sd).
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The masses of free cholesterol and phospholipid in LDL were significantly higher in 
pregnancy and lactation and the mass of protein significantly lower in both states. 
There was a significant reduction in the triglyceride content of HDL in the pregnant 
ponies. However when these data were compared with the values for the 12 non- 
pregnant Shetland pony mares, none of these changes in LDL or HDL composition 
were o f statistical significance.
There were no significant differences in the activities of LPL and HL in 
pregnant, and HL in lactating ponies (Table 23). However, the activity of LPL was 
significantly higher in the lactating ponies, with individual values increased by 
between three and six fold over the mean of healthy ponies (Appendix 23).
4. DISCUSSION
4.1. Exogenous Lipoprotein Metabolism in the Horse
The comparison of lipoprotein profiles in fed ponies with those fasted prior to sample 
collection was conceived as a means of assessing how the equine lipoprotein profile 
might change when lipids of dietary origin enter the system. The results did not 
provide any concrete evidence for a post-prandial phenomenon, such as that seen in 
other monogastrics, for the reasons discussed below. The plasma concentrations of 
triglyceride and VLDL cholesterol were indeed higher in the fed ponies and might 
have reflected the presence of triglyceride rich chylomicrons in the circulation. For 
this is the reason why, in man, plasma triglyceride levels are increased by 30-50% 
approximately three hours after a normal meal (Durrington, Whicher, Warner, Bolton 
and Hartog 1976). The presence of chylomicrons in plasma of the fed ponies would 
also explain the enrichment of the <1.006 g/ml fraction with triglyceride, and account 
for its reduced cholesteryl ester content as chylomicrons are poor in cholesterol 
relative to VLDL. However, in conflict with this was a body of data that indicated 
that feeding had no effect on the lipoprotein system. First, although the protein 
content o f the chylomicrons isolated from the foals was less than 50% of that of 
VLDL, there was no reduction in the protein mass of the density <1.006 g/ml fraction 
of the fed ponies. Secondly, the ratio of apoB-100 to apoB-48 was unchanged. 
Thirdly, while the presence of chylomicrons in foal plasma accounted for moderate 
hypertriglyceridaemia, the cholesterol concentrations of VLDL were lower, not 
higher, than those found in adult ponies due to the inferior contribution of cholesterol 
to the mass of these particles. Finally, the activities of neither LPL or LCAT were
increased in response to feeding.
Some of the variation between the fed and fasted animals may have due to the 
fact that the groups were small in size and that single samples were taken on each
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occasion. The day to day variation in serum triglycerides in man, after laboratory 
errors have been excluded, is in the region of 25% (Hammond, Wentz, Statland, 
Philips and Winkel 1976) and similar fluctuations may have accounted for some of 
the observed differences. However, the changes in plasma triglyceride concentration 
and VLDL composition might be better explained by consideration of the fact that in 
the rat, a species whose lipid transport system has much in common with that of the 
horse, the hepatic secretion of VLDL triglyceride is greater in the fed than the fasted 
state (Wilcox and Heimberg 1987). Thus it is possible that in the horse, the absorption 
of short and medium chain fatty acids in the small intestine, and volatile fatty acids in 
the large intestine, leads to increased output of triglyceride rich VLDL from the liver. 
In the absence of post-prandial chylomicronaemia, as shown by the retinyl palmitate 
studies, this would cause the differences observed in the concentration and lipid 
composition of VLDL, and no significant change in the ratio of apoB-100 to apoB-48 
in the density < 1.006 g/ml fraction.
The uncertainties raised by the above data were compounded by the results 
from the oral fat tolerance tests. In man, plasma triglycerides increase following an 
oral fat load peaking at 2  hours and return to fasting values within 8  hours of the meal 
(Cohen 1989). The magnitude of this response in healthy volunteers is proportional to 
the fat content of the meal, such that 100 g fat given to a 70 kg person produces an 
approximate three fold increase in plasma triglyceride concentrations (Demise, 
Hauptman and Dunton 1989). The fat content of the oral load used here approximated 
to 1 2 0  g fat/70 kg and yet provoked no such lipaemia or incorporation of retinyl 
palmitate into the density <1.006 g/ml fraction. In man, plasma retinyl ester 
concentrations rise after the meal, peaking at 6  hours, and then decline but remain 
greater than baseline at 12 hours (Krasinski et al. 1990). In contrast, retinyl palmitate 
was found in the density <1.006 g/ml fraction of one the ponies at 8  hours and in two 
others only at 24 hours. This would not appear to be the result of the hay offered after 
the eight hour sample as the vitamin A content of sun dried forages is negligible 
(Cunha 1991).
Why should the horse differ so greatly in its response to oral fat from that of 
other monogastrics? Although there are no records of oral fat tolerance tests of this 
type being performed in the horse, the protocol was based on that used for oral 
glucose tolerance testing, a common clinical practice which in healthy horses gives 
rise to a peak of plasma glucose at 2 - 4  hours that declines to baseline by 8 - 1 0  hours. 
A delay in gastric emptying, or slow small intestinal transit, would therefore appear 
unlikely to account for the flat response to the fat load. The explanation must 
therefore reside in the events that start with the digestion of fat in the small intestine 
and culminate in the appearance of chylomicrons in the circulation. Although the
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horse does not possess a gall bladder and has a bile pool approximately 1 0 % the size 
of that of man, mature animals appear capable of digesting diets containing up to 18% 
animal fat (Hintz, Schryver and Lowe 1973). This capability is far in excess of the fat 
content of grass, hay and proprietary concentrates which is in the region of 2-5 g/lOOg 
dry weight (Givens and Moss 1990) with a total sterol content 10-50 mg/lOOg fresh 
weight (Weinrauch and Gardner 1978).
While the primary site for the absorption of dietary fatty acids is presumed to 
be the small intestine (Hintz et al. 1973), the appearance of retinyl palmitate in the 
later samples might indicate that the label, together with the fatty acid products of 
triglyceride hydrolysis, were absorbed in the large intestine. If this was the case, then 
why were the products not absorbed through the small intestine? One possible 
explanation may reside in an adaptation of the adult horse to its diet which is low in 
fat and rich in short and medium chain fatty acids that are absorbed without the need 
for chylomicron synthesis. Such adaptation would, however, need to be age related as 
lipoprotein particles with the physical and chemical features of chylomicrons were 
found in the plasma of suckling foals at a time when the fat content of their diet was 
high (approximately 2 g/lOOml, 18% of the total solids; Ullrey, Struthers, Hendricks, 
and Brent).
4.2. Lipoprotein Metabolism in the Suckling Foal
The lipoprotein profile of foals contrasted with that of adult horses in that LDL was 
the predominant class in terms of cholesterol and accounted for the higher plasma 
total cholesterol concentration. As discussed above, the lipaemic appearance of the 
plasma and the decreased VLDL cholesterol concentrations were explained by the 
presence of lipoproteins with the features of chylomicrons. As in humans, the 
presence of chylomicrons in the circulation was the likely stimulus for the higher 
activities of LPL and LCAT seen in the foals compared with the adults, further 
evidence of a more typical monogastric response to dietary fat.
Despite washing the chylomicron fractions twice, there still remained slight 
albumin contamination which will have exaggerated the protein content of these 
particles. In common with human chylomicrons, the C peptides and apoA-I were 
prominent apolipoprotein components. The presence of apoB in trace and 
unquantifiable amounts was puzzling as this protein is absolutely essential for the
synthesis of chylomicrons in man.
As the neutral lipid content of VLDL reflects that of the liver, the greater mass 
of cholesterol in this fraction was probably the result of an increased flux of 
cholesterol to the liver in the form of chylomicron remnants. The significant mass of 
free cholesterol may have been due to differences in the hepatic activity of ACAT
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between the foal and the adult animal. The composition of foal LDL was unusual 
because the ratio of esterified to free cholesterol was out of proportion with that in the 
VLDL precursors, the proportions of phospholipids to protein were reversed 
compared with those in adult LDL, and there were significant contributions to protein 
mass from albumin and apoA-I. It is therefore likely that certain particles in this 
density range were derived independent of VLDL precursors. In fact the composition 
of this fraction resembles a mix of that of adult equine LDL and Lp-X, the latter of 
which contains significantly higher amounts of phospholipids (61%) and free 
cholesterol (25%) and has albumin and apoA-I representing 30% and 2% of its 
protein mass, respectively (Kostner and Lagger 1989). The origins of such particles in 
apparently healthy foals is unclear, but would not appear to be related to defective 
hepatic function or LCAT activity.
4.3. Lipoprotein Metabolism in Pregnancy and Lactation
The results from the six ponies clearly showed that moderate hyperlipidaemia is 
prevalent in the last trimester of pregnancy. The changes in VLDL composition were 
strikingly similar to those seen in ponies with hyperlipaemia in the following Chapter. 
Thus it is possible that this might represent a subclinical form of hyperlipaemia, and 
that any additional disruption in the control of lipid metabolism could rapidly lead to 
the development of clinical disease. This was perhaps evident in the responses of the 
two pregnant ponies to fasting prior too the oral fat tolerance tests where plasma 
triglyceride levels had rose steeply after only a 16 hour period of food withdrawal in 
marked contrast to the non-pregnant animals.
There is little in the literature to confirm or deny the significance of these 
findings. Forenbacher et al. (1960) commented that the concentration of neutral fats 
was increased by nearly four fold in a single pregnant mare and Stammers, Silver and 
Fowden (1989) reported triglyceride levels of 1.3, 0.6, 5.5, 12.7 and 1.9 mmol/1 in the 
uterine vein of five pony mares between 250 and 300 days of gestation, and showed 
that the latter value rose to 10.6 mmol/1 when the pony concerned was fasted for 30 
hours. Prior to this, Fowden et al. (1984) demonstrated that there are marked changes 
in carbohydrate metabolism during pregnancy in the mare which included 
hyperinsulinaemia, enhanced resistance to the action of insulin and exaggerated 
response to feeding and fasting. The net effect of these changes is to divert glucose to 
the uterus, with the result that up to 7 5 % of the available maternal glucose pool is lost 
to the rapidly developing foetus (Silver and Fowden 1982). Together with the 
reduction in voluntary feed intake that is an universal feature of pregnancy, this 
clearly places severe demands on maternal energy metabolism with the consequence 
that adipose stores are drawn upon to meet any deficit. In support of this, Stammers et
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al. (1989) showed that plasma FFA concentrations were normal (0.71 and 0.54 
m mol/1) in two pregnant pony mares that were well nourished, but elevated ( 1 .3 , 1 . 5  
and 2.27 mmol/1) in three others that were on a low plane of nutrition.
Although lactation is also recognised as a risk factor for hyperlipaemia, the 
plasma concentrations of triglyceride returned to normal after foaling as the 
composition of VLDL tended towards normality. In common with lactation in other 
species, the activity of LPL was increased presumably as the result of induction of the 
enzyme in mammary tissue by prolactin (Scow and Chernick 1987). This higher level 
of activity probably accounts for the decrease in the levels of VLDL in the lactating 
mares, as triglyceride is channelled to the mammary gland for milk production. The 
increases in plasma FFA concentration, although not statistically significant, might be 
due to the mobilisation of fatty acids from adipose tissue to help meet the demands of 
lactation, or alternatively reflect the increased activity of LPL. If the former is the 
case, then any interruption in the supply of dietary energy coupled with the factors 
that lead to peripheral insulin insensitivity might well precipitate massive 
mobilisation of FFA and explain the incidence of hyperlipaemia in lactating pony 
mares. However, the activity of LPL in lactation was approximately 50% greater than 
in the animals with hyperlipaemia, suggesting that lactating mares might be better 
able to cope with any increase in VLDL production and are therefore protected to 
some extent against hyperlipaemia.
In conclusion the data presented here clearly shows that the risk of 
hyperlipaemia in pregnancy is related to underlying changes in lipid and lipoprotein 
metabolism and indicate that there may be a place for the routine screening of plasma 
triglyceride concentrations in the management of pregnancy in the pony mare. 
Animals then identified as at risk of developing hyperlipaemia might be candidates 
for lipid lowering therapies as a preventive strategy, which is discussed in Chapter 
V f f l .
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CHAPTER VI
PLASM A LIPOPROTEIN CONCENTRATION AND COMPOSITION, AND 
ENZYME ACTIVITY IN PONIES WITH HYPERLIPAEMIA
1. INTRODUCTION
The early evidence for the biochemical mechanisms behind hypertriglyceridaemia in 
man came from examining how the concentration and composition of the plasma 
lipoproteins were altered in affected subjects (Fredrickson et al. 1967). It is therefore 
reasonable to expect that the lipoproteins in ponies with hyperlipaemia might also 
hold similar aetiological clues. The equine condition was defined as 
hyperprebetalipoproteinaemia by Morris et al. (1972) and subsequent studies have 
confirmed the predominance of VLDL in ponies with naturally occurring disease 
(W ensing et al. 1975) and experimental reproductions of the condition (Bauer 1983, 
Freestone et al. 1991). However, analysis of the composition of the lipoproteins has 
not been rewarding. Morris et al. (1972) reported that the VLDL in two 
hyperlipidaemic ponies was depleted of cholesterol, particularly of the esterified 
form, relative to human and rat VLDL but presented no data from healthy ponies for 
comparison. Wensing et al. (1975) commented that the triglyceride content of VLDL 
and LDL was increased in the more severely affected of nine ponies relative to a 
single control, but Bauer (1983) found no significant change in the composition of 
VLDL in four hyperlipidaemic ponies compared with two controls.
More recently, progress in understanding the fundamental biology of 
lipoprotein metabolism has led to the unravelling of the genetic, molecular and 
metabolic aetiologies of hyperlipidaemia in man and certain experimental species. 
Despite this, the mechanisms that underlie equine hyperlipaemia are not known. The 
consensus of opinion believes that affected animals mobilise fatty acids from adipose 
stores in response to an energy imbalance. The mobilisation is thought to proceed in 
an uncontrolled fashion, because of peripheral insulin insensitivity, so that the FFA 
are re-esterified in the liver and secreted in VLDL as triglyceride (Jeffcott and Field 
1985b). However, this has not been supported by experimental data to date. Rather, 
attempts to quantify VLDL secretion by blocking its hydrolysis with Triton led 
Morris et al. (1975) to conclude that the "mechanism resides in the suppression of 
lipoprotein degradation". Bauer (1983) made a similar speculation on the basis that he 
found little change in the chemical composition of VLDL, and Freestone et al. (1991) 
concluded that their failure to show differences in the hyperlipidaemia induced in
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normo- and hyperinsulinaemic ponies by fasting was because "some aberration in the 
degradation o f VLDL was responsible" for the disease.
In the studies described here, the plasma concentration and chemical 
composition o f the lipoproteins from 18 ponies with hyperlipaemia were examined. 
This defined the lipid phenotype associated with the disease and showed that, in 
contrast to previous work, there are significant changes in the composition of the 
lipoproteins. The activities of LPL and HL were measured for the first time in ponies 
with hyperlipaemia and, in an attempt to explain some of the changes in lipoprotein 
composition, the activities of LCAT and CETP were analysed. This series of cases 
constitutes the first report of the disease in the United Kingdom and the clinical 
picture presented is rationalised with previous records from other parts of the World. 
The findings provided important clues to the aetiology of equine hyperlipaemia and 
established the focus for metabolic studies described in the following Chapter.
2. M A T ER IA LS AND METHODS
2 .1 . Subjects an d  Samples
The clinical details of the 18 cases of hyperlipaemia are summarised in Appendix 25. 
Five cases were diagnosed at Glasgow University Veterinary School. The remainder 
were recruited following notice of the study in the Veterinary Record (1989, 144, 
474), a newsletter of the British Equine Veterinary Association, and Equine 
Veterinary Education (1990, 2, 230). In this, attending veterinarians were invited to 
submit blood samples from cases in which they suspected hyperlipaemia, which was 
then confirmed or excluded by measurement of triglyceride concentrations. A routine 
blood chemistry panel was also run to identify hepatic and renal dysfunction and to 
help in offering a prognosis for each case. Three cases were subsequently referred to 
Glasgow University Veterinary School and the author visited another at the Royal 
(Dick) School of Veterinary Studies, University of Edinburgh. Blood for lipid and 
lipoprotein analysis, including PHP and plasma for the preparation of LPDP, was 
collected from these cases prior to the institution of therapy as described in Chapter
II. The nine other cases were managed in general practice and the practitioners 
submitted further blood samples prior to therapy; these were collected into potassium 
EDTA and the plasma was either separated before dispatch or immediately upon 
arrival in Glasgow where it was used within two days of collection.
2.2. M ethods
The methods used here were described in Chapter II. Plasma lipid and lipoprotein 
concentrations were measured and the lipoprotein particle size distribution examined
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by gel filtration on columns of 6 % and 2% agarose gel. The size of particles in VLDL 
was measured by electron microscopy. Rate-zonal ultracentrifugation was not used 
for the reason that insufficient plasma was available from all the cases, and where it 
was obtained from an early case (HLP-2) there was ineffective fractionation of HDL 
and LDL because of the massive amounts of VLDL. The size of HDL particles was 
therefore estimated by electrophoresing HDL prepared by sequential flotation 
ultracentrifugation on non-denaturing polyacrylamide gels. However, the 
concentration o f LDL prepared by this route was inadequate for the loading of the 
gels so that the size of these particles was not examined.
Lipoprotein fractions were prepared by sequential flotation ultracentrifugation 
for analysis of lipid and apolipoprotein composition with the following modification. 
It was found that by initial ultracentrifugation at density <1.006 g/ml, 20k rpm for 20 
mins. the samples could be cleared of their lipaemia. Complete clearance required 
between one and four spins; the supernatants were pooled, labelled VLDL1? and 
cleaned o f plasma lipoprotein contamination by gel filtration on 6 % agarose. The 
conventional VLDL fraction collected by the subsequent spin at d <1.006 g/ml, 39k 
rpm for 18 hours was then called VLDLj. The plasma concentrations of VLDLj was 
estimated by dividing the total cholesterol concentration of this 1 ml fraction by 4 (the 
original volume of plasma) and subtracting from the plasma VLDL cholesterol 
concentration. The VLDL 2  concentration was taken as the difference between the 
two. These data were compared with that from 18 healthy Shetland ponies in Chapter
in.
The activities of LPL and HL were determined in PHP using the selective 
assay conditions developed in Chapter IV, and the activities of LCAT and CETP were 
measured using the assay conditions detailed in Chapter n. The enzyme activities 
were compared with those presented for healthy Shetland ponies in Chapter IV.
3. RESULTS
3.1. The Clinical Disease
The mean (±sd, range) age of the affected ponies was 8.9 years (±4.6, 18 months to 
20 years). Eleven of the cases were Shetland ponies (61%), four were of Welsh 
Mountain pony stock (22%). there was one Fell pony (6 %), and the remainder were 
described as riding ponies of mixed breeding. Four of the animals were geldings 
(22%). the rest were mares of which nine (50%) were known to be in foal (gestation 
5-10 months, mean 8.4) and two (11%) were lactating. The geographic spread of 
cases was from Cornwall in the South to Shetland in the North of the United 
Kingdom. Underlying or concurrent diseases were identified in six animals (33%);
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these were lamimtis (two cases), chronic diarrhoea due to intestinal lymphosarcoma 
(one case) and large intestinal parasitism (two cases), and dysphagia caused by 
oesophagitis of undetermined aetiology (one case). Veterinary attention was sought 
for the remaining 12 cases (67%) because of inappetance and/or dullness, depression 
and lethargy. Over the three year period of the study, there was no seasonal pattern of 
incidence with six cases in the Spring months (March to May), five in the Summer 
(June to August), four in the Autumn (September to November) and three in the 
Winter (December to February).
Blood chemistry showed that liver enzymes (alkaline phosphatase and 
gamma-glutamyl transferase) were markedly elevated in 13 cases (72%) and evidence 
of renal dysfunction (elevated urea and creatinine concentrations) in seven (3 9 %) 
animals. Four cases (22%) were euthanased without therapy, three because of a grave 
prognosis for an underlying complaint and the fourth (HLP-18) on humane grounds. 
Therapy for the remaining 14 animals centred on maintaining energy balance with 4% 
glucose solutions or Lectade (Beecham), giving five litres four times daily per os or 
via a nasogastric tube. Insulin (50-100 iU im bid) and heparin (100 iU/kg iv bid) were 
used in combination in four animals, and insulin alone in two cases. Six animals 
(33%) recovered and eight died (44%), giving an overall mortality rate of 67%. The 
outcome was not dependent upon the type of therapy, as only one each of the cases 
given insulin/heparin or insulin recovered, whereas four of the eight cases supported 
solely with glucose survived. The length of time from the first recognition of clinical 
signs by the owner to death or euthanasia ranged from 3 to 24 days, with a mean (±sd) 
of 10 (+7) days. Somewhat surprisingly, the outcome of therapy was not related to the 
severity of hyperlipidaemia as the plasma triglyceride concentrations at the time of 
diagnosis in the six animals that recovered (27.24 +17.11 mmol/1, mean ±sd) were 
similar to those in the animals that died (28.76 ±9.95 mmol/1). Nor were there any 
differences in any of the indices of hepatic or renal pathology between the two 
groups.
3.2. Plasma Lipid and Lipoprotein Concentrations (Appendix 26)
Bloods samples from all cases were noticeably lipaemic and the plasma was found to 
clear when left standing at 4°C for one to four days as a creamy supernatant 
developed at the surface (Fig. 24). The plasma triglyceride concentrations were ten to 
165 fold higher than in healthy ponies (p < 0.001) and ranged from 4.70 to 78.75 
mmol/1 (25.43 +18.09; mean ±sd). Plasma cholesterol concentrations were increased 
by approximately two to eight fold and ranged from 3.45 to 16.90 mmol/1 (7.51 
±3.44; p < 0.001). These changes were accompanied by VLDL cholesterol 
concentrations that were increased by five to 52 fold (5.55 ±3.45, p < 0.001). The
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concentrations (mmol/1) of LDL (0.60 ±0.20) and HDL (1.36 ±0.50) cholesterol were 
similar to those in the control groups (0.54 ±0.22 and 1.32 ±0.29, respectively).
Plasma FFA concentrations were higher than the control group (0.39 ±0.16 
mmol/1) in all but one of the animals where they ranged from 0 . 9 4  to 3.32 mmol/ 1  
(1.67 ±0.80), representing a 2.4 to 8.5 fold increase (p < 0.001). The FFA 
concentration in the exceptional case was 0.41 mmol/1. In the entire group of 18 
animals, there were significant correlations between concentrations of FFA and total 
cholesterol (r = 0.51), triglyceride (r = 0.44), and VLDL cholesterol (r = 0.49). The 
plasma concentrations of VLDLj ranged from 0.50 to 14.65 mmol/1 and were 
positively correlated with those of total VLDL cholesterol (r = 1.0, p < 0.001), and 
represented a percentage of the VLDL fraction that increased with the degree of 
hyperlipidaemia, from between 33% in the case with the lowest plasma triglyceride to 
nearly 100% in those with severe hypertriglyceridaemia. In contrast, the VLDL2  
cholesterol concentration was relatively constant with a mean (±sd) for the 18 cases 
of 0.40 (±0.30) that was similar to the VLDL cholesterol concentration of the control 
group (0.29 ±0.14), and which was not correlated with the degree of hyperlipidaemia.
Figure 24. The appearance of plasma from a pony with hyperlipaemia (centre) 
compared with that from a healthy pony on the right. The sample on the left was left 
standing at 4° C for two days, after which time the plasma cleared as a creamy
supernatant accumulated at the surface.
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3.3. Lipoprotein Size Distributions
A typical elution profile of density <1.225 g/ml lipoproteins from a 6 % agarose gel 
column is shown in Fig. 25. The pattern for each of nine hyperlipaemic ponies 
exam ined was similar and striking in the predominance of the VLDL peak. In fact, the 
fractions contained within this required to be diluted by five to ten fold to achieve an 
absorbance within the limits of the spectrophotometer. The elution profiles (Appendix 
27) generally showed greater variability between individuals in the elution volume 
and width of each peak compared with those from the healthy animals. Much of this 
might have been due to changes in the column's properties over the 16 month period 
that encompassed the analysis of the nine samples. Although there was a tendency for 
VLDL and HDL to elute earlier than in the healthy ponies, there were no statistical 
differences between the elution volumes (mean ±sd) of VLDL (73.1 ±6.3; normal 
78.9 ±1.2 ml), LDL (109.7 ±9.2; normal 110 ±3.9 ml), and HDL (145.3 ±11.9; 
normal 154.7 ±3.5 ml). The VLDL peak was significantly wider in the hyperlipaemic 
ponies (19.8 ±4.3; normal 11.1 ±0.8 ml), while those of LDL and HDL were similar 
to the healthy ponies (LDL 29.9 ±3.3; normal 31.6 ±3.5 ml, HDL 37.8 ±5.3; normal 
36.2 ±2.9 ml).
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F igure  25. Distribution of plasma lipoproteins in a pony with hyperlipaemia. 
Lipoproteins were isolated from plasma at density < 1.225 g/ml and eluted from a 
column of 6 % agarose with phosphate buffered saline.
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Despite the heterogeneity in VLDL noted in the ultracentrifuge, discrete 
VLDL subpopulations were not found when the density <1.225 g/ml fraction of 
plasma was applied to columns of 2% agarose gel.
The average particle size in VLD L1 and VLDL2 from four animals, assessed 
by electron microscopy, was 65 nm and 50 nm, respectively, representing increases in 
diam eter of 44% and 11% over the mean of VLDL in healthy ponies. The diameter of 
HDL, m easured by non-denaturing polyacrylamide gradient gel electrophoresis, was 
8.61 ±0.20 nm (n=9), which was similar to that of HDL prepared from healthy ponies 
by either flotation ultracentrifugation (8.43 ±0.17 nm, n=9) (Appendix 28) or by rate- 
zonal ultracentrifugation (8.37 ±0.08 nm, n=8) in Chapter III (Appendix 5).
3.4. Lipoprotein Composition
The chemical compositions of the VLDL1? VLDL2, IDL, LDL and HDL fractions 
isolated by sequential flotation ultracentrifugation (Appendix 29) are compared with 
those from healthy ponies in Table 26. Both VLDLj and VLDL2 were significantly 
enriched in triglyceride (by 25% and 10%, respectively) and depleted of protein (by 
59% and 30%, respectively) relative to VLDL from the healthy ponies. The 
phospholipid content of VLDLj was significantly reduced (by 27%) while that of 
VLDL^ was similar to the control group. The masses of phospholipid and protein 
were significantly correlated with that of triglyceride in both VLDLj (r = -0.57 and r 
= -0.59, respectively) and VLDL2 (r = -0.47 and r = -0.60, respectively). The total 
cholesterol contents of both VLDLj (8.3%) and VLDL2 (9.7%) were similar to the 
controls (10.1%) but, in contrast to the healthy animals, free cholesterol was detected 
in both VLDLj and VLDL^ where it comprised 63.3% and 32.9% of the total 
cholesterol mass, respectively. The mass of free cholesterol was significantly higher 
in VLDLj than VLDL2, while that of cholesteryl esters was significantly greater in 
VLDL^ than VLDLj. The masses of cholesteryl esters and free cholesterol were 
significantly correlated in VLDL2 (r = -0.75, p < 0.001) but not in VLDLj (r = -0.39).
The LDL fraction had a significantly reduced cholesteryl ester content (by 
30%) and the triglyceride mass of these particles was significantly higher (by 
approximately three fold) than that of the controls. The masses of free cholesterol, 
phospholipids and protein in LDL and HDL were similar to those in healthy animals. 
The triglyceride content of the HDL fraction was significantly increased (by three 
fold).
The apolipoprotein composition of each lipoprotein fraction (Table 27; 
Appendix 30). In the VLDL! fraction, the mass of apoB-100 was reduced by an 
average of 46% while that of apoB-48 was unaltered, so that the ratio of apoB-100 to 
apoB-48 was approximately 0.9:1 compared with 1.8:1 in VLDL from healthy ponies.
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Percentage Particle Mass
Lipoprotein Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
VLDL! HLP 2.5 ** 73.9** 5.3 11.1** 6.8 **
±2.4 ±4.6 ±1.6 ±2.7 ±2.6
VLDL2  HLP 6.5* 64.5* 3.2 14.8 11.7**
±4.3 ±6.3 ±2.7 ±2.3 ±4.3
VLDL SP 10.1 58.9 ND 15.3 16.6
±1.7 ±3.9 ±2.3 ±2.4
LDL HLP 29.0 ** 19.1 ** 4.1 21.3 27.9
±9.2 ±8.5 ±4.4 ±3.6 ±5.4
SP 41.0 5.7 4.0 24.0 24.0
±5.2 ±2.2 ±2.4 ±3.6 ±6.6
HDL HLPa 19.4 2.3** 2.5 25.4 50.5
±3.3 ±1.6 ±1.4 ±5.4 ±8.5
SP 19.7 0.7 2.8 27.2 49.5
±4.1 ±0.4 ±1.0 ±4.4 ±7.7
* p < 0 .0 1 , * * p <  0.001; an=17; ND, not detected
T able 26. Chemical composition of plasma lipoproteins isolated by flotation 
ultracentrifugation from 18 ponies with hyperlipaemia (HLP) compared with the 
results from 18 healthy Shetland ponies (SP) (the data for VLDLj has been compared 
with that of VLDL from the healthy ponies) (mean ±sd).
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Both VLDLj and VLDL2  were significantly enriched in apoE, but were 
similar to normal VLDL in respect of their apoA-I, apoC-II and apoC-III content. The 
protein composition of V LD Lj was almost identical to that o f healthy ponies and the 
percentage masses of apoB-100 and apoB-48 were unaltered and present in a ratio of 
1.9:1. The protein composition of LDL was not statistically different to that from 
healthy ponies. In HDL, there were significant increases in the masses o f apoE, apoC- 
II and apoC-III, while that of apoA-I was significantly lower.
Lipoprotein
Percentage of Protein Mass
B-100 B-48 E A-I C-II C-III A-II
VLDL! HLP 11.4 ** 12.4 15.5 * 8.6 23.8 29.8
±3.6 ±2.8 ±5.7 ±3.8 ±8.1 ±8.1
VLDL2  HLP 19.3 10.2 10.2 5.4 21.7 31.4 —
±4.4 ±3.0 ±4.8 ±4.2 ±5.2 ±5.3
SP 20.8 11.5 9.5 8.1 22.5> 31.3 — -
±3.9 ±2.8 ±4.8 ±4.0 ±6.1 ±7.1
LDL HLPa 69.1 -------- 10.0 — 10.9 10.1 —
±12.5 ±5.9 — ±6.0 ±5.7
SPb 77.8 --- 6.5 . _ _ _ 7.0 8.9 _ _ _
±6.2 ±2.5 ±2.3 ±5.0
HDL HLP __ __ 5.1 66.9* 11.1 * 11.8* 5.6*
±2.8 ±9.3 ±5.5 ±5.5 ±3.9
SP _____ _____ 4.3 79.5 4.5 5.1 7.1
±2.7 ±4.9 ±2.4 ±2.0 ±3.5
* p < 0 .0 1 , * * p <  0.001, an=14, b n=16
Table 27. Apolipoprotein composition of plasma lipoproteins isolated by flotation 
ultracentrifugation from 18 ponies with hyperlipaemia (HLP) compared with those 
from 18 healthy Shetland ponies (SP) (mean ±sd).
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3.5. L ipoprotein  Enzym e Activities
The activities of LPL, HL and LCAT were measured in 12 ponies with hyperlipaemia 
(Appendix 31) and are compared with those from 12 healthy ponies matched for age 
and sex in Table 28. The activities of LPL and HL were significantly higher than 
those of the control group, with the mean values increased by approximately two and 
three fold, respectively. The activity of LPL was correlated with the plasma 
concentrations of cholesterol (r = 0.48), triglyceride (r = 0.40), VLDL cholesterol (r = 
0.45) and FFA (r = 0.42), although these were not statistically significant. The activity 
o f HL was not correlated (-0.4> r <0.40) with any of these variables. The activities of 
LPL and HL were significantly correlated (r = 0.79).
The activity of LCAT was more variable than in healthy ponies and ranged 
from 15.09 to 46.33 nmolCE/ml/h, but there was no significant difference in activity 
between the hyperlipaemic and control ponies (Table 28).
No CETP activity was found in LPDP from nine of these ponies (Appendix
32).
Lipoprotein Lipase Hepatic Lipase
LecithinrCholesterol 
Acyl Transferase
umolFA/ml/h nmolCE/ml/h
Hyperlipaemic Ponies 8.12* 13.20* 25.30
±2.87 ±5.13 ±10.99
Healthy Ponies 3.65 4.99 23.76
±1.58 ±1.45 ±4.22
* p < 0.001
T ab le  28. Activity of lipoprotein lipase, hepatic lipase and lecithinrcholesterol acyl 
transferase in 12 ponies with hyperlipaemia, compared with 12 age and sex matched 
healthy Shetland ponies.
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4. DISCUSSION
4.1. The Clinical Disease
This, the first description of the clinical picture presented of hyperlipaemia in the 
United Kingdom was consistent in many respects with reports of the disease from 
H olland (Schotman and Wagenaar 1965), Norway (Eriksen and Simesen 1970), 
Australia (Gay et al. 1978) and North America (Naylor et al. 1980). The apparent 
predisposition of the Shetland pony was reiterated, and the disease's associations with 
pregnancy and lactation were confirmed. However, in contrast with earlier reports, 
there was no obvious underlying disease in the majority of cases. Of the concurrent 
diseases that were identified, three (intestinal neoplasia, parasitism, dysphagia) would 
have had serious consequences for gastro-intestinal function and the energy balance 
of the affected animals. A role for the other, laminitis, as a cause of hyperlipaemia is 
less obvious. Certainly affected animals are often inappetant and stressed by the pedal 
pain. Alternatively, the clustering of laminitis and hyperlipaemia in obese and often 
pregnant ponies might reflect the role that has been suggested for insulin insensitivity 
in the aetiology of both conditions (Coffman and Colles 1983, Field and Jeffcott 
1989). The fact that there was no clear seasonal incidence in the present report was 
probaly related to the extended U.K. pony breeding season and the relatively higher 
number o f geldings and non-pregnant mares than in previous case series.
Unfortunately, the mortality associated with hyperlipaemia in the U.K. 
appears no less than elsewhere in the World. Clearly the outlook for those with 
untreatable underlying or coexistent diseases is not good, and together with those 
animals that are in an advanced state of hepatic or renal failure, deserve euthanasia on 
humane grounds. It was somewhat of a surprise to find that in contrast with Schotman 
and W agenaar's (1969) original findings, there was little difference in the severity of 
hyperlipidaemia between those that survived and those that succumbed to the disease. 
In addition, the outcome was not predicted by any of the biochemical parameters 
screened. Although the 18 animals in the present study are an insufficient data base on 
which to develop predictive models of the disease, it was disappointing to find that 
the outcome was not predicted by either the severity of hyperlipidaemia or the 
heaptic/renal pathology.
The efficacy of any therapy is also hard to assess in such a small series and 
case controlled studies have to date not been presented. While there are arguments in 
favour of using insulin and heparin, their clinical efficacy has not been borne out by 
this series or the experiences of others (Gay et al. 1978). Considering the degree of 
hepatopathy and likely coagulopathy encountered with hyperlipaemia, the use of 
heparin is hard to justify. Any additive effect that this agent might have on the 
function of LPL is debatable, although the LPL activities measured (4.05-13.51
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umolFA/ml/h) were in all but two cases below those found in healthy lactating ponies 
(10.03-20.20 umolFA/ml/h) in the previous Chapter suggesting that there may be 
some reserve capacity on which heparin might draw. Given that insulin insensitivity is 
believed to be central to the pathogenesis of hyperlipaemia, the efficacy of exogenous 
insulin is questionable. Transient collapsing episodes consistent with hypoglycaemia 
were reported in two of the present series following the administration of insulin by 
the attending veterinarians.
4.2. Plasma Lipid and Lipoprotein Concentrations
The severity of the hypertriglyceridaemia reported here was comparable with that 
recorded from four ponies with spontaneous hyperlipaemia (plasma triglycerides 
39.18 ±12.0 mmol/1; Eriksen and Simesen 1970) and from a series of nine cases in 
which the condition appeared secondary to other diseases (16.5 ±10.0 mmol/1; Naylor 
et al. 1980). It is worthy of note that here, and in both of those reports, plasma 
triglyceride levels were higher in animals with apparently idiopathic hyperlipaemia 
than those with obvious underlying disease. Also the degree of hyperlipidaemia seen 
in the natural disease is in excess of that induced by fasting, where triglyceride levels
2.5 ±1.0 mmol/1 (Baetz and Pearson 1972) and 10.1 ±8.3 mmol/1 (Bauer 1983) were 
reported following 184 hours of food deprivation.
The changes in lipoprotein concentration found were not unexpected, as Bauer 
(1983) and Freestone et al. (1991) reported similar findings from their experimental 
animals. The moderate hypercholesterolaemia seen in ponies with hyperlipaemia is 
attributable to increased VLDL cholesterol concentrations, as the levels of LDL and 
HDL are unaltered. Although the normality of LDL and HDL concentrations has not 
previously attracted comment, they are significant in indicating that VLDL is 
progressing through its lipolytic cascade. For the generation of LDL from VLDL 
precursors, and HDL from the surface remnants, is dependent upon the activity of 
LPL, such that the subnormal levels of LDL and HDL seen in humans with common 
types hypertriglyceridaemia are blamed on reduced activity of this enzyme (Shepherd 
and Packard 1987).
Increased plasma FFA concentrations have been previously reported in ponies 
with hyperlipaemia (Naylor et al. 1980). In addition, a number of studies have shown 
that FFA concentrations rise soon after the onset of fasting to plateau by about 64 
hours at levels similar to those in ponies with hyperlipaemia, and return to baseline on 
refeeding (Baetz and Pearson 1972; Morris et al. 1972; Naylor et al. 1980; Rose and 
Sampson 1982). This rise precedes that of triglyceride by approximately 48 hours and 
is parallelled by free glycerol suggesting that the FFA are coming from adipose tissue 
(Naylor et al. 1980). This, together with the correlations observed between
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concentrations of FFA and triglyceride in the latter and the present studies, suggests 
that plasma FFA might be driving the synthesis and secretion of triglyceride by the 
liver. However, caution should be exercised as it is possible, given the massive 
plasma pool of VLDL and increased activity of LPL, that fatty acids released from 
VLDL triglyceride exceed cellular uptake and spill into the general circulation. In 
support of this, there was positive correlation between LPL activity and the plasma 
concentration of FFA, and while not statistically significant, was similar in magnitude 
to that between FFA and triglyceride concentrations. For this reason, the recycling of 
FFA from VLDL triglyceride is considered in the following chapter where 
radiolabelled palmitic acid and glycerol were used as tracers of VLDL triglyceride.
The potential role of FFA in driving hepatic triglyceride synthesis is also 
supported by the fact that ponies with hyperlipaemia are not ketotic (Eriksen and 
Simesen 1970; Gay et al. 1978; Naylor et al. 1980) and the finding that plasma ketone 
levels do not rise when horses are fasted (Naylor et al. 1980; Rose and Sampson 
1982). If, as these data suggest, the pathways for ketone synthesis are poorly 
developed in the horse, this will explain why the mobilisation of FFA in this species 
results in such massive hypertriglyceridaemia, while parallel conditions in the cow 
and the sheep result in overt ketoacidosis.
Isolation of the lipoprotein classes by flotation ultracentrifugation showed that 
much of the lipaemia was due to the presence of buoyant triglyceride rich 
lipoproteins, such that by repeated short spins the plasma could be cleared. The 
precise identity of these particles was at first a puzzle, for they demonstrated the 
buoyancy of chylomicrons when left to stand at 4°C and in the ultracentrifuge, and 
yet were obtained in profuse quantities from animals that were virtually anorexic. In 
addition, their chemical composition was quite distinct from that of chylomicrons 
isolated from suckling foals in the previous Chapter.
The characteristics of this VLDL! fraction may well explain the confusing 
data presented by Schotman and Wensing (1977). These authors described three lipid 
phenotypes in ponies with hyperlipaemia; the first characterised by increased VLDL 
(analogous with human type IV hyperlipoproteinaemia), and the second (type V) and 
third by increases in VLDL and chylomicrons, with the contribution of chylomicrons 
being much less in the third. This was based on the study of W ensing et al. (1975) 
where the chylomicron fraction was isolated by initial ultracentrifugation. However, 
neither the lipid composition of this fraction or the fact that the majority of these 
animals were reported as inappetant justified the conclusion that these particles were 
chylomicrons. Rather, the fraction was composed of particles of similar composition 
to those identified here as VLDLj. In the present study, the contribution of this 
fraction to the total VLDL pool increased with the severity of hypertriglyceridaemia,
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whereas that of VLDL2 remained constant. Thus in ponies with low levels of VLDL, 
VLDL} represented much less of the density <1.006 g/ml fraction than in ponies with 
higher VLDL concentrations where it was responsible for almost all o f the fraction. 
This gradation would explain how Wensing et al. (1975) differentiated their 
phenotypes, for they found no "chylomicrons" in ponies with low plasma triglyceride 
concentrations (3.2-7.3 mmol/1) and many in those with high triglycerides (29.4-33.0 
mmol/1).
4.3. Lipoprotein Particle Size and Composition
Given that the increase in VLDL concentrations seen in the ponies with 
hyperlipaemia was accounted for almost entirely by the appearance of V LD Lj, it was 
hoped that analysis of the structure and composition of this lipoprotein would hold 
information on both its origin, and the aetiology of the disease. It did not disappoint. 
The particles contained within this fraction were radically different to those in VLDL 
from healthy ponies; as they were enriched in triglyceride and depleted of 
phospholipid and protein. This increased ratio of core to shell volume would account 
for the buoyant behaviour of the VLDLj fraction and the increased size of the 
particles visible under the electron microscope. As the lipoprotein shell exists as a 
single monolayer of constant depth, much of the reduction in phospholipid and 
approximately one half of the protein mass could also be explained by relative 
dilution of surface mass by the expanded core of triglyceride.
Analysis of the apolipoprotein content of VLDLj suggested that the reduction 
in protein content was also due to a change in the ratio of apoB-100 to apoB-48. The 
contribution of apoB-100 to total protein mass was reduced by nearly 50% so that the 
ratio of the masses of apoB-100 and apoB-48 was approximately 1:1, instead of 2:1 as 
in healthy ponies. Because VLDL particles contain a single molecule of apoB, this 
would have reflected in VLDL! an approximate two fold increase in the number of 
particles that contain apoB-48 rather than apoB-100. It is exciting to speculate that 
this reflects the ability of the liver to increase its triglyceride secretory capacity by 
producing VLDL particles that accommodate a greatly expanded core volume, in the 
way that chylomicrons do, by virtue of having apoB-48 as their structural protein. 
This would necessitate a fundamental switch in hepatic apoB synthesis, but is not 
without precedent, as the rat hepatocyte appears able to coordinate the secretion of 
triglyceride with the expression of its shorter form of apoB (Coleman et al. 1988).
If this is indeed a mechanism by which the equine liver can enhance the export 
of triglyceride, it is further evidence that overproduction of triglyceride is the 
pathogenic mechanism of the equine hypertriglyceridaemia. For it would be hard to 
explain how such fundamental changes in lipoprotein structure arise if the disease is
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simply the result of defective VLDL catabolism. However, because the apoB-48 
containing particles do not reach the LDL density range, one might argue their 
increased number simply reflects a defect in their (receptor mediated) clearance. If 
this were so, and given the evidence that VLDL lipolysis does not appear to be 
compromised in the equine disease, one would expect to find a lipoprotein pattern 
similar to that seen with the apoE2/E2 phenotype or hepatic lipase deficiency in man 
which is characterised by the accumulation of cholesteryl ester rich remnants of 
VLDL and chylomicrons. This is clearly not the case and we are left with the exciting 
prospects the hypothesised changes in hepatic apoB synthesis present for developing 
our understanding of the metabolic regulation of the editing of apoB message.
It is hard to attach any significance to the changes in composition o f VLDL2 
given that, in the majority of animals, this fraction presented a negligible contribution 
to the total VLDL pool and that the apolipoprotein content was indistinguishable from 
that o f normal VLDL. The cholesterol content of VLDLj and VLDL2 does however 
deserve mention because, in contrast to healthy ponies, free cholesterol was detected 
in both fractions and represented a considerable portion of the total cholesterol mass. 
This was not simply because more particles were present raising the concentration of 
free cholesterol to levels detectable by the assay as free cholesterol was identified in 
the VLDL2 fraction, the plasma concentration of which were similar to those of 
VLDL in healthy ponies. Rather, because the appearance of free cholesterol was 
balanced by a reduction in the mass of cholesteryl esters, this appears the result of 
defective esterification of VLDL cholesterol. This could arise from reduced activity 
o f hepatic ACAT or plasma LCAT. The activity of LCAT is reduced in humans with 
liver disease and is associated with impaired cholesterol esterification (Riesen and 
Kloer 1989). While LCAT has been shown capable of esterifying cholesterol in 
VLDL from healthy ponies (Yamamoto et al. 1975b), the activity of the enzyme was 
normal in the hyperlipaemic ponies examined here and the mass of HDL cholesteryl 
esters, the prime focus of LCAT activity, unchanged. Therefore reduced ACAT 
activity is a more likely explanation. Although this could have arisen from defective 
synthesis of the enzyme by diseased hepatic tissue, there was evidence of defective 
cholesterol esterification in the cases without sign of significant hepatic pathology. 
Hence it is likely that the deficiency of esterification reflected failure of the enzyme to 
keep pace with an increased rate of VLDL assembly and secretion, further evidence 
that this hyperlipidaemia results from massive overproduction of VLDL by the liver.
The increases in the triglyceride contents of LDL and HDL are less easy to 
explain. Although triglyceride enrichment of IDL, LDL and HDL2 is a feature of HL 
deficiency in man (Breckenridge et al. 1982), the plasma concentration and 
composition of lipoproteins in the density <1.006 g/ml fraction is generally normal in
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such patients, in conflict with the lipoprotein changes seen in the ponies here. In 
addition, HL activity was normal in each of the animals from which PHP was 
obtained. However, it is possible that the fractional rate of removal of triglyceride 
from LDL was reduced because of the increased flux of particles from VLDL.
The increase in HDL triglyceride to 2% was associated with a small increment 
in particle size (to 8.6 nm), but these particles remained distinct from human H D L ^ 
which are approximately 9.5-12.0 nm in diameter and typically have triglyceride as 
8% o f their mass. This, in conjunction with the failure to detect significant CETP 
activity in the animals examined, would indicate that the triglyceride enrichment of 
HDL was not the consequence of neutral lipid exchange with the lower density 
lipoproteins. However, given the hugely expanded pool of triglyceride in the 
circulation, it may be possible that non-protein mediated or chance exchange/transfer 
of triglyceride was taking place as the probability of collision between HDL and 
triglyceride rich lipoproteins increased, in both the circulation and in the samples after 
collection. Alternatively, triglyceride may be excreted by the liver as a minor 
component of the nascent HDL particle. The increased triglyceride content of HDL 
did not appear the result of contamination of this fraction by LDL as apoB-100 was 
absent on SDS-PAGE. However as a single ultracentrifuge tube was used for the 
preparation of VLDL through to HDL, contamination of the tube surface or the later 
fractions by VLDL debris might explain some of the triglyceride enrichment of the 
later fractions.
With regard to the non-apoB components of the isolated lipoproteins, the 
normal presence of the C peptides in both VLDL fractions was evidence against 
deficiency of apoC-II or excess of apoC-III as primary mechanisms in the 
accumulation of VLDL in the circulation. It is interesting that the apoE content of 
V LDLj was increased, as it is possible that the apoB-48 VLDL particles can 
accommodate more apoE and that this is related to their (hypothesised) removal from 
the circulation by cell surface receptors. Direct tissue uptake of these particles may go 
some way to explaining the widespread fatty infiltration of body organs found at 
necropsy in cases of hyperlipaemia. The apoE content of HDL was also increased and 
this may suggest that the circulating pool of apoE is expanded in a coordinate 
response to the increased secretion of apoB-48 containing particles by the liver, which 
may also explain the increased masses of apoC-II and apoC-III in HDL.
4.4. Lipoprotein Lipase and the Pathogenesis of Hyperlipaemia
The activities of both enzymes involved in the lipolysis of triglyceride lipoproteins 
were found to be increased in ponies with hyperlipaemia in what appeared to 
represent a physiological response to increased concentrations of their substrates. This
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was especially true for the activity of LPL which positively correlated with the degree 
of hyperlipidaemia. If defective catabolism of VLDL was the primary mechanism of 
the disease, then one would expect to find a negative correlation between plasma 
triglyceride concentrations and LPL activity. Although this was not the case here, the 
possibility remains that the fractional activity of LPL is reduced in the face of the 
increased VLDL concentrations and that this contributes to the hyperlipidaemia once 
triglyceride levels reach a certain threshold.
Thus the weight of evidence presented in this Chapter suggests that the 
massive hypertriglyceridaemia found in ponies with hyperlipaemia results from 
hepatic overproduction of VLDL. This appears to be driven by increased plasma 
concentrations of FFA, such that a larger, triglyceride enriched particle is produced to 
meet the demands of hepatic triglyceride export. In contradiction with previous 
speculation, the results indicate that defective catabolism of VLDL is not the primary 
mechanism of the hyperlipidaemia. Attention should be therefore directed to 
quantifying the rates of VLDL synthesis and its fractional catabolism, with particular 
focus on the role that FFA play in the pathogenesis of the hyperlipidaemia. This is the 
subject of the next Chapter.
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C H A PTE R  VH
KINETIC ANALYSIS OF FREE FATTY ACID AND VERY LOW  DENSITY  
LIPOPROTEIN TRIGLYCERIDE METABOLISM IN HEALTHY PONIES 
AND PONIES WITH EQUINE HYPERLIPAEMIA
1. INTRODUCTION
Hypertriglyceridaemia is a heterogeneous condition that arises from a variety of 
genetic, molecular and metabolic defects. One of the major approaches to 
understanding its origins, and thereby selecting therapy, has involved kinetic analysis 
of the production and catabolism of the triglyceride rich lipoproteins. Thus, elevations 
in plasma triglyceride concentrations can be defined as the consequence of increased 
input into, or decreased clearance of these lipoproteins from the circulation, or a 
combination of the two mechanisms.
In studying the metabolism of VLDL, two separate approaches have been 
adopted. In the first, VLDL is isolated from the subject and radiolabelled in its protein 
moiety, by iodination with 125I or 131I (Shepherd, Bedford and Morgan 1976), and 
then re-injected. Presently, the use of stable isotopes such as [12C]leucine and 
[15n]glycine to label apolipoproteins in vivo is being heralded as a safer and more 
informative way in which to trace the synthesis and catabolism of the apolipoproteins 
(Parhofer, Barrett, Bier and Schonfeld 1991). In the second approach, radiolabelled 
precursors of triglyceride, usually 14C and 3H labelled fatty acids or glycerol, are 
injected into the subject and re-isolated in VLDL-triglyceride (Kekki and Nikkila 
1975). This provides more reliable information on the metabolism of the plasma 
precursor pools and on the synthesis and secretion of VLDL-TG from the liver. Also, 
because the VLDL is labelled in its triglyceride moiety, the disappearance of activity 
gives direct insight into the function of lipoprotein lipase rather than the receptor and 
non-receptor mediated mechanisms that clear apoB.
In order to establish the metabolic basis for the changes in VLDL 
concentration and composition found in ponies with hyperlipaemia, the VLDL-TG 
approach was chosen here. The turnover of plasma FFA and VLDL-TG were 
determined in four healthy ponies using radiolabelled palmitic acid and glycerol. The 
results were analysed by a multicompartmental model, the components of which were 
justified by fitting the data calculated by the model to match the observed tracer 
curves. The modelling of the hepatic pathways was strengthened by the measurement 
of triglyceride activity in small amounts of liver obtained by percutaneous biopsy at 
one or two time points during the procedure. The model was then used to interpret the
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data from identical turnover studies performed in two ponies with hyperlipaemia. The 
results confirmed the suggestion from Chapter V that hepatic overproduction, rather 
than defective plasma catabolism, of VLDL is the cause of this hypertriglyceridaemia 
and show how therapy for the condition could be improved.
2. SUBJECTS AND METHODS
The control group consisted of four healthy normolipidaemic Shetland pony mares, 
three of which were barren (subjects 1, 2 and 3) and one (subject 4) that was seven 
months pregnant. The subjects were fasted for 16 hours prior to the test to remove any 
possible contribution from intestinal triglyceride production and this was continued 
for the first 8 hours of the procedure, after which they were allowed access to hay. 
The procedure was carried out according to the protocol described in section II.7.
Two Shetland ponies with hyperlipaemia (subject A was H LP-14 and subject 
B was H LP-15 in Chapter V) were studied with the modification of the protocol 
detailed in section II.7.4. One of the hyperlipaemic ponies had access to hay and 
concentrates prior to the test but had been inappetant, the other was denied access to 
food and had been given balanced oral electrolyte/glucose solution (Lectade, 
Beecham; 5 1 every 4 hours via nasogastric tube). Both cases were then maintained on 
Lectade (5 1, qid) and received no other therapy, but were given 70 iU/kg heparin iv 
approximately 24 hours after the start of the procedure to obtain PHP for the analysis 
of LPL and HL activities. Both subjects were pregnant, and recovered from the 
condition to give birth to healthy foals three and two months after the procedure, 
respectively.
For the samples separated by extraction and TLC, the recovery of activity was 
extraction was found to be 71%, necessitating that the measured cpm be multiplied by 
1/0.71 in the calculation of SA. The plasma masses of FFA and VLDL-TG were 
estimated as the product of the plasma volume and the plasma concentration of each, 
the plasma volume was taken to equal 46.2 ml/kg (Mattheeuws, Kaneko, Loy, 
Cornelius and Wheat 1966). The data were analysed using a linear, 
multicompartmental model which can be described mathematically by a simultaneous 
set o f first-order differential equations. These equations were solved and the model 
parameters adjusted to give a least-squares fit of the calculated to the observed data 
using the CONSAM 30 programme supplied by the Resource Facility for Kinetic 
Analysis, Seattle, USA. A fractional standard deviation of ±5% was attached to the 
observed data in the input file to allow for random variation in the estimation of 
specific activities. The model development was based on that proposed for the 
metabolism of FFA and VLDL-TG in man by Shames, Frank, Steinberg and Berman
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(1970) and Zech et al. (1979). In the model, the fractional transfer of material from 
one com partment e.g. I to another e.g. J is represented by L(J,I); the mass of material 
in I is M(I); the product M(I)*L(J,I) is the rate at which material leaves compartment I 
for J, which in a steady state is equal to the production rate (PR). The model was used 
to calculate the residence time of triglyceride in the VLDL fraction of plasma, and the 
reciprocal o f this value was the fractional catabolic rate (FCR) of VLDL-TG.
3. RESULTS
3.1. Model Development
Following injection of the tracers, there was an initial and rapid decay in plasma FFA 
activity (Fig. 26) that was followed by flattening of the curve.
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Figure 26. The disappearance of intravenously injected [14C]palmitic acid from 
plasma of a healthy Shetland pony mare (subject 2).
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This curve was fitted with a bi-exponential function in which the steep part of the 
curve was explained in the model by irreversible loss of the tracer from the plasma 
compartment (L0,4). The late part was modelled by loss of tracer into and its 
subsequent re-entry from an extravascular exchange pool (5). The steepness of the 
slope was proportional to the inverse of L(4,5), such that at slow rates of re-entry (as 
in subject 4) the slope tended towards the horizontal.
The characteristics of the [14C]VLDL-TGFA and [3H]VLDL-TG curves were 
similar (Fig. 27). There was an initial time delay so that significant activity was first 
detected between 0.4 and 1.0 hours after injecting the tracers; the mean (±sd) interval 
to the appearance of [3H]VLDL-TG was 0.43 (±0 *0 5 ) hours and for [14C]VLDL- 
TGFA 0.69 (±0.24) hours (differences not significant). There was then a rapid rise in 
activity so that both tracers peaked simultaneously in each subject between 0.93 and 
1.67 hours (mean ±sd; 1.27 +0.28 hours). Following the rapid rise, the peak then 
flattened before decaying with a slope of two parts. The first appeared first-order, but 
was succeeded by a second slower part that became obvious 5-11 hours after the 
injection of tracer so that a small amount of activity (approximately 3-10% of peak 
activity) was present in VLDL one day later.
The features of the VLDL-TG curves were modelled as follows. The initial 
delay in the appearance of VLDL-TG activity was reproduced by the entry of the 
tracers into a hepatic component (10) that had an integral delay function before 
releasing VLDL particles into the circulation (compartment 1). The rapid rise in 
VLDL-TG activity suggested that this hepatic component was rapidly turning over 
and was mimicked by giving the L(l,10) function a high value. The slope of the 
initial decline in VLDL-TG activity was determined by the amount of material lost 
from compartment 1 i.e. L(0,1), as shown by comparison of the slopes of subjects 2 
and 3. However, the fitting of this part of the curve did not explain the flattening of 
the peak or the late slope, as the calculated curve decayed ffom a single peak value in 
a mono-exponential fashion.
The flattening of the peak was reproduced by introducing a chain of 
compartments (6, 7, 8) within the VLDL density range that were linked to 
compartment 1 to represent a delipidation cascade. Thus, in addition to loss of 
material from compartment 1 to 0, a fraction of 1 remained in the VLDL density 
range and moved into compartment 6 where it continued to contribute to the total 
VLDL-TG activity. The flatness of the peak was then governed by the magnitude of 
L (6 ,l), as shown by comparison of subjects 1 and 3. As the activity counted in the 
density < 1.006/ml fraction was then the sum of compartments 1, 6, 7 and 8, these 
were joined by a function represented by compartment 9.
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Figure 27. Typical plasma specific activity curves obtained for [ 14C] VLDL-TGFA 
(top) and [3H] VLDL-TG (bottom) in a healthy Shetland pony mare (subject 1).
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The fractions of material lost and transferred from each of the VLDL 
compartments to the next were assumed to be equal along the cascade so that L(0,6) 
and L(0,7) were set to equal L(0,1); L(7,6) and L(8,7) equal to L (6 ,l); and L(0,8) 
equal to L(8,7)+L(0,l).
To explain the late part of the VLDL-TG curves, a second, slowly turning 
over, hepatic compartment (24) was introduced so that L(l,24) was approximately 
one tenth of the magnitude of that of the rapidly turning over pathway, L (l,10). Thus, 
as L (l,24 ) approached zero the late part of the curve became horizontal (see subject 
1). The significance of the late part was determined by the fraction of the tracer that 
was channelled through this pathway, i.e. the ratio of L(24,4) to L(10,4), which was 
3:1 in subject 1 where the late part predominated compared with 1:3 in subject 4 
where the VLDL-TG activity was dominated by the first part of the curve. Although 
in the model shown in Fig. 3, compartment 24 is linked directly with compartments 4 
and 1, the data were equally fitted when 24 was introduced in exchange with 
compartment 10 or was fed from 4 and fed into 10. As the hepatic biopsy data did not 
distinguish triglyceride activity in the two synthetic pools, the masses and activities of 
compartments 10 and 24 were summed and represented by compartment 11.
Two alternative explanations for the late part of the VLDL-TG curves were 
considered and rejected. In the first, a slowly metabolised species of VLDL, such as 
6-VLDL, was introduced in parallel with the cascade of compartments 1, 6, 7, and 8. 
W hile this provided some flattening of the tail, the calculated mass of this component 
represented a major portion of the total VLDL-TG mass and was thus unacceptable in 
terms of the composition of equine VLDL. In the next, the effect of tracer recycling, 
i.e. that released during the metabolism of VLDL, was assessed by allowing the 
components of the delipidation cascade to feed back into compartment 4. This 
function had no discernible impact on the shape of the VLDL-TG curves in any of the 
four ponies indicating that recycling was not the origin of the tails.
However, as discussed in the previous Chapter, recycling might be important in the 
generating plasma FFA in ponies with hyperlipaemia and for this reason the function 
was retained in the model. For the reasons outlined for the parameter L (6 ,l), the 
values o f L(4,6), L(4,7) and L(4,8) were set equal to L(4,l).
The final version of the model is represented schematically in Figure 28, 
overleaf.
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F igure  28. Scheme of the compartmental model developed for the analysis of plasma 
FFA and VLDL-TG kinetics in healthy ponies. The tracers were injected into 
com partment 4, and their activities measured in compartments 4, 11 and 9.
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3.2. K inetic Analysis of FFA and  VLDL-TG M etabolism  in F ou r H ealthy Ponies
The data from each subject were then analysed using the following approach. The 
[14C]FFA data were fitted first. The FFA curve was fitted by setting parameters 
L(0,4), L(5,4) and L(4,5) and the input into the liver, L(10,4) and L(24,4), adjusted to 
give an approximate fit of the hepatic triglyceride activity. The [ 14C] VLDL-TGFA 
data were then fitted by adjusting the input and output from the two hepatic 
compartments, and the fraction of material lost or transferred at each compartment 
within the delipidation cascade. Once the ratio of the calculated to the observed data 
was less than 100 for the three solutions (FFA, hepatic- and VLDL-TG), the computer 
programme was allowed to change each of the parameters in turn, in a process called 
iterating, until there was no further improvement in the sum of the squares of the 
residuals. At this point, the values for each parameter were taken as the best fit of the 
data. The model calculated masses for each of the compartments; that of M(4) was 
fixed in the input data file while that of M(9) was forced to the observed values by a 
separate equation.
The [3H]glycerol data were then analysed. As no information was obtained on 
the kinetics of the glycerol precursor pool, the initial rate constants were set equal to 
those obtained for the 14C solutions. In fact for each animal, the [3H]glycerol and 
[3H]VLDL-TG data were fitted following adjustment of L(0,4) only. Therefore to 
improve the strength of the model, the files for the two tracers were combined and 
solved simultaneously with the parameters for the 3H data were set equal to those of 
the 14C data, with the exception of L(0,4). The convergence process was then 
repeated so that the estimated parameters described the behaviour of both tracers. 
Typical fits obtained for the FFA, [14C] VLDL-TGFA and [3H]VLDL-TG curves are 
shown in Figs. 29 and 30(Appendices 33 and 34).
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Figure 29. An example of the curve fitting obtained for the disappearance of plasma 
FFA specific activity in a healthy Shetland pony (subject 2).
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Figure 30. An example of the curve fitting obtained for [14C] VLDL-TGFA (top) and 
[3H]VLDL-TG (bottom) specific activities in a healthy Shetland pony (subject 2).
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The parameters describing the precursor systems are detailed in Table 29. 
Only a small fraction of the injected FFA entered the hepatic triglyceride 
compartments (4.2 +1.4%; mean ±sd), with the rest split between the exchangeable 
(35.0 ±24.7%) and non-exchangeable (60.9 ±25.2%) extravascular pools. In contrast, 
the vast majority of the glycerol was irreversibly lost (95.3 ±2.4%), and the fractions 
that entered the exchangeable (4.2 ±2.4%) and hepatic (0.5 ±0.2%) pools were much 
less. The balance of the input into the two hepatic pools was variable, the slow 
pathway was favoured in three animals (subjects 1, 2 and 3) in which the transport of 
precursor into compartment 24 was 2-3 times that into the compartment 10. In subject 
4, the transport into the fast was 1.5 times greater than that into the slow pathway.
The parameters describing the hepatic and VLDL-TG systems are detailed in 
Table 30. In three of the animals (subjects 1, 2 and 3), the slow hepatic pathway 
accounted for the bulk of the transport of VLDL-TG into compartment 1 (96%, 74% 
and 91%, respectively), while in the fourth the fast pathway was responsible for 68% 
of the VLDL-TG entering compartment 1. The parameterL( 1,10)was found to hold no 
constraint on the model as long as it was equal to or greater than L(10,4) and was 
therefore set to equal this value. The delay time associated with compartment 10 was 
0.65 (±0.11) hours. The total production rate of VLDL-TG varied five fold between 
the four ponies and ranged form 2.45-12.74 mmol/hour.
At each step in the delipidation cascade, 24-75% of the VLDL-TG activity 
was lost according to the equation L(0,l)/L (0,l)+L(6,l). The residence time for 
VLDL-TG was between 1.2 and 3.7 hours, giving values for the FCR of between 0.27 
and 0.83 pools/hour. The curves for all four ponies were fitted without recycling, i.e. 
L (4 ,l)= 0  and this parameter remained at zero following convergence by the 
programme.
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Param eter 1
Subject 
2 3 4 Mean fsd
Body weight (kg) 237 186 239 234 224 0.11
1. FFA
M(4) mmol 4.83 8.59 6.21 4.11 5.94 0.33
M(5) 1.33 18.50 17.28 25.18 15.56 0.65
L(0,4) /h 17.76 40.50 7.78 16.31 20.59 0.68
L(5,4) 1.53 16.49 18.16 10.62 11.70 0.64
L(4,5) 5.56 7.66 6.54 1.73 5.38 0.42
L(10,4) 0.16 0.70 0.37 1.30 0.63 0.79
L(24,4) 0.49 1.10 0.74 0.46 0.70 0.43
R(0,4) mmol/h 85.10 348.02 48.34 67.10 137.31 1.03
R(5,4) 7.39 141.70 112.80 43.69 76.40 0.81
R(10,4) 0.77 6.02 2.30 5.35 3.61 0.69
R(24,4) 2.37 9.45 4.60 1.89 4.58 0.76
2. Glycerol 
M(4) mmol 0.90 0.89 0.96 0.65 0.85 0.16
M(5) 0.25 1.92 2.65 3.97 2.20 0.71
L(0,4) fh 157.42 246.59 1255.60 206.40 466.50 1.13
R(0,4) mmol/h 141.68 219.47 1205.38 134.16 407.59 1.17
R(5,4) 1.38 14.67 17.43 6.90 10.10 0.73
R(10,4) 0.16 0.62 0.36 0.85 0.50 0.61
R(24,4) 0.49 0.98 0.71 0.30 0.62 0.47
fsd, fractional standard deviation
T ab le  29. Kinetic parameter values for FFA and glycerol precursor pools in four 
healthy Shetland ponies.
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Parameter 1
Subject
2 3 4 Mean fsd
1. Liver
M(10) mmol 0.56 4.67 1.20 3.11 2.38 0.79
M(24) 131.17 430.83 53.22 44.83 165.15 1.10
DT(10) hours 0.71 0.78 0.53 0.58 0.65 0.18
L (l,10) /h 0.16 0.70 0.37 1.30 0.63 0.79
L (l,24) 0.018 0.022 0.086 0.043 0.04 0.74
R (l,10) 0.09 3.26 0.44 4.04 1.96 1.02
R (l,24) 2.36 9.48 4.58 1.93 4.59 0.73
2. VLDL
M (l) mmol 1.49 1.48 2.40 4.61 2.50 0.59
M(6) 1.14 0.94 0.59 2.36 1.26 0.61
M(7) 0.81 0.59 0.14 1.03 0.64 0.59
M(8) 0.60 0.38 0.04 0.62 0.41 0.66
M(9) 4.01 3.39 3.17 8.80 4.84 0.55
L(0,1) /h 0.36 0.23 0.83 0.32 0.43 0.63
L (6 ,l) 1.15 0.39 0.27 0.34 0.54 0.76
L (4 ,l) 0.00 0.00 0.00 0.00 0.00 —
FCR 0.46 0.27 0.83 0.34 0.48 0.53
R(0,1) mmol/h 0.54 0.33 1.98 1.48 1.08 0.72
R(0,6) 0.41 0.31 0.49 0.76 0.49 0.39
R(0,7) 0.29 0.14 0.12 0.33 0.22 0.48
R(0,8) 0.91 0.24 0.04 0.41 0.40 0.93
R (6 ,l) 1.72 0.58 0.65 1.55 1.13 0.52
R(7,6) 1.31 0.37 0.16 0.80 0.66 0.77
R(8,7) 0.93 0.34 0.09 0.35 0.43 0.83
T able 30. Kinetic parameter values for the hepatic and VLDL triglyceride systems in 
four healthy Shetland ponies.
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3.3. Kinetic Analysis of FFA and VLDL-TG M etabolism in Two Ponies with 
Hyperlipaemia
The FFA curves from both hyperlipaemic ponies had long tails that meant that 
significant activity was present in the plasma 18 and 20 hours after injection of the 
tracers (open squares in Fig. 31). The VLDL-TG curves (Figs 32 and 33) also 
contrasted markedly with those of the normal ponies. The rise in activity was very 
much slower such that the peak was reached between 4 and 5 hours instead of 0.9-1.7 
hours in the controls. The flattening of the peak was also very much more 
pronounced. After this, the curves decayed at a slow rate in an almost mono­
exponential fashion so that significant activity (20-30% peak activity) was present 
nearly two days after the injection of the tracers.
The extended portion of the FFA curves could not be fitted by manipulation of 
the precursor pool parameters in the way that the slope in the normal animals could. 
However, a reasonable fit was obtained over the first three hours of the curve that 
allowed the convergence process to proceed once the VLDL-TG data had been fitted. 
During this process, the computer explained the slow decay of these curves by 
significant recycling of tracer from VLDL-TG to compartment 4 to give an excellent 
fit of the data (Fig. 31). The parameters of the precursor pools are summarised in 
Table 31. The plasma FFA mass was increased by 2.3 and 3.8 fold in subjects A and 
B, respectively, over that of the controls. In both cases, the model calculated that none 
of the FFA were lost to compartment 0, and that the fractions transferred to the 
hepatic triglyceride compartments were increased from around 8% in the controls to 
73% and 61% in subjects A and B, respectively. The fraction of FFA that entered the 
exchangeable pool was similar to the controls in both cases. The input into the slow 
hepatic pathway accounted for 99% and 96% of the FFA that entered the hepatic 
triglyceride compartments in subjects A and B, respectively. The trend for glycerol 
was similar, with the fraction lost from the precursor system reduced from around 
95% in the controls to 86% and 56% in A and B, respectively. The fraction that 
entered the hepatic triglyceride pools was increased from 0.5% to 10.1% and 5.4%, 
with 99% and 96% of this input directed to compartment 24. The transport of both 
precursors into the fast pathway was within the range of the controls, while that into 
the slow was increased by over 30 fold in both subjects. In subject A, the mass of 
triglyceride in compartment 10 was higher than that in the controls. The mass of 
compartment 24 was increased in both subjects to approximately eight times that of 
the controls.
The VLDL-TG mass was increased by over 100 fold to 511.78 and 603.69 
mmol/1 in subjects A and B, respectively (Table 32).
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Figure 31. Disappearance of [14C]palmitic acid from the plasma of two ponies with 
hyperlipaemia (top, subject A; bottom, subject B).
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Parameter
Subject
A B Controls
Body W eight (kg) 234 246 224
1. FFA
M(4) mmol 13.73 22.85 5.94
M(5) 89.68 66.76 15.56
L(0,4) /hour 0.00 0.00 20.59
L(5,4) 3.87 4.38 11.70
L(4,5) 5.93 1.50 5.38
L(10,4) 0.13 0.28 0.63
L(24,4) 10.23 6.46 0.70
R(0,4) mmol/hour 0.00 0.00 137.31
R(5,4) 53.14 100.08 11.70
R(10,4) 1.73 6.49 3.61
R(24,4) 140.46 147.61 4.58
2. Glycerol
M(4) mmol 5.84 6.12 0.85
M(5) 38.10 17.89 2.20
L(0,4) 87.58 14.35 466.50
R(0,4) 511.46 87.82 407.59
R(5,4) 22.60 26.81 10.10
R(10,4) 0.74 1.74 0.50
R(24,4) 59.74 39.53 0.62
T able 31. Kinetic parameter values for FFA and glycerol precursor pools in two 
Shetland ponies with hyperlipaemia compared with the mean of four healthy controls.
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F igure  32. Specific activities and curve fitting of [14C]VLDL-TGFA (top) and 
[3H]VLDL-TG (bottom) in a hyperlipaemic pony (subject A).
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Figure 33. Specific activities and curve fitting o f [ 14Q  VLDL-TGFA (Top) and 
[3H]VLDL-TG (Bottom) in a hyperlipaemic pony (subject B i
CHAPTER VII 163
Parameter
Subject
A B Controls
1. Liver
M(10) 0.00 5.92 2.38
M(24) 1998.40 752.00 165.15
DT(10) 0.00 0.41
L(l,10) 0.00 0.04 0.63
L(l,24) 0.09 0.26 0.04
R(l,10) 0.00 0.24 1.96
R(l,24) 187.85 193.30 4.59
2. VLDL
M (l) 511.78 410.25 2.50
M(6) — 128.62 1.26
M(7) — 40.33 0.64
M(8) — 28.36 0.41
M(9) 511.78 607.56 4.04
L(0,1) /h 0.25 0.11 0.43
L (4,l) 0.15 0.44 0.00
L (6 ,l) 0.00 0.25 0.54
FCR 0.39 0.56 0.48
Table 32. Kinetic parameter values for hepatic and VLDL-triglyceride systems in 
two ponies with hyperlipaemia, compared with the mean of four healthy controls.
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The rate constant L (l,24) was ten fold greater than the controls in both cases 
so that the transport of triglyceride was increased by over 30 fold to 187.85 and 
193.30 mmol/h, respectively (Table 32). The rate constants describing the loss of 
triglyceride from each compartment in the delipidation cascade, 0.35 in each case, 
were similar to the control animals (0.43 ±0.23), although 40% in subject A and 71% 
in subject B of the products of lipolysis were recycled to the plasm a precursor pool 
(Table 32). The residence time of VLDL-TG in the two hyperlipaemic ponies was 2.9 
and 2.4 hours, giving values for the FCR of 0.35 and 0.42 /hour that were within the 
range of the control ponies (0.48 +0.25 /hour).
4. DISCUSSION
These studies have shown, for the first time, the qualitative and quantitative metabolic 
behaviour of VLDL in the horse. The results are of significance for their contribution 
to the interpretation of VLDL-TG kinetics and for providing a direct insight into the 
pathogenesis of equine hyperlipaemia.
4.1. Plasma FFA and VLDL-TG Metabolism in Healthy Ponies
One of the constraints placed upon the analysis of lipoprotein kinetics is that 
the model must be compatible with data collected from a number of sources. Here, 
and in contrast to the majority o f human studies, the strength or uniqueness of the 
model was maximised by using two tracers of VLDL-TG in the same individual and 
measuring their activity in all three of the model's systems. The activity was traced in 
VLDL rather than plasma because the latter reflects the kinetics of triglyceride in 
lipoprotein species other than VLDL which have very different metabolic 
characteristics (approximately 30% of the plasma triglyceride of the Shetland pony is 
carried in LDL and HDL). Although the model did not consider the possible exchange 
of triglyceride between VLDL and the higher density lipoproteins, such a feature was 
not required for accurate fitting of the data consistent with the fact that the horse, as 
shown in Chapter IV, lacks CETP activity. The final version of the model appears 
similar to that proposed for the analysis of human VLDL-TG kinetics by Zech et al. 
(1979), suggesting that the pathways of triglyceride metabolism are similar in both 
species. Although the human model is 12 years old, it has withstood rigourous testing 
(Phair 1982) and remains widely used in studies of VLDL-TG metabolism (Harris, 
Connor, Illingworth, Rothrock and Foster 1990).
Several features of the model deserve mention. The two compartment portrayal of the 
precursor system was identical to that arrived at to explain the behaviour of palmitic 
acid in the rat (Baker and Schotz 1967) and man (Shames et al. 1970). The fraction of
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material irreversibly lost from plasma represents that which enters extravascular 
tissues, predominantly the liver, where it is oxidised to CO 2  or ketone bodies. The 
nature of the exchangeable pool is unclear; it may represent FFA that are esterified to 
triglyceride and then hydrolysed in adipose tissues, or the uptake and release o f fatty 
acids from the capillary endothelium, interstitial fluid, or extrahepatic cells. In this 
study, the fractional rates at which palmitic acid and glycerol entered and left the 
exchange pool {i.e. L(5,4)) were identical suggesting that exchange mechanism is 
common to both molecules and as such may well represent a rapidly turning over pool 
o f triglyceride. The fractional and mass transport (on a per kg basis) of the precursors 
found here were similar to those reported for human FFA (Eaton, Berman and 
Steinberg 1969) and glycerol (Zech et al. 1972).
The biochemical nature of the time delay incorporated in compartment 10 was 
not resolved by the model, but conceivably resides in the time taken to synthesis 
triglyceride from the precursors. However, this might not be the case as Baker and 
Schotz (1967) found virtually no delay in the appearance of labelled triglyceride in 
the livers of rats injected with [14C]palmitic acid. However, the magnitude of the 
delay was consistent with the 30 minutes required for the synthesis and secretion of 
VLDL-apoB by hepatocytes during the course of pulse chase experiments (Siuta- 
M angano, Janero and Lane 1982). Thus it is likely that the delay function represents 
the assembly, intracellular transport and secretion of VLDL proteins rather than the 
synthesis of its lipids (Janero and Lane 1983).
In contrast to compartment 10, the rate constant for precursor entering 
com partment 24 was approximately seventeen times greater than that of triglyceride 
leaving. Thus it is possible that the slow turnover of this compartment was due to 
newly synthesised triglyceride entering large storage pools within the liver, consistent 
with the very large calculated mass of compartment 24 relative to that o f 10. 
Although compartment 24 was modelled in parallel with 10, the data were equally 
fitted when 24 had no direct input from plasma, but exchanged with compartment 10. 
Thus rather than representing discrete hepatic pools, it is possible that the two pools 
are linked, with the fast pathway being readily saturable so that excess precursor 
enters the slowly turning over hepatic pool. Physiologically, this may be explained by 
the entry of precursor into a common synthetic pathway, the exit from which is 
limited by the rate of VLDL assembly and secretion, and specifically by the synthesis 
of apoB. Once this capacity is exceeded, the newly synthesised triglyceride enters a 
slowly turning over storage pool reflected by the mass of compartment 24.
The hepatic triglyceride masses calculated by the model represented 
approximately 1.5% of total wet liver weight (assuming that the liver weighs 4% of 
body weight). This value is similar to that of 2% in man (Shames et al. 1970), but
CHAPTER VII 166
underestimated the mass of triglyceride in the biopsy specimens by two to six fold. 
This is probably not of concern given the small size of the biopsies and the potential 
errors in the extraction of lipids, and the likelihood that triglyceride is not distributed 
equally throughout the liver. Human VLDL-TG studies with direct hepatic data are 
rare, but Farquhar, Gross, Wagner and Reaven (1965) obtained biopsies from four 
patients and required a third hepatic "sink" compartment in their model to equate the 
measured and calculated hepatic triglyceride masses. A similar compartment could 
conceivably explain the discrepancy in the present data, although the physiological 
identity of a non-exchangeable pool of this type is hard to rationalise (Phair 1982).
It was perhaps of little surprise that the parameters describing the behaviour of 
the two precursors in the hepatic and VLDL-TG compartments were identical, 
considering that the synthesis and catabolism of triglyceride is unlikely to be different 
if the molecule is labelled in its glycerol or fatty acid moiety. The impact of the tracer 
VLDL-TG kinetics was addressed by Farquhar et al. (1965) who found no difference 
in the curves obtained with glycerol labelled in the 2 position with [3H] and in the 1 
and 3 positions with 14C. However, the VLDL-TG curves for [ l - 14C]palmitic acid 
and [2-3H]glycerol differed in that the slow late component was present in the 
palmitic but not the glycerol curve of the single subject studied. This was later 
contested by Zech et al. (1979) who found significant tails in each of 13 healthy 
subjects studied.
The metabolic origins of these late tails has been the subject of extensive 
debate (Zech et al. 1979, Phair 1982). In the early human studies (Farquhar et al. 
1965, Eaton et al. 1969) they were attributed to recycling of the FFA precursors, but 
Zech et al. (1979) then showed that recycling of glycerol had very little effect on the 
shape of the curves. Zech et al. (1979) also presented convincing evidence that the 
tails do not arise form exchange of VLDL-TG with other lipoproteins or extravascular 
tissues, or the presence in the density <1.006 g/ml fraction of a slowly turning over 
VLDL species such as B-VLDL. The authors concluded, as here, that they are the 
result o f the slowly turning over hepatic compartment. Much of the success in 
describing the origins of these tails in the present study was because the late parts of 
the VLDL-TG curves are much more significant in the pony than they appear in man, 
and thus required more exact modelling. Their prominence was reflected by the fact 
that the transport of triglyceride from the slowly turning over pathway was on average
2.5 times that from the fast, where in man triglyceride synthesis from the fast is 
approximately three times that from the slow (Zech et al. 1979).
Early studies of VLDL-TG kinetics modelled the plasma VLDL-TG pool as a 
single compartment (Baker and Scotz 1964; Farquhar et al. 1965; Eaton et al. 1969; 
Shames et al. 1970). Consideration of the physiology of VLDL catabolism and the
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need to explain the flattening of the VLDL activity peaks then led to the introduction 
of a cascade (Phair 1982). The data were fitted here with four compartments, although 
in reality this is an oversimplification constrained by the insensitivity of the data; if 
many samples had been taken over the period of the peak more compartments may 
have been required for a fit. At each step in the cascade, a portion of the VLDL-TG is 
lost due to the action of LPL and the rest passes onto the next compartment. Thus 
hydrolysis drives the particles through the cascade until their density is >1.006 g/ml 
and they are lost from the VLDL pool to IDL and LDL. In interpreting the data, the 
rate constant L(0,1) was assumed to represent lipolysis although it may also include a 
small fraction of particles lost from the compartment to cellular uptake.
The model used here paid no attention to heterogeneity in the size and 
triglyceride content of VLDL, and it was assumed that all newly secreted VLDL 
entered compartment 1. This was the limitation of the data, although in reality smaller 
VLDL particles secreted by the liver might enter compartment 6 , 7 or 8 . If this is the 
case, then the residence time (and FCR) in plasma of VLDL-TG is not be solely 
determined by the activity of LPL, but also by the size of the particle when it is 
secreted. Differences in the kinetics of large and small VLDL-apoB are well 
established in man (Packard et al. 1984, Packard, Demant and Shepherd 1987, 
Demant et al. 1988) and Barrett, Baker and Nestel (1991) have recently shown that 
this heterogeneity is extended to VLDL-TG. This is clearly of concern to the present 
studies, given that equine VLDL appears to be composed o f particles that contain one 
or another of two distinct species of apoB that are likely to dictate significant 
differences in the assembly, secretion and clearance of their host particles.
4.2. The Pathogenesis of Equine Hyperlipaemia
The analysis of VLDL-TG kinetics in two ponies with hyperlipaemia has provided a 
clear insight into the pathogenesis of the condition and vital information on which to 
base novel therapies for the disease. In contrast to previous speculation (Morris et al. 
1972; Bauer 1980; Freestone et al. 1991), the hypertriglyceridaemia is not the result 
of defective clearance of triglyceride rich lipoproteins but arises from massive 
overproduction of VLDL by the liver stimulated by very significant changes in 
plasma FFA and hepatic triglyceride metabolism.
Although the size of plasma precursor pool was increased by only three fold, 
but the fate of the FFA was very different to that in the control subjects. The fractions 
of FFA that entered the oxidation or hepatic triglyceride pathways were reversed so 
that virtually none were lost to oxidation and ketone synthesis, and the majority were 
directed to the hepatic triglyceride synthesis. In addition, the transport into the fast 
hepatic pathway was reduced to negligible proportions while that into the slow
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pathway was increased as a result of increases in the precursor pool size and the 
fraction of precursor entering compartment 24. The output from this compartment 
indicated that it was the flux of FFA into the liver that was driving triglyceride 
synthesis.
The failure of oxidation and ketone synthesis to dispose of the increased flux 
of FFA into the liver is perhaps a key event in the pathogenesis of this 
hypertriglyceridaemia. This is reflected in the fact that ketonaemia is not prominent in 
ponies with hyperlipaemia (Naylor et al. 1980) and, as Rose and Sampson (1982) 
found, blood ketone concentrations do not rise (while FFA do) in horses fasted for 96 
hours. Taken together, these findings suggest that the pathways for ketone synthesis 
are not well developed in the horse. This is in marked contrast to the cow and the 
sheep where overt ketosis, rather than hyperlipidaemia, is a common sequel to the 
mobilisation of FFA from adipose tissue during late pregnancy and early lactation. In 
the absence of this pathway, and faced with an increased FFA load, the equine liver 
has no option but to channel the FFA into the triglyceride synthetic pathways that lead 
to the export of VLDL. As the fast pathway is readily saturable, an ever greater 
proportion of the FFA enter the slow production pathway as shown in the model by 
the normal mass of triglyceride in compartment 10, while that in 24 is increased many 
fold. The accumulation of triglyceride in this pool would then explain the massive 
intracellular fatty infiltration seen in the liver of ponies with hyperlipaemia. The 
model failed to justify any time delay in subject A and gave a value for this function 
in B that was below that of the controls. This is likely to have been a reflection of the 
domination of the VLDL-TG kinetics by the slow pathway, so that the curves held 
little or no characteristics of the fast pathway for the model to interpret.
The hypertriglyceridaemia was entirely accounted for by the transport of 
triglyceride into compartment 1 as the rate constants and fractional losses from each 
compartment in the delipidation chain were within the range of the controls. This 
meant that the residence time and FCR for VLDL-TG were within the control range, 
and was consistent with the values for LPL activity obtained in Chapter V. Thus, 
despite the massive VLDL-TG synthesis the catabolism of these particles does not 
appear compromised. For this reason, heparin might not provide any therapeutic 
benefit and it was worthy of note that the heparin given to both subjects for the 
collection of PHP had no significant affect on the curves of VLDL-TG kinetics.
In contrast to the controls, the recycling of the precursors from VLDL-TG was 
of qualitative and quantitative significance. This is likely to have resulted from the 
increased activity of LPL on the expanded VLDL pool, so that the FFA released 
overwhelmed the normal cellular uptake mechanisms and spilled over into the general 
circulation. This was of such magnitude that the hourly transport of FFA from VLDL-
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TG into compartment 4 represented 6  and 12 times the mass of FFA in that 
compartment in subjects A and B, respectively, and 38% and 69% of the total FFA 
leaving that compartment (i.e. for the exchange and hepatic compartments), 
respectively. There are two reasons, why in the face of this recycling, peripheral 
blood FFA concentrations rose only three fold. First, the transport of FFA out of the 
plasma pool was increased. The second explanation considers the fact that LPL 
activity is concentrated in adipose tissue, a large proportion of which in the pony is 
located in the abdomen so that the FFA released may well have been removed by the 
liver on their first pass through the portal vein. This latter phenom ena would expose 
the liver to much higher FFA levels than when the hydrolysis occurs elsewhere in the 
body and would exacerbate the stimulation of triglyceride synthesis. Clearly recycling 
can only contribute to the pathogenesis of the hyperlipidaemia once a certain 
threshold has been breached, indicating that the initial stimulus for triglyceride 
synthesis must come from the mobilisation of FFA from adipose stores. However, it is 
obvious from the data presented here that recycling creates a vicious circle in which 
triglyceride synthesis, the mass of hepatic triglyceride and VLDL-TG secretion could 
be forced even in the absence of adipose lipolysis.
In conclusion, the data presented here has considerably advanced our 
understanding of the pathogenesis of hyperlipaemia and has shown how the 
mobilisation of FFA leads to massive hypertriglyceridaemia. The potential that these 
results hold for improving the therapy of the condition is discussed in the following 
Chapter.
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CH APTER VIH 
CO N CLU SIO N S AND FU TU RE ST R A T E G IE S
The aim of this work was to identify the defect in lipoprotein metabolism that is 
responsible for the hypertriglyceridaemia in ponies with hyperlipaemia. This 
objective has largely been met, and in doing so our understanding of lipoprotein 
metabolism in the horse has advanced considerably. As the biochemical, 
physiological and comparative implications of these findings have already been 
discussed, the purpose of this conclusion is to highlight what I feel are the important 
contributions of this work, to draw attention to the questions that remain, and to 
suggest investigative strategies that might provide the answers.
1. L IP O P R O T E IN  M ETA B O LISM  IN TH E H O R SE
The foundation of the studies of lipoprotein metabolism in ponies with hyperlipaemia 
was the characterisation of lipid transport in healthy horses and ponies. From this, the 
following features of significance emerged. The first was the confirmation of the 
absence of heterogeneity within the HDL class, with the particles possessing the 
character of the denser HDL subfraction found in man. The "trapping" of these 
particles at the far extreme of the HDL spectrum was later attributed to deficiency of 
CETP activity. However, in contrast with other species that lack CETP, HDL particles 
enriched in apoE and cholesteryl esters were not present. The reason for this may 
reside in the fact that post-prandial lipaemia, which is necessary for the generation of 
HDLj from HDL 3 , is not prominent in the adult horse. Given that, it would be of 
interest to examine the size and density of HDL in the suckling foal, as these animals 
appear more typical of other monogastric species in their response to dietary fat.
That equine LDL is polydisperse was also confirmed and a third, previously 
unrecognised, subfraction was identified early in the LDL density range. The subject 
of LDL heterogeneity in man and some animal species is presently in vogue because 
of the realisation that certain subfractions are more atherogenic than others. Because 
coronary heart disease does not occur in the horse, this species has little to contribute 
to these investigations. However, in discussing the origins of LDL heterogeneity it 
should be remembered that in the adult horse the subfractions are present in absence 
of CETP activity and significant post-prandial lipaemia.
The presence of multiple species of apoB in the lower density lipoproteins was 
perhaps the most exciting feature of the early work. All the evidence indicated the 
equine liver has the capacity to secrete both large (apoB-100) and small (apoB-48)
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forms of this protein. Those particles that possess apoB-48 would appear to behave in 
a similar fashion to human chylomicrons in that they are removed from the circulation 
before their density reaches that of LDL. As in the rat, the expression of these proteins 
appears to be subject to metabolic control such that the secretion of triglyceride is 
coordinated with the synthesis of the smaller protein. The evidence for this came from 
the fact that an increase in the ratio of apoB-48 to apoB-100 was associated with 
higher plasma triglyceride and VLDL concentrations, and triglyceride enrichment of 
VLDL, in the Shetland ponies compared with the Thoroughbred horses, and in the 
ponies with hyperlipaemia compared with healthy ponies.
Despite this, a number of questions remain to be answered. That the multiple 
species of apoB are synthesised and secreted by the liver needs to be proven. This 
would involve examining the size of apoB in hepatic cell homogenates or preferably 
in those proteins secreted in vitro by an equine hepatocyte cell culture. The molecular 
basis for the difference in size of the two larger proteins also needs to be established 
by consideration of the posttranslational modifications to which human apoB-100 is 
subject. To confirm that the apoB-48 originates from the editing of the apoB-100 
message would be technically difficult as the cDNA and mRNA sequences of equine 
apoB are unknown. To show if the introduction of a stop codon into the message 
causes the premature end to translation would require the reverse transcription of 
mRNA, amplification of the cDNA by the polymerase chain reaction and sequence 
analysis of the product. In the meantime, the arrival of stable isotope tracer 
technologies offers the ability to study the turnover of these proteins in vivo by 
endogenous labelling of apoB with e.g. [ 1 5 N]glycine and measuring the enrichment of 
each protein isolated from apoVLDL by SDS-PAGE, as recently described for human 
apolipoproteins by Patterson, Hachey, Cook, Amann and Klein (1991).
The final feature of the equine lipid transport system that deserves mention is 
the failure of the adult ponies to show a typical monogastric post-prandial response to 
feeding or fat loading. This was in part rationalised by considering that the fat content 
of their diet was low and lacking in long chain fatty acids, and that the adults had 
"lost" the ability to synthesise chylomicrons. This adaptation was presumed to be age 
related as particles with the characteristics of chylomicrons were found in suckling 
foals that were being presented with a high fat load. This assumption needs to be 
strengthened by performing oral fat tolerance tests in foals. If the adults do indeed fail 
to produce chylomicrons, then the molecular basis for these would need to be 
determined. The most obvious mechanism for this would involve a downregulation in, 
or loss of, the intestine's ability to synthesise apoB. This could easily be examined by 
visualisation of apoB in sections of small intestine using an immunoperoxidase
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technique such as that described for the expression of apolipoproteins in the human 
intestine (Green, Lefkowitch, Glickman, Riley, Quinet and Blum 1982).
2. THE PATHOGENESIS OF EQUINE HYPERLIPAEM IA AND 
PROSPECTS FOR THERAPY
Examination of the plasma lipoproteins in ponies with hyperlipaemia confirm ed that 
the massive hypertriglyceridaemia was the result of the accumulation of VLDL in the 
circulation. Further, it showed for the first time that this was due to the emergence of 
a novel, triglyceride enriched, variant of VLDL. These particles seemed to be 
designed to maximise the export o f triglyceride from the liver by having apoB-48 
rather than apoB-100 as their structural protein. This, together with the observations 
that LPL was active and its cofactor present, indicated that contrary to previous 
speculation the hyperlipidaemia was the result of overproduction rather than defective 
catabolism of VLDL. The synthesis of triglyceride, and hence the secretion o f VLDL, 
appeared to be driven by increased plasma FFA concentrations, but it was unclear 
whether these originated from adipose lipolysis or the action o f LPL on VLDL. 
Although the absolute activity of LPL was not compromised, it remained possible that 
the fractional catabolism of VLDL was reduced in the face of the massive increases in 
substrate concentration.
These remaining questions were resolved by kinetic analysis of plasm a FFA 
and VLDL-TG turnover. This confirmed that the increased triglyceride VLDL 
concentrations were entirely attributable to increased production of VLDL-TG by the 
liver, and that this was driven by a greatly increased flux of FFA into hepatic 
triglyceride synthesis. The absolute and fractional catabolism of VLDL was 
unaffected, but recycling of FFA from the lipolysis of VLDL-TG was indeed a 
significant source of plasma FFA and contributed to the input into triglyceride 
synthesis. Thus it is likely that the origin of the hypertriglyceridaemia lies in the 
mobilisation of FFA from adipose, but that recycling of precursors from VLDL-TG 
maintains the stimulus for triglyceride synthesis. These developments are summarised 
schematically in Figure 34, in which the pathogenesis of this hyperlipidaemia is 
explained.
Why should the pony respond in this way to the mobilisation of body fat, 
which afterall is a natural response to an energy deficit? One of the explanations 
certainly lays in the observation of others that the pony, and especially those animals 
that are obese and/or pregnant, are resistant to the action of insulin. This would 
conceivably allow adipose lipolysis to proceed in an uncontrolled fashion such that 
the flux of FFA to the liver becomes great. This resistance might well reflect the fact 
that obesity is prevalent in the pony breeds, in which a significant amount of the body
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fat is stored within the abdomen. For in man, abdominal rather than gluteal-femoral 
obesity is associated with insulin resistance and hypertriglyceridaemia (Kissebah and 
Peiris 1989). The accumulation of fat in the abdomen is associated with hypertrophy 
of the adipocytes, which renders them more responsive to lipolytic stimuli, e.g. by 
catecholamines, so that they release FFA more readily (Mauriege, Despres, 
Prud'homme, Pouliot, Marcotte, Tremblay and Bouchard 1991). This results in higher 
systemic FFA concentrations than in non-obese and non-abdominally obese humans, 
and because of the proximity of omental fat cells to the portal circulation, the liver is 
exposed to even higher FFA concentrations and responds by increasing triglyceride 
synthesis and VLDL secretion (Despres 1991).
If a similar situation exists in the abdominally obese equine it may well 
explain the fact that plasma concentrations of FFA, triglyceride and VLDL are higher 
in ponies than in larger types of horse. In consensus with this, we found in a close 
relation o f the horse, the donkey, that plasma triglyceride and VLDL concentrations 
were higher in obese animals rather than those of ideal body weight, and that these 
concentrations were positively correlated with those of FFA (Watson, Packard, 
Shepherd and Fowler 1990). Thus it is possible that abdominal obesity can explain the 
increased incidence of hyperlipaemia in ponies and donkeys that are overweight. 
Interestingly in man, the basal turnover of FFA is higher in abdominally obese 
women than men (Despres 1991), which might also help account for the higher 
incidence of hyperlipaemia in mares rather than geldings or stallions.
The second feature of the pony that renders its response to adipose 
mobilisation peculiar is the failure of oxidation and ketone synthesis to dispose of the 
FFA. This had been suggested by the fact that ketonaemia is neither a feature of 
hyperlipaem ia nor apparent when ponies are fasted, and was confirmed here by 
kinetic analysis of FFA turnover. In other species that mobilise FFA in response to an 
energy imbalance, such as the cow and the sheep, the fatty acids released are taken up 
by the liver and converted to ketones with resulting ketosis (Bruss 1989). Kinetically, 
this would be shown by an increase in FFA irreversibly lost from the plasma 
com partment rather than the pattern seen in the two hyperlipaemic ponies where the 
majority of FFA leaving plasma entered the hepatic triglyceride synthetic pathways. 
W hether the deficiency of fatty acid oxidation is specific to ponies or is a feature of 
the equine species as a whole is unclear, and at the moment cannot explain the almost 
exclusive incidence of hyperlipaemia in the pony breeds.
W hilst the kinetic data presented is convincing, there remain opportunities for 
building upon the findings of the last two Chapters. The number of turnovers carried 
out in ponies with hyperlipaemia was restricted to two. This was because it would 
have been unwise to transport animals whose condition was of concern, and of those
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that reached Glasgow or were diagnosed there, four were euthanased almost 
immediately on humane grounds. Thus it might be more convenient if future turnover 
studies were based on the experimental reproduction o f the disease by fasting ponies 
for two to three days. Concerns over the use o f radioactive tracers would also be 
allayed if these studies were to use stable isotopes o f glycerol or palmitic acid. 
Indeed, in combination with tracing the metabolism of apoB-48 and apoB-100, such 
studies would provide a powerful tool with which to examine the pathogenesis of this 
hyperlipidaemia and to investigate the metabolic regulation and coordination of 
hepatic apoB and triglyceride synthesis. With the experimental model of the disease, 
it would be interesting to see how the Thoroughbred horse differs in response to 
fasting in an attempt to explain the resistance of the larger types of horse to 
hyperlipaemia.
Finally I would like to discuss the prospects that the data presented in this 
thesis hold for improving the medical management of hyperlipaemia. Of the variety 
of lipid lowering agents available for the treatment of hyperlipidaemia in man, three 
groups possess suitable actions. The first of these, the fibric acid derivatives e.g. 
bezafibrate and gemfibrozil, are widely used in the treatment of primary 
hypertriglyceridaemia in man where reductions in plasm a triglyceride concentrations 
of 54% have been reported (Saku, Gartside, Hynd and Kashyap 1985). The exact 
mode of action of these agents is unclear, although both decreased hepatic triglyceride 
synthesis and enhanced VLDL catabolism are thought to occur (Gaw and Shepherd 
1991). The former appears secondary to a reduction in peripheral lipolysis and the 
flux of FFA to the liver, while the latter results from stimulation of lipoprotein lipase 
activity (Vessby and Lithel 1990) such that the residence time of VLDL-apoB is 
decreased to one third of pretreatment values (Shepherd, Packard, Stewart, Atmeh, 
Clark, Boag, Carr, Lorimer, Ballantyne, Morgan and Lawrie 1984). Inhibition of 
adipose lipolysis is the main mode of action of the second group, nicotinic acid and its 
derivatives e.g. acipimox, which exert their triglyceride lowering effect by reducing 
VLDL-TG synthesis (Grundy, Mok, Zech and Berman 1981). While reductions in 
plasma triglycerides in the region of 60% are attainable (Packard, Stewart, Third, 
Morgan, Lawrie and Shepherd 1980), tolerance can be poor in some patients, 
particularly those on nicotinic acid, because of cutaneous hyperaemia (Fattore and 
Sitori 1991). The final group, the fish oils, are also potent in reducing plasma 
triglyceride concentrations when used as dietary supplements (Sanders, Sullivan, 
Reeve and Thompson 1985) and appear to act primarily by reducing VLDL-TG 
synthesis (Harris et al. 1990).
Given the role that FFA mobilisation appears to play in the pathogenesis of 
equine hyperlipaemia, those agents that inhibit peripheral lipolysis and reduce FFA
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flux are attractive candidates. To test the efficacy of these agents in a clinical situation 
would be restricted by the number of patients required for a case controlled study. It 
might therefore be more appropriate to examine their effects on FFA and VLDL 
metabolism in ponies in which hyperlipidaemia has been induced by fasting. This 
could be done in two ways. First by analysing FFA and VLDL-TG kinetics in ponies 
that are fasted while being treated with the appropriate agent and comparing the 
results with those from the ponies when fasted without therapy. This would provide 
data on how effective the agents are in preventing FFA mobilisation and triglyceride 
synthesis in response to fasting and create the possibility o f prophylactic therapy for 
ponies identified as at risk of developing hyperlipaemia, e.g. those with mild 
hypertriglyceridaemia in late pregnancy.
Secondly, the acute effects of these drugs in the hyperlipaemic pony should be 
examined, as in man both the fibrates and nicotinic acid derivatives are used for 
longer term management of hypertriglyceridaemia. This could be achieved using a 
constant infusion turnover protocol in which the drug is administered intravenously 
and immediate changes in FFA and VLDL-TG kinetics observed. This would provide 
the rationale on which to base therapy for the clinically hyperlipaemic pony and thus 
satisfy the longer term objectives of these studies, which are to offer an effective 
treatment for ponies with hyperlipaemia.
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Figure 34. Schematic Representation of the Pathogenesis of Equine 
Hyperlipaemia.
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i) In the healthy, fed pony above, there is a low basal rate of adipose triglyceride 
turnover which feeds FFA into the liver where they are oxidised to CO 2  (and a small 
amount of ketones) or esterified and secreted as triglyceride in VLDL.
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ii) When the animal enters a negative energy balance, or when the hormone sensitive 
lipase is activated by stress, adipose lipolysis and the flux of FFA to the liver increase. 
Because of the limited oxidative capacity of the equine liver, these FFA are resecreted 
as triglyceride, in the form of larger, triglyceride rich particles.
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iii). As plasma VLDL concentrations rise, the activity of lipoprotein lipase (LPL) 
increases to the point that the FFA released overwhelm adipose uptake mechanisms 
and spill over into the general circulation. This recycling of FFA exacerbates the 
stimulus for triglyceride synthesis and VLDL concentrations continue to rise.
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iv). Contrast the equine situation with that in ruminants, where the mobilised FFA are 
channelled into the oxidative and ketogenic pathways within the liver rather than 
those of triglyceride synthesis.
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Suppliers of Reagents and Equipment
Amersham International pic
Amersham Place, Little Chalfont, Amersham, Bucks. HP7 9NA.
Amicon Ltd
Upper Mill, Stonehouse, Glos. GL10 2BJ.
Analytichem International
Jones Chromatography Ltd
Tiry Berth Industrial Estate, New Road, Hengoed, M id Glamorgan.
Baker Systems
Baker Instruments Ltd
Rusham Park, W hitehall Lane, Egham, Surrey, TW20 9NW.
Baxter Health Care Ltd
8  Tollpark Place, W ardpark East, Cumbernauld G 6 8  OLN.
Beckman Instruments, Inc.
Beckman Instruments (UK) Ltd Analytical Sales and Service Operation 
Progress Road, Sands Industrial Estate, High W ycombe, Bucks. HP12 4JL. 
BDH Laboratory Supplies 
McQuilkin and Co.
21 Polmadie Avenue, Glasgow G5 OBB.
Bio-Rad Laboratories Ltd
Bio-Rad House, Marylands Avenue, Hemel Hempstead, Herts. HP2 7TD. 
Boehringer Mannheim GmbH
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd 
Bell Lane, Lewes, East Sussex BN7 1LG.
Brownlea Aquapore 
Anachem Ltd
20 Charles Street, Luton, Beds. LU2 OEB 
Denley-Tech Ltd
Denley Instruments Ltd
Natts Lane, Billinghurst, Sussex, RH14 9EY.
Dow Chemical Ltd
Uniscience Ltd
Wildmere Road, Banbury, Oxon. 0X 16 7JU.
Dynatech Laboratories Ltd
Daux Road, Billingshurst, West Sussex, RH14 95J
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Gelman Sciences Ltd
Brackmill Business Park, Caswell Road, Northampton NN4 OES.
Gilson HPLC System 
Anachem Ltd
20 Charles Street, Luton, Beds. LU2 OEB.
Hewlett-Packard Ltd
Cain Road, Bracknell, Berks. RG12 1HN.
H oefer Scientific Instruments
Scottish Biotechnology Instrumentation
Blairgowrie Business Centre, 60 High Street, Blairgowrie, PH 10 6 AF.
Isco Instrument Specialities Co.
Jones Chromatography Ltd
Tiry Berth Industrial Estate, New Road, Hengoed, Mid Glamorgan CF 8  8 AU. 
Leo Laboratories Ltd
Longwick Road, Princes Risborough, Aylesbury, Bucks. HP 17 9RR.
LKB Bromma
Pharmacia Ltd, Pharmacia LKB Biotechnology Division 
Midsummer Boulevard, Central Milton Keynes, Bucks. MK9 3HP.
Nycomed Pharma AS
Nycorned (UK) Ltd
Nycomed House, 2111 Coventry road, Sheldon, Birmingham B26 3EA.
Paar Scientific Ltd
594 Kington Road, Raynes Park, London SW20 8 DN.
Packard Instrument Co.
Canberra Packard Ltd
Brook House, 14 Station Road, Pangbourne, Berks. RG 8  7DT.
Pharmacia AB
Pharmacia Ltd, Pharmacia LKB Biotechnology Division 
Midsummer Boulevard, Central Milton Keynes, Bucks. MK9 3HP.
Randox Laboratories Ltd
Ardmore, Diamond Road, Crumlin, Co. Antrim BT29 4QY.
Resource Facility for Kinetic Analysis 
Centre for Bioengineering
FL-20, University of Washington, Seattle, WA 98195, USA.
Roche
Roche Products Ltd
P.O. Box 8 , Welwyn Garden City, Herts. AL7 3AY.
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Scottish Antibody Production Unit
Law Hospital, Carluke, Lanarkshire M L 8  5ES.
Sartorius Ltd
Longmead Business Centre, Blenheim Road, Epsom, Surrey KT19 9QN.
Sigma
Sigma Chemical Company Ltd 
Fancy Road, Poole, Dorset BH17 7TG.
Spectrum Medical Industries Inc.
Orme Technology
P.O. Box 3, Stakehill Industrial Park, Middleton, Manchester M24 2RH.
Techne
Scotlab
Kirkshaw Road, Coatbridge, Lanarkshire ML5 8 AD 
TSK-Gel HPLC Columns and Packings 
Laboratory Impex Ltd
111-113 Waldegrave Road, Teddington, Middlesex, TW 11 8 LL 
W ako Chemicals GmbH
Alpha Laboratories Ltd
40 Paman Drive, Eastleigh, Hampshire S 05  4NU.
W hatman International Ltd
Whatman Labsales Ltd
St. Leonard's Road, 20/20 Maidstone, Kent ME 16 OLS.
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Derivation of Equation for Calculating Post-heparin Lipolytic Activity
Activity (umolFA/ml/hr) = [Sample cpm - Blank cpm] x 755.1
Total cpm - background cpm 
W here 755.1 = 1.5059a x 3b x 100° x 2.45d
2.05e x l f x 0.7158 
a is umol triolein/assay tube
b three fatty acids are released from one molecule of triolein 
c to correct 1 0  ul sample to 1  ml
d volume of upper phase after extraction (2.45 ml +0.05, n=64) 
e volume of lower phase after extraction (2.05 ml +0.05, n=64) 
f incubation time in hours
8  % oleic acid extracted into upper phase from Belffage and Vaughan (1969)
184
APPENDIX 3
Chemical Composition of Lipoprotein Classes Isolated by Gel Filtration
Lipoprotein Animal
% Particle Mass
Cholesterol Triglyceride Phospholipid Protein
VLDL TB-13 19.9 39.5 18.1 2 2 . 6
TB-14 14.3 46.2 21.4 18.1
TB-15 13.7 57.0 9.2 1 0 . 1
TB-16 11.3 54.2 14.0 17.5
TB-23 14.2 55.8 16.8 13.2
TB-30 10.4 48.6 16.0 25.0
TB-32 22.5 49.3 8.7 19.5
TB-51 19.8 49.1 12.9 18.2
SP-1 12.9 50.9 14.4 2 1 . 8
SP-2 17.8 48.0 15.1 19.2
SP-7 1 0 . 2 64.0 13.6 1 2 . 0
SP-9 12.9 59.8 17.6 9.5
SP-10 1 0 . 0 54.5 1 1 . 0 14.5
SP-11 15.8 55.3 11.9 16.9
SP-12 18.9 53.4 10.4 17.3
SP-25 16.6 56.9 12.3 14.2
SP-26 15.9 57.0 12.5 14.6
SP-27 12.4 58.4 17.2 1 2 . 0
SP-28 14.5 52.4 16.5 16.6
SP-31 18.9 59.3 15.0 16.8
LDL TB-13 40.5 5.4 25.3 30.8
TB-14 32.3 4.5 28.1 35.1
TB-15 49.7 5.6 18.3 26.4
TB-16 38.2 2.7 27.5 31.5
TB-23 40.8 7.4 2 1 . 6 30.2
TB-30 46.4 6.5 16.3 28.9
TB-32 45.7 9.4 2 2 . 0 22.9
TB-51 47.8 8 . 0 21.9 32.3
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% Particle Mass
Lipoprotein Animal Cholesterol Triglyceride Phospholipid Protein
SP-1 42.2 4.7 22.4 30.7
SP-2 44.7 6 . 2 24.2 24.9
SP-7 57.8 3.7 18.3 2 0 . 1
SP-9 40.2 4.7 27.2 27.5
SP-10 47.2 3.8 24.5 24.5
SP-11 34.7 6.5 26.4 32.4
SP-12 44.8 5.0 20.7 29.5
SP-25 41.3 4.6 26.1 28.4
SP-26 51.3 4.0 24.9 19.7
SP-27 37.2 5.5 25.7 32.0
SP-28 39.2 6 . 6 23.7 30.4
SP-31 45.5 5.8 24.4 24.2
TB-13 2 2 . 8 3.4 28.5 45.2
TB-14 — — — —
TB-15 27.0 13.8 26.5 42.8
TB-16 19.2 1 0 . 0 2 2 . 6 48.2
TB-23 21.7 4.0 25.0 29.2
TB-30 27.0 1 . 6 24.6 46.8
TB-32 25.2 3.4 25.9 45.5
TB-51 19.4 12.4 34.8 38.4
SP-1 2 1 . 6 1 0 . 1 2 2 . 8 45.5
SP-2 28.9 5.5 34.1 41.4
SP-7 17.9 1 0 . 1 2 1 . 2 44.8
SP-9 23.2 8 . 0 23.9 42.9
SP-10 27.9 1 0 . 0 24.4 37.2
SP-11 29.5 0 . 8 26.2 43.4
SP-12 19.7 4.1 25.2 51.0
SP-25 2 2 . 0 0 . 0 30.5 47.3
SP-26 19.6 2.3 32.8 45.3
SP-27 24.0 0.9 24.6 50.5
SP-28 2 1 . 0 1 . 0 27.1 50.8
SP-31 13.1 9.2 27.1 50.6
186
A PPEN D IX  4
Agarose Gel Filtration Elution Profile Parameters
Animal
VLDL LDL HDL
Vol.aWidthb Height0 Vol. Width Height Vol. Width Height
TB-13 84 1 0 0 . 1 0 118 30 0.13 156 34 1.32
TB-14 82 1 1 0.42 119 28 0.15 162 38 2.05
TB-15 80 9 0.09 1 2 0 24 0.06 157 29 1.77
TB-16 81 1 0 0.18 117 30 0.17 157 35 1.95
TB-23 78 1 1 0.18 116 32 0 . 2 2 154 32 1.93
TB-30 81 1 0 0 . 1 0 1 2 1 31 0 . 1 1 161 37 1.69
TB-32 78 1 1 0.14 1 2 0 26 0.08 157 36 1.82
TB-51 79 1 1 0.16 124 26 0 . 1 2 157 37 1.90
SP-1 80 1 0.51 115 32 0.14 154 38 1.97
SP-2 79 1 1 0.35 1 2 1 38 0.09 149 39 1.43
SP-7 79 1 2 0.92 114 38 0.23 152 33 1.47
SP-9 78 1 2 0.56 114 32 0.25 156 34 2.42
SP-10 81 1 1 0.38 125 29 0.16 162 34 2.34
SP-11 79 9 0.45 119 26 0.18 156 30 2.40
SP-12 78 1 1 0.23 118 31 0 . 1 0 155 35 1.87
SP-25 80 1 1 0.26 118 29 0 . 1 2 157 38 1.93
SP-26 77 1 2 0.81 113 30 0 . 2 2 150 38 2.46
SP-27 78 1 1 0 . 1 2 116 30 0 . 1 0 154 39 1.37
SP-28 80 1 1 0.41 1 1 1 32 0.15 157 39 2.16
SP-31 78 1 1 0.48 115 32 0 . 1 2 154 37 1.89
a peak elution volume (ml), belution width of peak (ml), cpeak height (OD 28(W
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A PPEND IX  5
Particle Size and Composition of VLDL, LDL Subfractions, and HDL 
Isolated by Rate-zonal Ultracentrifugation
Percentage Particle Mass
Animal/ Diameter Cholesteryl Triglyceride Free Phospholipid Protein 
Lipoprotein (nm) Esters Cholesterol
VLDL
TB-13 nd 1 1 . 6 55.0 ND 14.4 19.0
TB-14 nd 13.9 55.3 ND 11.9 18.8
TB-30 nd 9.1 64.9 ND 1 0 . 2 15.8
TB-32 nd 23.3 40.8 ND 7.2 28.7
SP-1 nd 11.5 55.5 ND 12.7 20.3
SP - 8 nd 1 2 . 2 6 6 . 1 ND 13.8 17.9
SP-9 nd 2 2 . 1 44.7 ND 12.3 19.2
SP-10 nd 15.0 48.0 ND 16.9 2 0 . 1
LD LX
TB-13 26.8 47.4 9.4 5.4 2 0 . 2 17.6
TB-14 26.3 42.5 5.2 ND 15.3 26.9
TB-30 31.2 42.6 8.4 ND 19.2 29.8
TB-32 24.4 38.4 9.2 ND 21.4 35.5
SP-1 27.3 38.5 14.0 4.7 16.1 26.7
SP-2 25.4 45.5 0 . 0 ND 19.6 34.9
SP-9 25.6 42.4 14.5 1 . 0 17.6 24.5
SP-10 27.8 47.7 11.7 ND 1 1 . 1 29.5
LDL2
TB-13 25.8 45.5 8 . 8 5.2 2 0 . 2 2 0 . 2
TB-14 24.2 48.9 15.9 ND 14.7 2 0 . 6
TB-30 25.7 31.2 4.0 7.2 2 0 . 2 37.4
TB-32 23.8 36.7 6 . 2 8.4 23.0 35.7
SP-1 24.1 42.4 11.4 ND 19.6 26.6
SP - 8 23.6 48.7 3.5 4.3 2 2 . 1 21.4
SP-9 23.6 45.6 9.0 5.1 17.6 22.7
SP-10 25.5 48.7 12.5 2 . 8 16.2 2 1 . 8
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APPENDIX 5 (continued)
Percentage Particle Mass
Animal/ Diameter Cholesteryl Triglyceride Free Phospholipid Protein 
Lipoprotein (nm) Esters Cholesterol
l d l 3
TB-13 23.0 46.9 9.5 ND 15.4 28.2
TB-14 22.3 59.5 7.1 ND 1 2 . 8 2 0 . 6
TB-30 23.4 40.8 3.9 4.0 17.4 34.1
SP-1 22.4 47.4 5.4 3.9 20.9 2 2 . 6
SP - 8 21.4 52.8 6 . 2 ND 17.0 24.0
SP-9 21.5 58.5 3.8 1 . 1 17.1 19.5
SP-10 2 2 . 8 43.5 3.6 ND 2 2 . 0 30.9
HDL
TB-13 8.30 22.7 0 . 0 ND 24.9 52.4
TB-14 8.24 21.5 8 . 1 1.7 26.8 41.8
TB-30 8.48 23.1 0.7 ND 31.0 45.2
TB-32 8.36 29.4 7.3 ND 26.3 37.0
SP-1 8.36 2 2 . 8 0 . 0 ND 32.8 44.4
SP - 8 8.30 23.5 4.5 1.5 26.0 44.5
SP-9 8.42 25.2 8.5 ND 27.8 38.5
SP-10 8.46 23.4 1.7 1 . 6 32.4 40.9
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A PPENDIX 6
Composition of Plasma Lipoproteins Isolated from 18 Thoroughbred Horses and 
18 Shetland Ponies by Sequential Flotation Ultracentrifugation
Percentage Particle Mass
Lipoprotein/ Cholesteryl Triglyceride Free Phospholipid Protein 
Animal Sex Cholesterol
VLDL
TB-53 F 9.0 50.3 — 13.9 26.8
TB-54 F 8.9 59.1 — 1 1 . 0 20.9
TB-55 F 8 . 6 58.8 — 13.7 18.9
TB-56 F 6 . 0 56.9 — 1 1 . 1 26.0
TB-57 F 7.9 55.2 — 16.2 20.3
TB-58 F 8.9 58.8 — 13.7 18.9
TB-62 F 3.9 53.7 — 18.2 24.3
TB-64 F 8 . 1 58.3 — 15.0 18.6
TB-72 F 7.1 65.1 — 1 2 . 6 15.4
TB-13 G 5.9 54.5 — 14.7 24.9
TB-14 G 7.1 54.6 — 14.2 24.1
TB-15 G 11.4 60.7 — 10.4 17.5
TB-59 G 10.7 56.3 — 14.0 19.0
TB-60 G 7.7 61.6 — 14.3 16.4
TB - 6 6 G 8.3 59.6 — 14.3 17.5
TB-67 G 6.4 52.2 — 1 1 . 8 29.5
TB - 6 8 G 7.6 55.0 — 16.2 2 1 . 1
TB-69 G 7.6 63.6 — 12.9 15.8
SP-1 F 1 0 . 0 58.5 — 13.3 18.2
SP-2 F 9.6 58.7 — 14.8 16.9
SP-3 F 1 0 . 8 58.7 — 17.6 14.6
SP-7 F 1 0 . 0 58.4 — 13.4 18.2
SP - 8 F 9.2 59.3 — 13.6 17.9
SP-11 F 13.9 58.8 — 13.9 1 2 . 6
SP-37 F 7.2 59.6 — 18.1 14.9
SP-L F 8 . 2 61.5 — 16.5 16.4
SP-R F 9.2 58.6 — 18.9 18.9
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A PPEN D IX  6 (continued)
Lipoprotein 
Animal Sex
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
V LD L
SP-B F 9.9 58.7 — 18.4 18.4
SP-T F 9.1 60.9 — 13.9 16.0
SP-S F 9.0 63.0 — 13.8 13.8
SP-5 G 11.5 58.9 — 14.9 14.7
SP-9 G 11.5 47.2 — 18.5 2 2 . 8
SP-10 G 13.5 54.8 — 14.1 17.5
SP-12 G 1 0 . 6 57.4 — 14.8 17.2
SP-41 G 9.0 59.2 — 16.7 16.7
SP-PA G 8.7 67.1 — 1 0 . 8 13.4
LD L
TB-53 44.6 6 . 0 6 . 2 19.0 24.2
TB-54 46.4 9.5 13.5 30.7
TB-55 44.0 7.0 5.2 18.3 25.5
TB-56 44.3 6 . 2 6.3 18.9 24.4
TB-57 46.6 5.5 5.6 17.7 24.6
TB-58 41.4 7.3 4.0 2 0 . 8 26.3
TB-62 43.6 3.1 3.5 19.4 30.5
TB-64 46.0 3.7 4.2 19.7 26.4
TB-72 36.9 5.1 4.7 23.5 29.9
TB-13 48.2 3.6 7.4 26.0 14.8
TB-14 40.7 5.1 5.1 2 2 . 6 26.6
TB-15 26.2 4.9 7.5 30.0 33.4
TB-59 44.7 6 . 8 — 2 1 . 0 27.7
TB-60 41.3 6 . 6 4.9 21.4 25.8
TB - 6 6 42.7 3.1 6 . 0 2 2 . 8 25.3
TB-67 40.5 2.9 4.1 21.9 30.9
TB - 6 8 39.6 2.9 6 . 1 2 2 . 6 28.8
TB-69 36.4 7.5 4.6 2 2 . 1 29.4
SP-1 35.7 9.0 5.3 24.1 25.6
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APPENDIX 6 (continued)
Lipoprotein 
Animal Sex
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
LD L
SP-2 34.2 3.6 4.7 34.1 23.4
SP-3 34.6 5.7 4.5 24.0 31.2
SP-7 38.8 8.5 3.8 23.3 23.6
SP-8 44.1 6.2 4.7 24.6 20.4
SP-11 40.1 7.2 5.6 25.6 21.5
SP-37 37.9 10.4 — 23.0 24.7
SP-L 41.5 3.8 3.7 22.9 28.1
SP-R 41.7 4.0 — 19.3 34.9
SP-B 44.5 6.7 — 19.8 25.9
SP-T 43.1 5.6 — 22.2 29.1
SP-S 38.5 4.7 3.5 21.4 31.9
SP-5 33.9 5.4 6.7 20.5 25.7
SP-9 51.9 2.5 6.6 26.2 12.9
SP-10 51.6 4.7 5.4 27.2 11.1
SP-12 43.8 8.2 5.1 28.1 12.5
SP-41 43.8 3.9 4.8 19.6 25.9
SP-PA 41.9 2.9 6.9 25.3 23.1
H D L
TB-53 24.3 1.9 2.1 23.4 48.2
TB-54 22.3 1.7 2.1 24.9 49.0
TB-55 23.1 1.4 2.2 25.0 48.4
TB-56 23.4 1.5 2.1 24.3 50.3
TB-57 24.3 1.3 1.8 22.3 50.3
TB-58 22.8 0.9 2.6 30.8 42.9
TB-62 18.2 0.5 2.1 26.2 53.1
TB-64 21.8 0.4 4.2 35.6 38.6
TB-72 14.8 0.3 3.5 29.5 51.9
TB-13 17.6 0.4 1.9 21.9 56.3
TB-14 17.5 0.4 2.0 22.0 56.2
TB-15 20.7 0.4 2.8 23.8 52.7
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APPENDIX 6 (continued)
Percentage Particle Mass
Animal
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
HDL
TB-59 22.4 0.0 2.1 30.6 44.8
TB-60 24.0 0.6 4.8 33.7 40.4
TB-66 16.7 5.5 2.4 27.3 53.0
TB-67 16.2 0.3 3.5 27.9 52.0
TB-68 17.4 0.5 2.1 27.3 52.6
TB-69 16.8 0.3 3.3 27.4 52.1
SP-1 22.4 0.9 3.0 28.5 45.1
SP-2 18.0 0.7 1.9 25.3 54.1
SP-3 14.2 0.4 1.5 20.2 63.9
SP-7 19.7 0.7 3.0 27.5 49.2
SP-8 20.8 0.6 2.9 26.6 46.2
SP-11 30.3 0.3 2.5 23.2 45.7
SP-37 21.5 0.8 3.1 36.8 38.6
SP-L 20.7 0.9 2.5 28.1 47.7
SP-R 13.4 1.1 3.2 30.8 51.6
SP-B 19.7 0.8 2.4 26.5 51.5
SP-T 19.2 1.7 2.8 28.9 47.3
SP-S 23.3 0.5 5.9 35.0 35.3
SP-5 16.8 0.3 2.2 24.2 56.5
SP-9 20.3 0.3 3.1 27.7 48.5
SP-10 21.4 0.6 3.2 24.9 49.9
SP-12 13.4 0.4 1.2 19.6 65.4
SP-41 . 20.6 0.6 3.1 28.2 47.5
APPENDIX 7
A polipoprotein C om position of L ipoproteins Isolated from  E igh t T horoughbred  
H orses and  Shetland  Ponies by Flotation U ltracen trifugation
Lipoprotein/
Animal B-100 B-48
Percentage of Protein Mass 
E A-I C-II C-III A-II
VLDL
TB-13 20.5 10.6 9.9 7.3 23.8 28.0
TB-14 27.4 10.1 7.2 3.2 25.3 26.7 —
TB-15 20.2 9.4 17.4 3.5 19.3 30.3 —
TB-62 23.2 11.7 11.9 4.4 21.6 27.2 —
TB-64 23.6 10.9 14.4 4.7 22.2 24.2 —
TB-66 27.6 14.0 7.2 3.5 19.9 27.8 —
TB-68 23.1 8.7 11.6 5.2 20.3 31.2 —
TB-72 23.4 11.4 4.3 2.8 31.0 27.1 —
SP-1 19.2 13.1 10.6 12.0 26.6 29.4 —
SP-2 22.9 9.9 3.9 8.4 22.2 28.2 —
SP-3 23.0 6.8 11.8 3.9 18.9 41.6 —
SP-5 17.1 12.5 13.6 11.2 29.0 27.6 —
SP-7 19.2 11.3 11.2 13.6 29.0 35.5 —
SP-8 27.8 13.1 18.1 11.8 11.2 34.4 —
SP-9 19.2 16.4 3.6 11.2 9.7 39.9 —
SP-10 12.7 9.1 12.9 10.9 32.2 23.1 —
SP-11 28.3 9.2 18.1 9.7 20.8 27.6 —
SP-12 18.7 13.1 6.6 6.9 22.7 33.5 —
SP-37 22.1 14.7 12.2 12.1 15.3 19.1 —
SP-41 20.0 13.2 9.8 8.3 18.2 28.8 —
SP-L 20.5 10.5 10.6 10.1 25.6 20.0 —
SP-R 21.0 16.4 11.3 6.4 20.6 25.0 —
SP-B 17.0 9.7 3.2 1.4 26.2 45.5 —
SP-T 19.8 7.7 6.6 2.0 24.8 39.2 —
SP-S 20.0 11.6 3.0 4.9 27.5 33.0 —
SP-P 26.3 8.6 4.3 1.2 25.1 34.6 ---
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A PPEND IX  7 (continued)
Percentage of Protein Mass
Animal B-100 B-48 E A-I C-II C-III A-I]
LD L
TB-13 70.3 11.4 11.3 7.1
TB-14 70.2 . . . 4.9 — 11.5 13.4 —
TB-15 83.8 . . . 3.3 — 4.4 8.5 —
TB-62 67.1 . . . 8.6 — 12.1 12.1 —
TB-64 79.5 — 2.9 . . . 6.1 11.6 —
TB-66 73.0 — 5.9 . . . 10.3 10.7 —
TB-68 77.8 — 7.9 — 7.2 7.1 —
TB-72 65.2 — 6.8 — 12.1 14.0 —
SP-1 73.1 . . . 6.8 — 9.1 9.1 —
SP-2 74.2 . . . 5.1 — 10.3 5.7 —
SP-3 67.8 — 8.9 — 10.6 10.1 —
SP-5 83.2 . . . 3.9 — 7.5 11.0 —
SP-7 71.5 — 4.2 — 5.5 12.8 —
SP-8 79.0 . . . 7.9 — 5.1 12.9- —
SP-9 76.5 — 10.7 — 6.4 6.3 —
SP-10 79.1 . . . 3.9 — 9.0 8.0 —
SP-37 87.2 . . . 7.0 — 3.0 2.9 —
SP-41 82.7 — 4.7 — 6.8 5.8 —
SP-L 84.7 — 5.9 — 6.0 3.4 —
SP-R 75.1 — 2.2 — 7.8 14.9 —
SP-B 73.0 . . . 8.4 . . . 8.5 10.1 —
SP-T 67.1 . . . 12.3 — 7.0 13.5 —
SP-S 81.9 — 9.3 — 3.2 15.5 —
SP-P 84.9 — 2.9 . . . 5.0 7.2 —
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A ppendix 7 (continued)
Lipoprotein/
Animal B-100 B-48
Percentage of Protein Mass 
E A-I C-II C-III A-II
HDL
TB-13 6.3 78.2 5.6 2.6 7.3
TB-14 — — 13.8 73.8 3.7 4.2 4.5
TB-15 — — 4.5 81.5 1.2 2.0 10.8
TB-62 — — 6.1 85.2 1.9 1.5 5.3
TB-64 — — 7.3 80.6 1.9 2.5 7.6
TB-66 — — 10.3 82.4 0.9 1.1 5.3
TB-68 — — 12.2 70.8 2.5 3.6 10.9
TB-72 — — 10.1 68.3 8.7 8.7 6.7
SP-1 — — 0.7 87.3 1.8 4.8 5.4
SP-2 — — 0.4 79.8 8.8 9.3 1.8
SP-3 — — 2.6 71.9 9.4 5.0 11.1
SP-5 — — 2.5 85.3 6.6 6.1 12.2
SP-7 — — 3.9 74.5 6.0 6.0 9.6
SP-8 — — 1.9 75.2 7.9 5.1 10.0
SP-9 — — 4.7 77.4 3.7 3.7 9.5
SP-10 — — 2.4 77.6 5.8 5.8 9.7
SP-12 — — 5.5 79.7 5.0 6.4 3.3
SP-37 — — 6.9 79.8 2.8 3.3 7.2
SP-41 — — 3.9 86.4 0.9 6.8 2.0
SP-L — — 3.7 84.4 3.1 4.7 4.1
SP-R — — 8.7 77.8 3.2 3.5 6.8
SP-B — — 4.2 83.8 2.2 5.5 4.4
SP-T — — 11.0 76.5 3.6 1.1 7.9
SP-S — — 3.8 84.9 3.6 2.8 4.9
SP-P — — 4.1 76.4 3.0 3.5 13.1
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A PPENDIX  8
P lasm a C holesterol, T riglyceride, F ree F atty  Acid (FFA) and  L ipoprotein
C holesterol C oncentrations in H ealthy T h o roughbred  H orses (TB) and  Shetland
Ponies (SP)
Animal
Plasma Concentration (mmol/1)
Cholesterol Triglyceride VLDL LDL HDL FFA
TB-13 2.50 0.30 0.10 1.00 1.40 nd
TB-14 2.00 0.25 0.20 0.60 1.20 nd
TB-15 2.00 0.20 0.05 0.50 1.45 nd
TB-53 2.65 0.35 0.30 1.10 1.25 nd
TB-54 2.20 0.65 0.35 0.45 1.04 nd
TB-55 2.45 0.35 0.25 0.65 1.55 nd
TB-56 2.50 0.30 0.20 0.70 1.60 nd
TB-57 2.35 0.30 0.30 0.90 1.15 nd
TB-58 1.75 0.35 0.30 0.40 1.05 nd
TB-59 1.90 0.20 0.10 0.50 1.30 nd
TB-60 2.45 0.40 0.20 0.65 1.60 nd
TB-62 2.00 0.15 0.15 0.40 1.45 nd
TB-64 2.00 0.30 0.20 0.65 1.15 nd
TB-66 2.20 0.70 0.20 0.70 1.30 nd
TB-67 2.15 0.15 0.05 0.45 1.65 nd
TB-68 1.90 0.15 0.10 0.45 1.35 nd
TB-69 2.55 0.50 0.25 0.45 1.85 nd
TB-72 2.50 0.45 0.35 0.50 1.65 nd
SP-1 2.05 0.40 0.15 0.45 1.40 0.36
SP-2 1.95 0.15 0.20 0.40 1.35 0.41
SP-3 1.65 0.15 0.10 0.30 1.25 0.30
SP-5 2.00 0.70 0.35 0.20 1.45 0.15
SP-7 2.15 0.55 0.10 0.65 1.40 0.22
SP-8 2.95 0.70 0.25 0.65 2.05 0.24
SP-9 2.80 0.25 0.25 1.05 1.50 0.52
SP-10 2.55 0.45 0.30 0.75 1.50 0.33
nd, not determined
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APPENDIX 8 (continued)
Plasma Concentration (mmol/1)
Animal Cholesterol Triglyceride VLDL LDL HDL FFA
SP-11 2.50 0.70 0.30 0.55 1.65 0.31
SP-12 1.40 0.58 0.15 0.45 0.80 0.55
SP-37 2.35 0.55 0.45 0.70 1.20 0.32
SP-41 2.15 0.40 0.10 0.65 1.40 0.36
SP-L 2.20 0.45 0.35 0.70 1.15 0.58
SP-R 1.85 0.40 0.35 0.35 1.15 0.62
SP-B 1.75 0.50 0.45 0.30 1.00 0.55
SP-T 1.60 0.50 0.45 0.25 0.90 0.62
SP-S 2.35 0.55 0.45 0.80 1.10 0.11
SP-P 2.10 0.70 0.55 0.50 1.50 0.48
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A PPENDIX 9
Selective Measurement of Lipoprotein Lipase and Hepatic Lipase Activity
Intra-assay performance: Post-heparin plasma with low and high LPL and HL 
activity was analysed in duplicate in a single assay run.
Aliquots
Activity (umolFA/ml/h)
LPL HL
Low High Low High
A 2.10 5.68 2.52 7.28
B 2.34 5.82 2.51 7.28
C 2.16 5.16 2.58 7.42
D 2.06 6.24 2.70 7.69
E 2.02 6.37 2.78 6.24
F 2.27 6.13 2.86 7.08
G 2.14 6.25 2.95 7.31
H 2.65 6.04 2.91 6.72
I 2.04 6.16 3.05 6.80
J 2.31 6.18 2.95 7.42
Interassay Performance: Post-heparin plasma with low and high LPL
activity were analysed in duplicate in seven consecutive assays.
Activity (umolFA/ml/h)
LPL HL
Date of Assay Low High Low High
23/10/90 2.00 5.52 2.30 6.42
30/10/90 1.76 5.59 2.68 6.39
31/10/90 2.21 6.10 2.78 7.12
05/11/90 2.05 6.47 2.67 6.74
08/11/90 2.30 7.02 2.87 7.20
09/11/90 2.26 5.90 2.78 6.72
11/12/90 1.76 5.73 2.59 6.34
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A PPEND IX  10
Lipoprotein Lipase and Hepatic Lipase Activities in Post-heparin Plasma from  
Eight Thoroughbred Horses (TB) and 16 Shetland Ponies (SP)
umolFA/ml/h umolFA/ml/h
Animal Sex LPL HL Animal Sex LPL HL
TB-K F 2.71 2.92 SP-L F 5.42 6.47
TB-20 F 2.75 3.53 SP-R F 3.85 5.66
TB-34 F 4.87 3.18 SP-B F 2.95 4.45
TB-64 F 4.78 5.50 SP-T F 2.88 1.97
TB-14 G 1.73 1.78 SP-7 F 3.43 6.46
TB-15 G 2.12 1.38 SP-S F 2.27 4.43
TB-16 G 3.96 2.63 SP-8 F 2.28 5.25
TB-D G 3.53 4.81 SP-37 F 3.25 7.29
SP-C F 2.00 2.30
SP-2 F 7.76 5.09
SP-9 G 4.28 4.60
SP-10 G 3.13 5.03
SP-BA G 2.33 3.22
SP-12 G 2.58 1.04
SP-41 G 6.07 4.78
SP-PA G 2.11 3.25
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APPENDIX 11 
Activation of Equine Lecithin:ChoIesteroI Acyl Transferase 
by Equine and Human ApoA-I
LCAT Activity (nmolCE/ml/hr)
Animal + Equine ApoA-I + Human ApoA-I
TB-13
TB-14
TB-15
SP-L
SP-R
22.61
21.48
17.84
24.38
21.59
22.20
20.92
21.00
20.29
24.36
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APPENDIX 12
Lecithin:C holesterol Acyl T ran sfe rase  A ctivity
in 12 T horoughbred  H orses (TB) an d  12 S hetland  Ponies (SP)
LCAT LCAT
Animal Sex nmolCE/ml/h Animal Sex nmolCE/ml/h
TB-34 F 18.62
TB-B F 22.80
TB-C F 20.86
TB-K F 15.54
TB-P F 25.95
TB-S F 25.64
TB-13 G 16.96
TB-14 G 21.48
TB-15 G 15.82
TB-16 G 19.53
TB-D G 19.79
TB-E G 19.51
SP-L F 20.05
SP-R F 29.71
SP-B F 23.14
SP-7 F 22.86
SP-T F 18.26
SP-8 F 29.26
SP-37 F 23.65
SP-C F 18.09
SP-F F 26.30
SP-9 G 23.63
SP-10 G 29.34
SP-B G 21.47
202
A PPENDIX 13
Lecithin:Cholesterol Acyl Transferase Activity 
and HDL Composition in 12 Shetland Ponies
Animal
LCAT
nmolCE/ml/h
% Particle Mass
Cholesteryl Triglyceride 
Esters
Free
Cholesterol
Phospholipid Protein
SP-L 14.74 17.6 1.0 3.9 29.7 47.9
SP-R 18.71 17.9 1.0 3.0 28.8 49.3
SP-B 20.76 19.2 1.1 3.1 29.2 47.4
SP-7 23.96 20.5 1.1 3.0 29.3 46.1
SP-T 18.79 20.3 1.1 2.8 27.9 47.9
SP-8 23.12 19.6 1.3 2.3 27.1 49.8
SP-37 19.30 18.7 1.2 3.4 30.1 46.6
SP-9 25.63 19.1 1.0 3.4 28.8 47.7
SP-10 27.64 20.1 1.2 3.1 29.9 45.8
SP-B 21.62 18.2 0.7 3.9 33.3 43.9
SP-F 26.30 19.6 0.9 3.9 31.0 44.6
SP-C 17.25 19.0 0.6 4.2 33.8 42.4
Mean 21.49 19.15 1.0 3.3 29.9 46.6
SD 3.94 0.9 0.2 0.6 2.0 2.2
Correlation with LCAT (r) 0.47 -0.04 -0.14 0.16 -0.30
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A PPENDIX  14
Cholesteryl Ester Transfer Protein Activity in 
Four Thoroughbred Horses (TB) and Four Shetland Ponies (SP)
% Transfer/2.5h
Animal 1 ul 2.5 ul
Volume of LPDP 
5 ul 10 ul 35 ul
Protein
ug/ul %T/ug
SP-1 1.4 -1.7 0.5 -1.9 4.0 42.0 -
SP-4 -4.9 -4.5 -1.5 2.9 11.1 45.0 *0.007
SP-5 -0.9 -1.7 4.9 3.9 0.7 47.5 -
SP-6 2.0 3.6 3.3 1.5 6.1* 44.5 *0.004
TB-14 0.7 -1.1 4.3 4.3 11.2* 44.3 *0.007
TB-C -10.2 3.0 1.5 -0.9 4.8 47.5 -
TB-D 0.5 7.0* 4.9 -1.6 2.6 41.5 *0.077
TB-16 2.4 -8.0 -15.2 -9.4 -3.7 44.0 -
%
cv of blanks was ±5.6%, values greater than this are marked and used to give 
%T/ug.
204
A PPEN D IX  15
Cholesteryl Ester T ransfer P ro te in  Activity in 12 Shetland Ponies (SP)
Animal
% Transfer
Protein
ug/ml %T/ug1 ul 5 ul
Volume of LPDP 
10 ul 20 ul 35 ul
SP-L - - 3.0 4.5* 4.5* 49.0 *0.004
SP-R - - 4.8* 1.7 7.5* 56.5 *0.006
SP-B - - -0.4 2.1 -2.3 55.5 -
SP-7 - - 1.7 9.6* -2.7 38.5 *0.012
SP-T - - 1.8 12.3* -2.4 52.5 *0.012
SP-8 - - 1.8 3.8* -4.5 62.0 *0.004
SP-37 - - 0.8 4.7* 0.5 66.5 *0.004
SP-9 - - 3.7* 4.9* 3.5* 51.5 *0.005
SP-10 - - 4.0* 4.6* 2.5 56.0 *0.005
SP-B - - 1.8 5.6* -0.8 30.0 *0.009
SP-C - - 2.0 1.4 18.2* 39.0 *0.013
SP-F - - -18.8 9.0* -2.9 56.0 *0.008
cv o f blanks was ±3.1%, values greater than this are marked , the %T/ug calculated 
from  the mean of these values.
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Cholesteryl Ester Transfer Activity and CETP Inhibitory Activity 
in LPDP Eluted from Phenyl Sepharose
Fraction
Eluant
15% Ethanol 0-100% Ethanol
% Transfer3 % Inhibitionb % Inhibition0
1 -7.4 nd +29.9
2 -3.2 nd +52.1
3 -6.0 nd +23.4
4 -4.6 nd +18.0
5 -5.4 nd -2.4
6 -10.7 nd +16.2
7 8.8 nd +37.1
8 -3.1 nd +4.2
9 -8.2 nd -9.6
10 -8.6 +34.2 +47.3
11 -6.0 +44.6 +33.5
12 -6.3 +49.4 +10.2
13 -2.7 +41.6 +30.5
14 -5.2 +42.8 -1.8
15 1.2 +49.8 +15.6
16 -2.0 +16.7 -13.2 .
17 -3.1 +6.7 +19.2
a 35 ul of each fraction from column one was assayed for CETP activity. 
b 25 ul of each fraction was added in duplicate to the assay of 10 ul of a 1:3 dilution 
of human LPDP that gave 40.4% transfer (0.269 5T/ug).
c 50 ul of each fraction was added to 10 ul of a 1:10 dilution of human LPDP that 
gave 10.0% transfer (0.167 %T/ug).
N.B. The data for both inhibition assays show the percentage change in CETP 
activity, with negative results representing inhibition (nd; not determined).
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APPENDIX 17
Plasma Cholesterol, Triglyceride and Lipoprotein Cholesterol Concentrations 
In 12 Shetland Ponies at Grasss (Fed) and Following an Overnight Fast (Fasted)
Animal
Plasma Concentration (mmol/1)
Cholesterol Triglyceride VLDL LDL HDL
Fed SP-42 1.60 0.50 0.45 0.25 0.90
SP-43 2.20 0.45 0.35 0.70 1.15
SP-44 1.85 0.40 0.35 0.35 1.15
SP-45 1.75 0.50 0.45 0.30 1.00
SP-46 2.80 0.95 — — —
SP-47 2.00 0.35 — — —
SP-48 1.55 0.35 — — —
SP-49 1.90 0.35 — — —
SP-L 2.35 0.55 0.45 0.80 1.10
SP-R 2.10 0.70 0.55 0.50 1.05
SP-B 2.75 0.55 0.40 0.85 1.50
SP-37 2.75 0.75 0.45 0.75 1.55
Fasted SP-42 2.70 0.35 0.20 0.50 2.00
SP-43 2.35 0.30 0.20 0.45 1.70
SP-44 2.10 0.40 0.30 0.20 1.60
SP-45 2.00 0.25 0.20 0.30 1.50
SP-46 2.75 0.40 0.20 0.45 2.10
SP-47 2.15 0.35 0.20 0.35 1.60
SP-48 2.15 0.30 0.30 0.30 1.55
SP-49 2.15 0.20 0.20 0.35 1.60
SP-L 2.50 0.50 0.20 0.65 1.65
SP-R 2.65 0.60 0.30 0.55 1.80
SP-B 3.05 0.70 0.35 0.95 1.75
SP-37 2.60 0.65 0.30 0.75 1.55
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APPEND IX  18
Chemical Composition of Density <1.006 g/ml Lipoproteins in 
Four Shetland Ponies at Grass (Fed) and Following an Overnight Fast (Fasted)
1. Chemical Composition
Percentage Particle Mass
Animal
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
Fed SP-L 5.9 71.1 ND 11.0 11.9
SP-R 5.2 63.3 ND 12.0 19.4
SP-B 6.2 67.4 ND 11.4 14.9
SP-37 5.6 65.2 ND 9.9 19.2
Fasted SP-L 8.2 61.5 ND 13.9 16.4
SP-R 9.2 58.6 ND 13.2 18.9
SP-B 9.1 60.9 ND 13.9 16.0
SP-37 9.9 58.7 ND 13.0 18.4
2. Apolipoprotein Composition
Percentage of Protein Mass
Animal B-100 B-48 E A-I C-II c-ni
Fed SP-L 14.8 9.3 11.4 8.9 19.0 36.7
SP-R 14.5 9.1 17.0 0.0 26.1 33.2
SP-B 16.9 10.2 16.0 8.9 14.6 33.5
DP-37 19.8 7.7 16.6 2.0 14.8 39.2
Fasted SP-L 24.7 15.0 5.6 1.0 20.2 33.5
SP-R 37.8 10.8 6.9 1.7 11.9 30.9
SP-B 15.5 17.0 14.9 6.7 19.9 26.7
SP-37 17.0 9.7 3.2 1.4 26.2 42.5
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Lipoprotein Lipase, Hepatic Lipase, and Lecithin:ChoIesterol Acyl Transferase
Activities in Four Shetland Ponies 
Sampled after an Overnight Fast and after Access to Hay (Fed)
Animal LPL HL LCAT
umolFA/ml/h umolFA/ml/h nmolCE/ml/h
Fast SP-L
SP-R
SP-B
SP-37
1.96
1.85
2.86 
2.90
2.16
3.03
3.62
3.68
18.09
21.47
18.26
22.86
Fed SP-L
SP-R
SP-B
SP-M
2.82
2.43
2.86
3.02
3.08
2.63
2.34
4.34
19.07
23.79
20.88
31.86
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A PPEND IX  20
P lasm a Cholesterol, T riglyceride, F ree  Fatty  Acid (FFA) and  L ipopro tein  
C holesterol C oncentrations in Six S hetland  Pony M ares in L ate  P regnancy  
an d  E arly  Lactation, and  in th e ir Foals Aged O ne to  F ou r W eeks
Plasma Concentration (mmol/1)
Animal Cholesterol Triglyceride VLDL LDL HDL FFA
Foals
F-L 3.70 0.65 0.45 1.80 1.45 0.14
F-R 3.85 1.05 0.20 2.10 1.55 0.12
F-B 3.10 0.60 0.20 1.50 1.40 0.09
F-M 5.00 0.95 0.20 3.00 1.80 0.14
F-S 2.65 0.90 0.20 2.55 1.60 0.07
F-T 4.30 1.05 0.15 2.55 1.60 0.09
P reg n an t M ares
SP-L 2.55 1.20 0.40 0.60 1.55 0.23
SP-R 2.75 0.95 0.55 0.80 1.40 0.43
SP-B 3.25 2.15 0.75 0.65 1.85 0.79
SP-M 3.00 1.20 0.55 0.70 1.75 0.43
SP-S 2.85 1.75 0.55 0.45 1.85 0.27
SP-T 3.05 0.90 0.50 0.55 2.00 0.45
L ac ta ting  M ares
SP-L 1.85 0.10 0.20 0.20 1.45 0.50
SP-R 2.05 0.15 0.10 0.30 1.65 0.49
SP-B 3.25 0.30 0.25 0.15 1.85 1.06
SP-M 3.85 0.50 0.20 1.45 2.20 1.78
SP-S 2.60 0.80 0.35 0.70 1.55 0.96
SP-T 3.05 0.60 1.05 1.80 1.82
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A PPENDIX 21
C hem ical Com position of L ipoproteins from  Six Suckling Shetland Pony Foals
Percentage Particle Mass
Lipoprotein/
Animal
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
C hylom icrons
F-L 5.8 88.8 0.4 ND 5.1
F-R 1.5 89.9 1.1 ND 7.6
F-B 2.6 84.8 1.6 ND 10.9
F-M 2.2 90.7 0.3 ND 6.8
F-S 2.0 89.2 1.1 ND 7.7
VLDL
F-L 5.6 60.7 1.1 13.7 18.9
F-R 7.6 55.2 1.5 13.1 22.6
F-B 12.1 48.5 3.6 11.4 24.3
F-M 8.9 50.7 3.5 11.7 25.2
F-S 12.5 49.4 1.8 12.1 24.2
F-T 9.4 51.3 1.9 16.2 21.2
LDL
F-L 20.6 1.9 23.8 34.9 18.9
F-R 33.9 1.3 16.3 30.3 18.2
F-B 24.4 1.9 21.9 32.4 19.5
F-M 21.8 2.5 21.6 40.4 13.7
F-S 24.3 1.8 13.1 35.8 19.0
F-T 35.6 1.4 14.3 36.6 13.3
HDL
F-L 15.8 0.3 4.9 26.5 52.5
F-R 21.9 0.4 4.1 28.5 45.1
F-B 21.9 0.4 4.4 28.9 44.3
F-M 15.4 0.1 5.2 29.7 49.1
F-S 15.5 0.6 3.4 30.2 50.4
F-T 20.8 0.7 5.3 29.5 43.6
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A PPENDIX 22
Apolipoprotein Composition of Foal Lipoproteins.
Percentage of Protein Mass
VLDL
LDL
Foal B-100 B-48 E A-I c-n C-III A-II
F-L 18.5 28.6 52.8
F-R — — 7.0 36.9 11.1 45.0 —
F-B — — — 20.1 17.8 62.1 —
F-M — — — 30.1 17.2 52.8 —
F-S — — — 33.1 20.7 46.2 —
F-T — — — 22.0 27.6 50.4 —
F-L 18.6 6.5 7.1 6.9 20.4 40.5 —
F-R 17.6 10.1 9.3 7.8 23.4 31.9 —
F-B 12.4 4.9 7.3 3.5 28.9 43.1 —
F-M 16.3 3.2 5.2 5.3 23.1 46.8
F-S 27.0 10.4 12.0 9.3 18.0 28.3 —
F-T 24.1 7.3 17.2 10.8 14.8 25.8
F-L 80.6 — 7.6 2.4 3.1 6.4 —
F-R 90.3 — 3.4 0.7 1.5 4.0 —
F-B 80.7 — 7.7 1.7 3.5 6.4 —
F-M 81.8 — 6.5 5.1 1.3 5.3 —
F-S 73.0 — 5.6 3.2 3.9 14.4 —
F-T 79.1 — 7.4 4.2 3.7 5.5 —
HDL F-L — — 4.5 81.6 4.5 5.4 4.0
F-R — — 3.6 82.9 5.2 3.3 5.0
F-B — — 8.8 82.9 2.7 2.8 2.8
F-M — — 2.0 84.2 3.3 2.7 7.9
F-S — — 4.2 84.8 2.3 2.7 6.0
F-T — — 4.7 83.4 4.0 4.2 3.7
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Lipoprotein Lipase, H epatic Lipase and Lecithin:Cholesterol Acyl Transferase  
Activities in Six Shetland Pony M ares in Late Pregnancy and Early Lactation
A PPE N D IX  23
is
and in Their Foals Aged One to Four W eeks
Anim al umolFA/m l/h umolFA/ml/h nm olCE/m l/h
Foals
F-L 18.44 12.83 44.60
F-R 9.64 7.23 35.74
F-B 12.69 7.48 42.11
F-M  9.81 1.18 nd
F-S 10.20 9.15 42.69
F-T 4.77 3.76 34.85
Pregnant Mares
SP-L 2.95 3.21 nd
SP-R 3.99 2.84 nd
SP-B 4.45 4.04 nd
SP-M  4.29 4.27 nd
SP-S 4.01 4.04 nd
SP-T 5.01 5.19 nd
Lactating Mares
SP-L 14.53 8.04 nd
SP-R 10.03 3.67 nd
SP-B 20.20 8.69 nd
SP-M  13.68 13.02 nd
SP-S 10.31 11.02 nd
SP-T 19.82 14.24 nd
nd, not determined
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A PPEN D IX  24
Chem ical Composition of L ipopro teins from  Shetland Pony M ares 
in L ate P regnancy  an d  E arly  L actation
Percentage Particle Mass
Lipoprotein/ Cholesteryl Triglyceride Free Phospholipid Protein 
Animal Esters Cholesterol
V LD L
Pregnant SP-L 1.5 67.9 5.4 15.9 9.3
SP-R 1.2 65.9 10.0 13.3 9.6
SP-B 0.7 71.5 6.8 15.0 6.0
SP-S 0.0 67.9 9.6 15.3 7.3
SP-T 0.3 69.2 7.0 15.5 8.0
Lactation SP-L 6.4 67.3 ND 9.8 16.5
SP-R 8.6 62.0 ND 9.5 19.9
SP-B 5.7 65.1 ND 8.2 21.0
SP-M 8.2 66.5 ND 11.0 14.3
SP-S 6.4 70.1 ND 10.9 12.5
SP-T 4.2 75.8 ND 7.5 12.7
LD L
Pregnant SP-L 35.5 5.4 6.7 26.6 25.7
SP-R 38.6 6.1 5.3 23.7 23.5
SP-B 43.6 6.1 3.9 21.9 24.5
SP-S 36.4 4.2 14.8 26.2 18.4
SP-T 35.1 7.6 9.1 24.5 23.6
Lactation SP-L 40.9 3.2 8.0 21.0 36.9
SP-R 41.9 2.9 6.9 25.3 23.1
SP-B 43.6 7.8 4.8 18.9 24.8
SP-M 28.5 3.1 16.6 24.9 26.8
SP-S 20.7 6.1 17.1 33.2 23.0
SP-T 31.5 4.0 5.5 40.5 18.6
2 1 4
APPENDIX 24 (continued)
Percentage Particle Mass
Lipoprotein/ Cholesteryl Triglyceride Free Phospholipid Protein 
Animal Esters Cholesterol
HDL
Pregnant SP-L 17.5 0.4 4.0 31.0 47.2
SP-R 24.5 0.4 4.6 28.5 42.1
SP-B 19.2 0.4 3.6 32.2 44.4
SP-S 24.6 0.4 5.2 30.0 39.9
SP-T 18.8 0.6 3.2 30.1 47.3
Lactation SP-L 18.3 0.3 3.6 26.3 51.4
SP-R 21.4 0.5 4.7 34.6 58.5
SP-B 24.1 0.8 4.2 25.9 45.0
SP-M 20.0 0.5 3.9 25.9 49.7
SP-S 18.4 0.8 3.8 29.1 47.9
SP-T 21.8 0.8 4.0 26.7 46.6
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APPENDIX 26
Plasma Cholesterol, Triglyceride, Lipoprotein Cholesterol 
and Free Fatty Acid (FFA) Concentrations in 18 Ponies with Hyperlipaemia
Animal
Plasma Concnetration (mmol/1)
Choi. Trig. VLDL LDL HDL FFA V L D L ^
HLP-1 4.80 10.70 2.65 0.50 1.65 1.45 2.25
HLP-2 8.90 39.10 7.90 0.55 0.45 1.71 7.60
HLP-3 8.75 27.50 6.75 0.45 1.55 2.56 6.65
HLP-4 5.45 15.80 3.40 0.35 1.70 2.03 3.00
HLP-5 6.65 24.65 5.90 0.45 0.30 1.91 5.65
HLP-6 8.15 24.60 6.15 0.70 1.30 2.20 6.00
HLP-7 7.60 17.20 4.90 1.00 1.70 1.27 4.75
HLP-8 5.05 15.15 2.95 0.85 1.25 0.41 2.90
HLP-9 3.45 4.70 1.50 0.50 1.45 1.23 0.50
HLP-10 4.30 8.25 2.45 0.45 1.40 1.64 2.15
H LP-11 6.45 21.00 4.80 0.90 0.75 0.98 4.65
HLP-12 5.10 16.15 3.25 0.50 1.35 0.94 2.90
HLP-13 7.95 22.00 5.60 0.85 1.50 1.15 4.70
HLP-14 4.85 16.89 2.75 0.60 1.50 1.27 1.75
HLP-15 13.65 55.00 11.15 0.35 2.15 3.32 10.60
HLP-16 10.85 40.45 8.45 0.45 1.95 3.31 8.40
HLP-17 16.90 78.75 15.20 0.80 0.90 1.44 14.65
HLP-18 6.90 19.91 4.20 0.50 1.70 1.70 3.85
Choi., cholesterol; Trig., triglyceride
a The concentration of cholesterol in the VLD Lj fraction was calculated by 
subtracting the cholesterol concentration of the VLDL2 fraction (divided by 4, as it 
was isolated from 4 ml plasma) from the total VLDL cholesterol concentration.
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A PPEN D IX  27
Elution Profiles from 6% Agarose Gel of Density >1.225 g/ml Lipoproteins from
Nine Ponies with Hyperlipaemia
Animal
VLDL LDL HDL
Vol.aWidthb Height0 Vol. Width Height Vol. Width Height
HLP-1 82 16 >3.5 115 25 0.20 154 50 1.90
HLP-2 80 16 >3.5 118 31 0.23 159 38 1.97
HLP-3 71 18 >3.5 105 36 0.35 141 38 1.83
HLP-4 73 19 >3.5 107 31 0.28 141 38 1.48
HLP-5 67 20 >3.5 90 32 0.40 122 38 2.36
HLP-6 70 16 >3.5 104 30 0.20 140 36 1.84
HLP-7 80 24 >3.5 118 28 0.23 159 34 1.97
HLP-8 64 29 >3.5 115 30 0.11 152 30 1.97
HLP-9 71 20 >3.5 115 26 0.20 140 38 1.84
a peak elution volume (ml); b width o f peak (ml); c peak height (OD280nm)
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A PPEN D IX  28
Gradient Gel Electrophoresis of HDL Prepared by Flotation Ultracentrifugation  
from Nine Ponies with Hyperlipaemia and Nine Healthy Shetland Ponies
Animal Diameter (nm) Animal Diameter (nm)
HLP-2 8.42
HLP-3 8.66
HLP-4 8.24
HLP-5 8.54
HLP-6 8.84
HLP-7 8.68
HLP-8 8.60
HLP-9 8.88
HLP-10 8.61
SP-5 8.76
SP-6 8.56
SP-7 8.60
SP-8 8.48
SP-9 8.42
SP-10 8.46
SP-L 8.20
SP-R 8.30
SP-B 8.38
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APPEND IX  29
Chemical Composition of Lipoproteins Isolated by Flotation Ultracentrifugation
from 18 Ponies with Hyperlipaemia
Lipoprotein/
Animal
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
V L D L X
HLP-1 0.0 77.1 6.5 11.5 4.9
HLP-2 3.0 70.8 3.3 9.0 13.9
HLP-3 3.9 73.7 4.1 14.0 4.3
HLP-4 2.0 70.4 6.9 13.1 7.6
HLP-5 1.5 71.4 6.1 12.7 8.3
HLP-6 1.7 72.5 7.4 13.0 5.3
HLP-7 5.2 70.1 4.5 11.0 9.8
HLP-8 5.9 70.5 4.1 10.9 8.6
HLP-9 5.7 68.1 5.3 13.1 7.7
HLP-10 7.9 73.5 2.7 10.9 5.1
HLP-11 0.7 69.5 4.5 7.8 9.3
HLP-12 0.4 78.5 7.1 6.4 7.5
HLP-13 3.7 74.9 4.0 11.4 6.0
HLP-14 1.3 86.8 3.1 4.7 4.1
HLP-15 0.0 71.3 7.6 15.2 6.0
HLP-16 0.0 75.0 6.6 13.7 4.7
HLP-17 1.7 76.2 5.1 11.5 5.5
HLP-18 0.5 80.1 6.0 9.5 3.9
v l d l 2
HLP-1 2.3 75.7 4.1 8.7 9.2
HLP-2 11.8 6.06 0.0 14.6 12.9
HLP-3 8.2 66.3 2.7 14.7 10.8
HLP-4 2.9 65.3 2.9 12.6 16.3
HLP-5 4.0 73.0 1.6 13.0 8.5
HLP-6 13.7 62.3 0.0 12.7 11.3
HLP-7 6.8 52.9 4.6 14.6 21.0
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APPENDIX 29 (continued)
Animal
Percentage Particle Mass
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Protein
v l d l 2
HLP-8 11.2 58.5 0.0 15.2 15.2
HLP-9 13.6 53.2 0.0 15.2 18.1
HLP-10 3.1 61.0 7.1 18.0 10.8
HLP-11 9.4 65.5 0.0 16.2 9.0
HLP-12 5.0 71.6 2.1 14.1 17.2
HLP-13 6.0 67.8 3.3 15.3 7.7
HLP-14 1.8 67.5 8.1 14.0 8.5
HLP-15 3.8 65.4 5.0 18.0 7.8
HLP-16 4.0 63.6 3.4 16.6 12.3
HLP-17 6.1 59.8 7.3 18.4 8.4
HLP-18 3.5 71.2 5.2 14.7 5.4
LDL
HLP-1 22.7 16.7 11.4 23.6 26.2
HLP-2 29.0 16.1 4.7 21.9 28.3
HLP-3 41.2 11.1 6.0 25.0 16.8
HLP-4 33.1 17.9 0.0 24.5 24.4
HLP-5 36.7 29.5 11.8 18.2 30.3
HLP-6 39.4 15.8 0.0 20.8 24.0
HLP-7 37.4 6.2 3.9 15.7 36.9
HLP-8 39.5 13.5 0.0 22.3 22.3
HLP-9 36.5 8.7 5.5 21.6 27.8
HLP-10 26.0 30.1 0.0 20.4 23.8
HLP-11 22.7 27.5 0.0 18.7 31.1
HLP-12 35.2 24.0 0.0 19.0 21.9
HLP-13 14.6 33.3 0.0 15.1 37.0
HLP-14 13.2 31.8 8.3 16.8 29.9
HLP-15 19.6 13.4 12.3 28.6 26.1
HLP-16 34.6 10.0 3.8 28.5 4.7
HLP-17 20.6. 21.7 3.5 24.5 29.8
HLP-18 20.1 15.7 3.4 24.4 36.4
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A PPEND IX  29 (continued)
Percentage Particle Mass
Animal
Cholesteryl
Esters
Triglyceride Free
Cholesterol
Phospholipid Proteir
HDL
HLP-1 21.9 1.4 4.7 33.3 38.5
HLP-2 15.0 2.6 1.3 18.4 61.0
HLP-3 26.5 1.9 3.0 35.1 33.0
HLP-4 - - - - -
HLP-5 17.2 1.4 1.3 19.7 60.4
HLP-6 17.2 1.4 1.5 17.7 64.5
HLP-7 21.8 2.1 2.6 24.8 48.7
HLP-8 19.1 0.9 2.4 25.9 51.6
HLP-9 17.6 0.9 2.4 24.6 54.5
HLP-10 21.7 5.5 1.1 26.2 45.5
HLP-11 14.1 5.3 4.3 25.4 50.9
HLP-12 23.7 4.5 1.5 20.0 50.4
HLP-13 17.9 3.6 1.1 20.2 57.2
HLP-14 19.1 2.5 5.6 31.1 41.7
HLP-15 19.1 1.4 4.2 31.1 44.2
HLP-16 23.0 0.0 1.3 30.4 45.3
HLP-17 18.2 2.8 1.3 21.6 56.0
HLP-18 16.4 0.6 2.1 24.4 55.4
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A PPEN D IX  30
Apolipoprotein Composition of Lipoproteins 
from 18 Ponies W ith Hyperlipaemia
Lipoprotein/
Animal apoB-100 apoB-48
Percentage Protein Mass 
apoE apoA-I apoC-II apoC-III
VLDL!
HLP-1 6.6 14.6 14.4 12.4 29.8 22.1
HLP-2 12.6 15.0 10.0 13.9 28.3 20.2
HLP-3 10.0 11.0 13.9 7.0 26.7 31.4
HLP-4 8.0 13.1 13.9 11.4 29.8 24.8
HLP-5 4.3 8.3 12.6 6.0 46.7 23.4
HLP-6 16.9 13.8 25.2 9.7 12.8 21.6
HLP-7 11.6 9.0 16.6 12.6 19.5 30.7
HLP-8 9.2 10.0 10.0 3.5 28.6 39.6
HLP-9 13.4 13.0 9.3 11.6 18.8 44.0
HLP-10 12.8 14.7 8.5 5.4 29.0 29.6
HLP-11 17.2 12.6 15.4 7.9 21.2 25.1
HLP-12 11.5 13.0 24.4 2.5 15.1 33.5
HLP-13 13.5 14.3 8.4 4.5 20.6 38.7
HLP-14 13.6 16.9 14.8 8.6 23.4 22.8
HLP-15 8.8 8.5 27.4 14.5 13.4 27.4
HLP-16 14.1 14.7 16.9 3.4 16.4 34.7
HLP-17 6.7 7.2 17.6 8.3 26.8 33.3
HLP-18 14.5 13.7 19.5 11.6 21.4 19.3
v l d l 2
HLP-1 12.6 9.0 16.6 12.6 19.5 31.0
HLP-2 22.5 12.7 14.2 7.4 21.6 21.6
HLP-3 20.7 6.9 10.3 3.4 25.7 33.1
HLP-4 28.9 8.7 8.7 4.4 18.1 31.0
HLP-5 14.1 10.2 12.4 13.1 27.1 23.0
HLP-6 21.6 9.2 4.6 3.5 25.0 30.1
HLP-7 13.2 12.9 12.5 0.0 20.0 25.6
HLP-8 21.0 4.0 9.9 2.1 28.0 35.0
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APPENDIX 30 (continued)
Percentage Protein Mass
L ipopro tein /----------------------------------------------------------------------------------------  -
Animal apoB-100 apoB-48 apoE apoA-I apoC-II apoC-III
v l d l 2
HLP-9 22.5 14.8 4.2 1.7 2 2 . 2 34.6
HLP-10 2 2 . 6 14.6 4.0 0.5 21.5 36.8
HLP-11 17.6 12.4 4.1 2 . 6 31.8 31.5
HLP-12 19.2 8 . 8 10.5 1 1 . 0 2 0 . 2 26.7
HLP-13 2 0 . 6 1 2 . 8 12.5 8 . 6 15.0 33.5
HLP-14 18.4 1 0 . 8 7.9 5.1 22.7 35.1
HLP-15 1 1 . 6 11.5 23.0 6.7 10.9 36.3
HLP-16 19.2 8 . 8 1 0 . 2 1 . 0 13.5 42.6
HLP-17 17.2 5.4 13.0 9.4 22.9 32.1
H LP-18 23.6 1 0 . 8 1 0 . 6 3.7 25.1 26.3
LDL
HLP-1 58.2 — 7.5 — 17.8 16.6
HLP-2 56.9 — 9.8 — 1 0 . 6 22.7
HLP-3 58.4 — 17.6 — 1 0 . 8 13.2
HLP-4 83.6 — 2.4 — 5.1 8.9
HLP-5 88.7 — 4.3 — 4.5 2.5
HLP - 6 59.6 — 2 0 . 2 — 13.0 7.4
HLP-7 73.8 — 5.1 — 10.3 1 0 . 8
HLP - 8 82.2 — 3.8 — 6.9 7.2
HLP-9 57.0 — 1 0 . 6 — 25.4 7.1
HLP-10 82.0 — 8 . 1 — 7.8 2 . 1
HLP-11 73.5 — 14.9 — 2.9 8.7
HLP-14 52.9 — 17.5 — 13.9 15.7
HLP-15 71.5 — 7.2 — 12.4 9.0
H LP-18 79.4 — 7.7 — 4.1 8.9
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APPENDIX 30 (continued)
Percentage of Protein Mass 
Animal apoE apoA-I apoC-II apoC-III apoA-II
HDL
H U M 2 . 0
HLP-2 0 . 0
HLP-3 6.3
HLP-4 11.7
HLP-5 6.4
HLP - 6 3.4
HLP-7 4.0
HLP - 8 5.2
HLP-9 4.0
HLP-10 4.0
HLP-11 4.2
HLP-12 6 . 0
HLP-13 2 . 1
HLP-14 7.0
HLP-15 9.7
HLP-16 2 . 2
HLP-17 6 . 1
HLP-18 6 . 8
75.2 7.9
82.0 8 . 1
75.3 5.7
59.9 10.9
65.3 8 . 6
61.6 17.1
66.9 1 2 . 8
60.3 1 2 . 0
62.8 18.7
59.7 1 0 . 2
51.7 8.4
75.4 3.2
54.1 25.1
6 6 . 1 12.7
64.7 10.4
64.3 15.4
8 6 . 6 2 . 1
72.5 1 0 . 0
5.1 1 0 . 0
7.8 2 . 1
1 1 . 2 1.5
7.2 1 0 . 2
19.7 4.0
16.2 1.7
10.3 6.4
13.9 13.8
1 1 . 6 3.0
15.5 1 0 . 6
26.9 8.9
1 0 . 2 5.2
10.9 7.7
1 2 . 6 1 . 6
1 2 . 0 3.2
10.7 7.5
3.1 1.9
7.9 2.3
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APPENDIX 31
Lipoprotein Lipase, Hepatic Lipase and Lecithin:Cholesterol Acyl Transferase 
Activities in 12 Ponies with Hyperlipaemia.
LPL HL LCAT
Animal umolFA/ml/h umolFA/ml/h nmolCE/ml/h
HLP-1 6 . 0 2 5.10 nd
HLP-2 7.43 7.90 15.82
HLP-3 nd nd 15.09
HLP-4 nd nd nd
HLP-5 nd nd nd
HLP - 6 nd nd 22.23
HLP-7 9.80 21.41 44.41
HLP - 8 6.36 9.02 nd
HLP-9 9.95 14.04 15.96
HLP-10 7.60 16.72 18.43
HLP-11 5.85 11.07 33.08
HLP-12 1 2 . 0 0 18.76 21.98
HLP-13 9.17 14.51 31.48
HLP-14 5.68 11.35 20.76
HLP-15 13.51 19.50 18.05
HLP-16 nd nd nd
HLP-17 nd nd nd
HLP-18 4.05 9.03 46.33
nd, not determined
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A PPEN D IX  32
Cholestery Ester Transfer Protein Activity in Nine Ponies with Hyperlipaemia
Animal
%Transfer/2.5h
Volume of LPDP 
10 ul 35 ul
Protein
ug/ml %T/ug
HLP-1 7.9* 1.4 18.3 *0.043
HLP - 6 3.1 1.7 18.5 -
HLP-7 4.7 8.7* 25.5 *0 . 0 1 0
HLP-9 -5.0 0 . 0 19.0 -
HLP-10 - 1 . 6 - 1 . 0 14.3 -
HLP-11 6.4 11.4* 17.0 *0.018
HLP-12 6.3 1 . 8 13.0 -
H LP-13 0.7 6.3 10.5 -
HLP-14 4.6 0 . 2 14.0 -
Human (TW) 24.0 47.0 11.4 0.180
cv of blanks was +7.6%, values greater than this are marked * and used to calculate 
%T/ug.
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A PPENDIX 33
Plasm a Decay C urves of [14C]FFA  Activity in F ou r H ealthy  Shetland  Ponies
Subject 1
cpm /um ol
1 0 0 0 0 0
10000
1000
1 0 0
Q Observed Calculated
0.80.60.2 0.4 10
Time (hours)
Subject 2
cpm/umol
1 0 0 0 0
1 0 0 0
1 0 0
E Observed Calculated
0 0.1 0.2 0.3 0.4 0.5 0.6
Time (hours)
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A PPEND IX  33 (continued)
Subject 3
c p m /u m o l
1 0 0 0 0  n
□ O bserved Calculated
1000  :
100  ;
1 0
1.50 0.5 21
Time (hours)
Subject 4
c p m /u m o l
1 0 0 0 0 0  q
1 0 0 0 0  ;
1 0 0 0  :
100  :
□  O bserved Calculated
0 0 . 2 0.4 0.6 0.8 1.2 1.41
Time (hours)
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A PPEN D IX  34
Plasm a [14C]VLDL-TGFA and  [3H ]V LD L-TG  Specific Activity C urves
in F our H ealthy  Shetland  Ponies
cpm/umol
1 0 0 0  q
100  =
n  Observed —-  Calculated
12 148 10640 2
Time (hours)
VLDL-TGFA
cpm/umol
1 0 0 0  q
100  =
& Observed - — Calculated
4 6 8 10 12 142
Time (hours)
VLDL-TG
Subject 1. Top [14C]V LD L-TG FA
Bottom  [3H ]V LDL-TG
APPENDIX 34 (continued)
cpm /um ol
1000
100 =
□  O b s e r v e d C a l c u l a t e d
0.1
10 12 14 16 18 20 22 246 842
Time (hours)
VLDL-TGFA
cpm/umol
1000 q
100 d
A  O b s e r v e d C a l c u l a t e d
16 18 20 22 241410 126 842
Time (hours)
VLDL-TG
Subject 2. Top [14C]VLDL-TGFA
Bottom  [3H]VLDL-TG
APPENDIX 34 (continued)
cpm /um ol
1 0 0  =
n  O b s e r v e d C a l c u l a t e d
10 12 14 16 18 20 22 244 6 80 2
Time (hours)
VLDL-FA
cpm/umol
100  —
O b s e r v e d C a l c u l a t e d
4 6 8 10 1412 162 18 20 22 240
Time (hours)
VLDL-TG
Subject 3. Top [14C]VLDL-TGFA
Bottom  [3H]VLDL-TG
APPENDIX 34 (continued)
cpm /um ol
1000 g
100 e
10 e
n  O b s e r v e d C a l c u l a t e d
10 12 14 16 18 20 22 2482 4 6
Time (hours)
VLDL-TGFA
cpm/umol
1000 3
100 e
A  O b s e r v e d C a l c u l a t e d
0.1
10 12 14 16 18 20 22 244 6 82
Time (hours)
VLDL-TG
Subject 4. T op [,4C]V LD L-TG FA
Bottom  [3H]VLDL-TG
GLOSSA RY
apo apolipoprotein(s)
ACAT acyl Co A cholesterol acyl transferase
CAD coronary artery disease
CETP cholesteryl ester transfer protein
Ci curie
cm centimetre
cpm counts per minute
Da Dalton
DEAE diethyaminoethyl
dH20 distilled water
dl decilitre
dpm distintegrations per minute
DTNB 5,5'-Dithio-Z?/s-(2-Nitrobenzoic acid)
EDTA ethylenediaminetetra-acetate
FDB familial defective apoB-100
FFA free fatty acids
g gram
h hour
HDL high density lipoprotein(s)
HL hepatic lipase
HLP hyperlipaemia
HPLC high performance liquid chromatography
IDDM insulin dependent diabetes mellitus
IDL intermediate density lipoprotein(s)
k kilo
kb kilobases
1 litre
LCAT lecithin:cholesterol acyl transferase
LDL low density lipoprotein(s)
Lp lipoprotein
LPDP lipoprotein deficient plasma
LPL lipoprotein lipase
LRP LDL receptor related protein
LTP lipid transfer protein(s)
mg milligram
min. minute
mins. minutes
GLOSSA RY  (continued)
ml
mm
mM
mmol
mRNA
Mr
N
nd
ND
NIDDM
nm
nmol
OD280nm
PBS
PHP
RER
Rf
rpm
sd
SDS
SDS-PAGE
SER
SP
T
TB
TEMED
TLC
u
ul
umol
VLDL
VLDL-TG
VLDL-TGFA
v/v
millilitre
millimetre
millimolar
millimole
messenger ribonucleic acid 
relative molecular mass 
normality 
not determined 
not detected
non-insulin dependent diabetes mellitus
nanometre
nanomole
optical density at 280nm 
phosphate buffered saline 
post-heparin plasma 
rough endoplasmic reticulum 
relative band speed 
revolutions per minute 
standard deviation 
sodium dodecyl sulfate
sodium dodecyl sulfate polyacrylamide gel electrophoresis 
smooth endoplasmic reticulum 
Shetland pony 
transfer
Thoroughbred horse
N,N,N',N',-tetramthylethylenediamine
thin layer chromatography
micro
microlitre
micromole
very low density lipoprotein(s)
very low density lipoprotein triglyceride(s)
very low density lipoprotein triglyceride fatty acids
by volume
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